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—From the Foreword by Dr. Reddy

Intellectual property can be a powerful tool. When effectively and ethically
managed, it can accelerate the development of lifesaving, poverty-alleviating
innovations and provide access to them.
This Executive Guide, companion to the Handbook, discusses and summarizes
each of the 17 sections of the Handbook and distills best practices related to
each of the major topics. They are presented in brief, simply worded lists that
address the concerns of policymakers, heads of universities and R&D centers,
scientists, and technology transfer officers.
This book will be invaluable for anyone seeking to use intellectual property
strategically and put intellectual property to work.
“A resource for translating IP rights into realistic deals and practical solutions,
the Executive Guide demystifies intellectual property, making the subject accessible to all. ”
—From the Foreword by Sam Dryden

“Pragmatic IP management is building bridges between the world’s islands, be they economic,
institutional, or geographic. The choice of this metaphor is not accidental. It affirms a key claim
that reverberates within the pages of this book: the global IP system and innovation management
are not about changing islands. Rather, it is about building bridges between them.”
—From the Preface by Anatole Krattiger
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Dear Reader,

Judith Rodin
President

Over the last decade, the world has been paying increasing attention to the
agricultural, health, and economic disparities between industrialized and
developing countries. The Rockefeller Foundation is proud to have helped develop
and launch some of the numerous initiatives to address these issues—initiatives
such as the African Agricultural Technology Foundation, the Alliance for a Green
Revolution in Africa, the International AIDS Vaccine Initiative, the Global Alliance
for TB Drug Development, and others.
We believe, however, that launching the success of these and other similar
initiatives requires that we both engage directly with research universities in the
industrialized world and encourage the growing innovation capacity of developing
countries. The Public Intellectual Property Resource for Agriculture (PIPRA) and
the Centre for the Management of Intellectual Property in Health Research and
Development (MIHR) were created for precisely these reasons. Their mission
is to enhance the power of publicly funded research institutions to harness new
technologies and to ensure that the benefits of globalization are shared more
equitably. This Executive Guide and the companion Handbook and online version
are a natural outcome of their efforts to contribute new solutions to this two-fold
challenge. A follow-on interactive electronic version will reach an even wider
audience and, we hope, provide even greater benefits.
The Rockefeller Foundation is delighted to have supported the creation of this
unique resource. It holds lessons that are valuable (in many senses of the word)
for policy makers, leaders of research institutions, researchers, and technology
managers alike—in both industrialized and developing countries. Indeed, this
Executive Guide and Handbook, a testament to the committed, excellent work
of MIHR, PIPRA, and bioDevelopments-International Institute, might be the
most thorough primer on intellectual property management for the public interest
ever assembled. As such, it will be an indispensable tool for both planners and
practitioners for years to come.
With best wishes,

420 Fifth Avenue
New York, New York
10018-2702
Tel 212.852.8400
Fax 212.852.8277
president@rockfound.org
www.rockfound.org
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Foreword by Dr. K. Anji Reddy
The instinctively appealing proposition that knowledge ought to be used for the public
good—the common cause—is at the core of the debate surrounding the ethics of intellectual property. This notion of the role of knowledge in advancing the public good has
deep roots in numerous cultures and communities. Rabindranath Tagore, the universally
celebrated poet and Nobel laureate penned a stirring plea of hope:
Where knowledge is free
Where the world is not broken up into fragments by narrow domestic walls
… Into that heaven of freedom, my Father
Let my country awake!
The debate is particularly intense in relation to health and food, areas in which restrictions
to access can profoundly affect the human condition. Jonas Salk, the inventor of the first
polio vaccine, refused to patent it and famously said: “Who owns my polio vaccine? The people! Could you patent the sun? ” But the debate over what constitutes patentable subject matter has actually intensified over the years, as concerns have deepened over access. Nowhere
is this more pertinent than with antiretrovirals, with the patenting of live organisms, cell
lines, and plant varieties.
A persistent disparity in the human condition has accompanied us into the 21st century. This disparity is mirrored by differences, within our global community, regarding access
to knowledge and technology, between the rich and the poor. Despite grave incongruities,
there is consensus that new knowledge and innovation can contribute significantly to rectifying the inequalities. The faster and more efficient the flow of knowledge “through narrow
domestic walls,” the faster global equity and prosperity will replace global disparity.
The ethical debate over intellectual property rights focuses on the flow of knowledge.
But there must be innovation initially to trigger the flow. The great centers of education
and research in the public sector have made enormous contributions to furthering knowledge that have significantly improved the human condition, directly or through inventive
augmentation by others. Private corporations and individuals have contributed stunning
advances as well, and have promoted productive and creative uses of knowledge through
science and technology. The crucial question, therefore, is how to increase investment—in
Reddy KA. 2007. Foreword. In Executive Guide to Intellectual Property Management in Health and Agricultural
Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA
(Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International
Institute (Ithaca, USA). Available online at www.ipHandbook.org.
© 2007. KA Reddy. Sharing the Art of IP Management: Photocopying and distribution through the Internet
for noncommercial purposes is permitted and encouraged.
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both the public and private sectors—to accelerate innovation and facilitate its flow for the
greatest possible benefit.
Though the question may be simple, the answer is not. Yet, clear is the message from the
writers of the Executive Guide to Intellectual Property Management in Health and Agricultural
Innovation: A Handbook of Best Practices—that innovation, which can be transformed into
intellectual property and then owned and sold for profit in order to sustain investment
for further innovation, can be managed to benefit all people, and particularly those who
are poor and stand to benefit most from this process. Most experts acknowledge that the
notion of intellectual property rights is a compromise between the twin imperatives of
providing a reward system that will spur investment in innovation, on the one hand, and
use it to effect the greatest public good, on the other. Like all compromises, this one too may
be imperfect, but it is actionable and practical.
Winston Churchill foresaw the potential of the knowledge economy and asserted that
“the empires of the mind are the empires of the future.” The “haves” of the world own the lion’s
share of global intellectual property and it is no coincidence that they represent the lion’s
share of global wealth. The challenge for the “have nots” among nations, most of which
have not had the benefit of experience with a robust intellectual property system, is to
rapidly develop legislative and policy frameworks to foster a culture of innovation and to
manage intellectual property for the greatest benefit. This Executive Guide includes many
thought-provoking ideas that will support such transformations.
Remarkable in its scope, the Handbook not only provides discussion of broad, general,
and theoretical issues, it also provides practical ideas that can help institutions and companies strategically manage their intellectual property. The Handbook is an epic compilation of over 2000 pages in two volumes, with contributions from nearly 200 authors. It
is an invaluable and instructive sourcebook for scholars and students, policymakers and
practitioners.
Now, the vast knowledge represented by the Handbook has been distilled in the companion Executive Guide, which summarizes the Handbook’s 17 sections and presents key
implications and best practices related to each of the major topics. I am delighted to recommend the Executive Guide. It will serve as a concise guide for experts and provide fascinating insight for all citizens of the Brave New World.
September 2007
Hyderabad, India

Dr. K. Anji Reddy, Chairman, Dr. Reddy’s Laboratories Ltd., 7-1-27 Ameerpet, Hyderabad 500 016, India.
drreddy@drreddys.com
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Foreword by Sam Dryden
Intellectual property! The concept seems to some individuals to represent a vague abstraction.
To others it represents a contradiction. But to many, without doubt, intellectual property is a
powerful tool. Intellectual property refers to a set of global practices with undeniably real effects. Indeed, the fundamental cultural, intellectual, and commercial enterprises of any nation
increasingly intersect with the implementation of intellectual property rights. This is especially
true with respect to the life sciences, and specifically to health care and agriculture, because the
way intellectual property is managed dramatically affects the pace of innovation, the dissemination of knowledge, and the delivery of new technologies.
These reasons alone are enough to warrant the publication of this Executive Guide
and companion Handbook on intellectual property and innovation. But there are more
ambitious and more practical reasons as well. These essays (together with the companion
Handbook) offer a truly global snapshot of the emerging worldwide practice of IP management. Depending on your point of view (and these essays integrate many points of
view)—or on how you practice it—IP management either retards or stimulates innovation and access to new technologies. The authors’ views converge, however, on two main
points: the growing reach of the emerging global IP rights system and the importance of IP
management practice by the public sector. All agree that both the current IP rights systems
and IP management practices, in general, are far from perfect. Yet it is evident that solid IP
management can be a powerful tool for advancing the public interest. To manage intellectual property well, however, requires knowledge—not simply the knowledge necessary to
navigate these systems, but an understanding of the concepts that govern the systems and
the values that activate them. With informed use, the public benefits that IP rights regimes
are capable of providing can be maximized, especially in developing countries.
Even to function minimally in the modern global economy requires a thorough understanding of how IP systems work. Governments that wish to be part of the global economy
will need to radically adjust their approaches to intellectual property; indeed, both intellectual and real property should be reexamined and redefined in both the public and private
realms. As new systems evolve, they will need to be understood, established, and enforced
by countries’ legislative and judicial branches. Innovations will have to be both protected
and exploited. These demands have broad commercial implications for all parties involved
Dryden S. 2007. Foreword. In Executive Guide to Intellectual Property Management in Health and Agricultural
Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA
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in the development and use of intellectual property, including private inventors, academia,
corporations, and, more recently, farmers.
To many people in the plant sciences, these evolving global systems appear to go against
the grain of many time-honored precepts, such as breeders’ rights, farmer-saved seed, and
the free dissemination of germplasm. Many misconceptions exist. Some individuals believe
IP rights function simply to enable the developed world to take advantage of the developing world (for example, by depriving farmers of seed that could support their livelihood or
by depriving nations of the value of their indigenous germplasm). But the exercise of IP
rights is far more complex than these suspicions represent and the provisions for adapting
IP rights agreements are much more flexible than is commonly imagined.
This Executive Guide is important in many ways. It explains what makes IP systems
work and how the public sector, in particular, can best use the system to achieve its mission
and objectives. An authoritative undertaking written by world authorities on the subject,
this Executive Guide is an exceedingly valuable—and timely—contribution to the fields
of IP management and economic and social development. The Guide is a manual for understanding, not just the mechanics of IP rights, but also their conceptual foundations. A
resource for translating IP rights into realistic deals and practical solutions, the Executive
Guide demystifies intellectual property, making the subject accessible to all. We hope that
this Guide will level the playing field with respect to developed and developing nations,
open up new avenues of collaboration between the public and private sectors, and move us
all in the direction of a healthier and more equitable world.
September 2007
Boulder, Colorado, U.S.A.

Sam Dryden, 1900 9th Street, Boulder, CO 80302, U.S.A. sdryden@wolfensohn.com
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Foreword by Ismail Serageldin
Today, about two-thirds of global research and development (R&D) is being done by the
private sector. That enormous investment in science, and the technology that ensues from
it, would not be possible without a system of intellectual property protection that rewards
innovators and allows the investors to recoup their investments. No one would want to
jeopardize this enormous investment that advances human welfare so much.
However, it is increasingly apparent that in many quarters, such as in research and
academia in developing countries, it is difficult to undertake the basic research needed to
generate new knowledge rather than simply to be users of technology developed elsewhere.
Obstacles include costs as well as a lack of strategic patented technologies as inputs into the
research process. True, most of the time a research exemption is included in national law,
but it is usually accompanied by a “reach back” clause that comes into play if the research
yields some useful product.
To navigate the shoals of this new legal terrain, many researchers and decisions makers
need help in setting priorities, developing effective research strategies, and drawing on new
knowledge and on the experiences of others to make better and more informed decisions.
It is here that this marvelous book becomes absolutely essential.
This Executive Guide, a summary of a massive two-volume work, is both readable and
authoritative. It represents the fruits of enormous effort and much deep thinking by the
people who are most knowledgeable about these complex subjects. The authors are to be
congratulated for having put at the fingertips of executives and researchers this most valuable guide and to the authoritative resource that they have produced. I recommend this
Guide to anyone interested in the practice of science in the twenty-first century or in the
promotion of R&D in this new age of globalization of knowledge and trade, where the
agenda is increasingly driven by the enormous resources of the private sector.
September 2007
Alexandria, Egypt
Ismail Serageldin, Librarian of Alexandria, Director of the Bibliotheca Alexandrina, P.O. Box 138, Chatby,
Alexandria 21526, Egypt. secretariat@bibalex.org
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Preface

“No man is an island, entire of itself,” wrote John Donne. The concept was apropos in the
17th century and remains so today, perhaps more so. Today, our actions affect everyone,
our lives knit ever tighter, and the world is now our community. The strength of myriad
environmental, economic, media, technological, and knowledge connections is propelling
globalization forward in a complex network of products, people, images, ideals, and aspirations. Intellectual property is perhaps the most scrutinized component of the process of
globalization, being a process of ever-increasing interconnectedness. Respecting each other’s
property (intellectual, cultural, or physical), and sharing one’s own properties, is a fundamental principle of building useful and strong connections between people, institutions, cultures,
and continents. This is why the Executive Guide is so timely. It lays out the major ideas and
concerns of the companion Handbook in compact, lucid examinations of the full range of
intellectual property (IP) issues. It is a virtual map of the basic contours of the IP management response to the increasing interconnectedness. This Guide offers readers quick access
to current information about IP essentials, particularly as they relate to the public sector, to
developing countries, and to making the world a better place.
Even a cursory glance at the Guide will reveal the momentous changes that have already taken place in the field of intellectual property and innovation management and the
enormous potential that has been generated. The public sector has begun to recognize the
value of sound IP management. The result: new, creative relationships between the public
and private sectors that are helping to address the urgent health and agricultural needs of
people in developing, as well as developed, countries.
Pragmatic IP management is building bridges between the world’s islands, be they economic, institutional, or geographic. The choice of this metaphor is not accidental. It affirms a key claim that reverberates within the pages of this book: the global IP system and
innovation management is not about changing islands. Rather, it is about building bridges
between them.
The Executive Guide mirrors the principle of building bridges. Approaching topics
from various expert perspectives, the Guide allows the reader to bridge the conceptual
structures, case studies, and IP models contained within it to see new connections and craft
new approaches.
Krattiger A. 2007. Preface. In Executive Guide to Intellectual Property Management in Health and Agricultural
Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA
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Through the Guide and Handbook, we hope to liberate the potential of the global IP system, and
we believe that such liberation will come through the readers as they react to the chapters, draw their
own conclusions, imagine their own solutions, and create a positive outcome.
This is clearly not a time for complacent isolation. In fact, it is impossible, as interconnectedness
continues to increase. The task at hand is to engage in the process of connecting, with awareness and
intention, to ensure that the needs and wishes of the poor in developing countries are not (once again)
overlooked or disregarded. It is therefore time to join your voices, your values, your knowledge, and
your actions to pursue networks of partnerships that will nurture global access to innovation. Solo
efforts at innovation, as I wrote in the Prelude to the Handbook, will be ineffectual without collaboration; the components of a partnership create a dynamic entity that achieves more than any one party
could achieve. Imagining and cultivating such partnerships, however, requires an understanding and
orchestration of numerous components.
This Executive Guide opens the door to such an understanding and, I hope, will not only empower
its readers to envision a more equitable world but will also inspire them to realize that vision.
Anatole Krattiger
September 2007
Fréjus/St. Raphaël, France

Anatole Krattiger, Research Professor, the Biodesign Institute at Arizona State University; Chair, bioDevelopments-International Institute; and Adjunct Professor, Cornell University, P.O. Box 26, Interlaken, NY, 14847, U.S.A.
afk3@cornell.edu
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Executive Summary
of Key Implications
and Best Practices

EDITORIAL

The road from sound principles to best practices must include a broad, clear vision
of a more equitable world, because when vision is limited, action is circumscribed
and constrained. One way to achieve this vision is by expanding and accelerating
access—especially in developing countries—to life-saving and poverty-alleviating innovations in health and agriculture. A belief in this path to equity is shared by all of
the contributors to the Executive Guide and the Handbook. The Message from the
Editorial Board included in the Handbook elaborates on this path as well as on the
relationship of intellectual property (IP) to innovation management as this critical
interface is perceived by the board members. The key points are:
First, intellectual property is a tool to foster innovation. Intellectual property is
here—and here to stay—because of its undisputable value as a business asset and an
instrument to achieve humanitarian objectives. Since inventions can become property
and can therefore be owned and sold, many individuals have been encouraged to invest
in innovation, based on the profit potential from resulting technologies. But because
IP protections by definition—or by design—exclude competitors and encourage higher
pricing, they limit and, in some cases, can altogether prevent access by some individuals
and populations. There are many ways, however, for intellectual property to be distributed and utilized and put to work for the public interest. Hence we agree that intellectual
property should be neither feared, nor blindly embraced; rather, it should be managed to
maximize the benefits of innovation for all of society, especially the poor.
Second, IP rights are a compromise and an imperfect solution, representing the
search for balance between public domain and granting ownership. Historically, we
have seen that this balance encourages investment—and reinvestment—in innovation, although the innovation too infrequently is directed toward the needs of the
poor. Fortunately, as numerous case studies have shown, the public sector can craft
effective solutions that can approach or even achieve a suitable balance. This can be
accomplished by using the existing IP system, especially as it addresses situations in
which companies agree to donate or otherwise share their intellectual property.

EDITORIAL

Abridged Message from
the Handbook’s Editorial Board

Krattiger A,RT Mahoney,L Nelsen,JAThomson,AB Bennett,K Satyanarayana,GD Graff,C Fernandez,and SP
Kowalski. 2007. Abridged Message from the Handbook’s Editorial Board. In Executive Guide to Intellectual
Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A,
RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz,
Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). Available online at
www.ipHandbook.org.
© 2007. Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the
Internet for non-commercial purposes is permitted and encouraged.
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Third, genius can flourish anywhere, and the emerging global systems of innovation in health and agriculture open up new prospects for innovation everywhere.
This notion has profound implications for the management of innovation, technology transfer, market competition, and economic development in every country.
Irrespective of whether inventions are home grown or originate abroad, authoritative
IP management will play a crucial role in enabling and preserving access to the resulting technologies.
Fourth, policies to promote the creation and management of intellectual property by public sector institutions should give first priority to advancing the mission
of those institutions. Put differently, technology transfer should support the larger
mission and not merely be seen as potential revenues.
Fifth, intellectual property has historically benefited mostly the affluent. This is
due, in part, to the fact that insufficient attention has been paid by the public sector
to managing intellectual property. This lack of focused attention must be corrected.
Fortunately, there is growing interest, within both the public and private sectors, in
putting intellectual property to work for public benefit, although concurrently, there
is a lack of knowledge and capacity to use IP appropriately and responsibly.
This Executive Guide and companion Handbook are designed to help address these
complex needs. We hope the pages that follow (particularly the Key Implications and
Best Practices) will encourage all parties to take greater advantage of the unprecedented opportunity to strategically manage intellectual property to especially benefit
those who have been unable to benefit from technology. Seizing this opportunity will
lead, in turn, to a healthier and more equitable world. n
Anatole Krattiger, Research Professor, the Biodesign Institute at Arizona State University; Chair,
bioDevelopments-International Institute; and Adjunct Professor, Cornell University, P.O. Box 26,
Interlaken, NY, 14847, U.S.A. afk3@cornell.edu; Richard T. Mahoney, Director, Vaccine Access,
Pediatric Dengue Vaccine Initiative, International Vaccine Institute, San Bongcheon-7dong, Kwanakku, Seoul 151-818, Republic of Korea. rmahoney@pdvi.org; Lita Nelsen, Director, M.I.T. Technology
Licensing Office, Massachusetts Institute of Technology, Five Cambridge Center, Kendall Square, Room
NE25-230, Cambridge, MA, 02142, U.S.A. lita@MIT.edu; Jennifer A. Thomson, Professor, Dept.
of Molecular and Cell Biology, University of Cape Town, Private Bag, Rondebosch 7701, South Africa.
Jennifer.Thomson@uct.ac.za; Alan B. Bennett, Associate Vice Chancellor and Executive Director,
PIPRA, Office of Research, University of California, Davis, 1850 Research Park Drive, Davis, CA,
95616, U.S.A. abbennett@ucdavis.edu; Kanikaram Satyanarayana, Chief, IP Rights Unit, Indian
Council of Medical Research, Ansari Nagar, New Delhi 110029, India. kanikaram_s@yahoo.com;
Gregory D. Graff, Agricultural & Resource Economics, B306 Clark Hall, Colorado State University,
Fort Collins, CO 80523, U.S.A. Gregory.Graff@colostate.edu; Carlos Fernandez, Director, Strategic
Studies, Foundation for Agriculture Innovation (FIA), Loreley 1582, La Reina, Santiago, Chile. carlos.
fernandez@fia.com; Stanley P. Kowalski, The Franklin Pierce Law Center, 2 White Street, Concord,
NH, 03301, U.S.A. spk3@cornell.edu and skowalski@piercelaw.edu
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Throughout this Guide, best practices refers to the strategies and approaches that
the public sector in particular can employ to achieve its goals within an evolving IP
framework. These proven ways that arguably represent the best or most innovative
ideas in IP management can help the public sector better mobilize the resources to
take products through the process of innovation, and collaborate with the private
sector throughout that process. Best practices, therefore, include:
• enactment of comprehensive national laws and policies
• formulation of institutional IP policies and effective IP management
strategies
• application of creative licensing practices that ensure global access and
affordability
• building institutional IP management capabilities
• the creation of functioning national IP systems that include efficient patent
offices and transparent IP court systems

EXECUTIVE SUMMARY

Executive Summary of
Key Implications and Best Practices

It is important to note that the Key Implications and Best Practices throughout
this Guide are intended as starting points to be adapted to specific institutional contexts and national circumstances. Some practices are evolving and will depend on
context; but most are applicable across countries and continents, and within many
institutional contexts.1
The pages that follow present in a highly condensed manner the Key Implications
and Best Practices distilled from this Guide. They are presented in four parts and are,
in language and content, specifically aimed at four different constituencies (who
need to act in concert to make innovation work). These are:
• Government Policymakers (see page 7)
• Senior Management (university presidents, R&D managers, etc.) (see page 10)
• Scientists (see page 14)
• Technology Transfer Officers (see page 18)
Krattiger A and SP Kowalski. 2007. Executive Summary of Key Implications and Best Practices. In Executive
Guide to Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best
Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz
Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA).
Available online at www.ipHandbook.org.
© 2007. Krattiger and SP Kowalski. Sharing the Art of IP Management. Photocopying and distribution
through the Internet for noncommercial purposes is permitted and encouraged.
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We look forward to feedback on all of the best practices given in this Guide,2 and
we encourage all parties to take greater advantage of the unprecedented opportunity to
strategically manage intellectual property to benefit especially those who have, so far, been
left behind. Seizing this opportunity will lead, in turn, to a healthier and more equitable
world. n

EXECUTIVE SUMMARY

Anatole Krattiger, Research Professor, the Biodesign Institute at Arizona State University; Chair, bioDevelopments-International Institute; and Adjunct Professor, Cornell University, P.O. Box 26, Interlaken,
NY, 14847, U.S.A. afk3@cornell.edu
Stanley P. Kowalski, The Franklin Pierce Law Center, 2 White Street, Concord, NH, 03301, U.S.A.
spk3@cornell.edu and skowalski@piercelaw.edu

1

The publishers, editors, and authors have given their best efforts in preparing this publication,
and, while we believe the Executive Guide (including the Handbook and the online version) will
all be useful resources relating to intellectual property and the management thereof, the Executive Guide and the Handbook are not intended to serve as the sole source of information on the
topic. Readers are advised to seek independent legal counsel and/or other professional advice for
all intellectual property and contractual matters with regard to appropriate practices for specific
situations and countries. No warranties or representations of any kind are made as to the accuracy,
usefulness, or completeness of any suggestions or information provided in the Executive Guide.
Neither bioDevelopments-International Institute, MIHR, PIPRA, Oswaldo Cruz Foundation, nor any
of the contributors to the Executive Guide, nor the editors, funding agencies, or sponsors will be
liable for any loss or damage arising out of the use of any information or suggestions in the Executive Guide and Handbook. This comprehensive limitation of liability applies to all damages of any
kind, including (without limitation) compensatory, direct, or consequential damages; loss of data,
income, or profit; loss of or damage to property; and claims of third parties. All Web pages have last
been accessed between 10 and 21 September 2007.

2

The online version (www.ipHandbook.org) contains, for each of the 153 chapters of the Handbook,
a detailed Editor’s Summary, Implications, and Best Practices. These are more detailed than the
summaries provided in this Guide. The Web site will also, in future, contain a blog and discussion
forum where users can discuss the best practices presented here and share additional ones.
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KEY IMPLICATIONS AND BEST PRACTICES

FOR GOVERNMENT POLICYMAKERS
The Intellectual Property–Innovation Nexus
4

4

4

4

Whether viewed as a legal concept, a social construct, a business asset, or an instrument
to achieve humanitarian objectives, intellectual property is an important driver of
innovation. (p. 25)
The use of the IP system, via balanced patenting and sound licensing strategies, can
serve the public interest through private rights. This has profound implications for the
management of innovation, technology transfer, market competition, and economic
development in every country. (p. 25)

Innovation is a complex process, stimulated by coordinated and structured policies and
programs. An IP management system is one of six important factors in determining a country’s,
or institution’s, ability to innovate. Others are R&D capacity of the public and private sectors;
safe and effective regulatory systems; the ability to produce new products to high standards of
quality; a national distribution system in both the public and private sectors; and international
distribution systems and trade in technologies. (p. 25)
Policies promoting the management of intellectual property by public sector institutions can
advance the missions of these institutions, fostering creativity and innovation. (p. 25)

GOVERNMENT POLICYMAKERS

The page numbers refer to the page in this Executive Guide where the specific concept is discussed in detail.

Public Sector Institutions and Intellectual Property
4

4

4

4

4

When public research institutions own IP rights, they can use licensing to control how
technology is deployed, meeting both commercial and noncommercial goals. (p. 35)

Best practices in IP management will facilitate global access, provided the entire
innovation process is considered from the outset. This includes a mission-driven mindset
to establish optimum goals for the public sector. (p. 35)

An important best practice by the public sector is incorporating humanitarian use
reservation provisions in commercial licenses whenever possible. (p. 35)

Public sector institutions should have IP policies and institutional capacity for
implementing best practices in IP management. Licensors are more likely to grant licenses
to institutions that respect and protect third party IP rights. (p. 35)

Public sector institutions need strategies that balance the public domain and IP rights.
Commercial and humanitarian objectives are not in conflict, but rather are complementary,
indeed mutually reinforcing, aspects of best practices in IP management. (p. 111)

Building IP Management and Technology Transfer Capacities
4

4

4

4

Technology transfer converts scientific findings into useful products or services for society.
In the increasingly global economy, technology transfer collaborations are particularly
effective when spanning geographic boundaries. (p. 73)

Strategies for establishing and operating a TTO must be grounded in realistic economic
expectations. Technology transfer will not make an institution rich. It takes time (ten
years or more) to build an IP portfolio, establish contacts, and develop skills in technology
transfer. Furthermore, a critical mass of R&D activity is necessary to justify the costs of a
fully functioning TTO. (p. 73)

Alternative models for an institutional TTO are possible. For example, costs can be shared
among a consortium of universities or research institutions. Such hub-and-spokes
configurations allow essential policy decisions and scalable functions to be centralized,
while keeping essential context-specific functions localized. (p. 73)

Technology transfer is a talent-based business. Building networks is essential for success.
Governments should encourage the creation and operation of national technology transfer
associations that concurrently build international linkages. (p. 73)
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GOVERNMENT POLICYMAKERS

4

Putting pressure on TTO officers to break even or to generate revenues can constitute a
perverse incentive, forcing a TTO to go with up-front payments. (p. 101)

Statutory IP Considerations
4

4

4

4

4

4

4

4

4

The statutory tools of IP (patents, copyright, trademarks, trade secrets, plant variety
protection) are per se neutral; what matters is how these tools are used. (p. 57)

Membership in the Patent Cooperation Treaty (PCT) will provide national institutions
(public and private) with greater opportunities for international technology transfer,
licensing, product development and penetration of global markets. Membership in the PCT
can also provide for cost-effective examination of patent applications. (p. 111)

Providing for legislation, or for amendments to current statutes, that facilitates patent
filing by foreign entities can be an important component of technology transfer and
development. (p. 111)
Patent licenses are most valuable when coupled with access to associated know-how. Trade
secret laws are thus conducive to the transfer of know-how through licensing. Patents and
trade secrets are thus complementary forms of IP protection. (p. 121)
Successful licensing of crop varieties (and of accessing improved varieties from other countries)
increasingly depends on the strength of plant variety protection legislation. Such legislation
can support the interests of the variety owner and the farmer and also facilitate the transfer of
technology and provides incentives for further investments. (p. 121)

Trademarks allow public and private institutions to capture value. To benefit from
trademark strategies, internationally harmonized legislation is important, as is the
maintenance of high quality standards and stewardship, since trademarks (and geographical
indications) serve as indicators of source and quality. (p. 121)

Although IP rights are governed by national statutory protection, contract law is also
important, as contracts are the legal mechanisms that structure the orderly exchange of
intellectual property. (p. 121)

A functioning court system is essential to encouraging partnerships and to accelerate
national and foreign investments. Indeed, suppliers of biological materials (and of confidential
information and intellectual property) will be encouraged to enter into agreements if the
suppliers are confident that their property rights will be protected and that agreements will
be enforced. (p. 85)
Pursuant to the TRIPS Agreement and the Doha Declaration provisions on parallel trade,
countries can implement patent rights exhaustion regimes that either permit or
restrict parallel importation. Despite the evident benefits of parallel trade, there are also
disadvantages. (p. 163)

Public and Private Sector Intersections
4

4

4

4

Product development partnerships (PDPs), essentially alliances between the public and
private sectors, facilitate and accelerate the flow of public and philanthropic investment
through the innovation pipeline. The ultimate measure of success should not be maximum
profit but maximum social benefit. (p. 133)
PDPs enable industry to invest and apply its expertise to address the needs of the poor. In
many contexts PDPs are now driving the drug-development pipeline in neglected-disease
R&D. National institutions in developing countries should be encouraged to participate in
PDPs. (p. 45)

Negotiating agreements between public and private sectors is an opportunity to forge a
long-lasting and mutually beneficial relationship. But every partnership is different. National
institutions need much latitude and flexibility to craft appropriate deals. (p. 133)

Negotiation and technology marketing skills are fundamental for successful licensing and
technology transfer. People working in the public sector generally need better negotiating
skills, thereby enabling institutions to take advantage of their own R&D efforts and to
realize broad public sector and commercial goals. (p. 133)
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Commercialization of Public Sector R&D

4

4

4

4

4

4

Rather than venture capital driving the creation of new companies, it is usually the
creation of new companies that attracts venture capital. (p. 143)
While a government cannot legislate entrepreneurship, it can encourage entrepreneurship by providing a favorable environment for creating and growing new companies.
(p. 143, 153)

Policies and legislation that benefit biotechnology companies and start-ups can
accelerate the pace of innovation, particularly when it comes to commercializing publicsector-generated inventions. (p. 133)

Much of the success of a spinout or start-up will depend on the entrepreneurial spirit
at the institution. The more entrepreneurial, the more likely it will be that someone wants
to set up a new company. Spinouts can create jobs, enhance economic development and
create international opportunities. (p. 143)

Cluster formation fosters the movement of new technologies into existing industry. This
requires a commitment to science education and research, a strategically situated anchor
institution with a technology transfer office, and reliance on market forces as the engine
for technology transfer. (p. 45)

GOVERNMENT POLICYMAKERS

4

Governments can encourage regional economic development by fostering and financing
business incubators. (p. 143)
As intellectual property becomes more prevalent in health and agricultural research, public
sector institutions need to consider the intellectual property of third parties. Knowledge
of “who owns what” is needed. That is what a freedom to operate (FTO) analysis provides,
facilitating the handling of products for further development or commercialization, even
if the goal is to address the needs of the poor. (p. 153)

IP Dispute Resolution
4

4

4

4

A country’s statutory code, combined with a reliable system of adjudication and
enforcement, is the basis for enforcing IP rights. (p. 163)

Alternative dispute resolution procedures for settling differences between parties to an
agreement can be an effective strategy for public sector institutions. These procedures are
particularly important in international contract dispute resolution. (p. 163)

Governments and public institutions can help make arbitration or mediation procedures
accessible by identifying and supporting neutral institutions that can provide costefficient, timely dispute-resolution services. The World Intellectual Property Organization
offers such services through the WIPO Arbitration and Mediation Center. (p. 163)
IP protection mechanisms depend upon effective and equitable enforcement by national
governments. This requires effective, transparent, and enforceable contract law. (p. 57)

Biodiversity, Traditional Knowledge and Bioprospecting
4

4

4

Indigenous communities often play a significant role as gatekeepers to a country’s
biodiversity wealth. They are the regional specialists with respect to the flora and fauna.
Their knowledge can often exceed that of leading scientists. (p. 173)
Patent laws per se do not “create” biopiracy. Rather, biopiracy is a form of misappropriation, unfair acquisition, and inequitable sharing of benefits with respect to biological resources. (p. 173)

Formulate procedures for equitable access to traditional knowledge held by indigenous
societies. However, this requires balance: access should be granted only via authorized
permission, yet the price that is assessed for permission to bioprospect should not
dissuade potential development. (p. 173)
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KEY IMPLICATIONS AND BEST PRACTICES

SENIOR MANAGEMENT

FOR SENIOR MANAGEMENT
(University President, R&D Manager, etc.)

The page numbers refer to the page in this Executive Guide where the specific concept is discussed in detail.

Intellectual Property in the Innovation Context
4

4

4

4

4

4

4

Benefits from public sector health and agriculture investments have tremendous global
potential. Government-sponsored research can thus make a big difference in meeting the
needs of the poor, nationally, regionally and globally. (p. 25)

Intellectual property, as a tool to foster innovation, is a compromise, balancing the
public domain with limited grants of ownership. An appropriate balance requires sound IP
management and capacity to do so in the public sector. (p. 35).

Balancing public benefit and economic returns can be influenced through government
policy. (p. 1). But decisions to place inventions in the public domain can only meaningfully
be determined on a case-by-case basis. (p. 45)
In order to fulfill both commercial and noncommercial goals, public research institutions
can, through IP management and licensing strategies, control how their patented
inventions are deployed and developed. (p. 25, p. 45)

By working with their respective governments to implement national policies, public
sector institutions can help establish a national IP system that fosters best practices in IP
management in the public sector. (p. 93)

Well-crafted contracts based on best practices can be instrumental in achieving global
access, provided the entire innovation process is considered from the outset. Such an
approach requires preparation, detailed knowledge, and a public sector mission-driven
mindset. (p. 45)
The use of IP rights is not a panacea for the management of innovation, nor is the public
domain. Both public and private goods have utility and limitations. The art of innovation
management is in using both public and private goods and to manage the interface
between them. (p. 111)

Institutional Mission and Policy
4

4

4

4

A sound institutional IP policy typically addresses ownership, conflicts of interest and
commitment, confidential information, broad IP licensing approaches, and IP generated
revenues. (p. 65) Other important considerations include ethical guidelines for IP
management (p. 35) and the reservation of humanitarian rights (also called philanthropicuse provisions) on IP and the retention of research and teaching rights of all inventions
and technologies. (p. 45, 121)

An effective institutional IP strategy describes long-term goals and the allocation of resources
necessary for their realization. Public sector institutions have much to gain by articulating how
their IP management strategies foster global access to innovations. (p. 65)

IP audits can be useful mechanisms that form the basis for an internal review and revision
of an institution’s IP strategy and IP policy. (p. 65)
Government policies ought to be flexible and enable research institutions to customize
technology transfer strategies that align with the institutions’ missions. Different
approaches will serve different types of research and academic organizations working
within various disciplines and cultures. (p. 101)

IP Management Principles and Technology Transfer
4

4

Technology transfer invariably brings conflicts of interest. These should not be viewed as
negative. They can usually be managed in a transparent and consistent manner. (p. 65)

Technology transfer and licensing are context-specific. (p. 35). Licensors, public or
private, are more willing to license to institutions that consistently protect third-party
property. This builds confidence and thereby promotes licensing and technology transfer.
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4

4

4

4

4

4

4

4

4

The core element for successful technology transfer is people. The technology transfer
office (TTO) should be led by an individual who understands the details of running a
business. (p. 73).

Successfully establishing and operating a TTO will require visible and sustained
support, financial and otherwise, from senior administration. Clear mandates will
help technology transfer professionals choose among competing priorities. (p. 73). This
includes the implementation of rigorous IP-related policies and procedures. (p. 57) Above
all, it requires TTO officers’ ability to assume risks knowing that they have backing from
senior management. (p. 73)
A critical mass of R&D activity is necessary (typically $100-$500 million) to justify the costs of
a fully functioning TTO. Consortium approaches to technology transfer can ameliorate this
imposing initial requirement by pooling resources and expertise. (p. 73)

SENIOR MANAGEMENT

(p. 45) A successful approach is to allow maximum flexibility whereby institutions can
set, or negotiate, the terms that best fit the mission and goals of the institution and the
purpose of the partnership. (p. 85)

For companies, the ultimate purpose of IP management is to enhance competitiveness
and reduce risk. For public sector institutions, the purpose of IP management should be to
serve the greater public interest. These are not mutually exclusive goals, and they can be
reconciled through sound technology marketing and licensing practices. (p. 133)

Scientists should be encouraged to use public domain technologies as research
inputs whenever feasible to reduce possible future constraints in the downstream
commercialization of innovations. In many circumstances, however, relying on patented
technologies may be the more effective way to go, particularly when the goal is to develop
products. (p. 111)

Building strong institutional capacity in IP management will enable technology managers
and scientists alike to understand the complex array of options that should be considered
before publishing research results or filing patent applications. (p. 111)

An important element during the development of an IP strategy is to document the
technologies that already exist in the organization, plus those technologies in development.
This can be achieved through an IP audit, among other approaches. (p. 111)
Management should encourage good laboratory practices and diligent record keeping of
data to ensure that research can later be used in possible regulatory filings. Doing so could
lower costs and reduce the time to market. (p. 111)

To benefit from trademark strategies, the maintenance of high quality standards is
important, since the trademark (brand) indicates the source and quality of the product.
(p. 121)

Supporting Entrepreneurship
4

4

4

4

4

The creation of business incubators as a tool for stimulating local economic development
should not be underestimated. Incubated companies have a dramatically higher rate of
survival than the average spinouts. (p. 143)

A spinout often creates enhanced opportunities for its faculty. If spinouts remain in
the region, faculty inventors can remain active as consultants. Also, a university’s success
with spinouts can attract new talent. But much of the success will depend on the
entrepreneurial spirit at the institution. The more entrepreneurial, the more likely it will
be that someone wants to set up a new company. (p. 143)
If public sector institutions found ways to reduce the risk of investing in agricultural
projects, more venture capital would be attracted. (p. 143)
Rather than venture capital driving the creation of new companies, it is usually the
creation of new companies that attracts venture capital. (p. 143)

Robust innovation clusters require a commitment to science and entrepreneurship, a
strategically situated anchor institution, and reliance on market forces as the engine for
technology transfer. Cluster formation will strengthen the ability of local and national
economies to absorb new technologies into existing industry or entrepreneurial
sectors. (p. 25)
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Licensing
4

4

4

4

4

4

4

4

4

4

4

Nonexclusive licensing can be a strategy to maximize the utilization of research tools.
Exclusive licensing, on the other hand, can be quite effective for broad dissemination of
patented products, particularly when coupled with milestone clauses. Complementary
strategies are market segmentation, field-of-use licensing, and the negotiation of tiered
pricing clauses. (p. 45)
The dual goals of economic growth and social/humanitarian benefits through licensing
are not mutually exclusive. Indeed, they are often complementary. Much will depend on a
sound institutional licensing strategy and on good relationships with licensees. (p. 121)

Business decisions, more than legal aspects, should determine licensing terms. Nevertheless,
lawyers should ensure that the contracts comply with prevailing law. (p. 121)
Confidentiality agreements rely on a culture of trust, not a culture of secrecy. They protect
sensitive information transferred between parties, and, when well managed, and are not
inconsistent with public sector missions or the publication of research results. (p. 85)

Patent licenses are most valuable when coupled with access to associated know-how,
which is often shared under confidentiality provisions. Comprehensive staff training in the
handling of confidential information from third parties is therefore critical. (p. 121)

Specific best practices in licensing terms that allow public sector entities to meet public
sector goals (ensuring broad access to innovation) include area of use, territory, price,
labeling, white-knight conditions, and royalties. (p. 133)
The key to successful negotiation is having a clear understanding of the value each party
brings to a relationship. Value may be monetary or non-monetary. (p. 133)
Negotiating between public and private sectors ought not be confrontational, but as
a first step in a long-lasting and mutually beneficial relationship. Negotiating a fair
licensing agreement should thus not be seen as a process of “bargaining” toward a winwin outcome. (p. 133)
For the public sector, a well-tested and successful approach to negotiating an agreement
is to offer initial terms to a company that the public sector organization itself would be
willing to agree to if it were on the other side of the negotiating table. (p. 133)
Senior management can set a positive tone for negotiation that will ensure that deals made
with others are a vehicle for building strong relations and trust between parties. (p. 133)

Networking is essential for successful technology marketing. Technology transfer officers
and scientists particularly should be encouraged and given opportunities to network. (p. 133)

Managing Risk, Maximizing Benefits
4

4

4

As public sector and nonprofit institutions pursue product development, freedom to
operate (FTO) will become a strategic component in an organization’s risk-management
strategy. Implementing the strategy requires clear pathways of communication and
dialogue between science managers, product development, licensing personnel, counsel,
and senior management. (p. 153)

FTO is an interdisciplinary endeavor and considered within the context of the institution’s
mission, business development, research and technology transfer, and tolerance for risk.
(p. 153)
The more downstream a research-based institution operates, the more important FTO
considerations become. A system should be in place to help decide whether, when, and how a
public sector institution should conduct or commission a legal FTO opinion. (p. 153)

Maintenance of IP Rights
4

It is important to have the flexibility to opt for legal action if this seems to be in their best
interests. But legal action is often complex due to cost, length of procedure, uncertainty as
to outcome, confidentiality/publicity, the difficulty of seeking action in foreign jurisdictions,
and the negative impact on existing business relationships. (p. 163)
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4

Biodiversity, Traditional Knowledge: Access and Equity
4

4

There is a strong interaction between bioprospecting activity and national scientific
capabilities. In countries with strong scientific capability, bioprospecting is robust.
Moreover, such capacity increases the negotiating strengths and benefit-sharing
opportunities. (p. 101)

The technology transfer office should work with senior management to establish policies
and systems for accessing indigenous or traditional knowledge (TK), bioprospecting
activities, and benefit sharing in an equitable manner. (p. 173)

SENIOR MANAGEMENT

Encouraging alternative dispute-resolution procedures can be a viable strategy and,
indeed, often a preferred one, for settling differences between parties to an agreement.
These are particularly important in international contract dispute resolution. (p. 163)

HANDBOOK OF BEST PRACTICES: EXECUTIVE GUIDE | 13

EXECUTIVE SUMMARy

KEY IMPLICATIONS AND BEST PRACTICES

SCIENTISTS

FOR SCIENTISTS

The page numbers refer to the page in this Executive Guide where the specific concept is discussed in detail.

Inventions, Inventors and Innovations
4

4

4

4

4

4

4

4

Research is one of the very foundations of innovation. Research leads to discovery;
discovery fosters invention; inventions nourish innovation. Your work is part of a larger
innovation process that spans R&D across the public and private sectors. (p. 35) As the
creator of inventions and technologies, your role in technology transfer is critical. (p. 65)
So please read on!
As a scientist, you recognize the interconnected web of science, R&D, technological
advance, and commercial investment. Take the time to share these insights with your
institution’s technology transfer office (TTO) and its senior managers. (p. 25)

Determining how to translate an invention into an innovation that makes a difference in
people’s lives (economically or socially) is one of the principal reasons TTOs exist. (p. 101)

The emerging global system of innovation in health and agriculture creates
opportunities worldwide. This key concept, that public interest can be served through
private rights, has profound implications for the management of innovation, technology
transfer, market competition, and economic development in every country, regardless of
its economic status. (p. 35)
Countries engaged in reforming their R&D and technology transfer efforts often include
royalty-sharing provisions for scientists in publicly funded research institutions. This
often requires assignment of ownership rights to the institution and a duty to disclose
inventions. This should be seen as an incentive to turn inventions into innovations that
benefit society. (p. 25)

While access to foreign technology is integral to development, it is also important to focus
on capturing the national innovation potential of any country. Through the activities of
your research program, you may be positioned to facilitate the development of indigenous
innovation and traditional knowledge. (p. 25)

Your continued interest in your invention’s development is important. This will help it
reach the marketplace, and especially benefit those who most need it, yet can least afford
it. (p. 35) Hence, as the inventor, you can significantly influence how your technology is
used. For example, you might request that licenses reserve your right to continue research
using your inventions or reserve rights for humanitarian uses of your technology. (p. 45)
Collaboration with private sector entities can significantly contribute to your institution’s
broader participation in innovative initiatives, particularly product development. (p. 45)

Networks
4

4

4

Collaborations create contacts. Contacts build networks. Networks provide opportunities.
(p. 133)

Collaboration is often based on establishing personal contacts and building strong
professional networks; these foster the formation of collaborative research projects
and are fundamental for effective sharing of know-how and show-how. (p. 25, 73)
Accessing other’s intellectual property can be facilitated through networks of committed
professionals. (p. 45)
Keep your TTO informed about your networking activities, particularly if there is a possibility of
shared research endeavors. These collaborative research projects, and your network in general,
can be starting points for technology transfer and licensing. (p. 73, 173)

IP Management
4

Your role can best be carried out if you have good relations with your TTO. But fulfilling
your role also requires an understanding of your institution’s IP policy. The policy will
likely articulate ownership of intellectual property, conflict of interest, the handling of
confidential information, and more. (p. 65)
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4

4

4

4

4

4

4

As your institution implements IP policies and patenting strategies, your right to publish
is not jeopardized. IP protection and licensing are but one form of knowledge transfer
that, if well undertaken, can very much be in the public interest. (p. 25)

SCIENTISTS

4

The purpose of such a policy, and more importantly of your institution’s IP strategy, is
not just to protect your inventions, but also to control technologies and IP assets such
as to determine how these can be managed to spur economic growth and contribute to
the greater public good. If your institution does not “own” anything, how can it place
conditions upon its use? (p. 65)

Philanthropic donors increasingly expect to find IP management components in grant
applications and to understand how intellectual property will be used to achieve global
access and humanitarian benefits. This is one reason why a close relationship with your
TTO is important since your colleagues at TTOs may increasingly be required to prepare
access strategies as part of your grant applications. (p. 65)
When your institution conducts or commissions an IP audit, view this as an opportunity
to better identify the intellectual property generated in your research program, to improve
and streamline the management of third-party intellectual property (allowing you to
concentrate more on research), and to contribute to the formulation and execution of an
IP strategy that benefits your program and its global impact. (p. 65)

It is your responsibility to disclose any potential conflict of interest. Know your institutional
conflict of interest policy. Most conflict of interest issues arise when procedures are not
properly followed. (p. 73) You are not guilty of anything if you have a potential, perceived,
or even real conflict of interest. It is only a matter of “managing” these conflicts. (p. 65)
Everyone in your group or laboratory should know the obligations entered into through
any agreement that affects your program. (p. 85)

Increasingly contracts will include milestones. Research schedules and goals may be
directly linked to specific milestones, and you need to know how such milestones might
impact your program. (p. 45)
Published information, or research tools provided by a colleague, may be covered by IP
rights. This should neither deter nor distract you from good science. An awareness of
basic IP management best practices will help you to understand and identify potential
IP issues. (p. 111) Encourage your TTO to organize occasional seminars on the basics of
IP management. This will facilitate communication with your TTO staff and answer your
questions about IP management. (p. 93)

Laboratory Notebooks and Records
4

4

4

4

Good data management and accurate record keeping through comprehensive laboratory
notebooks (p. 163), is the foundation for building a portfolio of IP assets. Essentially, best
practices in scientific record keeping should be precisely the same as best practices in
record keeping for purposes of IP management. (p. 57, 93)

The confidentiality of your data may be critical in ensuring global access. Data is a valuable
form of intellectual property that can be used in licensing negotiations. (p. 57)

Confidentiality agreements are meant to protect sensitive information exchanged
between parties and are not inconsistent with public sector missions or research
publication. Confidentiality agreements rely on a culture of trust, not a culture of
secrecy. (p. 85)
Make an especially strong effort to document the origin of biological and other materials
you use in your research, and keep a comprehensive record. (p. 121)

Invention Disclosures and Patenting
4

Recognize when you actually have an invention (it is generally much, much earlier than
most scientists think)! Invention disclosures are the first step in protecting intellectual
property. Disclose early and often. But expect only a small portion of your invention
disclosures to lead to patent applications. (p. 93)

HANDBOOK OF BEST PRACTICES: EXECUTIVE GUIDE | 15

EXECUTIVE SUMMARy

SCIENTISTS

4

4

4

4

4

4

By filing an invention disclosure with your TTO, you are initiating a dialogue. Even if the
TTO does not immediately file a patent based on your first invention disclosure, it is a
process that has started, and follow-up will be much easier. (p. 93)

Invite your TTO liaison to visit your laboratory occasionally and discuss with you and
your research team what you have been doing. Discussions with technology transfer
experts, especially patent attorneys, can help you to identify inventions. (p. 93)

If patenting and public disclosure are your goals, consult with your institution’s
technology transfer manager prior to disclosure. Your institution should have a mechanism
to determine whether or not a patent should be filed without significantly delaying
publication. Just be aware that premature publication can lead to a loss of IP rights. (p.
111)

Patents often disclose more technical and scientific information than academic
publications. Read published patent applications or issued patents in your field. You can
access this information for free on the Internet. (p. 57)

Your institution’s technology transfer managers will need your input in order to make
strategic decisions about where to pursue foreign patent applications. You likely know
where different competitors are located and where products arising from your research
are needed. (p. 111)
When you disclose an invention to your TTO officers, inform them of any ideas you may
have on the various fields of endeavor in which your invention could find applicability.
This will help the TTO plan patent applications and later design license agreements under
different field-of-use licenses. (p. 121)

Licensing Inventions and Marketing Technologies
4

4

4

4

4

4

4

4

4

The “unique selling proposition” of your invention or technology (the features,
advantages, or benefits it offers) may not be the science behind the technology, but your
invention’s use. (p. 133)

Technology marketing is a process by which owners of a technology create relationships,
between themselves and potential users, which will drive technology development and
availability, through commercialization or other methods. (p. 133)
When speaking to potential licensees or investors, it is often best to, in extremely simple
language, stress the potential applications of your invention rather than the superb
science. (p. 133)

Your role in field-of-use licensing is essential. You can provide your TTO with valuable
information on licensable components for different applications and entities. (p. 121)

In agreement negotiations, your role may be to share relevant information, advice and
insights. In some cases, especially with collaborative research agreements, you may be an
integral member of a team that will address issues such as research plans. (p. 85)

Detailed aspects of negotiations, such as collaboration or license agreements, are
conducted by the relevant offices of your institution. However, do participate in the
internal discussions prior to licensing negotiations. Your input will be important and
should be valued. (p. 121)

Material transfer agreements are tools for gaining greater access to tangible materials
from a number of sources (scientists from the public and private sectors, both in your
own country and abroad). (p. 85)
In most institutions, you will not be authorized to sign most agreements without review
by counsel or by your TTO. Know whether or not you are authorized to sign a given
agreement. (p. 85)
Understand the obligations that are attached to different funding sources. The impact of
joint public and private financial support can be complex but will increase, particularly
as your institution positions itself strongly within an innovation cluster and engages in
product development. (p. 25)
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Scientists and Entrepreneurs

4

4

Not all university inventors are entrepreneurs interested in being company founders,
and not all spinout company founders from a university are the technology’s inventors.
Involvement as a company founder entails a greater degree of risk and commitment to
move an invention to commercialization. (p. 143)
Much of the success of a spinout or start-up will depend on the entrepreneurial spirit at
the institution. The more entrepreneurial, the more likely it will be that someone wants to
set up a new company. (p. 143)

SCIENTISTS

4

Venture capital investors combine a broad view of the market with solid technical expertise.
Venture capital investors can be great allies, but will impose, for good reasons, distinct conditions
on the project. Be open, patient, and willing to work with investors. (p. 143)

Freedom to Operate
4

4

4

4

Collaboration among scientists and the professionals who conduct freedom to operate (FTO)
analyses is essential. The scientist can explain the science and technology to help others
understand the materials and methods. A scientist is the expert in the area of research and can
provide important leads to other scientific groups and publications. (p. 153)

Teams conducting FTO analyses will also need to understand precisely what the product
is, how it was developed, what materials were used, and what reports were prepared. The
purpose is to ascertain that all relevant information has been considered in the FTO analysis.
(p. 153)

The results of an FTO analysis may allow you to make better use of technologies in the
public domain and inform your choice of research tools or vector constructs. The analysis
also may alert you to scientific discoveries and inventions related to your work. (p. 153)
Knowledge of how to access, manipulate, and mine patent and publication search tools
for valuable information will serve you and your program well. Hence, become versed in
Internet database search skills, and ask your TTO to organize short patent search workshops.
(p. 153)

Maintaining IP Rights and Obligations
4

4

4

As a scientist, you should regularly review all of the agreements that relate to your projects.
This specifically includes ensuring that milestones are met, royalties paid, and that any
other obligations are taken care of. (p. 163)

Your institution should continuously monitor patent infringements through various
surveillance protocols. A lack of patent enforcement can lead to a loss of patent rights. Your
role in this is important, since you are well connected in the area of your research and can
indicate to the TTO which companies might be practicing your inventions. (p. 163)

If your institution conducts alternative dispute-resolution procedures such as mediation or
arbitration, you might be called upon to participate, particularly if aspects of your research
program are involved in the ongoing discussions. (p. 163)

Biodiversity, Bioprospecting, and Traditional Knowledge
4

4

When working with colleagues from foreign countries, be aware that those colleagues
may be authorized to make collections of biological materials only under specified
circumstances, ensuring fair and equitable terms with prior informed consent (p. 101.)
Before proceeding with joint activities, check with your institution’s TTO to make sure that
all the requirements have been met. (p. 173)

Scientists and anyone else accessing biodiversity must ask, and answer, the following
questions prior to initiating collecting activities: Under which conditions may I enter
another sovereign state’s territory in my scientific capacity? Under which conditions may I
collect biological material and related information? Under which conditions may I carry out
or export biological material and related information from that sovereign state’s territory?
Under which conditions may I make further use of collected biological material and related
information? (p. 173)
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The Innovation Landscape and Intellectual Property
4

4

4

The emerging global systems of innovation in health and agriculture open up new
prospects for innovation everywhere. This has profound implications for the management
of innovation, technology transfer, market competition, and economic development in
every country. (p. 25)

Innovation is complex and integral to all six components of innovation: IP management,
R&D in the public and private sectors, safe and effective regulatory systems, the ability to
produce new products to high standards of quality, a national distribution system in both the
public and private sectors, and international distribution systems and trade in technologies.
Consider this entire innovation process when making patenting and licensing decisions.
(p. 25)
The use of IP rights is not a panacea for the management of innovation, nor is the public
domain. Both public and private goods have utility and limitations. The art of innovation
management is in using both public and private goods and to manage the interface
between them. (p. 111)

The Role of the Technology Transfer Office
4

4

4

4

The traditional mission of technology transfer offices (to bring university-generated
intellectual property to benefit the public) is broadening, reaching the global community.
Technology transfer also enhances the reputation of academic institutions and facilitates
their missions of education, research, and community outreach, ensuring social impact. (p.
25, 45)
A TTO is responsible for creating incentives to move discoveries toward product development
by motivating public sector researchers, not by a promise of revenue streams, but by the
satisfaction of seeing their work applied to serve the public good. (p. 45)

The primary role of a technology transfer office should not be the generation of financial
returns; they can take years to come. Be realistic when making forecasts about expected
income; a positive return can take eight to ten years to achieve. (p. 45)

Your role in communicating the use of IP tools and the benefits of good IP management is
critical, thereby cultivates an IP management “culture” throughout the organization. Such
communication should be directed to senior management, your institution’s board, and to
scientists. (p. 57, 153)

IP Policy and IP Strategy
4

4

An IP policy should address, at a minimum, ownership of intellectual property, conflicts
of interest and conflicts of commitment, the handling of confidential information, the
principles of IP licensing approaches, the sharing of income derived from intellectual
property, and any rights the institution will retain (such as for research and for humanitarian
uses). (p. 65)

An institutional IP strategy addresses how IP management will be used to achieve global
access/humanitarian benefits of the inventions and products developed at an institution.
It should include how the institution deals with incoming third-party intellectual property,
how it deals with internally generated intellectual property, and how it will out-license its
intellectual property to third parties. (p. 65)

Agreements and their Uses
4

A public sector institution can use a variety of agreements to both manage and protect
intellectual property, regardless of whether that intellectual property is owned by the public
sector institution or by licensing partners in the private sector. The key issue is to allow for
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maximum flexibility whereby institutions can set, or negotiate, the terms that best fit the
mission and goals of the institution and the purpose of the partnership. (p. 85)
4

4

4

4

4

A template agreement should be used only as a starting point for discussions. (p. 85)

Contracts should be tailored to fit local customs and business practices. Be sensitive to
cultural and linguistic differences between parties to a contract. (p. 85)

Your office ought to be the official repository of all agreements dealing with incoming and
outgoing biological materials. (p. 85)

Legal jargon in agreements should be avoided. Instead, use short, clear sentences that are
free of vague adjectives and are written in the active voice. (p. 85)
Confidentiality agreements rely on a culture of trust, not a culture of secrecy. Make sure that
confidentiality agreements contain the necessary exceptions appropriate for the mandate
of your institution. (p. 85)

When negotiating collaborative research agreements, involve scientists. Their input will be
critical at various stages of the process. (p. 85)

Some IP Management Nuts and Bolts
4

4

4

4

4

4

Conduct occasionally comprehensive IP audits to determine where your IP assets are, when
IP protection is needed, whether there are potential IP liability issues, whether there are
licensing needs and/or opportunities, and whether there are inventions to be harvested.
(p. 157) IP audits can be useful mechanisms that form the basis for an internal review and
revision of an institution’s IP strategy and IP policy. (p. 65)

TECHNOLOGY TRANSFER OFFICERS

4

Technology transfer invariably brings conflicts of interest. The challenge is to manage them
in a transparent and consistent manner. Most problems arise when potential conflicts are
not disclosed. (p. 65)

All employees (and visitors in some cases) should be required to sign an invention assignment
agreement on their date of arrival. (p. 65)

Any TTO will have a wide range of legal matters to be addressed, and procedures for working
with external patent and general counsel should be well established. (p. 73)

Many technology valuation approaches exist. None is perfect. Considering that each deal
is highly context specific, each technology transfer office should be able to select the best
approach and adapt it to the specific circumstances. (p. 101)
When devising a patenting strategy, you will need to make three decisions: First, should you
seek patent protection? Second, what is the best patent-marketing approach? Third, what
license fees and/or royalties ought to be levied? (p. 101)

Modes of IP Protection
4

4

4

4

Trademarks are a critical, and often overlooked, option for IP protection. They can be used as
stand-alone IP protection, or they can be integrated into an overall strategy for integrated IP
protection. (p. 57)
Because public-domain technologies play an important role in publicly funded research,
defensive publishing can increase accessibility of technologies in the public domain.
Scientists need your help to ensure that such disclosure truly places the invention into the
public domain. (p. 111)
There are advantages in filing provisional patent applications (such as controlling costs and
providing additional time for weighing options as to whether it is worthwhile to pursue a
full patent application) but beware of the downsides. (p. 111)

For any invention, evaluate whether foreign patent rights are truly required. Keep in mind
possible applications in developing countries; a patent may be critical to ensure access. This will
require a combination of business, marketing, and legal analyses. (p. 111)

Licensing Inventions and Technology
4

Both nonexclusive and exclusive licenses can be applicable to meeting socio-economic
goals. Within exclusive licensing, there are many options, such as exclusivity limited to a
certain field of use, or geography, or for limited periods of time. (p. 35)
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4

4

4

4

4

4

Reserving rights for humanitarian use may require additional work and will likely not
generate licensing revenue; conversely, such provisions, if used in a strategic way, are
unlikely to lead to loss of revenues. (p. 35)

Though potentially useful, IP managers should be cautious of imitating open licensing
procedures in the field of biotechnology. It is still unclear to what extent the software
models of open source can be adapted to other technological fields. (p. 35)
Any organization engaged in high-volume licensing will find it useful to develop its own
internal template agreements that are then modified and adapted to suit each special
circumstance. Checklists for different types of recurring licensing negotiations should
be reviewed prior to and during negotiations. (p. 121) For the licensing of plant varieties,
certain software may be useful (p. 123)

Field-of-use licensing should be adopted as the preferred method of licensing whenever
possible. It allows you to gain greater control while maximizing the use and value of your
licensed technology. (p. 121)

In a license agreement, the rights (or prohibitions) to sublicense and assign a license
ought to be explicitly articulated. (p. 121)
Licensee agreements are contracts. Hence, a practical understanding of contract law
will be fundamental to negotiating and drafting good license agreements. TTOs can ask
counsel to ensure that agreements are compliant with national law. (p. 121)

Milestones
4

4

4

4

Creative licensing strategies will help your institution gain the greatest benefits from the
research it conducts. Such strategies include, at a minimum, the balancing of exclusive
and nonexclusive rights, defining field of use, setting appropriate milestones, requiring
the delivery of products to developing country markets, and exercising control over pricing.
(p. 25)

The public sector must specify in writing exactly what it wants to accomplish with
a commercial partner, detailing when and how this will be achieved by articulating
milestone obligations. (p. 35)

Avoid “best effort” clauses in agreements. Instead, draft comprehensive contracts with
articulated milestones. This up-front investment will pay off later if a problem arises. (p. 35)

Developing meaningful milestones that provide the appropriate balance of incentives,
rewards, and penalties requires detailed preparations, a sound understanding of the
processes related to developing and marketing the product, realistic forecasting of product
potential, and a mission-driven mindset. (p. 35)

“Moving” Technologies to the Market
4

4

One of your responsibilities will be to bring together individuals with different backgrounds
and experiences before negotiating agreements. Ideally, a team should include business
strategy, marketing, legal, scientific, regulatory, production, and finance expertise. (p.
133)
Marketing inventions should not simply be a push of technologies; rather, it should be an
approach that allows the needs of buyers to pull inventions. (p. 133)

IP Management and Entrepreneurship
4

4

4

One of the most important factors for a successful TTO is the institution’s entrepreneurial
culture. This is strongly influenced by the attitude and degree of support from senior
management. (p. 73)

Spinouts carry a number of risks, but with certain factors in place they can represent the
best opportunity for developing early-stage technology. (p. 143)

Potential investors in a spinout will ask two major IP questions. Could previously existing
intellectual property block the technology? Could your intellectual property dominate the
market and prevent entry by others? (p. 143)
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4

4

New ventures in developing countries have much to gain by attracting and building on
international investor networks. They have the potential to open new markets and bring
in new alliances. (p. 143)

It is often appropriate to strike a balance between reliance on licensing-out to existing
companies and investing time and resources in creating new companies. (p. 143)

Risk Management and Freedom to Operate (FTO)
4

4

4

The role of the technology transfer officer, and that of attorneys who may produce legal
FTO opinions, is generally to advise senior management on risks. It is a manager’s purview,
based on your input, to decide how to deal with the risks identified in your FTO analysis.
(p. 153)
A freedom to operate (FTO) analysis is an interdisciplinary endeavor best executed through
FTO teams. These teams, made up of legal, business, and scientific professionals, are in
themselves useful for strengthening intra-institutional dialogue and communications.
(p. 153)

TECHNOLOGY TRANSFER OFFICERS

4

When licensing to or creating new ventures, several key attributes are essential for
attracting venture capital investment: a strong management team, a viable technology,
a strong IP position, a large potential market, and location in an environment favorable for
entrepreneurship. (p. 143)

For an academic or public institution, legal FTO opinions are unlikely to be needed for the
majority of technology transfer functions. They would be relevant only if the institution is
engaged in downstream product development and commercialization. (p. 153)

Monitoring and Protecting Intellectual Property
4

4

4

4

4

4

Potential patent infringements should be monitored continuously through sound
surveillance protocols, and action taken to remedy infringement is an essential part of IP
asset management. The lack of patent enforcement can lead to a loss of patent rights. (p.
163)

Early communication with potential infringers and good license and licensee diligence,
are the foundations for policing and maintaining intellectual property, irrespective of
whether the intellectual property is owned by a public or a private entity. (p. 163)

Essential to contract management is a well-organized electronic filing system. A TTO
should establish such a system as early as possible and before the number of agreements
and licenses becomes large. An agreement management system (donated by the
Whitehead Institute for Biomedical Research) is available on the Handbook’s Web site for
download. (p. 163)

Most IP disputes should not end up in litigation, as there are many options and strategies
for resolving disputes. Good contracts and good licensing practices anticipate that disputes
arise with partnerships and licenses. (p. 163)

Mediation and arbitration can be effective dispute-settlement procedures, provided they
have been agreed upon and established in contract clauses at a time when a license or
partnership is being negotiated—and before any problems arise. (p. 163)

A technology transfer office must have systematic procedures to administer, monitor,
and enforce its technology licenses. This includes compliance with royalty payments and
reporting obligations in a non-confrontational manner. (p. 163)

IP Training and Capacity Building
4

4

When scientists learn the basics of IP management, communications with the technology
transfer office will improve. Public sector institutions should offer training to every scientist,
student researcher, and technicianwhen they join an institution. (p. 93)

Part of the aim of IP management training is team building that encourages communication
between your office and the scientists in your institution. It is part of creating a culture of
IP awareness and particularly useful to encourage invention disclosures. (p. 93)
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4

It is good practice to include senior management as participants in the training sessions.
This is especially useful when the training program includes case studies. (p. 93)

Intellectual Property, Bioprospecting, and Traditional Knowledge
4

The technology transfer office should work with senior management to establish policies
and systems for accessing indigenous or traditional knowledge (TK), bioprospecting
activities, and benefit sharing in an equitable manner. (p. 173)
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Innovation and IP Management:
A Contextual Overview
The pressures on innovative organizations and
countries are many and varied—economic, technological, organizational, environmental, political, and societal. Leaders of public sector institutions and private companies have limited control
in most of these areas. But a leader of any entity,
public or private, can exercise a high degree of control over the entity’s own intellectual property (IP)
through sound IP management and critical tools to
accelerate innovation. Section 1 of the Handbook1
presents an overview of innovation and IP management, which are the focal points of the entire
Handbook, and logically, the Executive Guide.
IP rights are a critical tool for fostering innovation. Managed judiciously, they balance private rights and public necessity in a manner that,
overall, encourages innovation. The first chapter
of the Handbook, by Mahoney and Krattiger,2
directly addresses the paradox that underlies the
Handbook: the pursuit of the public interest
through private rights. Focusing on the life sciences, the chapter asks how IP rights can best be
managed to promote public welfare. It finds an
answer, not in the system of IP rights, but in the
judicious and skillful use of proprietary science.
In short, the authors argue that creative management of IP rights, especially by public sector institutions, is essential for achieving public benefits.
Understanding how intellectual property
fits into the much broader context of innovation
and product development is important for any

public sector entity, whether in a developing or
developed country, for addressing neglected diseases, for alleviating poverty, for development in
agriculture, and for eliminating chronic malnutrition. Mahoney and Krattiger discuss how, within
the rapidly evolving global IP landscape, public
sector institutions can better mobilize resources
in order to accelerate products through the innovation pipeline through best practices in IP management. These best practices include creative
licensing practices that ensure global access and
affordability, improved institutional IP management capabilities, the formulation of comprehensive national IP policies, and the strengthening of IP court systems and patent offices.
Recent national and international changes in
IP treaties, legislation, and frameworks are having profound effects on innovation systems and
on how public and private research and development institutions implement their missions and
how health and agricultural innovations reach the
poor. Seen within this broader context, intellectual property is one of six interrelated components of innovation management3 that focuses
on developing a variety of issues:
• R&D capability by the public and private sectors
• safe and effective regulatory system that covers
drugs, vaccines, and agricultural products
• manufacturing capability for health products
and for the inputs into and outputs of agricultural production

Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski.
2007. 1: Innovation and IP Management: A Contextual Overview. In Executive Guide to Intellectual Property Management in
Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford,
UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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• expansion of national health or agricultural
delivery systems, including an attractive,
private sector domestic market for health
or agricultural products and services
• international trade systems for health products (including global procurement funds)
and agricultural inputs and outputs; and an
IP system (legal framework, judiciary to enforce it)
• institutional management capabilities
The authors raise important questions and
make significant proposals, framing IP management within a global context. This global approach is inexorably spreading and expanding at
an accelerating pace. Because of the increasing
interaction between developed and developing
economies and the increased number and complexity of relationships between the public and
private sectors, understanding the best ways to
forge and maximize partnerships has a high priority. Such partnerships will be the engines that
drive global innovation.
The chapter further reviews recent dramatic
developments in the institutional aspects of intellectual property, as well as global policy shifts and
international case studies. In the field of health,
changes have been particularly pronounced with
the founding of a novel form of institution for
innovation: product-development partnerships
(PDPs). Mahoney and Krattiger make the case for
a fundamental shift in the way IP management in
health and agricultural innovation is viewed and
conducted: the public sector can employ new
ways to achieve its goals within the evolving IP
framework. In response to rapid global evolution, nongovernmental organizations (NGOs)
and PDPs will have important roles to play in the
global IP environment, particularly for developing countries.
It is well established that intellectual property advances product development because intellectual property provides incentives for R&D,
commercialization, and product distribution.
Investors in biotechnological R&D naturally
want to protect their investments, and must,
therefore, secure IP rights for their inventions.
Before the creation of IP rights protection, the
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private sector had little incentive to develop safe
and efficacious pharmaceuticals. Historically,
the public sector had neither the funds nor the
capability to develop products. Yet, the world is
changing. As the public sector devotes more of its
efforts to humanitarian missions, and engages in
more development partnerships (such as PDPs)
in the fields of health and agriculture, it will also
have to consider the critical role of intellectual
property in a broader innovation context.
The permanence of intellectual property is
evident. If the public sector does not effectively
utilize the IP system, it will neither be serving
its own interests nor the interests of those it has
promised to serve. Without effective IP management skills, the public sector risks squandering
the rights, powers, and opportunities that the IP
system provides. Intellectual property is a tool,
and, like all tools, its impact depends on how
it is used, who uses it, and for what purpose. IP
strategies can serve to either restrict or expand
access to innovations; it’s all a matter of capacity, management, and context. These three aspects
are addressed in the creation of a best practices
document.
For IP management to efficiently function
within a larger framework of innovation, best
practices need to be documented. That is what
the Handbook and this Executive Guide seek to
do: to provide a teaching and capacity building
resource for IP management, with a focus on
health and agricultural biotechnologies. When it
comes to increasing developing countries’ access
to fundamental innovations in health and agriculture, success requires knowledge, capacity and
active engagement. This is what best practices in
IP management strive to bring about and what
the Handbook promotes.
To illustrate how best practices may be used,
Mahoney4 reviews the impact of the Agreement
on Trade-Related Aspects of Intellectual Property
Rights (TRIPS) on the development of the pharmaceutical industry in Korea. Korea was able to
implement a wide range of initiatives—including an upgrade of its IP regulatory systems—that
benefited its pharmaceutical industries. It is likely
that Korea’s success was largely achieved because
its IP systems aligned with those of developed
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countries. The empirical data gleaned from the
experience of Korea is promising, suggesting that
TRIPS compliance will improve biotechnological
capabilities in developing countries.
Building innovation capabilities in developing countries often relies less on the creation of IP
systems and more on the creation of markets and
support for R&D. Broadly speaking, the evolution of IP rights in developing countries involves
three basic stages (before reaching stage 4):
• Stage 1: In the early stage of development,
little intellectual property is generated domestically and few foreign companies are
interested in introducing their technologies to these countries due to inadequate IP
rights protection.
• Stage 2: At a later stage of development, the
country’s innovative capabilities improve,
but due to the same inadequate IP rights
protection, there is limited foreign investment in technology.
• Stage 3: Eventually, when domestic companies are able to generate their own
intellectual property, they demand moreeffective IP protection. With more-effective
protection, foreign investment in technology increases along with the presence of
foreign technologies.
Within the pharmaceutical industry (and
many parallels exist with the agri-biotechnology
industry), companies in developing countries
tend to move through four stages described in
Table 1. This shows that technological and IP
capacities tend to develop in tandem. However,
such a measured-pace “natural coevolution” is no
longer likely with TRIPS requirements in effect.
These state that signatory countries’ pharmaceutical industries must rapidly progress from either
Stage 1 or Stage 2 on to Stage 3. It remains to be
seen whether this mandatory accelerated development will hinder or help developing-country
pharmaceutical industries in the longer term and
to what extent TRIPS will facilitate the transfer of
technology to and within developing countries.
However, elsewhere, especially in the United
States, Europe, Japan, and parts of Australasia,
technology transfer from universities works and

works well. Examples of this are when we get into
a car and buckle up, when we sweeten our coffee
with saccharin, when we search the Internet using
Google™, or when we take advantage of the innumerable medical and agricultural advances of the
last quarter-century. In essence, we are reaping the
benefits of technology transfer. Universities do
not only educate the next generation and create
new knowledge, but also create knowledge that
enhances the quality of life, increases economic
productivity, and even saves lives.
Fraser6 points out that university–industry
collaborations and licensing have soared, for example, in the United States, ever since the BayhDole Act of 1980, which forces the moving of
inventions from laboratories to store shelves more
quickly. The law allowed U.S. universities and
public research institutions to patent inventions
that were based on federally funded research, then
to license those inventions to the private sector.
Some people continue to question the fairness of the global IP system, but others are using
new opportunities created by this system to improve lives in the developing world. Technology
transfer is thus changing rapidly. Traditionally,
the mission of technology transfer offices has been
to make university-generated innovation available to the public as rapidly as possible. However,
technology transfer offices now have a broader
purpose: to enhance the reputation of academic
institutions and to help them to achieve their
missions of education and outreach by assisting
in forming relationships with the private sector.
Technology transfer has the potential to benefit
the entire world. As technology transfer develops,
it will undoubtedly evolve again, in response to
new conditions.
University technology transfer professionals are already becoming increasingly aware of
their obligation to ensure that the underserved
communities of the world have access to medicines and agricultural biotechnology that have
been developed from basic research conducted
in their universities. But certain conditions need
to be remediated, for example: many university
administrators, technology transfer officers, and
businesspeople are unaware of the need for new
health technologies in developing countries; few
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Production on license or
by copy

Manufacture of
domestically developed,
high technology
products

Highest capabilities to
produce high technology
drugs and vaccines

Stage 2.
Capacity
Building

Stage 3.
Maturation
IDCs

Stage 4.
The MostDeveloped
Countries,
with a drug
or Vaccine
Industry

Source: Mahoney5

Importation of finished
goods or assembly
of parts into finished
products

Stage 1.
Establishing
the
foundation

Development of
Manufacturing

Highly profitable market
in both the public and
private sectors, generating
profits to support, in part,
advanced research

Rapidly growing domestic
market of interest to
foreign companies

Growing local market
of increasing interest to
foreign companies; import
substitution

Small domestic market

Global companies

Increasing exports
that account for a
growing share of GNP

Growing companies
learning how to
establish export
markets

Very little, except as
toll manufacturer

Development of Distribution Systems
National
International

Vast acceleration
of funding for R&D;
development of major
research centers;
linking with private
sector

Development of
university and
independent research
centers; capacity
building

Very little

Generous support for health research from basic
to applied; large research investment by private
companies, including large pharmaceutical
manufacturers and biotechnology companies

Small-scale, advanced
R&D effort capable of
creating new products
for domestic and export
market

R&D to understand
technology either to
produce on license or
to copy

Very little

Development of R&D Capability
Private Sector
Public Sector

Table 1: The Four Stages in the Development of Biotechnology

Sophisticated system
of IP management
operating according to
the requirements of the
TRIPS Agreement

Advanced IP system
but with certain
limitations such as lack
of enforcement

Interest growing among
foreign inventors; local
inventors starting to file
more patents

Initial development
allowing patents for local
inventors; no interest
from foreign inventors

IP Systems

Sophisticated agency
overseeing regulatory
approvals of drugs and
vaccines; government
oversees clinical trials and
production facilities and
enforces regulations

Advanced capabilities
but not at highest
level because of lack of
enforcement capabilities

Limited services but
without enforcement
capabilities

Very limited

Drug and Vaccine
Regulation
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people know how to incorporate patenting and
licensing practices into global access strategies;
and best practices for global access strategies have
not yet been defined.
Nelsen and Krattiger7 describe several possible strategies for ensuring both that everyone has
access to technologies and that for-profit companies have incentives to develop those technologies. The Association of University Technology
Managers (AUTM) has formed Technology
Managers for Global Health (TMGH), the
purpose of which is to draw attention to global
health issues and compile and promote a collection of best practices, policies, and licensing
terms. The National Institutes of Health (NIH)
issued guidelines on the patenting and licensing
of research tools as a way to increase global access
to health innovations. And this Executive Guide
serves similar and perhaps broader purpose.
Careful patent-filing strategies can help
ensure that developing countries have access to
the technologies they need. One example of this
is when using a prohibition of filing strategy, one
does not file for patent protection in developing countries if there is a very large market for
the product in developed countries. In fact, it
may be a good idea to file a patent in developing countries if those countries create a substantial demand for the drug or vaccine in question.
These patents can provide incentives for private
sector development, and also provide powerful
tools for the consolidation of resources via aggregation of developing-world markets (in addition
to enabling or at least strengthening technology
transfer through the licensing of know-how associated with patents).
Questions to consider include: whether it is
better to prohibit or to require filing patents in
developing countries, whether patents encourage private sector investment by aggregating the
developing world market, what kinds of licenses
should be granted, and what requirements for development milestones, product delivery in developing countries, pricing, or sublicensing options
work best for a particular situation.
There are a number of licensing strategies:
• Licenses can be exclusive, nonexclusive, or
a combination thereof.

• Licenses can specify milestones, such a requirement that the licensee has to contribute a minimum toward the development
of a product earmarked for developing
countries.
• Establish pricing controls in developing
countries.
• Insist upon sublicensing, which ensures
that the licensee finds partners who can
move the product to developing countries.
However, as the chapter points out, there
are no clear answers as to how best to increase
global access to necessary technologies. Each of
the above strategies has been tried, but they are all
relatively new, besides which each situation will
require a tailored solution. There is no one-sizefits-all approach nor are there boilerplate strategies that can be applied in a suite of different
contexts. For this reason, everyone has to build
upon his or her own experiences and find creative
solutions. Universities can take the lead. Indeed,
their public sector missions compel them to do
so. When universities implement consistent and
effective licensing strategies, they not only stimulate investment in R&D but also ensure that the
products of that research are affordable and widely available in developing countries. Where there
is a will, there is a way.
Some individuals and organizations have
denounced, on ethical grounds, any patents for
biotechnological applications, genes, or living organisms, especially patents on pharmaceuticals.
However, there is neither a single articulation of
such concerns nor is there a branch of any government that can address the concerns. For example,
patent offices are ill-equipped to address ethical
questions. In addition, any blanket prohibition
on patenting genes or other biological materials
would generally be inconsistent with TRIPS, which
requires countries to allow IP protection for most
biotechnology products. Still, under TRIPS, there
are exceptions to this general prohibition. TRIPS
also contains a provision that certain unethical inventions or innovations may be denied patents; a
similar provision is found in the European Union’s
ordre public clause. U.S. patent law, however, does
not have this kind of morality provision.
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But are some or all patents for genes and cells
unethical per se? How should tissue samples be
collected? And how exactly are patents used to
restrict access to medical and ag-biotech inventions? These are some of the fundamental ethical
questions addressed by Marchant.8
With respect to obtaining biological samples, the ethical norm is that people who donate
tissue for research purposes relinquish property
rights to the donated cells, genes, and other biological material. Problems can arise, however,
when human, animal, and plant materials and
specimens are collected in developing countries
and subsequently used to create biotechnological
inventions that are patented in developed countries; some people have questioned the ethics of
what they call biopiracy. Marchant explains that
ethically questionable situations can usually be
avoided if the following principles are followed:
• Prior informed consent should be obtained
from the relevant entities before taking any
samples.
• An organization agrees to share with a developing country any economic benefits
that result from patented inventions based
on biological materials collected in that
country, called benefit sharing.
The above methods help to minimize, but
do not eliminate, the ethical quandaries related
to the collection of biological materials. Many
questions remain: Who is authorized to give prior consent? Should more than one authority give
consent (for example, both tribal and government
officials)? How much must be disclosed about the
proposed research to ensure that the authorities
are adequately informed?
Benefit sharing can also be difficult to implement. First, many scientific researchers do not have
funding to properly compensate indigenous peoples
for their assistance. Second, who decides how benefits will be allocated? Third, if benefits are offered
to people who assist researchers, some individuals
may “assist” researchers purely for the money they
will receive, not unlike some blood donors.
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There are few laws that address the ethics
of patenting. In the absence of any clear consensus, ethical decisions concerning biotechnological patents will need to be made on a
case-by-case basis. The ethics of patenting is an
evolving field that currently is more gray than
black-and-white.
This is just one reason why it is hoped that
this Executive Guide and Handbook will encourage all parties to take greater advantage of the unprecedented opportunity to benefit from the strategic management of intellectual property aimed
at promoting the public welfare—especially those
people who have, until now, been unable to benefit from today’s technology—and that this will
contribute to building a healthier and more equitable world. n
All chapters refer to: Intellectual Property Management in
Health and Agricultural Innovation: A Handbook of Best
Practices. 2007. A Krattiger, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez
and SP Kowalski (eds.). MIHR: Oxford, U.K., and PIPRA: Davis,
U.S.A. Available online at www.ipHandbook.org. The online
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Intellectual property (IP) is a tool to foster innovation. Whether viewed as a legal
concept, a social construct, a business asset, or an instrument to achieve humanitarian
objectives, the value of intellectual property cannot be disputed.
IP rights are a compromise and an imperfect solution, representing the search for
balance between making all knowledge available within the public domain and
granting ownership of valuable discoveries to the inventors. Reaching an appropriate
balance requires continuous, sound IP management.
The use of the existing IP system, especially coupled with sound patenting and licensing
strategies, resolves the apparent paradox: the pursuit of the public interest through
private rights.

Key Implications and Best Practices: SETCION 1

FOR GOVERNMENT POLICYMAKERS

The emerging global systems of innovation in health and agriculture open up new
prospects for innovation everywhere. This notion, that the public interest can be served
through private rights, has profound implications for the management of innovation,
technology transfer, market competition, and economic development in every country,
regardless of its economic status.
Innovation is a complex process. It is stimulated by coordinated and structured policies
and programs. The IP management system is an important factor, but it is only one of
six factors that determine a country’s or institution’s ability to innovate.
Intellectual property is integral to all six components of innovation that are, in
addition to IP management: R&D in the public and private sectors; safe and effective
regulatory systems; the ability to produce new products to high standards of quality; a
national distribution system in both the public and private sectors; and international
distribution systems and trade in technologies.
Policies to promote the creation and management of intellectual property by public
sector institutions should give first priority to advancing the missions of those
institutions.
There are few laws that address the ethics of patenting. In the absence of a clear
consensus, ethical decisions concerning biotechnology patents will need to be made
on a case-by-case basis.
Protection and licensing go hand in hand. Public research institutions have much to gain
if they are permitted to protect their inventions. A system that allows technologies to
be patented and that encourages institutions to license them will both help countries
to reach their economic goals and better serve the poor.
Policymakers should encourage and fund national technology transfer managers’
associations to the extent that doing so is feasible. Such associations are working to
determine best practices in technology transfer and licensing.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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FOR SENIOR MANAGEMENT
(University President, R&D Manager, etc.)
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Intellectual property is a tool to foster innovation. Whether viewed as a legal concept, a
social construct, a business asset, or an instrument to achieve humanitarian objectives,
the value of intellectual property cannot be disputed.
IP rights are a compromise and an imperfect solution, representing the search for
balance between making all knowledge available within the public domain and
granting ownership of valuable discoveries to the inventors. Reaching an appropriate
balance requires continuous, sound IP management.
The use of the existing IP system, coupled with sound patenting/licensing strategies,
resolves the apparent paradox: the pursuit of the public interest through private
rights.
The emerging global systems of innovation in health and agriculture open up new
prospects for innovation everywhere. This notion, that public interest can be served
through private rights, has profound implications for the management of innovation,
technology transfer, market competition, and economic development in every country,
regardless of its economic status.
Innovation is a complex process. It is stimulated by coordinated and structured policies
and programs. The IP management system is an important factor, but it is only one of
six factors that determine a country or institution’s ability to innovate.
Public sector institutions that optimize their IP management capacity and those that
have capacity in any of the additional areas, such as regulatory systems, will be better
equipped to actively participate in innovation.
Often the most innovative organizations are those with the most dynamic networks,
and those that reach out to other entities and potential partners.
The case studies in the insert of the Executive Guide demonstrate how public sector
technology transfer can make a difference in the developing world and elsewhere.
Technology transfer officers should have ample opportunities for professional
development and networking. Technology transfer is a field in which much information
is shared informally.
Technology transfer and licensing are heavily context-specific. A one-size-fits-all
patenting and licensing policy and strategy is rarely effective for an institution.
Public sector institutions ought to have ethical guidelines for IP management that are
consistent with national laws and an institution’s mission.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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Intellectual property is a tool to foster innovation. Whether viewed as a legal concept, a
social construct, a business asset, or an instrument to achieve humanitarian objectives,
the value of intellectual property cannot be disputed.
IP rights are a compromise and an imperfect solution, representing the search for
balance between making all knowledge available within the public domain and
granting ownership of valuable discoveries to the inventors. Reaching an appropriate
balance requires continuous, sound IP management.
The use of the existing IP system, coupled with sound patenting and licensing
strategies, resolves the apparent paradox: the pursuit of the public interest through
private rights.

Key Implications and Best Practices: SETCION 1

FOR SCIENTISTS

The emerging global systems of innovation in health and agriculture open up new
prospects for innovation everywhere. This notion, that public interest can be served
through private rights, has profound implications for the management of innovation,
technology transfer, market competition, and economic development in every country,
regardless of its economic status.
Innovation is a complex process. It is stimulated by coordinated and structured policies
and programs. The IP management system is an important factor, but it is only one of
six factors that determine a country’s or institution’s ability to innovate.
Your work is part of a larger innovation process that spans R&D across the public and
private sectors, using regulatory systems, enabling the ability to produce new products
to high standards of quality, allowing for the national distribution of new products
through the public and private sectors, accessing foreign technologies, and managing
intellectual property in a way that fosters partnerships.
Research is the very foundation of innovation. Research leads to discovery; discovery
fosters invention; inventions nourish innovation.
Your sustained interest in your invention is important if it is to reach the marketplace,
especially if it is to benefit those who most need it.
It will be wise to consider the ethical implications of your research.
You should always obtain prior informed consent when you access other people’s
materials or samples irrespective where they originate.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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FOR TECHNOLOGY TRANSFER OFFICERS
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Intellectual property is a tool to foster innovation. Whether viewed as a legal concept, a
social construct, a business asset, or an instrument to achieve humanitarian objectives,
the value of intellectual property cannot be disputed.
IP rights are a compromise and an imperfect solution, representing the search for
balance between making all knowledge available within the public domain and
granting ownership of valuable discoveries to the inventors. Reaching an appropriate
balance requires continuous, sound IP management.
The emerging global systems of innovation in health and agriculture open up new
prospects for innovation everywhere. This notion has profound implications for the
management of innovation, technology transfer, market competition, and economic
development in every country, regardless of its economic status.
Innovation is a complex process and coordinated and structured policies and programs
stimulate it. The IP management system is an important factor, but it is only one of six
factors that determine a country’s or institution’s ability to innovate.
Intellectual property is integral to all six components of innovation which are, in
addition to IP management: R&D in the public and private sectors; safe and effective
regulatory systems; the ability to produce new products to high standards of quality; a
national distribution system in both the public and private sectors; and international
distribution systems and trade in technologies.
An IP manager should consider the entire innovation process when making patenting
and licensing decisions.
The traditional mission of technology transfer offices (to bring university-generated
intellectual property to the public as rapidly as possible) is broadening. Technology
transfer enhances the reputation of academic institutions and helps them achieve
their missions, both at home and abroad.
IP managers should join professional national and international licensing and
technology transfer societies whenever possible.
Creative licensing strategies will help your institution gain the greatest benefits from
the research it conducts. Such strategies include, at a minimum, the balancing of
exclusive and nonexclusive rights, defining field of use, setting appropriate milestones,
requiring the delivery of products to developing country markets, and exercising control
over pricing.
In benefit sharing, an organization agrees to share with a developing country any
economic benefits that result from patented inventions based on biological materials
collected in that country. Make sure the individuals in your organization who collect
biological resources are aware of this and obtain prior informed consent.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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(VOLUME 1: PAGES 41-144)

Specific Strategies and Mechanisms
for Facilitating Access to Innovation
Innovation is a wonderful thing. Innovation occurs when any new knowledge is introduced into
and utilized in an economic and/or social setting.
People and institutions (agents) orchestrate this
process. Simple economic theory states that such
agents act in a rational way, responding to price
signals as a way of maximizing investments. But
modern innovation research indicates that this
is not so, particularly when noncommercial or
humanitarian goals are being pursued. Agents,
both public (governments, universities, extension
services) and private (small, medium, and large
companies, as well as farmers, individual consumers, and communities) are essentially strategists who respond to other agents’ behaviors. For
example, a governmental “behavior” in this context would be changing a range of policies, such
as research, regulatory, trade, and IP (intellectual
property) policies. Each of these agents directly or
indirectly engages in the production, processing,
marketing, or distribution of products and services. Simultaneously, agents engage in the processes
of knowledge creation or dissemination and the
application of knowledge through both market
and nonmarket relationships.
Using this definition of innovation, public
research institutions and universities may be invention creators. They are not necessarily innovators per se but are important actors in the innovation process. Their roles are strengthened if they
are well connected. That is, they are stronger if

they function in partnerships that extend beyond
their primary missions and include others who
can turn inventions and knowledge into products
and services that become economically successful
or that have major social and humanitarian impacts. This impact can be measured through three
key conditions that jointly determine whether an
innovation is adopted. These are:
• availability
• affordability
• acceptability1
In addressing the needs of developing countries, achieving these three conditions concurrently can conveniently constitute global access.
But translating the three into an effective innovation management plan or operational strategy
is more challenging. To manage these goals, a
strategy that consists of six thrusts should be
considered:2
1. Development of R&D capability by the
public and private sectors
2. Development of a safe and effective regulatory system that covers drugs, vaccines, and
agricultural inputs and outputs
3. Development of manufacturing capability
for health products, seed production systems, and value-added processing
4. Development of an IP system (legal framework, judiciary to enforce it, and institutional management capabilities)

Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 2007.
2: Specific Strategies and Mechanisms for Facilitating Access to Innovation. In Executive Guide to Intellectual Property
Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.).
MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopmentsInternational Institute (Ithaca, USA). Available online at www.ipHandbook.org.
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for
noncommercial purposes is permitted and encouraged.
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5. Development and expansion of national
health or agricultural delivery systems, including an attractive, private-sector domestic market for health or agricultural products and services
6. Development of international trade systems for health products (including global
procurement funds) and agricultural inputs
and outputs
Although IP management is but one of six
components, it can be viewed as the thread that
runs through the innovation process or as the glue
that holds partnerships together. Partnerships are
based on the mutual interests of two or more parties and agreed upon in contracts. The terms and
provisions of a contract can be almost limitless
(provided they are both legal and agreed to by
the parties) and are discussed elsewhere in great
detail.3 The present section focuses on the components that are most specific to global access.
And one of the first and foremost sets of licensing terms, at least for universities and other public sector research institutions in the licensing of
invention, is the reservation of certain rights.
Indeed, Bennett4 urges universities and public
sector institutions to ensure that they preserve the
right to use licensed technologies for educational,
research, and humanitarian goals—including distribution rights in developing countries.
In essence, the terms of a license can subdivide the rights with respect to a technology. Rights
can be segmented and apportioned across:
• technological fields, markets, or economic
contexts in which the technology is used
(such as farm size, farm income, or income
derived from a particular crop, in the case
of agriculture; or certain drugs to combat
neglected diseases in the case of health)
• income levels (for example, per capita gross
domestic product)
• geographic regions (by country, or by lowland or highland agricultural systems) or by
customer (public procurement or private
hospitals and pharmacies)5
This practice can be used by any technology owner to maximize the application of its
36 | HANDBOOK OF BEST PRACTICES: EXECUTIVE GUIDE

inventions. Most importantly, subdividing and
field-of-use licensing can allow both commercial
and noncommercial uses of the technology to
proceed in parallel and, thus, constitutes a central
element in a global access strategy. Bennett provides suggestions for creating explicit reservation
of rights in a commercial technology license. This
will ensure that institutional objectives to support
humanitarian applications of technologies that
have applications to the needs of the poor are not
inadvertently compromised.
The global importance of humanitarian licensing is also discussed in detail by Brewster,
Hansen, and Chapman6 with pragmatic answers
about the why, who, and how of the process. The
authors encourage IP managers, in both private
and public sectors, to adopt such strategies, noting
in particular that they are not incompatible with
commercially driven businesses. The why for humanitarian-use licensing is obvious, with the vast
unmet health and agricultural needs of developing
countries. The who is increasing as more and more
organizations have been using IP management
practices to promote the health and food security
of poor people (and the chapter offers many recent
examples). The how is discussed through a number of case studies7 on humanitarian licensing. The
authors conclude, with others, that much can be
achieved using best practices, many of which are
enumerated at the end of the chapter.
Eiss, Hanna, and Mahoney8 look at the same
topic but on the basis of how various productdevelopment partnerships (PDPs) seized upon
public and private sector strengths and how they
are leveraging existing infrastructure and research in developed and developing countries.
Although each of the PDPs reviewed are very
different, they nonetheless share some common
strategies for maximizing IP management for
global health. These include:
• defining a discrete territorial market
• establishing different structural incentives
in public sector and private sector markets
• extending field of use to make the product applicable to diseases in developed
countries
• using royalties to benefit the party that
needs the most incentive
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• providing access to the developed technology, should the private sector not follow
through on the project
The authors conclude that whereas these issues can be complex, they should be addressed as
early as possible in the formation of partnerships.
But most importantly, the chapter concludes
with the observation—grounded in much experience—that an approach that takes into account
the six components of innovation discussed at the
beginning of this chapter will have a much better
chance of success than those efforts that take a
piecemeal approach to product development and
distribution. Such a comprehensive effort should
not be considered daunting, but rather an opportunity for creativity.
It is widely acknowledged that IP rights are
important drivers of innovation, and this applies
equally to the private sector and the public sector. This is especially the case for product patents.
However, for research tools9 in both medical and
agricultural innovation, Clift10 demonstrates that
patents related to research tools can have negative implications and, hence, should be balanced
carefully with disclosure to place inventions in
the public domain. Developing countries need to
think about how to implement patent legislation
(that is consistent with the Agreement on TradeRelated Aspects of Intellectual Property Rights,
best known by its acronym TRIPS) while meeting their own objectives, particularly those related to genetic discoveries. For example, legislation
should be formulated to set forth appropriate research exemptions, and patenting and licensing
policies should be aimed at maximizing the availability of innovations in order to aid the development of urgently needed products.
For product patents, the decision to patent or not to patent is much simpler. For many
products, even those aimed at developing countries’ needs, patenting provides a mechanism
to extend licenses, with specific provisions for
licensees to meet these needs according to wellunderstood and well-defined market conditions.
But this only works if best licensing practices are
adopted (such as those defined and spelled out
throughout the Handbook). A compelling reason

for best practices in IP management is well illustrated by Stevens11 who discusses how student
activists ensured that Yale University and BristolMeyers Squibb quickly adopted humanitarian
licensing (also called fair-access licensing).12 The
objectives for such humanitarian licensing provisions should be to maximize the possibility that
the patented invention will be produced and to
structure arrangements for tiered pricing, which
will allow the poorest countries access to the drug
at the lowest cost.
Best practices adopted by PDPs have also had
the following important effects:
• Large companies have been motivated to
contribute their drug-discovery skills and
resources because they are assured that others are responsible for funding late-stage
clinical development.
• Small companies have secured funding to
develop technologies with dual-market
uses, with the PDPs securing license rights
for developing countries at zero or low royalty rates and the small company retaining
rights for use in developed countries.
• Academic institutions have had a new
channel to advance their neglected-disease
discoveries.
• Developing country pharmaceutical companies have found their production and
distribution skills in demand.
For products needed in developing countries,
it could be argued that the question of patenting should not even arise. Some argue that not
to patent would be the best strategy. Others believe that open source licensing may be an effective option for managing intellectual property.
Indeed, the chapter by Hope13 discusses the possibilities of open source licensing. Open source
does not mean to place something squarely into
the public domain nor does the decision to pursue open source licensing follow only from altruism: it can be based on commercial self-interest.
Open source licensing has been most successful
in the computer software field (Linux being the
most prominent example), where anyone, anywhere, and for any purpose is essentially allowed
to copy, modify, and distribute the company’s
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software (either for free or for a nominal fee)
and, therefore, anyone is allowed full access to
the software’s source code. The only condition is
that everyone has to share its improvements with
everyone else.
Open source is thus a form of IP licensing,
and so it differs significantly from placing technology in the public domain via publication.14
An open source strategy may indeed be a viable
approach to encourage the widespread adoption
and development of an innovation. Some innovations (such as software) are automatically protected by copyright, so a license clarifies the terms
of its use. An open source license gives the innovator the right to set terms of use and exclude
users who will not abide by those terms. But most
of the incentives for open source licensing are indirect: cost savings, productivity gains, the capital
provided by a good reputation, and, most importantly, an expanded user base, which correspondingly expands complementary goods and services.
As the market expands, revenues from sales, onetime licenses, dual licensing, and complementary
products and services may be enough to offset the
opportunity cost of open source licensing. IBM
has successfully used this approach. Importantly,
open source licensing can place an institution in
a network of innovation with enormous collaborative potential. Finally, open source licensing
can encourage the development of alternatives to
proprietary technologies. The greater the number
of nonproprietary tools in a given tool kit, the
greater the incentive for everyone in the field to
invest in developing substitutes for the remaining
proprietary technologies, since it will allow freedom to operate for the whole tool kit.
All of the foregoing relates to software licensing. Despite several attempts to adapt open
source approaches to the biological sciences in
both health and agriculture, none has been successful. Given the possible benefits associated
with open source licensing, pursuing it further
is warranted but will require additional work.
Hope discusses the various unresolved challenges
in the biotechnological field. She distinguishes
between “copyleft” and “academic” forms of
open source licensing. Using a proposed five-step
decision-making process, Hope shows how open
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source technologies, for example, can be tailored
to serve small agricultural and pharmaceutical
markets in developing countries. And given the
growing reliance on computer technologies in the
life sciences—bioinformatics software programs,
for example—the possibilities for open source licensing in this field have great potential.
Returning to the PDPs and their goal of moving candidate products through various stages up
to clinical development and eventual distribution, many PDPs face a series of highly practical
challenges. The central challenges are ensuring
high-quality and low-cost production, sustained
supply, affordable pricing, and effective delivery of their products. Indeed, the World Health
Organization’s Commission on Intellectual
Property and Innovation in Health has found
that many PDP research-and-development contracts defer issues related to manufacturing and
distribution.15 As a result, PDPs now increasingly
face both negotiating and operational challenges regarding manufacturing sites, pricing to the
public sector, market segmentation, market sizing, ensuring the lowest sustainable cost of production while guaranteeing sustainable supplies,
quality control, and post-launch issues, such as
pharmacovigilance and product liability.
Elaborating the requirements and approaches for global access early on is critical; otherwise,
plans are developed incrementally or even after
the product is developed. This leads to delays
and creates large inefficiencies for the crucial last
steps of distribution in developing countries. In
addition, negotiating power may be diminished
after development. In such cases, product uptake can be sluggish or stalled due to a variety
of downstream considerations. A useful way to
approach these situations is to apply milestones
in the initial licensing agreements to ensure that
key goals are met along the product development
pathway. The kinds of milestones will vary based
on product profiles and target markets, but in all
cases, as Oehler16 states, milestones require the
following:
• intensive preparations
• detailed knowledge of the processes related
to developing and marketing the product
• realistic forecasting of product potential
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• persistence in quantitative forecasting and
establishing a master plan for the entire
product rollout
• a mission-driven mindset to establish optimum goals for the public sector
When public-private partnerships manage
intellectual property, they are trying to balance
the private sector’s commercial interests with the
public sector’s goal of obtaining access to pharmaceutical products at the lowest possible cost.
Although the goals and paradigms of the public
and private sectors may appear too far apart, this
chapter provides the tools and materials required
to build the contractual architecture to span that
divide. According to Oehler, a large part of the
problem is simply a failure to communicate between the public and private sectors. Discussions
between the public sector and industry are crosscultural, no matter how well public sector players
think they understand industry. In such a crosscultural environment, there is nothing more dangerous and conducive to misunderstandings than
to assume the obvious, since what is obvious for
one person with a public sector background will
not necessarily be the same for the other partner.
Obligations and contractual performance cannot
be left to vague best efforts and common sense.
The experiences of the Concept Foundation,
which are the platform for the chapter by Oehler,
demonstrate the successful use of milestones as
a tool. The Foundation’s business model initially considers downstream issues such as product
delivery, and it utilises contractual milestones to
achieve its principal goal of providing developing
countries access to new medicines.
Milestones and open source are but one way
for institutions to have easier access to inventions
from third parties; there are many other mechanisms to assemble intellectual property. Krattiger
and Kowalski17 provide a brief overview of different IP assembly options (royalty collection
agencies, information clearinghouses, technology
clearinghouses, open source innovation clearinghouses, brokers and other kinds of facilitators,
IP management services, IP commercialization
agents, integrated commercial services, company-to-company arrangements, and other public

technology transfer and financing mechanisms).
The authors focus on the pros and cons of patent
pools, which are receiving more and more attention as possible tools for improving technology
transfer to developing countries.
There are many forms of patent pools: essentially they all allow for the interchange (cross-licensing) of rights to essential patents by a number of entities. They also include an agreed-upon
framework for out-licensing the pooled intellectual property to third parties. A patent pool
offers several benefits, a major one being that it
cuts through patent thickets. But patent pools are
also risky: the agreement to share technologies
may run into problems based on antitrust legislation. Other considerations vis-à-vis patent pools
include:
• They allow for the transfer of intellectual
property. Know-how and trade secrets
may also be required to use the intellectual
property.
• They have generally flourished when all
companies in a sector are stymied by restrictions on access to intellectual property.
This makes them willing to compromise.
It is unclear whether or not pharmaceutical companies feel similar inclinations. In
agriculture, the interests of companies are
not aligned to make patent pools feasible at
the moment but this could be different for
public sector organizations.
• They have been most successful in the electronics industry, since they facilitate industry-wide standards that create larger markets. Again, this may not apply to drug or
agricultural biotechnology companies.
• They are typically expensive to create and
maintain.
Despite these reservations, the benefits of
patent pools are strong. They create an efficient
“one-stop shop” for intellectual property, eliminate stacking licenses, avert litigation, decrease
research and administrative costs, and can greatly
improve the speed and efficiency of technological development. It is worth remembering, however, that patent pools are not the only ways to
achieve these benefits. To help policymakers
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determine the appropriateness of patent pools for
their unique situations, Krattiger and Kowalski
provide a ten-step checklist for deciding whether or not to set up a patent pool and a ten-step
procedure for setting one up. The authors point
out legal pitfalls associated with patent pools and
general suggestions are offered for identifying and
avoiding them.
In sum, the reservation of rights, open source
licensing, milestones, and different forms of IP
assembly are all part of the toolbox of best practices that facilitate access to innovation. But to determine which specific rights should be retained,
which elements should be licensed on an opensource basis, which milestones lead to the best results, and which assembly option works best, will
always be difficult to determine because the answers depend heavily on the context. The context
will include the actors involved in the innovative
process, their relationships, and their connectivity
within a global innovation network. Irrespective
of which options are selected for greater global
access, all strategies will require highly intensive
preparations, detailed knowledge of processes related to the development and marketing of the
product, detailed knowledge of markets, realistic
anticipation and forecasting of product potential,
and persistence in quantitative forecasting, as well
as a master plan for the entire product rollout.
The tools described in this section can be powerful for achieving public sector goals, and they are
certainly worth the effort. n
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One of the benefits of enabling public research institutions to own IP rights is that
institutions can control how technology is deployed through the terms of licensing
contracts, thus meeting both commercial and noncommercial goals.
Well-crafted contracts, based on best practices, can be instrumental in achieving
global access, provided the entire innovation process is given due consideration from
the outset. This includes consideration of R&D capabilities, regulatory environment,
manufacturing capabilities, IP management, access to markets, and trade-related
concerns. Such an approach requires a lot of preparation and detailed knowledge of
the processes related to developing and marketing the invention; realistic forecasting
of product potential; persistence in quantitative forecasting and establishing a master
plan for the entire product rollout; and a mission-driven mindset to establish optimum
goals for the public sector.

Key Implications and Best Practices: SETCION 2

FOR GOVERNMENT POLICYMAKERS

One of many components of best practices by the public sector is incorporating
humanitarian-use reservation provisions in commercial licensing contracts. This is
becoming increasingly common with certain universities around the world, particularly
with respect to agricultural inventions. There is conceptually no reason why this should
not become common practice globally.
Public sector institutions should have explicit IP policies and demonstrated institutional
capacity to implement best practices in IP management. Any licensor, public or private,
is more willing to give licenses to institutions that proactively protect third-partyproperty, which leads to confidence building and a higher degree of motivation to
proceed with more licensing and technology transfer arrangements.
Open source may offer an alternative mechanism for facilitating access to innovations
in health and agriculture, provided the open-source approaches that are so popular and
effective in the software area can be successfully adapted to the biological sciences.
More conceptual research is needed to make open source an effective way to accelerate
innovation in health and agriculture.
Other policies and laws can foster and enable efficient IP assembly (or in-licensing
by national institutions to obtain freedom to operate and the freedom to license
bundles of technologies to manufacturers). These may include patent pools and other
mechanisms.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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FOR SENIOR MANAGEMENT
(University President, R&D Manager, etc.)
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One of the benefits of enabling public research institutions to own IP rights is that
institutions can control how technology is deployed through the terms of licensing
contracts, thus meeting both commercial and noncommercial goals.
Well-crafted contracts based on best practices can be instrumental in achieving global
access, provided the entire innovation process is given due consideration from the outset.
This includes consideration of R&D capabilities, regulatory environment, manufacturing,
IP management, access to markets, and trade-related concerns. Such an approach requires
a lot of preparation and detailed knowledge of the processes related to developing a
mission-driven mindset to establish optimum goals for the public sector.
One of the central elements for public sector institutions is to have explicit IP policies and
demonstrated institutional capacity to implement best practices in IP management. Any
licensor, public or private, is more willing to license to institutions that proactively protect
third-party property, which leads to confidence building and a higher degree of motivation
to proceed with more licensing and technology transfer arrangements.
Humanitarian licensing can benefit both the research and public service missions of a
university or public sector research institution. Consider creating an institutional policy
that standardizes the reservation of humanitarian rights on all technologies, including, as
appropriate, the right to practice the invention for nonprofit goals. Potential licensees are
less likely to resist if they know that the terms being requested are “standard” and part of
the deal in doing business with an institution.
Implementing the various best practices discussed and presented in this section is complex
and requires experience. Public sector institutions need to plan and implement focused
capacity building in IP management.
Networks with individuals and organizations, such as foreign universities, corporations,
product development partnerships (PDPs), and government agencies, should be seen as
critical elements that enhance the innovative potential of any institution.
Indeed, partnerships are an important way to fill in the capacities that are required to
make an institution innovative. Few, if any, institutions have the entire range of capacities
to bring ideas to market.
Under many circumstances, patenting may be unnecessary and publication might offer
the widest dissemination. The decision to place inventions in the public domain should
be calculated and made on a case-by-case basis. Open source licensing might be another
complementary component of an IP management strategy.
Whenever possible, consider nonexclusive licensing as a strategy to maximize the utilization
of research tools. On product patents, exclusive licensing may, in many circumstances, be more
effective to reach broad dissemination, particularly if coupled with strong milestone clauses.
Complementary strategies are the segmenting or apportioning of markets, whereby
different licensees obtain exclusivity but only for one portion of the field of use. This
strategy can also be used to implement tiered pricing.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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As the inventor, in most circumstances, you can significantly influence how your
technology is used. For example, you can very reasonably request that your technology
transfer office draft license terms that reserve for you the rights to continue research
using your inventions or terms that reserve the rights for humanitarian uses of your
technology.
Notwithstanding the above, you must follow the IP policies of your institution. And there
is no reason a priori that your interests in licensing practices should not be reflected
in your institutional IP policies. Changing them, if necessary, requires a dialogue with
senior management and technology transfer personnel and a good understanding
of the purpose of intellectual property and how sound IP management can be put to
work for the benefit of the public sector.

Key Implications and Best Practices: SETCION 2
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Your interest and activities in licensing and partnership building can raise the profile of
your research program and also of your institution. It may create goodwill, catalyzing
additional scientific and development interest by partner organizations and individuals.
And it can lead to earlier and more efficient translation of your research findings into
useful products or services.
In particular, collaboration with private sector entities can be a most valuable
contribution to your institution’s broader participation in innovative initiatives,
particularly as it pertains to product development.
The R&D work that you carry out in your program can often (perhaps serendipitously)
lead to the invention of new research tools. But the patenting strategies for research
tools may need to be different from those related to products if maximum dissemination
and use are sought.
One such avenue for research tools in particular may be open source licensing. This is
a complex and evolving area in the biological sciences and requires further refinement
to be effective and useful.
Importantly, open source licensing is not the same as placing an invention into the
public domain. Open source entails contractual obligations. An open source license may
be extremely complex and may require your institution to agree to certain obligations.
Several universities are unable to sign such open source licenses because they cannot,
in good faith, agree to the conditions. Make sure you always consult your technology
transfer officers before signing any agreement.
Increasingly contracts will include milestones, which may affect your work, although
quite often not directly. Research schedules and goals may be directly linked to specific
milestones, and you need to know how such milestones might influence your program.
Accessing other people’s intellectual property can be facilitated through networks of
committed professionals; your contributions in this area can be substantial, and strong
professional networks will make you a more valued and essential member of the team.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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Licensing and valuation practices between a public sector institution and productdevelopment partnerships show that one valuation formula is to ask for the licensees in
developing countries to take over responsibility for future patent costs but to ask for no
up-front fees, no milestone payments, and no running royalties. Any financial return to the
university should be derived from opportunities in developed countries.
Both nonexclusive and exclusive licenses can be applicable to meeting socio-economic
goals. Within exclusive licensing, there are many feasible options, such as exclusivity
limited to a certain field of use, or geography, or for limited periods of time.
Certain equitable access provisions in licenses can be instrumental in enabling competition
in low- and middle-income countries.
The practice of reserving rights for humanitarian use may require additional work and will
likely not generate licensing revenue; conversely, such provisions, if used in a strategic way,
are unlikely to lead to loss of revenues.
Potential licensors of intellectual property connected to critical agricultural and health
care technologies will be motivated by your institution’s demonstrated IP capacity, and
will be more likely to enter into more licensing agreements.
If you are a licensor, put yourself in the position of the other party. If the roles of licensor/
licensee were reversed, would your position seem unreasonable? Inflexibility may be
detrimental when the licensee has technologies you may wish to utilize.
IP managers should be cautious of simply imitating the open licensing procedures of the
software industry. Such licenses are not generic enough to cross fields of endeavor, and it
is still unclear whether and to what extent biotechnology innovations in general will lend
themselves to open source licensing.
The public sector must specify in writing exactly what it wants to accomplish with
a commercial partner, detailing when and how this will be achieved by specifying
milestones—and related penalties should these milestones not be fulfilled.
Avoid “best effort” clauses in agreements. Instead, make the extra effort to draft
comprehensive contracts with articulated milestones. This up-front investment in time and
effort will pay off if a problem arises. During the drafting and negotiation of agreements
containing milestones, do not hesitate to involve people from other departments
(including business schools), outside consultants, and experts in the relevant industries
and markets.
Developing meaningful milestones that provide the appropriate balance of incentives,
rewards, and penalties requires detailed preparations, a sound understanding of the
processes related to developing and marketing the product, realistic forecasting of product
potential, persistence in quantitative forecasting and in putting together a master plan for
the entire product rollout, and above all, a mission-driven mindset.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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The Policy and Legal Environment for Innovation
Changes in both national and international legal
frameworks have profoundly affected how companies manage their intellectual assets in furtherance of economic and strategic business objectives and how they pursue their R&D. Moreover,
the changes have enabled a broader distribution
of health-related technology to people in developing countries. Public sector institutions likewise have had to adapt to an increasingly globalized knowledge-based economy. One adaptation
is the ever-increasing interaction between developed countries and developing economies, particularly more innovative developing countries
(for example, Brazil, China, India, Korea, South
Africa). A second adaptation is the increased
complexity of interactions between public and
private sector actors. A third involves an evolution in the judiciary: toward a clearer judicial
structure with more reliable and predictable
mechanisms of dispute resolution. Many innovative developing countries are undergoing farreaching changes within the judiciary, and experience from the creation of the Court of Appeals
for the Federal Circuit (CAFC) in the United
States offers many useful insights.
In order to help revitalize flagging technological innovation in the faltering economy of the late
1970s in the United States, a fundamental change
in the judicial structure took place in 1982. As a
judge at the CAFC, Newman1 describes the creation of the CAFC (the national appellate court

that would hear all patent appeals) as the first
profound change in over 100 years concerning
IP-related dispute resolution. A single appellate
court would better understand and correct policy
misperceptions, largely created by judicial decisions that had negatively influenced investment
incentives in relation to patenting. A uniform
and predictable application of the law across the
United States and a concomitant end to forum
shopping would promote innovation. And indeed
it has. The effects have been dramatic: industrial
activity, based on strengthened patent incentives,
has surpassed the most optimistic expectations.
In addition to the establishment of the
CAFC, two other critical events at the beginning
of the 1980s catalyzed the growth of the biotechnology industry. In 1980, the Supreme Court’s
landmark decision in Diamond v. Chakrabarty,
despite dire predictions to the contrary concerning the patenting of life forms, opened the nation’s economy to biotechnology as an industry,
enabling investment and commercialization in
this nascent field. Also in 1980, the Bayh-Dole
Act catalyzed the revitalization of commercial
products arising from government investments
in academic research. The combination of the
CAFC, the Chakrabarty decision, and the BayhDole Act synergistically drove the biotechnology
revolution in the United States.
Because of rapid scientific developments,
new issues of law constantly arise. Advances in
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health and agriculture raise legal questions for
which there are no direct precedents and about
which there is no consensus. Therefore, the courts
take an incremental approach to such questions,
building on indirect precedents that attempt to
balance the competing visions of patent theory
and that respond to the quick pace of scientific
discovery. In other words, the present builds on
the past to create a coherent and stable body of
law.
When technology and biology are involved,
the overview of jurisprudence (as well as decisions in individual cases) will affect the nation’s
economy and the public interest, and, additionally, have an even broader global impact. This
Handbook arises from the premise that the development of the products of science and technology profoundly benefits the public and that
both scientific and industrial participation are
required in order for their benefits to be realized.
This is a many-faceted concept; yet we exist in a
time of such pervasive scientific and technological advance that the development of these benefits and their movement into commerce among
nations warrant our most concerted efforts.
But are public research institutions really
delivering public goods? This question might
appear foolish. In the past 50 years, the intensity of research and the pace of discovery in the
biomedical and health fields have accelerated dramatically, not only in the United States, but in
many parts of the world, particularly in the more
innovative developing countries. As a result, the
number of safe and effective drugs, vaccines, and
medical devices for a broad range of illnesses and
conditions has skyrocketed, as have sales in developed countries. But in an increasingly global
world—in which the risk of disease and the benefits of research can come from any corner—the
benefits from public sector health investment
should be global. Keusch and Nugent,2 therefore, argue, on the basis of their experiences in
the United States, that the public-benefit aspect
of government-sponsored research investments
should include (the poor) in countries outside
the United States.
Because of the “public goods” aspect of
health, governments should fund health research,
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and indeed they do. For similar reasons, they also
fund agricultural research and extension services.
Such publicly supported research fills knowledge
gaps that private industry ignores, even though
public sector inventions are usually brought to
market by private sector product development.
The choice of whether to develop new ideas into
products is largely left up to the private sector.
Thus, technology development from public research proceeds largely according to private sector
priorities. So what role do public agencies have
in ensuring that the public benefits from its investments in health research? The answer is not
obvious. Under current arrangements, the public
sector has limited capacity and experience in the
downstream steps of developing and delivering
biomedical products to patients. These steps typically require a significant investment of money.
They are also not aligned with the public sector’s
comparative advantages.
The public sector, therefore, needs to be creative, and Keusch and Nugent outline several
ways that decision makers can strengthen and
reorient the public sector’s intellectual property
(IP) strategies to expand the ability of developing countries to access the benefits derived from
public research investments. They discuss several
strategies that public institutions can adopt to increase the resources and tools devoted to the public health needs of the developing world:
• At the upstream end, the public sector can
direct funds toward research on diseases in
developing countries and can partner with
private and nonprofit entities wishing to do
the same.
• At the downstream end, public sector institutions can directly provide products to users in poor countries, reduce barriers to the
transfer of technology that benefit developing countries, or partner with industry and
academia to expedite the development of
products from research.
As much as the Bayh-Dole Act successfully
created a large body of intellectual property from
publicly funded research, it has reduced, in some
regards, the availability of public goods for health
and agriculture. Current practice undervalues the
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public-benefit aspect of the mandate, especially
for the poor. As developing countries increasingly consider implementing Bayh-Dole-related legislation, these countries should carefully
study the conclusions from this chapter so they
may improve upon the experiences in the United
States. It should be pointed out that the intent
of Bayh-Dole was not to produce supplemental
revenue streams to universities. Rather, it was to
encourage private innovation and increase the use
of technology for economic development.
Graff 3 surveys the opportunities available
in 18 developing countries4 for new technologies to flow to the private sector and the public
policy issues needing to be addressed to facilitate this. Three key aspects of public policy are
considered:
1. The availability of IP protection
2. The designation of IP ownership
3. The existence of the infrastructure needed
to make IP protection and ownership a
reality
The chapter reveals that strong IP protection
capabilities are correlated with robust scientific
research efforts, to the strength of the countries’
IP laws through history, and support of, through
membership in, international trade agreements,
particularly the Agreement on Trade-Related
Aspects of Intellectual Property (TRIPS) and
the International Union for the Protection of
New Varieties of Plants (UPOV). Regarding IP
ownership issues, policies in most countries are
moving toward granting the rights and responsibilities of ownership to research institutions.
Finally, sophisticated institutional IP management is correlated to research capacity and to
government investment in public sector and
university research and development. Generally
speaking, vigorous IP protection policies and the
capacity to enforce and manage them are mutually strengthening. The biggest factor for this
strengthening is the amount of research and development a country conducts, followed by the
ability of its economy to absorb new innovations
into existing or new industries. Those seeking to
use intellectual property as part of an integrated
strategy to grow the economy through public

financing and commercialization of innovation
will find these trends worth considering.
In the chapter by Finston,5 the discussion
moves away from broad national policies to specific technology transfer policies. Finston reveals,
using many colorful examples, how such policies
can have a broad-ranging, positive impact for a
country, raising the standard of living, improving the economy, and opening many commercial
opportunities. Primarily addressing government
policymakers, this chapter defines the policy conditions needed for a robust national technology
transfer system:
1. Government support of science education,
research, and related infrastructure that together will create an enabling environment
2. Rule-of-law protections (predictable laws,
fair enforcement, judicial remedies), including those relating to intellectual property
3. A reliance on market forces, which foster
informed risk-taking and private sector investment, to determine which technologies
and products should be developed
Finston argues that these three factors are
mutually interdependent and should all be present to create a favorable environment for technology transfer. To support her claims, the experiences of five geographically and developmentally
diverse countries with existing technology transfer
policies are described: Brazil, Israel, Jordan, India,
and Ireland. As a result of technology transfer reforms, these countries enjoyed growth in R&D,
technology transfer, and economic activity. If one
or more of the above three requirements were
missing, a country would not have advanced as
far technologically or economically.
The key lesson offered by her chapter is that
the strength of government and of the private sector can be synergistically applied to improve the
lives of all. Technology transfer works best when
there is strong, consistent government support of
basic research, including science education and
technology-related infrastructure and robust IP
protection.
Given the success of technology transfer in
the United States, many countries’ expectations
of similar programs in their own countries are
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grossly overestimated (if not outright misdirected). Indeed, Heher6 points out that many policymakers in developing countries proclaim that
a technology transfer program should become a
major source of income. Too often, such programs
begin too optimistically, but within a few years,
end up disillusioned.
Unless the central reasons for undertaking
technology transfer (for long-term social and
economic benefits) are understood, a boom-andbust cycle, replete with unrealistic financial expectations, is likely to prevail at considerable cost
to those involved. Indeed, countries have yet to
develop answers to basic questions. For example,
what exactly is the nature of success in technology transfer? And what precisely are the elements
that make this success possible? This chapter uses
international technology transfer benchmark
data to benchmark and understand the implications of promoting technology transfer and the
likely outcomes of a technology transfer initiative
under realistic conditions.
Heher provides comprehensive data and
concludes that income generation from technology transfer is an inadequate—if not inappropriate—reason for an institution to invest in technology transfer. Governments should not expect
revenues from technology transfer to be able to
fund research institutions. Indeed, the financial
benefits of technology transfer activities are captured primarily at the national economic level
through business creation, with national returns
arising from indirect economic effects. The extended time period required for individual institutions to derive benefits together with the fact
that the benefits are largely felt by the national
economy suggest that appropriate national support measures are needed to encourage technology transfer.
Bringing this realistic approach to the institutional level is the topic of the chapter by
Taubman and Ghafele.7 First, the authors strongly endorse the indigenous innovation potential
of developing countries. Second, they detail the
inadequacies of a top-down approach to developing IP management policies and approaches,
as such an approach would almost invariably ignore the unique strengths of a particular country
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or institution. Rather, to seize on such strengths,
a thoughtful dialogue between policy-conscious
practitioners and practically informed policymakers is advocated by the authors. This requires
knowledge one to act flexibly.
Taubman and Ghafele insist that IP management for the public interest should go beyond licensing arrangements and consider the full range
of two continuums: degrees of exclusivity and
degrees of market engagement. To demonstrate,
the efforts of Jordan and Indonesia to manage
intellectual property for the public good are examined. Both countries have passed IP legislation
and have developed their IP policies in relation
to broader public policy goals. The authors conclude that success requires flexible use of market
mechanisms and the strategic deployment of the
full range of exclusive rights afforded by IP protection. This can lead to some creative solutions.
Public sector institutions should learn to use the
rules at least as well as their private sector counterparts to achieve their public policy aims. This
has never been more urgent than with the coming into force of the TRIPS Agreement in most
developing countries.
TRIPS mandates minimum IP protections
for patented pharmaceutical products.8 Within
this requirement, countries have considerable
freedom on many specific aspects of TRIPS, and
it is wise (if not imperative) for developing countries to exercise these flexibilities to the maximum
extent possible. Thus, TRIPS can have profound
effects on innovation, on the scope and magnitude of R&D investments, and on product availability. Product price in low- and middle-income
countries is vigorously debated. Predicting and
measuring the impacts of TRIPS on innovation
is an unwieldy task because of the numerous variables in play and also because TRIPS only came
into force in 2005, in many of the innovative developing countries. This is a short time to measure specific impacts; a simple measure like the
price of a product is but one of the factors that
determine “access” to patented health and agricultural products. Another factor would be the
types of drugs or vaccines that are becoming available. Indeed, based on a conference held in India,
the conclusion was drawn by Eiss, Mahoney,
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and Satyanarayana9 that much of the impact of
TRIPS will depend on how countries and institutions respond to the new IP regime.
There is every indication that IP management
skills appear to be one of the crucial elements
for harnessing the positive potential of TRIPS,
and mitigating the negative ones, and such skills
will allow developing countries to gain access to
emerging tools, technologies, and resources that
can dramatically improve the health and welfare
of their citizens. Effective IP management can allow public research institutions to use their own
research products to benefit the poor and to enter
into public-private partnerships that can direct
the power of industry to the needs of the poor.
Without knowledge of sophisticated IP management techniques, however, such efforts—and
their benefits—will be impossible.
The World Trade Organization (WTO)
offers many initiatives and instruments that
seek to enhance IP capacities in the developing
world. Specific initiatives and instruments are
also aimed at mitigating the possible negative effects of TRIPS. These are discussed by Watal and
Kampf10 and include compulsory licensing, the
Doha Declaration, elements of the Convention
on Biological Diversity, traditional knowledge
projects, technology transfer programs, and IP capacity building programs.
Of particular relevance here is the Doha
Declaration, which sought to address the potential constriction brought about by TRIPS regarding access to patented medicines in developing
countries. The Doha Declaration emphasizes that
the TRIPS Agreement does not and should not
prevent members from taking measures to protect
public health, and it reaffirms the right of members to use, to the full extent, the provisions of the
TRIPS Agreement that provide flexibility in terms
of accessing medicines. The Declaration states
that each member has the right to determine what
constitutes a national emergency, or other circumstances of extreme urgency, and explains that public health crises, including those relating to HIV/
AIDS, tuberculosis, malaria, and other epidemics,
can represent such circumstances.
By virtue of WTO member states having signed and ratified the agreement, TRIPS

constitutes international law. It must be translated or adapted into national law individually by
each member state. Though not directly related to
TRIPS, the chapter by Bremer11 provides an overview of key legal provisions in the United States
that have profoundly affected the evolution of IP
rights and technology transfer. The fundamental
basis underlying the transfer of technology as intellectual property is embodied in the country’s
Constitution, which embraces patents, copyrights,
and trademarks within its scope. The terms and
provisions governing these forms of intellectual
property are codified in various statutes, but two
pieces of legislation are especially important.
The first is the Stevenson-Wydler Act enacted
to promote the utilization of technology owned
by the government and generated with its help.
It aids the transfer of that technology to the private sector and government at the state and local
levels. The second law is the Patent and Trademark
Amendment Act of 1980—known as the BayhDole Act. The Bayh-Dole Act established a uniform federal patent policy and provided the first
statutory authority for the U.S. government to
take title to and hold patents through its agencies.
The success of this act makes it of special interest
to countries seeking to establish IP regulatory systems, and this chapter explains the structure and
history of Bayh-Dole.
Bremer also discusses the important interplay
between patents and antitrust laws, recognized as
complementary tools that enhance competition.
The laws are based on the important premise that
patents per se do not convey market power. Only
when coupled with other assets, or when acquired
in order to build a monopolistic behavior, can
patents create market power. Antitrust scrutiny is
triggered when patents (and certain other market
positions) are combined with apparent predatory
practices that restrain trade and competition. The
point of this chapter then becomes very clear: a
country strengthening its patent laws should,
concurrently, strengthen its antitrust laws as
well as its capacities to enforce them.
One such enforcement is the capacity of a
government to bring about a compulsory licensing action. A compulsory license is an authorization given by a national authority to a natural or
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legal person for the exploitation of the subject matter protected by a patent; the consent of the patent
holder is not necessary. Compulsory licenses may
be required to import or produce a given product or to use a patented technology for research.
They are especially important when there are no
close substitutes for a product or process and a research exception is not available or is too narrow.
Compulsory licenses are granted in order to attain
various public policy objectives, such as: to address
emergencies and public health needs, to counteract
anticompetitive business practices, or to permit the
exploitation of patents that are not used.
Correa12 discusses the usefulness of compulsory licensing and provides a step-by-step guide
to obtaining compulsory licenses to ensure that
the R&D of drugs needed by people in developing countries is kept free from unnecessary
entanglements in the global IP system. His chapter provides many illustrations and a useful discussion of the patenting and licensing strategies
of universities and other public sector research
institutions. These institutions often hold patents
on research tools, underscoring the importance of
the public sector retaining research-use and humanitarian-use rights in all licenses.13 While there
are several ways to circumvent patented upstream
technologies, and the compulsory license is especially powerful. But, perhaps due to its power,
the strategy also has drawbacks. The flexibility of
compulsory licensing should be considered in the
context of all of the options available to TRIPS
member countries. Importantly, applicants need
to be certain that they have the capacity to exploit the licenses and the financial ability to remunerate the patent holder or holders. Nonprofit
research institutions may often find this particularly difficult because, even with a compulsory license, commercial partners need to be willing to
produce and distribute products developed under
compulsory licenses. This is one reason for further investments in technological and IP capacity
building and the establishment of strong institutional networks.
Institutional networks are most powerful when formed around geographic clusters.
Innovation in health and modern agriculture relies on a sophisticated open system of knowledge
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sharing. Recent studies suggest that successful
innovation indeed requires development of clusters of institutions, businesses, and personnel.
“Location, location, location,” the battle cry for
property realtors everywhere, is heard increasingly with respect to innovation dynamics and
knowledge-based growth.
A cluster is a group of similar things positioned or occurring closely together. Although
companies and various not-for-profit entities in
the same sector or product market have traditionally located themselves in close geographic proximity (rather than spreading out evenly across the
geography or economy), the express search for
ways to encourage clustering has only recently
begun. One paradigm, as discussed extensively by
Phillips and Ryan,14 is that local competition is
the primary engine behind cluster development
and sustainability. Additionally, innovation now
involves and generates significant externalities;
innovators increasingly rely on an array of formal and informal collaborators, and the efficacy
of those relationships will determine their ability
to successfully launch an innovation into product
development.
Offering an overview of recent research on
clusters in Canada, this chapter observes that one
factor encouraging cluster formation is the development of a cost-effective, efficient IP management system. Equally important is the use of
social capital, which can lead to less formal collaborations that can better disseminate and utilize discoveries. While the traditional strategy of
protecting infant industries in order to develop
them made some sense in the industrial world,
its value in a knowledge-based world is unclear.
Knowledge-based development is inherently different from traditional industrial development.
Indeed, multiple types of knowledge are involved
in such a system, and Phillips and Ryan address
how clusters integrate four distinct types of
knowledge: “know-why,” “know-what,” “knowhow,” and “know-who.” A cluster’s ability to use
and share these types of knowledge is largely what
empowers individual entities within the cluster to
innovate. Basing their ideas on varied illustrations
and deep analysis, the authors conclude that governments have an important role to play in the
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process of cluster formation and that ensuring a
mix of “local buzz” and “global reach” is part of
the recipe for success.
A specific experience of cluster development and the role of government are presented
by Viljamaa,15 who discusses the case of Turku,
Finland. The city is home to a large concentration
of biotechnology activities. This model can be described as a science-led strategy, led from above,
with a range of important lessons for policymakers and institutional leaders alike. The experiences suggest that sharing facilities with companies
and combining forces with other universities and
R&D institutes are vital ways of building clusters
and momentum in innovation. Active partnerships with larger entities are important, as is a
global network of scientists. Viljamaa offers many
ideas that are particularly pertinent to developing
countries that wish to encourage the formation
of clusters. One is that building clusters from
scratch is basically impossible; success comes
from building upon existing strengths. Many
successful clusters have been based on older but
related industries.
Probably the most famous example of a
cluster that is grounded on entrepreneurship is
the biotechnology cluster of the greater Boston
area, which encompasses Massachusetts Institute
of Technology (M.I.T.), Harvard University,
Boston University, and others. M.I.T., some argue, has led the translation of university-generated research from the laboratory to the private
sector through the cultivation of an entrepreneurial culture. Indeed, the entrepreneurial activities of M.I.T. have served as an incubator for
generation after generation of entrepreneurial
engineers and scientists who view risk as an opportunity. Seeing risk and opportunity as two
sides of the same coin, students at M.I.T. don’t
utter, “Why do you want to do that?” but instead proclaim “Hey! Why not?” This positive
attitude, this sense of self-confidence, typifies
M.I.T.’s culture, from professors to students to
its licensing professionals.
Nelsen16 points out that M.I.T.’s licensing
office also has served as a focal point for the formation of the greater Boston area’s biotechnology cluster. By coordinating the management of

M.I.T.’s intellectual property, the office contributes
to the robust development of many companies
that form the cluster. This promotes further development, economic progress, investment in innovation, creation of networks, and ultimately, success.
Although Boston is quite unlike most developing-country cities, the fundamental principles that
drive its economic development are universal.
With respect to working with developing
countries, M.I.T. recognizes that there are often
special circumstances requiring creative practices
(for example, preferential pricing for developing country public sectors, strategic patent filing, and differential licensing practices). Hence,
with M.I.T. licensing, there are no rigid written
policies guiding how technologies are handled
(the exception to this is clear and nonnegotiable
conflict of interest policies and practices); instead,
the choices are left open in order to creatively craft
agreements to maximize access. This flexible management fuels the innovation engine, and this approach can be adapted by many other regions.
But what are the potentials for individual
countries to develop thriving cluster complexes
without misspending scarce funds? What variables
are essential for cluster development? In another
chapter, Phillips and Ryan17 identify six factors:
manufacturing capacity, domestic market, export
market, R&D, an IP system, and a functioning
drug regulatory system. The authors explore these
factors across three development stages to measure a country’s cluster capacity. The authors go
further and provide a five-stage process for realistic cluster building:
1. Assessing capacities, resources, and
opportunities
2. Choosing an anchor strategy (different
cluster approaches will have different sets
of requirements, leaders, and tactics, and
different success rates.)
3. Identifying organizational and institutional
leaders to take the lead in developing the
cluster.
4. Adopting proactive tactics, spanning numerous areas, including having the necessary legal and social structures, efficient
mechanisms to protect and adjudicate
property, the lowest possible barriers for
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entering or exiting key input and output
markets, the ability to trade domestically
and internationally, and effective tax, regulatory, and trade rules.
5. Sustaining the lifecycle of the cluster
(Recognizing that the evolutionary dynamics of markets are unavoidable, clusters
should re-invent themselves every now and
then to prevent cluster decay.)
Importantly, clusters thrive when local strengths
are nurtured rather than when companies are lured
with subsidies. Building infrastructure does not fill
the buildings with innovative enterprises, but rather, innovative enterprises make buildings happen.
Hence different types and sources of capital flow
are needed at different stages of cluster development. Government money sometimes gets in the
way of private money and vice versa.
The real and most effective catalysts for
change are key individuals who serve as ambassadors or entrepreneurs for geographic regions; they
cross-fertilize public-private partnerships which,
in turn, alert the public sector to market demands
and provide companies with access to basic research, infrastructure, and people capacity. This is
why many institutions look for “people policies”
to nurture clusters. Indeed, people are at the center also of these intellectual assets. Knowledgebased development is inherently different from
traditional industrial development. Today’s innovation potential requires, above all, global,
institutional, and personal links and networks.
They are the necessary fertile ground that enables innovation to flourish. n
All chapters refer to: Intellectual Property Management
in Health and Agricultural Innovation: A Handbook of
Best Practices. 2007. A Krattiger, RT Mahoney, L Nelsen, JA
Thomon, AB Bennett, K Satyanarayana, GD Graff, C Fernandez, and SP Kowalski (eds.). MIHR: Oxford, U.K., and PIPRA:
Davis, U.S.A. Available online at www.ipHandbook.org. The
online version contains for each chapter a detailed Editor’s
Summary, Implications, and Best Practices.
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Countries have considerable freedom to control the effects of TRIPS. Indeed, the impact
of TRIPS will depend on how countries and institutions respond to the new IP regime.
At a minimum, countries should take full advantage of the flexibilities offered by TRIPS,
in line with the Doha Declaration. For example, a country strengthening its patent
laws should concurrently strengthen its antitrust laws as well as capacities to enforce
them.
Technology transfer efforts can be powerful when combined with government’s efforts
to reorient the public sector’s IP strategies to enable the poor to benefit from public
investments in innovation. To be effective, this should acknowledge the inadequacies
of a top-down approach to developing IP management policies and approaches. Each
institution has its unique strengths. To seize on these strengths, thoughtful dialogue
between policy-conscious practitioners and practically informed policymakers should
be encouraged.

Key Implications and Best Practices: SETCION 3

FOR GOVERNMENT POLICYMAKERS

Public institutions’ IP policies should address the institution’s obligation, whenever
possible, to retain humanitarian-use rights to its inventions, and the government’s
right to a license for technology developed with public funds, in case the public benefit
is not being served adequately. Under extreme, well-defined circumstances, this may
include full “march-in rights” . The potential for such government action will encourage
companies to make products widely available in the market.
Public-private collaborations within publicly funded R&D programs can be powerful
arrangements for optimizing public research investment.
Public-private partnerships aimed at product development are effective arrangements
through which industry can invest and apply its expertise to address the needs of the
poor. In many contexts such product-development partnerships (PDPs) are now driving
the drug-development pipeline in neglected-disease R&D. National institutions in
developing countries should be encouraged to participate in PDPs.
The ability of the local and national economy to absorb new technologies into existing
industry or business sector can be strengthened through the encouragement of cluster
formation. They require a long-standing and durable commitment to science education,
research and related infrastructure, a strategically situated anchor institution with a
proactive technology transfer office, and reliance on market forces as the engine for
technology transfer.
Overall, public funds should be directed at product development partnerships that
create collaborations, as opposed to buildings with bricks and mortar. Such strategies
have proven most effective in strengthening and sustaining clusters.
Governments should support local entrepreneurship with much attention given to
endogenous development, specifically to local, small- to medium-size enterprises and
to spinouts. An effective short-term strategy may be to attract foreign companies to
the area. They will bring jobs and often knowledge and expertise.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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In an increasingly global world—in which the risk of disease and the effects of agricultural
disasters span borders and the benefits of research can come from any corner—the
society that benefits from public sector health investment will be global. The publicbenefit aspect of government-sponsored research investments should include the poor
in every society, including those of neighboring countries.
There are many strategies available to increase the resources and tools devoted to the
public good that do not run counter to economic development goals and private sector
interests. At the upstream end, funds can be directed toward research in developing
countries, and partnerships with private and nonprofit entities can be effective. At the
downstream end, funds can directly provide products to users in developing countries,
reduce barriers to the transfer of technology that benefits these countries, or partner
with industry and academia to expedite the development of products from research.
The main issue for universities is to ensure a high level of education, comprehensive
partnerships with other universities, and collaboration with the private sector. This
requires clear IP policies, transparent IP management practices, and sound management
of conflicts of interest.
Public-Private Partnerships and Product-Development Partnerships (PDPs) are novel,
tightly focused organizations, dedicated to providing products to benefit the poor in
developing countries. PDPs require that scientists put a priority on delivering global
benefits and that universities fully embrace their larger role in society and the global
community.
A major policy objective is to find a balance between public benefit and economic returns.
A university can include a public-benefit clause in its licenses to the private sector, invest
part of its royalty stream in a foundation, establish an “ethical” investment fund, license
technologies to nonprofits or others who would develop and manufacture products for
developing countries, and bundle technologies to encourage development of medicines
aimed at diseases of the poor.
The ability of the local and national economy to absorb new technologies into existing
industry or an entrepreneurial sector can be strengthened through the encouragement
of cluster formation. But robust innovation clusters are not created from scratch.
They require a long, durable commitment to science education, research, and related
infrastructure; a strategically situated anchor institution with a proactive technology
transfer office; and reliance on market forces as the engine for technology transfer.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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Global changes in IP regimes, especially changes that affect developing countries,
have been tremendous. Within the evolving IP regime, your country has considerable
freedom to control the effects of these changes. Indeed, much of the impact of these
changes will depend on how countries and institutions respond to the new IP regime.
An important response is the creation of an effective technology transfer program.
Your role in this process is essential.
As a scientist, you understand the interrelatedness of science, R&D, technological
advance, and commercial investment. Share these insights with your institution’s
technology transfer office, as well as with its senior managers.

Key Implications and Best Practices: SECTION 3

FOR SCIENTISTS

Countries engaged in reforming their R&D and technology transfer efforts are today
often including royalty-sharing provisions for scientists in publicly funded research
institutions. This approach also comes with obligations to assign ownership rights to
your institution and a duty to disclose inventions. All of these changes should be seen
as incentives to turn inventions into innovations that benefit society.
As your institution implements IP policies and patenting strategies, your right to
publish is not jeopardized. IP protection and licensing are but one form of knowledge
transfer that, if well undertaken, can very much be in the public interest.
While access to foreign technology is integral to development, it is increasingly
important to focus directly on capturing the national (or indigenous) innovation
potential of developing countries. Through the activities of your research program,
you may be positioned to facilitate such capture and development of the benefits
arising from indigenous innovation and traditional knowledge. These efforts should be
coupled with benefit-sharing provisions.
Understand the obligations that are attached to different funding sources when funds
are used within the same program. The impact of joint public and private financial
support can be complex but will increase, particularly as your institution positions
itself strongly within an innovation cluster and engages in product development.
As a scientist, you play an increasingly important role in knowledge-based innovation
clusters. Do not shy away from becoming an entrepreneur yourself.
Collaboration is often based on establishing personal contacts, for example, building
close connections and networks to other scientists and research groups in the same
field via conferences and reciprocal visiting arrangements; these all foster the formation
of collaborative research projects and are fundamental for effective sharing of knowhow and show-how.
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Traditionally, the mission of a technology transfer program was to bring universitygenerated intellectual property into use as rapidly as possible. But public sector
technology transfer has evolved to serve broader purposes: to enhance the reputation
of the institution. Successful technology transfer can help it achieve its missions of
education, research, and community outreach; to ensure social impact; and to provide
funds for further research.
The laws relating to new technologies are evolving. Recent court decisions may have
an impact on business and technological matters relevant to the operations of your
technology transfer office (TTO).
A TTO has much responsibility in creating incentives to move discoveries into the
product development arena, motivating public sector researchers, not by the promise
of revenue streams (which rarely appear), but by the satisfaction of seeing their work
developed and applied to serve the public good.
An understanding of not only the law, but also the public policy that underlies it.
For example, with the Bayh-Dole Act in the United States, the policy rationale is not
directed toward revenue generation, but rather toward moving publicly funded R&D
into the marketplace to serve the public good.
Financial benefits from technology transfer can take many years to realize—if they
ever do materialize—so it is important to be realistic when making forecasts about
expected income. International benchmark data indicate that a positive return can
take eight to ten years to achieve. It is prudent not to justify the cost of technology
transfer functions on the basis of financial returns.
The difficulties of managing and promoting technology transfer within a smaller
research institution need to be recognized, and the office should actively seek
partnerships with other entities, such as local venture capital firms, incubators, and
business development agencies. Alliances with other institutions, or a central TTO for
several institutions, may also constitute viable alternative strategies.
In a dynamic innovation cluster, authoritative IP management capacity, technology
transfer, and licensing are all essential. Flexibility in licensing and partnership
arrangements, and speedy action and decision making are equally important.
TTOs are often ideally placed to define and nurture an entrepreneurial culture in the
faculty. There can be large gains from such efforts.
TTOs can, if appropriately structured, become a source of creative networking and
collaboration, generating both academic and commercial success. Hence, this role in
driving the success of clusters will be absolutely essential.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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The IP Toolbox
Best practices in the management of intellectual
property require a basic understanding of the various forms of IP protection that are available. The
forms of IP rights in most countries include patents, trademarks, geographical indications, copyrights, and trade secrets. Special provisions for
plants are also offered in many countries in the
form of plant variety protection, or plant breeders’ rights. A further emerging type of protection
is that related to regulatory data, which can be
protected from disclosure or acquisition for a
certain period of time and offer data exclusivity.
Although each of these statutory mechanisms
of IP rights protect different forms of intellectual property, thus conferring different IP rights,
when used alone or in combination, they provide
a set of options for organizing and then making
the most out of an organization’s IP assets.
All of the above are reviewed in detail by
Dodds and Krattiger1 in Chapter 4.1, which includes short sections on institutional aspects including employee agreements, how to integrate the
various rights, and how to identify infringement.
Importantly, the form of protection chosen for a
given invention should be guided by the mission
of the institution (whether public or private), the
purpose of the work it conducts, and the nature of
the invention, or other intellectual property that
will be subject to IP rights protections.
A utility patent is a type of statutory IP protection covering inventions, that is, a grant by the

government to an inventor for any invention that
is a new and useful process, machine, article, manufacture, or composition of matter or any new and
useful improvement thereof. The invention, that is
the intellectual property itself, is a product of the
inventor’s mind. The patent, then, confers certain
rights to this property; it is the right to exclude
others from making, using, selling, or importing
the invention in the country where the patent is
granted, normally for a period of 20 years from
the date of the patent application.
In patents, many aspects of inventions are disclosed. Patents should thus not be seen as the exclusive domain of lawyers. Scientists in particular
are well advised to be up-to-date on patents issued in their field of endeavor, and Nottenburg2
in Chapter 4.2 provides a comprehensive guide
to patents, using biotechnology patents as an example, that instructs scientists and others how to
read utility patents.
Trademarks are a form of IP protection that
serves to distinguish the products or services of
one individual, company, or organization from
the products or services of others. A trademark
can be a word, phrase, symbol, design, or a combination thereof. Trademarks can even be sounds
or colors, if they are in some way distinctive, that
create an immediate association in the mind of
the consumer between the trademark and the
good. IP protection for a trademark confers an
exclusive right to use the mark in commerce.

Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski.
2007. 4: The IP Toolbox. In Executive Guide to Intellectual Property Management in Health and Agricultural Innovation: A
Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz
Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). Available online at
www.ipHandbook.org.
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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Trademarks are an often overlooked and undervalued form of intellectual property by the
public sector and this is well argued by Needle3 in
Chapter 4.3 on the basis of many colorful examples. Trademarks should be a valuable component
of any IP management strategy, complementing
the protection afforded by other forms of statutory IP protection. Trademarks can complement
other forms of IP protection, and, as in the case
of many pharmaceuticals, serve to strengthen the
period of proprietary rights to a product.
Geographical indications are signs used on
goods that have specific geographic origin and
possess qualities or a reputation that are derived
from their place of origin. Geographical indications are another type of intellectual property,
similar to trademarks in that they are source indicators. Most commonly, a geographic indication
consists of the name of the place of origin of the
particular goods (for example, Roquefort cheese
or champagne).
Copyright is a type of statutory IP protection for the original works of authors, such as the
chapters in the Handbook. Such works include literary, musical, dramatic, and architectural works.
The copyright protects the work immediately after it is fixed in a tangible medium, for example,
words on a page (what you are reading at this
very moment) are copyrighted. The owner of the
copyright, for example, we, the authors of this
chapter, have certain rights to the work. Typically,
these rights include moral rights (that is, having
our names associated with the work) as well as the
right to reproduce the work, to prepare adaptations of the work, and to distribute the work to
the public. However, these rights can be either
licensed or assigned to others. In the case of this
chapter, we agreed to make it freely available to all
through the Internet.
Trade secrets (in certain circumstances and
jurisdictions called know-how) are an important
form of intellectual property. Trade secrets protect know-how and any confidential information
so designated. To be protected as a trade secret,
the inrellectual property must, of course, be kept
secret, and must also confer some sort of commercial advantage to the holder. Enforcement
of IP rights for trade secrets is possible when a
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competitor has misappropriated and/or stolen
the trade secret.
A point often raised is when one should file
for a patent or maintain the information as a trade
secret. What is important to note is that patents
and trade secrets are not in conflict with each other but are complementary IP assets. Depending
on the nature of the know-how, or the invention,
the organization may choose to either file a patent
or to continue to hold as a trade secret. Dodds
and Krattiger in Chapter 4.1 discuss trade secrets
briefly, but they are fully discussed in the context
of licensing in another section of the Handbook.4
The protection of intellectual property related to plants, germplasm, and varieties is covered in several chapters because there are many
dimensions to the topic. Kesan5 in Chapter 4.4
describes the various forms of intellectual property applicable to plants. These are utility patents
(available in a few countries only), plant variety
protection (or plant breeders’ rights), plant patents, trade secrets, geographic indications, and
trademarks. The strengths and weaknesses and
pros and cons of each are discussed. It is worth
noting that the use of one form of protection is
not necessarily exclusive, in that a single plant
may be simultaneously covered by several forms
of IP protection.
Plant variety protection (PVP) is the most
common tool for protecting varieties, and many
countries have legislated and implemented a
PVP system. Lesser6 describes the PVP system in
Chapter 4.5. PVP regimes are implemented in
order to:
• provide breeders (both public and private
sectors) with an opportunity to receive a
reasonable return on past investments
• provide an incentive for continued or increased investment in future breeding
research
• recognize the legal right of the innovator to
be recognized as such
• acknowledge the economic right to remuneration for his or her efforts
In general, there are two exemptions to the
protection provided: 1) a research exemption and
2) a farmer’s exemption (this is not to be confused

IP TOOLBOX

with farmers’ rights). A research exemption allows
for breeders to develop a new variety by using a
protected variety; a farmer’s exemption allows for
the saving of seed for the sole use of replanting
the farmer’s land.
Given the advantages of a PVP system in attracting private investments and offering farmers
a broader range of improved varieties, countries
may gain substantially in internationally harmonizing their PVP regimes, as it lowers costs for
users, simplifies the introduction of new varieties,
and thus leads to the availability of more varieties
and choices for farmers.
Lesser also points out that those countries that
are members of the Agreement on Trade-Related
Aspects of Intellectual Property Rights (TRIPS)
agreed to implement special protection for plants
(the so called sui generis protection). Many elect
to follow the principles of the International
Convention for the Protection of New Varieties
of Plants (UPOV), an international treaty that
provides an effective framework for PVP.
Plants can also be protected through trade
secrets, trademarks, and geographical indications.
Geographical indications might be used to communicate to consumers the association between a
plant’s special characteristics and the territory from
which it originates. Trademarks can have particular value if the variety has market potential, and
consumers come to specifically associate the trademark with desirable characteristics and qualities of
the variety. Such value has important implications
for developing countries that are exporters of agricultural commodities and products, as it can add
significant additional value to their exports.
The management of intellectual property related to crops and germplasm is an essential function of a technology transfer office (TTO) and
is the focus of Chapter 4.6 by Dodds and colleagues.7 They also discuss specific issues related
to IP management involving genebanks and practical aspects on the establishment of a PVP office.
Blakeney8 in Chapter 4.7 reviews international
aspects, including the international exchange of
germplasm. A working knowledge of the relevant
international treaties related to genetic resources is important for anyone dealing with genetic

resources as they increasingly affect the international exchange and use of germplasm.
One such treaty is UPOV. Significantly, the
latest revisions of 1991 expanded the scope of
protections that could be granted to include essentially derived varieties. This has important implications for genetically modified organisms. These
revisions also allow countries to limit farmers’
rights, allowing them only to save seeds for use
on their own land.
Another agreement is the Convention on
Biological Diversity, particularly the provisions
concerned with informed consent to use of biological materials and equitable benefit sharing following access. Some people argue that
these requirements may be in conflict with this
requirement of TRIPS. In practice, however,
whereas UPOV and related sui generis systems
focus on plant varieties, the Convention on
Biological Diversity essentially deals with wild
genetic resources. Exceptions include the reach of
the Convention into genetically modified crops
through the Cartagena Protocol on Biosafety, but
this is not related to intellectual property.
The International Treaty on Plant Genetic
Resources for Food and Agriculture (the Treaty)
is a recent addition to international agreements.
The Treaty establishes a multilateral system that
embodies a sort of genetic commons within which
the exchange of germplasm in major crop varieties
between member states is facilitated. Conditions
limit the rights of recipients to seek IP rights in
material obtained and support the rights of donors to share in some form of benefit. The Treaty
further recognizes the contribution of farmers
and indigenous peoples’ traditional knowledge
to agricultural biodiversity. This is accomplished
through the development and conservation of
landraces, in primitive varieties developed to deal
with local climate and diseases and to appeal to
local tastes, by interbreeding locally occurring
undomesticated plants with cultivated plants, as
well as by exchanging different genotypes among
farmers and farms. Again, some argue that certain terms of the Treaty may not be compatible
with UPOV standards but overall this assessment
seems unlikely.
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A distinct but closely related topic is that of
information resources. These include computer
software and systems, databases, geographic
information systems (GIS), remote sensing (RS)
information, and library resources. The integration of these is increasingly prevalent in advanced
agricultural systems such as the forecasting of
disease and harvests. Dodds and colleagues9 in
Chapter 4.8 discuss the various IP elements related to information resources and how they can
be managed effectively. The chapter also addresses
licensing elements.
A very different topic is that of data protection and data exclusivity. These systems of protection are especially important in pharmaceuticals
and agricultural chemicals. Two chapters review
these complex topics, Chapter 4.9 by Clift10 and
Chapter 4.10 by Cook.11 In short, regulatory data
are the data that the researcher or manufacturer of
a product must provide to the appropriate regulatory agency in order to prove that the product is
safe and efficacious. Regulatory data are protected
from disclosure or acquisition for a certain period
of time, usually five to ten years from the product’s
first authorization to market, during which time
no other applicants are allowed to use it to obtain
marketing authorization for the same product.
Regulatory data protections are substantively
different from other sorts of intellectual protection, including confidential information protection and patents. The provisions in Article 39.3
of TRIPS, concerning the protection of regulatory
data, are broad and subject to interpretation. Both
the United States and the European Union have
interpreted and implemented the obligations in
different ways (as explained in Chapter 4.10).
The chapters by Clift and Cook also examine
data exclusivity from the perspective of specific
TRIPS requirements (Article 39) which essentially include three obligations on governments:
• protect data on new chemical entities, the
collection of which involved considerable
effort, against unfair commercial use
• protect such data against disclosure, except
where necessary to protect the public
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• protect such data against disclosure, unless
steps are taken to ensure that the data are
protected against unfair commercial use
It is important to note that these requirements do not create new IP rights (other than
defining the reach of trade secrets). Article 39.3
only articulates widely accepted trade secret and
unfair competition law and is not an invitation to
create new IP rights per se for test data. n
All chapters refer to: Intellectual Property Management
in Health and Agricultural Innovation: A Handbook of Best
Practices. 2007. A Krattiger, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez
and SP Kowalski (eds.). MIHR: Oxford, U.K., and PIPRA: Davis,
U.S.A. Available online at www.ipHandbook.org. The online
version contains for each chapter a detailed Editor’s Summary, Implications, and Best Practices.
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The statutory tools of IP, such as patents, copyright, trademarks, trade secrets, geographic
indications, and plant variety protection, are tools that can be used to achieve a goal.
The tool in itself is neutral; what matters is how the tool is used.
When setting up a patent office, notwithstanding considerable latitude provided
under TRIPS, there are advantages in implementing practices that are consistent
and compatible with the practices of other countries. Doing so will facilitate greater
opportunities for international collaboration in R&D and technology transfer.
Particularly important is making patent applications and issued patents available
online. This furthers innovation and licensing.
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Copyright is also an important form of IP that can be used to encourage innovation.
The recent trend, at least in the United States, to provide for ever-increasing duration
of protection (now exceeding four generations) should be avoided as this approach
prevents the availability of important commercially but insignificant works.
The use of trademarks is important for building integrity and stability in commerce
and for offering new opportunities for national innovations. Trademarks can also be
highly valuable for public sector entities.
Judicious plant variety protection of new varieties will encourage investments in the
development of crops that are essential for food security, a better environment, and
economic development. As with patents, domestic innovation, the transfer of foreign
varieties for increased production and productivity, and spurring national investments
in crop breeding can be enhanced significantly through membership in international
bodies, such as UPOV. This can lead to the earlier availability of improved varieties.
Notwithstanding the above, countries can exercise significant latitude in regulating
access to certain categories of plant genetic resources they consider strategically
important. Plant breeding, however, and the enhancement of crops, is based on the
stepwise improvement of existing varieties, and this requires broad access to genetic
material. Related to this are geographic information systems and corresponding data
protections that can add substantial value to biodiversity resources and traditional
knowledge.
Introducing stringent confidentiality of data and exclusivity laws can prevent early
introduction of generics and promote competition critical for improving access to life
saving drugs. There is a need to balance the various competing interests.
IP protection mechanisms, however, depend upon effective and equitable enforcement
by national governments. This requires effective, transparent, and enforceable contract
law that can be implemented to protect natural, cultural, and economic resources, all
by furthering useful interactions with the global community. This balance is critical.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.

HANDBOOK OF BEST PRACTICES: EXECUTIVE GUIDE | 61

Key Implications and Best Practices: SECTION 4

CHAPTER 4

FOR SENIOR MANAGEMENT
(University President, R&D Manager, etc.)

4

4

4

4

4

4

4

4

The implementation of a broad institutional IP policy, consistent with the institution’s
mission, can foster the integration of the various forms of IP protection in furtherance of
an institution’s mission and goals.
For public sector institutions, trademarks can be a valuable element in an institutional
strategy that aims at fostering a positive image (or brand) and generating value. Because
of the broad value of trademarks, they assist institutions in maintaining a good image
and brand, thus serving as a tool for senior management in maintaining and enhancing
the institution’s reputation, standing, and value.
Scientists can gain a lot from regularly reviewing newly issued patents from around
the world. Patents often disclose much more than scientific publications but are
generally overlooked as valuable sources of scientific and technical know-how. Such an
information-gathering approach requires appropriate staff training and the availability
of good Internet connections, which make it possible for patents to be downloaded. All
patent office Web sites provide patents free of charge as does the Worldwide Intellectual
Property Organization (WIPO).
A sound patenting strategy is an extremely useful tool to bring inventions to fruition
that make an impact on economic development and meeting public sector goals.
Although many public sector institutions have for years provided their improved germplasm
free of charge or at nominal costs to breeders and farmers, the protection of improved
varieties can be a critical tool in furthering broad access and simultaneously meeting
commercial and humanitarian objectives through appropriate “market segmentation.”
In many countries, but not in the United States, patent law includes a broad research
exemption. This should not be confused with possible restrictions on materials obtained
through material transfer agreements. Although extremely useful, material transfer
agreements should be used judiciously, particularly when intellectual property is also
embedded in material. This aspect also requires well-trained licensing/technologytransfer personnel and good management systems.
The delivery of innovation for the greater public good by public sector institutions is
not necessarily inconsistent with appropriate patent and other forms of IP protection.
Trade secret protection in particular may be a valuable—and cost effective—means of
achieving greater accessibility by disadvantaged members or groups of society. Whereas
academic institutions in particular may regard such protection as inappropriate, it
should be remembered that their mission is gradually shifting and increasingly include
the delivery of products. This requires adjustments in the way information and knowhow are managed. In turn, the changes require much internal discussion and sometimes
culture change.
Senior management’s backing of the technology transfer office is important as is its
support in the implementation of rigorous IP-related policies and procedures (such as
those related to confidentiality).

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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Research endeavors can go much further, in certain circumstances, if appropriate
IP protection is sought. If appropriately managed, this is not in conflict with the
broad dissemination of research results but encourages that your inventions serve
humanity.
Patents often disclose much more technical and scientific information than do
academic publications. Make it a habit of regularly reading up on newly published
patent applications or issued patents in your field. You can access this information for
free on the Internet (such as on www.uspto.gov).
Your institution’s good reputation and standing can be used as a valuable trademark or
brand. Maintaining the high reputation requires strict adherence to your institution’s
policy and best practices.
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Good data management, especially accurate record keeping through comprehensive
notebooks, is the foundation for building a portfolio of IP assets. Essentially, best
practices in scientific record keeping should be precisely the same as best practices in
record keeping for purposes of IP management.
Conversely, you should always know the origin and possible restrictions of data and
information you use, no matter how insignificant they might seem. Make sure you
document the source of important data and information in your laboratory notebook.
If you have questions, never hesitate to contact your technology transfer office for help
or clarifications.
Particularly if your research is related to product development, the confidentiality
of your data may be critical in ensuring global access. Data is a valuable form of
intellectual property that can be used to obtain certain price or access terms in licensing
negotiations. Whereas, as a researcher in an academic environment you may regard
such protection as inappropriate, remember that it is the goals of your research that
should drive the IP tools applied to your inventions. If you are engaged in the delivery
of products, adjustments in the way your information and know-how are managed
may be necessary to speed-up the translation of your research findings into innovative
products or services.
If a given invention cannot be patented in your own country (for example, a biological
invention, including gene sequences), the invention may still be patentable in another
country. The United States and Canada tend to have the broadest interpretations with
respect to the patenting of organisms and biological materials. In pursuing patenting
elsewhere, under certain circumstances, your research endeavors may leverage
additional investments required to bring the fruits of your research to benefit your
country and society at large and may also lead to additional research grants.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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Intellectual property is often perceived as constraining research, particularly in public
sector institutions. Your role in communicating the importance of judiciously using
patents, trademarks, trade secrets, and so forth, and the benefits of good IP management,
is critical. Such communication should be tailor-made to senior management, and
even to your institution’s board, as well as to scientists. Each responds to a different
language. (And different colleagues will require different degrees of understanding. For
example, your discussions on patents will necessarily differ with scientists and patent
counsel. Choose your words and the level of detail you provide judiciously.)
In many institutional settings, making better use of patents and other forms of
intellectual property requires a culture change to a greater or lesser degree. This may
include establishing an expectation for scientists in your institution to regularly review
patents. Encouraging scientists to share a broader IP awareness and culture will be
potentially powerful and valuable.
Trademarks are a critical, and often overlooked, option for IP protection. They can be
used as stand-alone IP protection, or they can be integrated into an overall strategy
for integrated IP protection, for example, a strong trademark for a patented product or
process.
Your job requires a judicious balance of work that relates directly to your benchmarks
and targets, and of contributing to the overall IP culture of an organization. The latter
is often not spelled out in your job description but it is important nonetheless. The
greater the general level of awareness related to intellectual property, the more likely
it is that the value of IP assets can be captured and utilized. And your job also becomes
easier when you gain a broader understanding of intellectual property.
Genebank management and that of genetic resources, in general, is increasingly
becoming a sensitive issue. An organized, stepwise approach is vital for effectively
managing a genebank and for avoiding difficulties. Ownership of genetic resources can
be tricky, so rigorous documentation and clear procedures on incoming and outgoing
genetic resources may be critical.
The above point applies equally to data, both incoming and outgoing. Particularly if
your institution conducts research related to product development (especially clinical
trials), the confidentiality of data may be critical in ensuring global access. Specific data
are a valuable form of intellectual property that can be used to obtain a certain price or
access terms in licensing negotiations.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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Institutional Policies and Strategies
The boundaries of any property must be clear. As
a farmer needs to know where his or her field begins and ends, an innovator must know exactly
the definition of his or her invention. But it is
more difficult by far to delineate where rights to
something intangible begin and end. In addition,
intangible assets can be difficult to keep track of,
to share, and to use. Yet in a research-and-development environment, intangible assets are often
the most valuable and important ones. How then,
can they be leveraged to reinforce the mission of
an institution? How can the specific objectives be
achieved more effectively and efficiently through
the incorporation of best practices in IP (intellectual property) management? What are these principles and practices? And how does an IP policy
relate to an operational IP strategy?
This section offers insights into achieving and
maintaining clarity about the ownership of intellectual property in public sector institutions and
stresses the value of IP strategies and IP policies.
These are important for achieving success and have
been increasingly encouraged—or required—by
certain donors as a strategy to ensure global access.
Global access, especially by the poor, and ownership
of intellectual property go hand in hand. Indeed,
the most important aspect of IP protection is that
it bestows control over intellectual assets. If an organization—especially a public institution—fails to
obtain IP rights for its inventions, it risks losing
control over them. Failure to maintain rights may

result in private entities appropriating elements of
the value without major regard to the mission of
public institutions, or it could lead to the intellectual assets becoming useless due to lack of further
investment and development. This is the most important reason why the public sector should take
IP management more seriously than it traditionally has. IP management is a fundamental element
in the public sector’s strategy of putting intellectual
property to work for the public good.
Appropriately, the first chapter in this section
of the Handbook is a comprehensive discussion
on IP strategy by Pitkethly.1 His definition of
strategy relevant to IP management is:
• the formulation and adoption of courses of
action enabling the reaching of long-term
goals and objectives of an institution
• the allocation of resources (financial and
human) necessary for carrying out these
actions
By extension, IP strategy is an integral part
of an overall business strategy that uses IP rights
to manage technology.
Pitkethly begins by mapping out how IP
rights systems fulfill four purposes:
• providing incentives for innovation
• allowing for the packaging of intellectual
assets into innovative processes
• encouraging the diffusion of technical
information
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• enabling the capturing of added value (economic and/or humanitarian) through the
control of intellectual assets
Viewed in this way, IP rights systems can be
instrumental in enabling the diffusion of technological information. For example, patent specifications provide detailed embodiments of inventions, which are available for all to see. Using the
Internet, these records can be accessed for free
anywhere in the world. This availability of and access to information greatly facilitates innovation,
since others will be able to work to improve or
invent around the disclosed patented invention.
Patents can also be useful sources of information
for scientists, since the patent application may be
the first and only publication about a competing
innovation.
Organizations should have both external and
internal IP strategies. Broadly speaking, this is
referred to as litigation, licensing, and learning.
An external IP strategy involves exploiting
inventions (by developing them in-house, selling them, or licensing them). Litigation denies
IP rights to others; licensing allows rights to others. Learning can be a part of technology out-licensing, since it not only gives others access to
these technologies but also provides learning opportunities for the organization. This strategy is
especially effective if an institution’s aim is to diffuse technology as widely as possible and ensure
global access.
As a result, donors are increasingly requiring grantees to take IP management seriously.
Ballantyne and Nelki2 of the Wellcome Trust (the
Trust) in the United Kingdom, a major charitable
funder of biomedical research, is one such pioneering funding entity. The Trust requires institutions that have produced intellectual property
using the Trust grants to determine whether the
public will benefit from the protection of that
property and whether all participants in the process receive proceeds proportional to the amount
of money, equipment, knowledge, or labor they
contributed. But above all, the Trust insists that
intellectual property arising from its grant awards
be adequately exploited; the Trust does not shy
away from taking over activities if grantees fail to
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adequately exploit the intellectual property. The
chapter ends with a series of case studies that illustrate the practical aspects of IP strategies.3
Grantees more and more frequently will
need to present IP management strategies as part
of their proposals. In the case of the Bill and
Melinda Gates Foundation, certain grantees are
required global access strategies4 that outline
how recipients will manage new and existing intellectual property. Certain minimum standards
may also be required, such as:
• keeping the research field open by prohibiting any licensee from enforcing intellectual
property against universities and research
institutions that carry out noncommercial
activities
• retaining licensable research rights to any
invention developed with donor funding
• obtaining freedom to operate for all background intellectual property owned by collaborating institutions
• ensuring good IP management, which includes exploitation of intellectual property,
with the goal of ensuring its use in developing countries
Some granting agencies also require prospective grantees to explicitly state their IP policies.
Kowalski5 reviews and discusses several institutions’ policies and concludes that, at a minimum,
an IP policy should define IP ownership, outline the patenting policy, describe the manner
in which an institution will handle confidential
information, set out the principles of its IP licensing and marketing approaches, explain how
income arising from intellectual property will be
distributed, and delineate the rights and obligations of inventors and the institution, as well as
any rights the institution will retain (such as for
research and for humanitarian uses).
Any new or revised IP policy (and IP strategy) will have to be “sold” to people both inside and outside an institution. It is important
to explain what the policy contains and why the
policy is designed the way it is. And perhaps staff
at multiple levels should be involved in developing and revising, as needed, the IP policy. This
group will be able to have extensive discussions
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about the role and function of intellectual property in the organization. These discussions will
be an effective mechanism for building capacity
and staff support of the policy. Some of the most
controversial issues can be resolved before they
become an obstacle, such as: Who owns what?
Who benefits and how?
These sometimes-troublesome questions are
discussed by Weidemier,6 who reviews how universities in the United States are handling these
aspects. Her chapter examines eight possible cases
that illustrate and clarify the somewhat abstract
principles of ownership of university inventions
and are followed by a series of hypothetical scenarios. Weidemier, among others, concludes that
universities should require all employees and visitors to sign invention assignment agreements on
their date of arrival. Neither an employee handbook that discusses patent assignment nor a published university patent policy may be enough to
ensure that the university is assigned ownership.
With the assignment of ownership rights to
an employer comes the duty to disclose that an
invention has been made. Indeed, an inventor is
responsible for and has much to gain by making
timely disclosures of his or her invention to the
technology transfer office (TTO), the first step
in enabling technology transfer. Di Sante7 points
out that successful commercialization is built on
a foundation of good relations between inventors and technology transfer professionals. Such
relationships should be established long before
the transfer services of the technology transfer office are required, since this will enable technology
managers to negotiate both faculty and business
concerns about licensing agreements whenever
the opportunity arises. The role of the inventor in
the entire IP protection and IP licensing/transfer process cannot be overstated and should continue throughout the life of the technology.8 For
example, years after a patent has been licensed,
the inventor may be the best-placed person to
alert a TTO that a certain product being sold
may infringe the patent.
But dealing with inventors is not always
easy.9 Inventors are prone to fall in love with
their own creations, and, perhaps unreasonably,
anticipate that theirs is the next great thing. It is

the technology transfer professional’s responsibility to tactfully ensure that the inventors’ expectations are kept in line with reality.
Establishing good relationships with inventors is an important way to identify the intellectual property being generated in the research institution. But from an institutional point of view,
a more comprehensive perspective on intellectual
property is often warranted. This applies particularly to times when an organization develops a
strategic plan or IP management strategy. In this
context, IP audits can be essential and often form
the basis for an internal review and a revision of
IP strategy. Blakeney10 provides a comprehensive
overview of IP audits. Indeed, the importance of
IP audits is becoming more and more apparent,
in the private sector as well as in the public sector,
as public entities increasingly deal with other parties’ intellectual property.
An IP audit seeks to accomplish three broad
objectives for an institution. First, it seeks to
identify the intellectual property generated by its
researchers. This intellectual property is an asset,
with value that an institution ought to identify, assess, and manage. Second, an audit seeks to identify and review the management of third-party
intellectual property as a way of avoiding liability
for misuse. The IP audit is thus a systematic, methodical identification of the intellectual property
within the institute.11 As the chapter shows, the
audit follows a procedure, from start to finish, so
that at the audit’s conclusion senior managers are
able to frame and implement good IP management practices. This is the third broad objective
of an IP audit: to contribute to the formulation
and execution of the IP policy and IP strategy.
From a practical point of view, an IP audit
reviews a number of existing practices and establishes the context in which intellectual property is
being handled. For example, a research institute’s
ownership and control over any intellectual property will depend on its legal status as an entity.
An IP auditor will review the incorporation documents to identify what powers the institute has to
own and to deal with intellectual property. For
universities and government institutions, such
a review will also include the prevailing government policies.
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The IP auditors will also scrutinize the IP
policy of the institute, if indeed there is a policy. It should ask questions, such as: Where is it
posted? What does it say? Are new employees
required to read it? IP audits may also uncover
potential conflicts of interest. Bennett12 offers a
primer on issues related to the management of
conflict of interest and conflict of commitment.
Conflict of interest occurs when the financial interests of an institution’s researchers are incompatible with the institution’s mission, policy, or
goals. Conflict of commitment may arise when
the time a researcher spends in external activities
related to, for example, downstream technology
development, interferes with his or her attention
to duties to the institution (for example, teaching
or extension responsibilities).
While conflicts of interest should not be seen
in a negative light, making exceptions to the rules is
both dangerous and potentially harmful. Someone
with a potential conflict of interest is not guilty of
anything; rather, he or she may actually be a more
valuable “asset” because of the potential conflict.
This applies most strikingly when a professor has
an interest in forming a spinout company based
on university research. Potentially, larger issues will
arise due to undisclosed conflicts of interest. What
a university needs is to define a clear chain of command and in rare circumstances to establish oversight committees. Committees tend to slow the
process with significant delays in time, which typically makes the process unmanageable and useless.
Most conflicts arise when potential conflicts
are not disclosed. Conversely, a major tactic in
managing conflict of interest is to disclose potential conflicts. And most conflicts of interest can be
managed fairly easily provided the policy is clear
and precise. M.I.T., for example, manages an unusually large number of spinouts and, therefore,
has a very strict conflict of interest policy (this is
discussed by Nelsen13). A technology transfer officer’s role is to creatively craft arrangements within
the rules, not to use these rules as deterrents. Put
differently, Nelsen describes M.I.T.’s operating
motto: “A firm wall between university and industry—but a wall with many doors… In sum,
technology transfer inevitably brings conflicts of
interest. The challenge is to manage them.”14 n
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There is an ongoing debate over how IP systems can achieve the optimal balance
between private rights and public benefits. However, experience suggests that IP rights
systems, if soundly applied and used by the public sector as well as by the private sector,
are better than any of the proposed alternatives in achieving public-goods objectives.
Government policies can be instrumental in helping public sector institutions find the
right balance.
As a specific requirement, public sector institutions should be required to develop and
publish their institute-specific IP policies that adapt broader principles to the specific
context of the institution’s mission and strategy. Such policies should include clear
conflict-of-interest policies.
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FOR GOVERNMENT POLICYMAKERS

Incorporating the goals of dissemination of public-sector-generated R&D to benefit
primarily the poorer segments of the population are goals that do not run counter
to benefiting economically from inventions. Much will depend on the specific context
and how these seemingly contradictory goals are managed.
Public sector institutions can achieve little with their intellectual property in the
absence of an enforceable system for protecting and promoting local innovation that
includes clear assignment rules regarding ownership of inventions.
A government may wish to analyze the interface between its laws governing charitable
organizations and how the laws may impact the freedom of nonprofit institutions in
owning and licensing both their own and third-party intellectual property.
Policymakers should consider the promotion of legislation that clarifies under what
circumstances employees in the public sector, including those at universities, shall
assign patent rights to their employers. This aspect has ramifications for statutory laws
in many countries with respect to “hired to invent,” “shop-right,” and other matters.
Technology transfer and IP management are complex, requiring the creative input
and participation of different professionals from varying fields of expertise. Therefore,
it is important to recognize that investments in public sector education and
training programs need to consider many aspects, including scientific, business and
entrepreneurial, legal, judicial, and policy.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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FOR SENIOR MANAGEMENT
(University President, R&D Manager, etc.)
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A sound IP policy should address, among others issues, clear ownership of intellectual
property generated, conflicts of interest and conflicts of commitment, the manner
in which an institution will handle confidential information, the principles of the
institution’s IP licensing approaches, how income arising from intellectual property will
be distributed, and any rights the institution will retain (such as for research and for
humanitarian uses).
An IP strategy, on the other hand, describes the courses of action enabling the reaching
of long-term goals of the institutions and the allocation of resources necessary to carry
out these actions. Public sector institutions may wish to specifically address in their
IP strategies how their research endeavors, in general, and IP management strategies,
in particular, will achieve global access of their products and how the endeavors will
benefit humanitarian objectives.
Components of such an IP strategy may include how the institution deals with
incoming third-party intellectual property, how it deals with internally generated
intellectual property (patenting and other protection strategies that should include
how the institution balances the public sector component of its mission with economic
imperatives), and how it will out-license its intellectual property to third parties.
Particular emphasis should be placed on global access strategies, not only because
philanthropic funding agencies increasingly require grantees to address them, but
because this approach is especially effective if an institution’s aim is to diffuse technology
as widely as possible.
The process by which an IP policy and IP strategy are developed may be valuable in
bringing about internal culture change and create strong support from staff.
Successful IP commercialization is built on a foundation of good relations between
inventors and technology transfer professionals. Such relationships should be established
long before the transfer services of the technology transfer office.
The importance of IP audits is becoming more and more apparent, in the private and
in the public sector, as public entities increasingly deal with third-party intellectual
property. IP audits can be useful mechanisms that form the basis for an internal review
and revision of an institution’s IP strategy and IP policy.
Technology transfer invariably brings conflicts of interest. The challenge is to manage
them in a transparent and consistent manner. Importantly, potential conflicts of interest
should not be viewed in a negative light. Most real conflicts arise when potential conflicts
are not disclosed.
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As the creator of inventions and technologies, your role in technology transfer is critical.
So please read on!
Your role can best be carried out if you have good relations with the technology transfer
office and officers. But fulfilling your role also requires a good knowledge of and
understanding of your institution’s IP policy. The policy will likely articulate ownership
of intellectual property, conflict of interest, the handling of confidential information,
and more. Become familiar with the content and the meaning of the various provisions
and how they may affect you.
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FOR SCIENTISTS

The purpose of such a policy, and more importantly of your institution’s IP strategy,
is not just to protect your inventions, but also to control technologies and IP assets in
such a way as to allow you and the TTO to determine how your inventions can—and
should—be used to spur economic growth and contribute to the greater public good.
Remember, few inventions will lead to blockbuster products, make millions of dollars,
or save billions of people. Have realistic expectations, especially regarding what it will
take for your invention to make a difference. It is not bad to love your own creations as
long as you have realistic expectations.
More and more philanthropic donors expect to find IP management components in
grant applications and to understand how intellectual property will be used to achieve
global access and humanitarian benefits. This is just one reason why a close relationship
with your TTO is important, and becoming even more so.
When your institution conducts or commissions an IP audit, view this as an opportunity
to better identify the intellectual property generated in your research program,
to improve and streamline the management of third-party intellectual property
(allowing you to concentrate more on research), and to contribute to the formulation
and execution of an IP strategy that benefits your program and its (global) impact.
One of the most important responsibilities you have is to disclose any potential conflict
of interest. You are not guilty of anything if you have a potential, perceived, or even real
conflict of interest. Most problems arise when conflicts are not disclosed. Clear conflict
of interest policies that are followed and implemented in a transparent manner is all
that is required to manage them.
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FOR TECHNOLOGY TRANSFER OFFICERS
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An IP policy should address, at a minimum, ownership of intellectual property, conflicts
of interest and conflicts of commitment, the handling of confidential information, the
principles of IP licensing approaches, the sharing of income derived from intellectual
property, and any rights the institution will retain (such as for research and for
humanitarian uses).
Public sector institutions will increasingly be expected to define an institutional IP
strategy that specifically addresses how IP management will be used to achieve
global access/humanitarian benefits of the inventions and products developed at
your institution. It should include how the institution deals with incoming third-party
intellectual property, how it deals with internally generated intellectual property, and
how it will out-license its intellectual property to third parties.
The process by which an IP policy and IP strategy are developed may be valuable in
bringing about internal culture change and create strong support from staff.
Successful IP commercialization is built on a foundation of good relations between
inventors and technology transfer professionals. Such relationships should be
established long before the establishment of transfer services of the technology
transfer office.
The importance of IP audits is becoming more and more apparent, in the private sector
and even in the public sector, as public entities increasingly deal with third-party
intellectual property. IP audits can be useful mechanisms that form the basis for an
internal review and revision of an institution’s IP strategy and IP policy.
Technology transfer invariably brings conflicts of interest. The challenge is to manage
them in a transparent and consistent manner without granting any exceptions,
irrespective of the prestige of the scientist or the amount of funding they attract.
Importantly, potential conflicts of interest should not be viewed in a negative light,
provided they are disclosed (and managed). Most problems arise when potential
conflicts are not disclosed. Few conflicts of interest are well managed by committees.
All employees (and visitors in some cases) should be required to sign an invention
assignment agreement on their date of arrival. Neither an employee handbook that
discusses patent assignment nor a published university patent policy may be enough
to ensure that the university is assigned ownership.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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Establishing and Operating Technology Transfer Offices
Technology transfer is the process of converting
scientific findings into useful products or services for society. A complex endeavor, it takes
place in the broader context of innovation. Any
country or institution can undertake health or
agricultural innovation to varying degrees, but
some developing countries that are more scientifically advanced are starting to reap the benefits
of decades of investments in education, health
research infrastructure, manufacturing and production capacity, and regulatory institutions.
Increasingly referred to as innovative developing
countries,1 these countries are characterized by,
among other things, sustained government support for research, the availability of venture capital, functioning regulatory systems, and an ability to partner with local and foreign public and
private research organizations. All of this requires
sound IP (intellectual property) management,
which makes such partnerships more effective
and allows technologies to be transferred not just
in one direction but in more complex and valuable ways, to benefit more people.
Technology transfer is thus a rewarding process for research-based institutions and
the people who make it happen. It leads to
new products, services, and jobs. But it is also
a multifaceted process with important policy, economic, and managerial ramifications.
Discussing these aspects in detail, Nelsen,2 who
leads the Technology Licensing Office of the

Massachusetts Institute of Technology (M.I.T.)
offers practical, timely advice about some of the
most important policy and strategy imperatives
for an institution starting up a technology transfer office (TTO) or intending to strengthen its
current endeavors in technology transfer.
Viable strategies to set up and operate a
TTO must be firmly grounded in realistic economic expectations. Technology transfer will
not really make your university or research institution rich because building a robust technology transfer program will take sustained financial
investment. It takes time (eight to ten years) to
build an IP portfolio, establish contacts, and develop skills in technology transfer. And it may
take up to two decades or more before a university technology transfer program (including entrepreneurial spinouts) substantially affects the
local economy. The ultimate impact, however,
may be very large—both economically and culturally—for the university, its graduates, and the
wider community.
Successfully implementing these plans will
require visible and sustained support—fiscal and
otherwise—from senior administration to set
the program’s mission, policies, and priorities.
Clear mandates will help technology transfer
professionals choose among competing priorities
and the ever-present trade-offs between business
and academic values. IP ownership policies, the
roles of researchers in interactions with industry,
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and other ground rules should be set up before
the program begins because conflicts of interest, both real and perceived, are inevitable. For
the same reason, clear policies and a well-understood review-and-appeal process need to be
put in place early. Finally, technology transfer
is a talent-based business. It is difficult to find
people who can speak the two languages of academia and industry and who also have the creativity to craft agreements that meet the needs
of both sides.
The chapter’s conclusion discusses some technology transfer pitfalls caused by unrealistic expectations. It emphasizes the role of senior management in the evolution of the culture (which
must begin with top-level administration), the
need for transparent conflict-of-interest policies,
and the importance of sufficient autonomy and
infrastructure support for technology transfer officers. A TTO can create many benefits for the
university, industry, and the surrounding community, but it requires carefully planned and
consistent long-term financial and administrative
support. And above all, it requires TTO officers
that are able—and willing—to take risks and
university presidents to support them.
Moving into the particulars of how to establish a TTO, Young3 stresses the importance of a
strong mission statement, attention to staffing
needs, and to the unique operating contexts of
each institution. Based on a lifelong experience in
establishing and running TTOs, with a chapter
that provides many examples of TTO launches
from around the globe (Australia, India, China,
Japan, England, South Africa, Russia, and the
United States), Young concludes that efficient
and effective TTOs possess the following key
characteristics:
• An articulated mission
• Transparent policies and procedures
• Entrepreneurial staffing and an entrepreneurial environment
• Customer-friendly relations with both internal and external constituents
• A highly supportive university administration and community
• Strong links to potential industry partners
• Access to risk, or venture, capital
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Even so, there is no “right” way to set up an
office, but success does require considering some
specific issues, as discussed by Campbell.4 One of
these issues is establishing business processes at
the outset. Adequate attention should be paid to
information management and realistically setting
budgets. Offices tend to be either a department
within the institution or a subsidiary company.
Either way, accountability lines will need to be
transparent. Like the preceding authors, Campbell
also stresses that the core element for successful
technology transfer is people. The TTO should
be led by an individual who understands the details of running a business. It is also useful to have
staff with experience working in the relevant business sectors. To be able to recognize new opportunities, the technology transfer manager needs to
win the confidence of academics, which is why it
is helpful for the TTO to be embedded within
the institution. Likewise, staff should be exposed
to both academics and business people.
Campbell discusses several examples of TTO
structures and policies based on her experience in
the United Kingdom, in particular King’s College
London (KCL). She also shares useful lessons
from Switzerland’s experiences with Unitechtra,
a subsidiary nonprofit technology transfer company jointly owned by the two universities of
Bern and Zürich. This model from a small, but
highly innovative country (when the number of
patents per capita is used as one measurement),
is particularly relevant for developing countries
with limited resources, where several institutions
may consider establishing a joint TTO to ensure
economies of scale and critical mass.
Fernandez,5 from Chile, develops a specific,
yet potentially powerful model for establishing or
improving technology transfer operations for universities and research institutes within developing
countries. The model takes into account several
key insights about technology transfer. Namely,
there is a critical mass of R&D activity necessary
to justify the costs of a fully functioning TTO.
Some estimates would put this figure within the
range of US$100 to $500 million in research
expenditures annually. While it is uncommon
for a single university within a developing country to attain a financial critical mass, a group of
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universities together can attain it relatively easily. In addition, some of the typical functions of
technology transfer are more easily scalable than
others, and are thus more easily shared by a group
of universities.
The model developed in this chapter essentially requires sharing the costs of technology
transfer services among a consortium of universities, with an additional startup subsidy provided
by government. A “hub-and-spokes” configuration is proposed, which allows essential policy
decisions and scalable functions to be moved
to the center and keeps essential context-specific and unscalable functions on campuses at
universities. This also allows for a more efficient
distribution of scarce resources and of key personnel who have the necessary skills, allowing a
few experienced professionals to selectively, yet
effectively, manage and mentor technology transfer staff across a range of institutions.
Fernandez openly points out the challenges
of implementing such a model, emphasizing the
need for articulated policies to be shared by all
consortium members in at least three areas. These
areas each represent potential points of real conflict within such multi-institutional systems. The
first area is a clear policy of ownership that ensures that everyone involved in the process knows
who bears ultimate responsibility for a given technology. The second is a clear policy on the distribution of income from commercialized technology. Such a policy should provide incentives that
will elicit the cooperation and support needed
from multiple players in the technology transfer
process. This is also important so that realistic
financial expectations are established, helping to
avoid disputes that could threaten the viability of
the system as a whole. The third area regards the
prevention and resolution of conflicts of interest. Such a policy is important to maintaining the
integrity of the university’s main educational and
research functions amid increased commercial
opportunities, so that any disputes that do arise
can be resolved in a systematic and fair manner,
likewise protecting the viability of the system.
An important feature of this model is that it
does not lock in its participating member institutions; it is open to competition. As the economy

grows and member universities’ R&D activities
increase, their local TTOs can take on more and
more of the functions that had been delegated to
the central office. A university would thus be able
to “graduate” from the system as its own TTO
becomes self-sustaining. Even prior to that, the
central TTO may be relied on only if it provides
effective management of technology transfer projects that member institutions cannot replicate
themselves or obtain elsewhere cost effectively. If
the centralized system fails to be competitive, the
member institutions can simply elect to manage
the commercialization of technologies in their
own offices or through other more competitive
channels.
Moving into the organizational aspects of
establishing a TTO, Dodds and Somersalo6 review the specific requirements in terms of human infrastructure, physical infrastructure, and
operational plans for the office. The latter is essential for defining office protocol for various
topics: patents, trademarks, copyrights, and trade
secrets; plant variety protection; contracts, agreements, and licenses; policy development; technology evaluation; invention marketing; conflict
analysis; negotiation support; and strategy inputs.
Importantly, any TTO must emphasize the importance of confidentiality in all its operations.
Other wide-ranging organizational matters that
need to be addressed early include; a coordinated staffing plan detailing authority, responsibilities, and work plans; a staff employment handbook
that explains the ethical standards that employees
must follow; a plan for addressing governmental
and state filing requirements; a tax plan (including accounting standards and auditing); considerations to establish an advisory panel, and criteria
for drawing on external expertise (such as consulting contracts, patent attorneys, general legal
counsel, licensing specialists, marketing specialists, and database specialists).
The specific organizational and administrative aspects of a TTO are discussed by Hines,7
based on her experience at Stanford University’s
Office of Technology Licensing. This chapter offers similar offices in developing countries a detailed outline of how an office can be structured
in terms of personnel and human resources. The
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structure consists of a director, seven licensing associates, eight licensing liaisons, one copyright
licensing specialist, and the equivalent of eight
and one-half administrative staff, in addition to
other administrative staff and industrial contracts
officers. Much action in such an office revolves
around the important technology licensing associates who work with the inventors (professors,
graduate students, and research staff) and with
prospective licensees. In addition to providing a
list of key personnel for a TTO’s operation, the
chapter also defines, and gives examples of complex cases, job descriptions, and a comprehensive
list of standard operating procedures (for licensing
agreements and for invention disclosures). Like
the other authors in this section, Hines stresses
the importance of a well-trained staff.
Continuing and practical training should be
an integral part of any TTO’s yearly work plan.
For this, Pefile and Krattiger8 present a few focused case studies that can be incorporated into
short courses in IP management. They stress
the importance of hands-on training programs
whereby participants play specific roles within
difficult case studies tailor-made to serve the particular needs of the TTO or its staff. Such approaches allow participants to see how a specific
professional role can affect the complex process of
crafting beneficial and creative partnerships that
lead to mutually beneficial solutions. Even for
those not involved in deal making, this approach
has great utility because it enables participants to
view their respective tasks in a broader context,
and thereby gain a perspective as to the challenges
presented at various stages in the overall process.
Indeed, the importance of building networks
in the technology transfer and licensing community cannot be overstated. To illustrate this,
Hersey9 uses the experience of the Association of
University Technology Managers (AUTM) as an
extended case study of the building of dynamic, productive, and sustainable networks. Her
chapter contains numerous lessons applicable
anywhere. Networking among peers in any profession is generally understood to be beneficial,
as it cements relationships between individual
practitioners and helps build and strengthen the
profession itself. By working through networks,
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practitioners exchange ideas and experiences,
forming best practices that become performance
standards for both individuals and their institutions. Networks thereby contribute to IP management capacity building at both the individual
and institutional levels, and this then feeds back
to further support and expands the network.
As groups of like-minded, mission-driven
professionals, networks can be formed at different geographical levels in order to serve various
functions. This multilevel approach allows organizations to address different aspects of their respective missions. Local networking creates opportunities to work with colleagues in the immediate
vicinity. National networking can be a mechanism
for working with colleagues to encourage national legislation addressing intellectual property
and technology transfer, as well as for designing
and implementing systems for appropriate IP
management, training, and education. Regional
networking provides opportunities to work with
neighboring countries in coordinated R&D endeavors and related IP management and technology transfer initiatives. Importantly, international
networking will become increasingly important as
globalization advances. Building networks with
colleagues around the world will provide opportunities for many forms of technology transfer
and IP management capacity building.
This is particularly relevant in the context of
TTOs working with external patent counsel as
developing countries increasingly wish to file patents in other jurisdictions. From a licensee point of
view, having patent coverage in the more lucrative
markets of the United States, Europe, and Japan
may be a prerequisite for licensing a technology
from a developing country. Similarly, if a patent is
drafted poorly or does not provide adequate coverage for the technology, licensing opportunities
may either be lost or significantly devalued. The
costs associated with inadequately drafted patents
can be significant, so it is important for a TTO to
carefully select a patent attorney whose work will
enhance the institution’s prospects for obtaining
optimal licensing arrangements.
Goldman10 reviews the process of selecting,
hiring, and interfacing with patent counsel. Of
course, central to this relationship is ensuring that
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patent counsel can prepare and prosecute patent
applications in a manner that achieves positive results in a cost-effective fashion. The chapter presents the steps in this complex process, and the
responsibilities that both counsel and the TTO
should assume. Patent attorneys can also provide
general counseling, resolve inventorship issues,
provide licensing and agreement support, and
resolve disputes. By selecting a qualified patent
attorney and developing a good working relationship, a TTO can develop a resource that will
ease the workload and facilitate its missions. This
choice of patent counsel is therefore essential for
operating a viable TTO and should be approached
thoughtfully. There are several factors that should
be carefully considered and weighed:
• size of the attorney’s firm11
• scope of the attorney’s legal experience and
capabilities
• the attorney’s experience with academic
institutions
• the attorney’s technological background
• the firm’s location
After a patent attorney is selected, determining how work will be allocated is important.
Generally, the less work that is sent to the attorney, the lower the TTO’s legal fees. Still, the more
work the TTO retains for itself, the less time its
staff will have for other matters. Another critical
aspect of the relationship between the patent attorney and the TTO is payment for services. The
chapter presents several possible methods and
schedules for payment, and also cautions against
certain related practices. For example, a letter of
retainer can, among other things, specify billing
procedures, such as fixed fees, hourly billing rates,
and equity combinations. Another feature of the
retainer letter will be a specification of the bill
content: an acceptable bill will include an indication of which attorney or attorneys worked on a
particular project, the amount of time spent daily
on that project, and what that work involved.
This will make clear the services for which the
TTO is being charged.
Dodds12 considers a broader picture of how
to hire an IP lawyer without going bankrupt.
While the process can be complex and costly,

Dodds outlines various strategies for how TTOs
can make the best use of attorneys. He points out
the value of retaining an IP attorney, especially
when a TTO is just getting established. A critical
initial role of the lawyer should be to work closely
with the TTO to develop an IP strategy that most
effectively delivers benefits to the office. If your
TTO strategy is ill conceived, all the remaining
activities will be irrelevant.
Any emerging TTO will have a wide range of
legal matters to be addressed. These include the
types of IP protection to be provided, when to
apply trademarks and copyright, how much to
rely on trade secrets, the development of contracts
and agreements, license reviews, and negotiations
support. The lawyer can also be used to think in
innovative ways about how to capture value from
an IP portfolio.
Importantly, the legal relationship between a
lawyer and a client is protected under a special set
of legal rules that make up the concepts of client
confidentiality and legal privilege. This umbrella
of confidentiality and legal protection from disclosure is a very important part of the relationship. The importance of confidentiality and trust
cannot be underestimated. Such confidentiality
requires excellent record keeping.
Indeed, a TTO needs to have a systematic
way of managing agreements and many other
forms of data as the amount of data will increase
significantly and year by year. Unfortunately, too
many TTOs still try to accomplish this task with
a paper filing system, which is cumbersome, slow,
and inflexible. Above all, this type of system severely limits the ability to analyze data creatively.
Using electronic systems, a manager can rapidly
formulate questions that in a physical file environment would be unthinkable, due to the time
required to locate, assemble, and analyze the information sets.
Electronic filing systems also provide shared
communication links and can utilize advanced
spreadsheet applications. The chapter by Sloman13
considers the relative merits of spreadsheets, flatfile databases, and relational databases as TTO
data management tools/systems. It emphasizes the benefits of the latter, highlighting both
their ability to transfer entire projects from one
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manager to another with the click of a button and
their unprecedented power to allow managers to
look at data and business models in creative ways.
Such a system requires less data entry and can
be easier to maintain and audit. For all of these
reasons, the relational database is frequently the
preferred system.
The sooner a functional contract management system is implemented, the easier it will be
to keep track of contracts and make the most of
them, both for the organization and for its collaborators. Two chapters, one by Hamzaoui14 and
one by Potter and Rygnestad15 discuss the importance, design, and implementation of contract
management systems from different, but equally
pragmatic perspectives. Hamzaoui bases her chapter on the practices of the Whitehead Institute for
Biomedical Research. Both chapters review the
specific approaches for actually implementing a
contract management system, including:
• accessibility (e.g., hard-copy filing, electronic filing, database systems)
• security (e.g., loss prevention, unauthorized
access)
• resources for implementation
• personnel time, training, and management
The value of the proper management of contracts and agreements is usually only seen in its
absence—lost deals, a poor reputation and, in
the worst case, lawsuits. Early investments to prevent these sorts of problems are like any prophylactic measure and the savings will certainly be
substantial.
Graciously, the Whitehead Institute agreed
to make available, for free, their proprietary
agreement management system, called WIIPS™,
through the online version of the Handbook.16
Users can download a fully functional version
that they can also modify and adjust to their
particular institutional needs. WIIPS™ is a relational database designed to automate essential
IP management and technology transfer functions. It simplifies record keeping and generates
useful reports for technology disclosures, patent
applications, joint invention agreements, licenses, and material transfer agreements. In addition,
the system stores essential information on every
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inventor, owner, and licensee who has interacted
with a given TTO.
Finally, the chapter by Pefile17 takes a broad
view and considers the mission of a TTO in the
context of knowledge transfer. Indeed, making
money will always be a consideration when setting objectives, but technology transfer adds value
in other important ways; as a resource to facilitate
innovation for the public good and as a way to
broker the exchange of knowledge between the
business and public sectors for society’s benefit.
Transferring knowledge across such disciplines as
the humanities, law, and social sciences is as important as transferring knowledge and technology across the applied sciences, and TTOs should
be set up to have the flexibility to accomplish this
broader knowledge-transfer objective.
An effective evaluation system should
strengthen an institution’s ability to maintain
leadership across the frontiers of scientific knowledge. The evaluation system also will stimulate
partnerships that promote investments in fundamental science and engineering, as well as the
overall more-effective use of physical, human,
and financial resources for social and economic
benefit. Without a measurement process, institutions cannot justify their efforts in R&D, IP
management, commercialization, and technology
transfer in relation to their economic and social
goals. Finally, Pefile calls upon all TTO managers
to take the time to reflect upon their operations
and ways in which they can be made more effective and beneficial for all. n
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FOR GOVERNMENT POLICYMAKERS
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Technology transfer is the process of converting scientific findings into useful products
or services for society. Hence encouraging public institutions and private sector
enterprises to work together is an important element in any national strategy aimed
at strengthening innovation.
In the increasingly interlinked and globalized worlds of science, technology, and
commerce, such collaborations should extend beyond national borders, as success
will increasingly be measured by the ability to form dynamic, integrated, and mutually
beneficial networks that span countries and institutions.
Government policies and laws regarding technology transfer ought to be flexible so
that each institution can shape its approach according to its own culture, mission, and
context.
Laws regarding IP ownership are essential for successful technology transfer.
National institutions often require governmental encouragement and sustained
funding to develop technology transfer offices (TTOs), as well as IP policies (conflict of
interest management, allocation of revenues, and so forth).
Viable strategies to set up and operate a TTO must be firmly grounded in realistic
economic expectations. Technology transfer will not make any institution rich
because building a robust technology transfer program will take sustained financial
investment. It takes time (ten years or more) to build an IP portfolio, establish contacts,
and develop skills in technology transfer. And it may take up to two decades or more
before a university technology transfer program (including entrepreneurial spinouts)
substantially affects the local economy.
A certain critical mass of R&D activity is necessary to justify the costs of a fully
functioning TTO. Some estimates would put this figure within the range of US$100 to
$500 million in research expenditures annually.
Several alternative models to an institutional TTO can be successful. Costs can be
shared among a consortium of universities or research institutions. Such hub-andspokes configurations allow essential policy decisions and scalable functions to be
moved to the center, while keeping essential context-specific and unscalable functions
embedded within individual institutions. This allows for a more efficient distribution
of scarce resources and of key personnel who have the necessary skills, allowing a few
experienced professionals to selectively, yet effectively, manage and mentor technology
transfer staff across multiple institutions.
Recognizing that technology transfer is a talent-based business, the importance of
building networks in the technology transfer and licensing community cannot be
overstated. Governments should encourage the creation and operation of national
technology transfer associations that concurrently build international linkages.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.

80 | HANDBOOK OF BEST PRACTICES: EXECUTIVE GUIDE

Establishing and Operating Technology Transfer Offices

(University President, R&D Manager, etc.)

4

4

4

4

4

4

4

4

4

4

Successfully establishing and operating a technology transfer office (TTO) will require
visible and sustained support—financial and otherwise—from senior administration,
which can set the program’s mission, policies, and priorities. Clear mandates will help
technology transfer professionals choose among competing priorities.
A TTO can create many benefits for the university, industry, and the surrounding
community, but it requires carefully planned and consistent long-term financial and
administrative support. And above all, it requires TTO officers able—and willing—to
take risks and senior management to back them.

Key Implications and Best Practices: SETCION 6

FOR SENIOR MANAGEMENT

Efficient and effective TTOs must have an articulated TTO mission, transparent TTO
policies and procedures, entrepreneurial staffing and an entrepreneurial environment,
customer-friendly relations between TTO staff and internal and external constituents,
a highly supportive administration, strong TTO links to potential industry partners, and
TTO access to risk, or venture, capital.
The core element for successful technology transfer is people. The TTO should be led
by an individual who understands the details of running a business. Additionally, staff
members with experience working in the relevant business sector are required.
An important factor for a successful TTO is the institution’s entrepreneurial culture.
Strategies to set up and operate a TTO must be firmly grounded in realistic economic
expectations. Technology transfer will not make any institution rich because building
a robust program will take sustained financial investment. It takes time (ten+ years) to
build an IP portfolio, establish contacts, and develop skills in technology transfer.
A critical mass of R&D activity is necessary to justify the costs of a fully functioning TTO.
Some estimates would put this figure within the range of US$100 to $500 million in
research expenditures annually.
Several alternative models to an institutional TTO can be successful. Costs can be shared
among a consortium of universities or research institutions. Such hub-and-spokes
configurations allow essential policy decisions and scalable functions to be moved to
the center, while keeping essential context-specific and unscalable functions embedded
within individual institutions.
Implementing a consortium model of a TTO across institutions presents many challenges.
These can be managed with clearly articulated policies of ownership, the distribution
of income from commercialized technology, and mechanisms for the prevention and
resolution of conflicts of interest.
An important feature of this model is to allow for a certain level of competition, a locally
embedded TTO officer, and an evolution of the model. As the member institution’s R&D
activities increase, local TTOs can take on more and more of the functions that had been
delegated to the central office.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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Your power to shape institutional policy should not be underestimated, especially in the
ways that the fruits of your research can be made to increase economic development
and benefit humanity.
Know your institutional conflict of interest policy. Most conflict of interest issues arise
when procedures are not properly followed.
Work with your TTO to ensure that your institution’s disclosure of information form is
simple and easy for you to use.
Understand why you might benefit from engaging in technology transfer and what
you want to get out of the relationship with the TTO.
A national or regional consortium of universities to develop a technology transfer
system could be beneficial to you and your colleagues because it would be more cost
effective and would have greater latitude and leverage in exploiting commercialization
opportunities than would a single campus office.
Establishing networks among colleagues will increase your awareness of opportunities
and also help you understand the broader implications of your research.
Keep your TTO informed about your networking activities, particularly if there is a
possibility of shared research endeavors. These collaborative research projects often
form the foundation of networks for technology transfer and licensing opportunities.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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You have a duty to ensure that senior management understands that a successful
technology transfer office (TTO) requires visible and sustained support, financial and
otherwise. Work with senior management on the definition of clear mandates that will
help you choose among competing priorities and the ever-present trade-offs between
business and academic values.
Above all, ensure that senior management knows that it requires TTO officers who are
able and willing to take risk and senior management to support you.
Efficient and effective TTOs must have an articulated TTO mission, transparent TTO
policies and procedures, entrepreneurial staffing and an entrepreneurial environment,
customer-friendly relations between TTO staff and internal and external constituents,
a highly supportive administration, strong TTO links to potential industry partners, and
TTO access to risk, or venture, capital.

Key Implications and Best Practices: SETCION 6

FOR TECHNOLOGY TRANSFER OFFICERS

One of the most important factors for a successful TTO is the institution’s entrepreneurial
culture. This is determined most often by the attitude and degree of support from
senior management.
A TTO must emphasize the importance of confidentiality in all its operations.
Any TTO needs to have, from the outset, a systematic way of managing agreements
and many other forms of data as the amount of data will increase significantly and
year by year. The sooner a functional contract-management system is implemented,
the easier it will be to keep track of contracts and make the most of them, both for the
organization and for its collaborators.
The Whitehead Institute’s proprietary agreement management system (called WIIPS™)
may constitute a viable software option for emerging and established TTOs. WIIPS™
can be downloaded for free from the online version of the Handbook.
The importance of continued hands-on training programs of TTO staff cannot be
overstated.
Similarly, the importance of building networks in the technology transfer and licensing
community is critical. By working through networks, practitioners exchange ideas and
experiences, forming best practices that become performance standards for both
individuals and their institutions.
When recruiting personnel to staff your office, consider key qualifications. The
importance of having the best professionals working for you cannot be overstated.
Staffing can have a significant impact on the success of your office.
Any TTO will have a wide range of legal matters to be addressed, and procedures for
working with external patent counsel and general counsel should be well established.
Make sure you are in, and stay in, the driver’s seat.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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Contracts and Agreements to Support Partnerships
A contract follows the deal that has been made
between two or more parties. Put differently, form
(contract) follows function (deal). And any deal
has a purpose: it is a means of transferring value
between parties. Ideally, the trust between partners permeates their relationship and interactions,
from the negotiations of an agreement, through
project implementation, and into future agreements, collaborations, and projects. However, in
practice, circumstances are rarely perfect. So negotiating agreements should be seen as an initial
step toward longer-term, productive, and mutually beneficial relationships.
There are many types of agreements, as noted
and discussed by Mahoney and Krattiger,1 and
those related to collaborations fall into one of
four broad categories:
• Confidentiality agreements protect confidential
information from disclosure to third parties.
• Materials transfer agreements (MTAs) protect
samples (tangible property) from misuse by
or unauthorized distribution to third parties.
• Co-development agreements and collaboration agreements outline the specific contributions of different parties who work toward a mutual goal.
• Patent licenses and technology licensing agreements allow one party to further develop,
use, make, or sell the patented (and/or
trade-secret-protected) technology of another party. Patent licenses may be specific

to one or several patents. Technology licenses usually include the transfer of know-how
(which may or may not be a trade secret)
and sometimes materials. Such licenses
may provide for the further development
of a technology or limit production/manufacture of a good or provision of a service.
Commercialization licenses are discussed in
part 12 of the Executive Guide: Dealmaking
and Marketing Technology to ProductDevelopment Partners.
In addition, parties may engage in research
agreements and distributorship agreements that
contain elements of the four types of agreements listed above. Many agreements, such as
MTAs contain confidentiality provisions; patent/
technology licenses often contain confidentiality and material transfer provisions as well. But
certain standard elements are integral to most
agreements:
• recitals, preamble, and “whereas clauses” that
lay out the broad motivations and goals of
the agreement
• a list of the parties entering into the agreement
• definitions of terms used in the agreement
• confidentiality clauses
• territory and exclusivity clauses that define
the geographic regions in which the licensee is permitted to make, use, and/or sell the
technology in question

Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 2007.
7: Contracts and Agreements to Support Partnerships. In Executive Guide to Intellectual Property Management in Health
and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK),
PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute
(Ithaca, USA). Available online at www.ipHandbook.org.
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for
noncommercial purposes is permitted and encouraged.
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• liability clauses that establish who will accept liability for a product and that set out
terms of liability
• payment clauses that define the forms of
payment, if any, of up-front fees and/or
royalties (Terms will ideally balance the
licensor’s need for short-term income and
the licensee’s capacity to make further investments for longer-term development.)
• an arbitration clause that establishes how
disputes will be handled
• term and termination, establishing how long
the agreement will last and under what conditions the agreement may be terminated
• jurisdiction, warranties, and notices, which
specify (1) where disputes are to be resolved,
(2) that the licensor does, in fact, own the
intellectual property to be licensed, and (3)
where official communications are to be
directed
• illegal/unenforceable provisions that specify
which terms can be discontinued due to invalidity without rendering the agreement void
• subject law, which specifies where the parties wish to have the agreement interpreted
and adjudicated
• signatories (These are representatives, called
agents, who have the authority to bind their
respective organizations, called principals, to
the terms and provisions of the agreement.)
Public sector research institutions can use a
variety of agreements to protect and manage intellectual property. These agreements are powerful tools to foster competition in the private sector and reduce prices for consumers in developing
countries. The authors emphasize the importance
of establishing and maintaining trust when negotiating and implementing agreements.
Although no agreement will ever be perfect,
there are good and not-so-good agreements (and
poorly written and highly ineffectual agreements).
The best agreements are generally those that do
not use technical or legal jargon, that use short,
clear sentences free of vague adjectives and written
in active voice. Business people (who have extensive technical knowledge but generally limited legal
knowledge) and judges (who generally have limited
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technical knowledge but extensive legal knowledge) should find such documents accessible.
Agreements that serve the parties best may
take longer to negotiate, but each time two parties have successfully developed an agreement, the
development of subsequent agreements should be
easier. Taking time to think through and discuss
the terms of an agreement fosters communication between the partners, although often template agreements2 can be used as starting points
in building trust.
During collaborations, and in some types of
licensing agreements, materials and confidential
information are passed from one party to another. Confidentiality, or nondisclosure, agreements are contracts that govern the disclosure
of confidential information by one party to another party and can be useful for building trust.
Kowalski and Krattiger3 explain that disclosures
may be unilateral, bilateral, or multilateral, and
confidential information is valuable precisely because it is not known to business competitors or
to the public. Key provisions in a confidentiality
agreement include:
• definition of the information
• important exceptions, which describe circumstances under which the obligation of
confidentiality is inapplicable (for example,
the information was already in the public
domain or is commonly known)
• conditions on the use of the confidential information, which is a detailed description
of the ways in which the receiving party
may and may not use the information
• requirements for documentation, which describe the requirements for written records
(may include keeping track of the disclosed
information, whether disclosed in writing
or orally)
An organization that enters into a confidentiality agreement must ensure that all who have access
to the confidential information understand that
they must keep sensitive information confidential.
Traditionally, scientists have freely shared information as well as research materials. However,
with fundamental research and commercial development merging ever closer, in both health and
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agricultural research, materials that once would
have been used exclusively for fundamental research increasingly have direct commercial value.
Therefore, universities, for-profit corporations,
and nonprofit research institutions now realize
that they must obtain proprietary protection for
their research materials. Unrestricted transfers of
research materials between scientists are becoming
less and less common, particularly transfers between scientists in industry and those in academia.
Biological materials are transferred still, though
not as freely as before, but now with conditions attached as part of MTAs. Increasingly important in
the life sciences, MTAs delineate the terms under
which tangible materials are transferred between
two or more parties. Technically, MTAs are bailments because they involve the transfer of possession but not of title. In other words, the party that
transfers the materials retains full ownership, and
the party that receives the materials holds them
“in trust”; an analogy for such a transfer might be
the act of leaving a watch at a watch-repair shop or
a suit with a dry cleaner.
Bennett, Streitz, and Gacel4 explain that an
MTA specifies the term of a transfer, delineates
how materials may and may not be used, and
provides for other related issues such as confidentiality. An MTA may also contain licensing provisions for the transfer of embedded IP rights (such
as patent rights). Thus, an MTA can be a hybrid
instrument, covering the transfer of both tangible
property (via bailment and contract) and intangible intellectual property (via licensing of patent rights). Thus, MTAs can be quite complex.
Besides the usual clauses included in MTAs, the
following are the perhaps the most critical to consider, especially for public sector institutions:
• reach through clauses, which describe the
extent to which the supplying party may
“reach”’ into the research and into new
intellectual property or material generated
from work with the supplied materials
• derivatives, clauses that explain who will
own modifications if the receiving institution makes modifications to the material

institutions must understand the implications of
such clauses if indeed they are included. As a result, material transfers between private- and public-sector institutions are typically much more
complex than MTAs between two universities.
It is less problematic for universities to transfer
materials than it is for materials to be transferred
between industry and academia. If a problem
does occur under a transfer arrangement, it is
usually because IP rights attached to the materials transferred have been exclusively licensed and
the terms of that agreement impose constraints
on the institution providing the material.
Collaborative research agreements and sponsorship agreements are generally more complex
than MTAs. A collaborative research agreement,
for example, often involves multiple partners
(who are increasingly a mixture of private- and
public-sector actors) working together on a research project. The partners each contribute an
amount of money, talent, and technology into a
central pool that all draw from. Chapters by Bair
Steinbock5 and Gold and Bubela6 explain how to
write collaborative research agreements and covering myriad issues, including licensing provisions.
The authors point out that the following elements
are the most critical in these agreements (besides
the usual must-haves for any agreement):
• statement of objectives, which explains what
the parties want to accomplish together
and why their collaboration is important
• statement of work, which explains the research plan, outlining approaches and
methodologies, specifying who will be responsible for work product, and delineating time frames, benchmarks, and delivery
dates
• work plan that specifies what each party will
be expected to contribute, how necessary
changes to the work plan will be made, and
how communication between the parties is
to take place
• dispute resolution plan, which explains procedures and mechanisms that would be
used in turn, should a dispute arise

Particular consideration should be given
to these all-important clauses, and receiving

Focusing on patent licensing, Krattiger7
points out that not every patent needs to be
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licensed per se. A special form of agreement—
which can also take the form of a public statement—is the nonassertion covenant (nonassert).
Such an agreement certifies that a party or parties
in possession of intellectual property will not assert and defend IP rights (typically patents). Such
nonasserts can be used in a broad range of IP
management scenarios. For example, nonassertion covenants are particularly useful for granting developing countries access to essential innovations in health and agriculture, since such
agreements offer simple and effective ways of
dealing with three major constraints common in
agri-biotechnology transfer and licensing:
1. Nonassertion covenants can be used to circumvent liability associated with licensing.
2. Nonassertion covenants can make research
tools available.
3. Transaction costs can be reduced because
such costs associated with nonassertion
covenants are lower than those associated
with bilateral and multilateral licensing
agreements.
From a legal perspective, nonasserts are preemptive patent-infringement settlement agreements that are designed and drafted with the purpose of resolving future infringement disputes.
There are no compelling reasons why nonasserts
could not become more widely used to foster
important advances and innovation that address
needs in developing countries.
A patentee’s public declaration of nonenforcement of a patent via a nonassert can have
wide-ranging implications in terms of enhancing public sector R&D. This would be the case
especially with patent rights covering research
tools, and particularly in the United States, due
to limitations on research exemptions. These are
critical for accelerating the development of essential biotechnological applications in both the
health and agricultural industry sectors. Carefully
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drafted, targeted nonasserts permitting the use of
these tools—anywhere in the world—to address
humanitarian needs (including in a commercial
setting) could have broad-ranging and significant
positive impacts. The approach reduces transaction costs, encourages innovation to help the
poor, and accomplishes this without much cost,
time, or loss of commercial opportunity. n
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and SP Kowalski (eds.). MIHR: Oxford, U.K., and PIPRA: Davis,
U.S.A. Available online at www.ipHandbook.org. The online
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A public sector institution can use a variety of agreements to both manage and protect
intellectual property, regardless of whether that intellectual property is owned by the
public sector institution or by licensing partners in the private sector. The key issue is to
allow for maximum flexibility whereby institutions can set, or negotiate, the terms that
best fit the mission and goals of the institution and the purpose of the partnership.
It is important to encourage partnerships that accelerate the development and use of
new technologies, whether they are domestic or foreign, and to provide support and
encouragement during negotiation in the form of tangible commitments to capacitybuilding, as well as to broader IP management training in patenting, licensing, and
technology transfer, for example.

Key Implications and Best Practices: SETCION 7

FOR GOVERNMENT POLICYMAKERS

Confidentiality agreements are meant to protect sensitive data that one party transfers
to another. They do not run counter to public sector missions or to publishing important
research findings. Many organizations, including public sector institutions, often
have information that is legitimately kept confidential. Such information can include
business plans, research proposals, and databases containing business contacts.
Confidentiality agreements rely on a culture of trust, not a culture of secrecy.
Predictably enforced and fairly construed contract laws will greatly facilitate the
formation and enforcement of contracts. A functioning court system is essential to
encouraging partnerships. Indeed, suppliers of biological materials (and of confidential
information and intellectual property) will be encouraged to enter into agreements
if the suppliers are confident that their property rights will be protected and that
agreements will be enforced. Such confidence fosters collaborative research, and drives
international collaboration.
It is important that the courts adjudicate contract disputes efficiently and fairly because
the quality of the judicial system will influence the quality and quantity of a country’s
international partnerships and agreements and also will influence the complexity and
sophistication of technologies transferred to and from a given country.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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A public sector institution can use a variety of agreements to both manage and protect
intellectual property, regardless of whether that intellectual property is owned by the
public sector institution or by licensing partners in the private sector. The key issue is to
allow for maximum flexibility whereby institutions can set, or negotiate, the terms that
best fit the mission and goals of the institution and the purpose of the partnership.
It is important to encourage partnerships that accelerate the development and use of
new technologies, whether they are domestic or foreign, and to provide support and
encouragement during negotiation in the form of tangible commitments to capacitybuilding, as well as to broader IP management training in patenting, licensing, and
technology transfer, for example.
Confidentiality agreements are meant to protect sensitive data that one party transfers
to another. They do not run counter to public sector missions or to publishing important
research findings. Many organizations, including public sector institutions, often
have information that is legitimately kept confidential. Such information can include
business plans, research proposals, and databases containing business contacts.
Confidentiality agreements rely on a culture of trust, not a culture of secrecy.
No agreement will ever be perfect. Technology transfer officers who negotiate
agreements that are in keeping with an institution’s policy, ought to be given full
support by senior management, especially when deals are criticized from outside of
the organization.
Senior management can be instrumental by signing off on certain template agreements
that can be used as a basis for negotiating deals. But a template agreement should be
used only as a starting point for discussion.
Any institution should have clear guidelines stating who is authorized to sign
agreements.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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A public sector institution can use a variety of agreements to both manage and protect
intellectual property, regardless of whether that intellectual property is owned by the
public sector institution or by licensing partners in the private sector. The key issue is to
allow for maximum flexibility whereby institutions can set, or negotiate, the terms that
best fit the mission and goals of the institution and the purpose of the partnership.
Confidentiality agreements are meant to protect sensitive data that one party transfers
to another. They do not run counter to public sector missions or to publishing important
research findings. Many organizations, including public sector institutions, often
have information that is legitimately kept confidential. Such information can include
business plans, research proposals, and databases containing business contacts.

Key Implications and Best Practices: SETCION 7

FOR SCIENTISTS

Confidentiality agreements rely on a culture of trust, not a culture of secrecy.
No agreement will ever be perfect. Technology transfer officers who negotiate
agreements that are in keeping with an institution’s policy are making their best effort
at getting deals that respect and strengthen the institution’s mission. Your role, however,
is to share with those who negotiate agreements all of the relevant information and
your insights. In some cases, especially with collaborative research agreements, you
may be an integral member of a team that will address issues such as research plans
and purpose.
In most cases, you will not be authorized to sign certain types of agreements without
review by counsel or by your technology transfer office. Make sure you know whether
or not you are authorized to sign certain agreements.
Everyone in your group or laboratory should know—and understand—the obligations
entered into through certain agreements that affect information, data, and materials
used in your laboratory and research program. This is especially important for material
transfer agreements and confidentiality agreements.
You will need to keep track of data and information related to confidentiality
agreements. Understand what can and cannot be disclosed and to whom information
can be disclosed. If you have questions, do not hesitate to contact your technology
transfer office for guidance.
An MTA should not be viewed as a barrier to materials access. In fact, MTAs are tools
for gaining greater access to materials from a wider range of sources (scientists from
the public and private sectors, both in your own country and abroad). However, not all
clauses in an MTA may be appropriate. Which clauses are appropriate will depend on
the circumstances, the purposes of the transfer, and the institution from which the
material is being received.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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A public sector institution can use a variety of agreements to both manage and protect
intellectual property, regardless of whether that intellectual property is owned by the
public sector institution or by licensing partners in the private sector. The key issue is to
allow for maximum flexibility whereby institutions can set, or negotiate, the terms that
best fit the mission and goals of the institution and the purpose of the partnership.
Recognizing that no agreement will ever be perfect, you will need to work with senior
management to obtain their full support and backing, especially when deals are likely
to be criticized from the outside.
Certain terms should be “negotiated” internally prior to negotiating with third parties.
Senior management can be instrumental by signing off on certain template clauses
that can be used as the basis for negotiating deals.
A template agreement should be used only as a starting point for discussions.
Contracts should be tailored to fit local customs and business practices. Be sensitive to
cultural and linguistic differences among parties to a contract.
Your office ought to be the official repository of all agreements dealing with incoming
and outgoing biological materials.
Legal jargon in agreements should be avoided. Instead, use short, clear sentences
that are free of vague adjectives and are written in the active voice. The vocabulary
should be accessible both to business people (who have extensive technical knowledge
but limited legal knowledge) and judges (who have limited technical knowledge but
extensive legal knowledge).
Confidentiality agreements rely on a culture of trust, not a culture of secrecy. Make
sure that confidentiality agreements contain the necessary exceptions appropriate for
the mandate of your institution. A tricky question is how broadly the term confidential
information should be defined. Too narrow a definition may leave out important
information; too broad of a definition may prevent the parties from getting on with
their work.
MTAs call for extra caution with respect to clauses that deal with reach through and
the ownership of derivatives. These clauses need not be negative. In fact, you may wish
to impose certain reach through clauses yourself. These decisions will depend on the
circumstances.
When negotiating collaborative research agreements, you should involve the scientists
to the maximum extent possible. Also, pay particular attention to a clear and detailed
work plan, how communication is to happen among the parties, how modifications to
the work plan are to be agreed upon, and how disputes are to be resolved.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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Inventors and Inventions
Universities, inventors, and inventions—and by
extension intellectual property—are all inextricably intertwined. Scientists are the central force
behind the research, teaching, and extension
missions of universities. And inventors can be
considered the central force behind intellectual
property, since they generate patentable inventions. Dealing with scientists, and inventors,
at least from an IP management perspective, is
not always straightforward or easy, but the technology transfer process and licensing are made
easier if scientists know some basics of IP management and of patenting, and are somewhat
familiar with best practices. This applies equally
to high-flying attention-seekers and low-key
geniuses.
A university research program must frequently make decisions about whether its researchers’ discoveries should be protected. The process
leading to this decision can place a tremendous
strain on the relationship between the technology
transfer office (TTO) and scientists. And it is one
of the principal reasons why scientists should be
given an opportunity, from the day they join a research institution, to learn the very basic concepts
of IP management to better understand the process and the challenges faced by TTOs and TTO
officers. How are decisions made as to when to
patent, what to patent, and how to protect an invention? When it comes to new inventions, unclear and non-transparent procedures lead to ten-

sions that can be costly in terms of money, time,
missed opportunities, and relationships between
scientists, heads of departments, and TTOs. So
it is important that university leaders and administrators—and scientists—work in concert on
policies and mechanisms that establish the procedures used for recording inventions, for invention disclosure, and for sharpening the interface
between scientists and technology transfer and
licensing offices.
Three conspicuous but usually neglected issues deserve special consideration up front. First,
it is often difficult to know when an invention has
actually been made. Training of scientists with respect to IP management and an institutional atmosphere that encourages inventions and invention disclosures are essential for making the most
of scientific endeavors. Second, inventors need to
have a clear understanding of their rights—and
responsibilities—when it comes to their inventions. Unrealistic expectations that are either too
high or too low will get in the way of optimally
productive research and can be a source of conflicts with TTOs. Third, inventions, per se, are
not necessarily innovations, though they may
become innovations.1
The section’s opening chapter by Mutschler
and Graff2 provides essential information that
university scientists and inventors need to know
in order to manage new and existing intellectual property and to deal with TTOs. University

Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 2007.
8: Inventors and Inventions. In Executive Guide to Intellectual Property Management in Health and Agricultural Innovation:
A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). bioDevelopments-International Institute (Ithaca,
USA), MIHR (Oxford, UK), PIPRA (Davis, USA), and Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil). Available online
at www.ipHandbook.org.
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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faculty and scientists anywhere need a working
knowledge of what intellectual property is and
what can be done with it so that they are able
to make decisions about their laboratories’ IP issues. These issues range from how to start and
run a research program (from an IP management
perspective), how to handle new inventions produced by that research, and how to manage the
property of their collaborators. Graduate students
and postdoctoral scientists should also acquire
a basic understanding of intellectual property,
since this knowledge will be valuable to them no
matter what their future careers hold, whether in
government, academia, non-governmental organizations, or industry.
Universities typically have—or should
have—institutional IP policies that must be
complied with by all personnel. In the United
States, these IP policies must conform to the
guidelines outlined by the Bayh-Dole Act of
1980. This act was intended, among other purposes, to promote private sector investment in
federally funded research to facilitate the transfer of federally funded research to industry. For
these reasons, university employees in the United
States must sign agreements that state that all
intellectual property generated under the university’s aegis belongs to that university (though
an inventor is typically given a share of the revenues that come from the sale of any intellectual
property that he or she generates). One major
exception to the policy of assigning IP rights to
the university, however, is copyrighted material
(books, papers, drawings, paintings, sculptures,
and so forth).
A university’s IP office or TTO is typically
responsible for protecting and developing commercial applications (including out-licensing
patents) for inventions developed at the university. Its functions typically include:
• determining the most effective way to
protect inventions
• evaluating the commercial potential of
inventions
• obtaining the appropriate protection for
inventions
• locating suitable commercial-development
partners and marketing inventions to them
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•
•

negotiating and managing IP licenses
encouraging and assisting the formation
of new companies around university-generated intellectual property (start-ups)

In addition to briefly reviewing the above,
Mutschler and Graff familiarize scientists with issues they face on a daily basis:
• how to deal with confidential information
• how to deal with materials from third parties
• what constitutes a public disclosure of scientific finding
• how the patenting process works
• understanding the basics of intellectual
property
If scientists read only one chapter in the entire Handbook, Chapter 8.1 is the one they should
read. But on a daily basis, a scientist’s responsibility goes further than having a basic understanding
of IP management. For authoritative IP management, university faculty, staff, and students need,
at a minimum, to appropriately document their
research findings, use of intellectual property not
owned by the university, dealings with collaborators outside the university, and places and times
of public disclosures of research results. Good
record keeping is not only important for preparing publications, reports, and grant proposals,
it is also essential for preparing IP-protection
documents and supporting IP rights. Universities
must be very careful when they use materials and
methods that do not belong to them, in order to
avoid infringing on the property rights of others. In a worst case scenario, third-party materials
may be used in research, which would mean the
new intellectual property generated through use
of that material would belong to that third party.
Ownership would depend on how the material
was obtained. Issues related to ownerships (material transfer agreement) are discussed elsewhere.3
But irrespective of the terms of access, good record keeping in general and laboratory notebooks
in particular are essential to possibly later disentangle ownership issues.
Scientists should be familiar with the ins-andouts of keeping a laboratory notebook to document research. As a matter of institutional policy,

INVENTORS AND INVENTIONS

the contents of laboratory notebooks should be
treated as confidential and valuable. Notebooks
should be stored in a safe place and any loss or
theft should be reported immediately. A laboratory notebook is owned by the institution where
work is conducted (essentially by the employer of
the scientist). Therefore, when a scientist leaves
an institution permanently, he or she should be
required to turn notebooks over to supervisors
(though copies can generally be kept by departing scientists).
Thomson,4 a scientist herself, shares the practical aspects of laboratory-notebook keeping and
her chapter offers a sample policy. Crowell5 examines the entire range of invention documentation. It cannot be overemphasized how important
is good documentation of research. It is a critical
component of best practices in IP management
for the following reasons:
• Well-kept laboratory notebooks are one of
the most important sources of documentation. A laboratory notebook should contain
detailed records of every experiment that
has been planned or executed (including
the date it was performed), the reasons
for performing it, the methodology used
in performing it, the results of the experiment, and the significance of the results.
• Laboratory notebooks are important instruments of institutional memory. Laboratories
invariably have high personnel turnovers:
scientists move on, post docs move up,
students graduate, and technicians are
promoted.
• Consistent documentation is important
to determine patentability, and may even
be essential for determining inventorship,
for drafting and prosecuting patent applications, and (if necessary) for protecting
patents from third-party challenges such
as prior-art challenges and (in the United
States) patent-interference proceedings.
Once scientists think they may have patentable inventions, they should file an invention disclosure to their TTO. McGee6 examines the entire
invention-disclosure process from a practical and
logistical point of view and stresses the importance

of involving inventors throughout the protection
and commercialization process. He discusses how
IP professionals can best work with inventors to
develop high-quality invention disclosures. An
invention disclosure is a description of something
novel and nonobvious that would allow anyone
of ordinary skill in the corresponding art to reproduce the invention. It may be simple in scope
and include most details in an attached draft of a
scientific paper (McGee also notes, quite appropriately, that carefully kept laboratory notebooks
can be used in place of an invention disclosure).
Importantly, an invention disclosure irrefutably
establishes the date and scope of an invention, as
well as the identity of the inventor(s). Disclosures
are essential for managing intellectual property,
preserving IP assets, “harvesting” inventions and
securing IP protection for those assets, and eventually translating the inventions into innovative
products or services.
Thus, an invention disclosure is the beginning
of what is sometimes a long but often rewarding
process that can benefit the institutions where the
disclosures are made, the society at large, and the
inventors in particular. n

All chapters refer to: Intellectual Property Management in
Health and Agricultural Innovation: A Handbook of Best
Practices. 2007. A Krattiger, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez,
and SP Kowalski (eds.). MIHR: Oxford, U.K., and PIPRA: Davis,
U.S.A. Available online at www.ipHandbook.org. The online
version contains for each chapter a detailed Editor’s Summary, Implications, and Best Practices.
1

See, also in this Executive Guide, part 9: Evaluation and
Valuation of Technologies.

2 Chapter 8.1 by M Mutschler and GD Graff titled
Introduction to IP Issues in the University Setting: A
Primer for Scientists, p. 747.
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See, also in this Executive Guide, part 7: Contracts and
Agreements to Support Partnerships.

4 Chapter 8.2 by JA Thomson titled How to Start–and
Keep–a Laboratory Notebook: Policy and Practical
Guidelines, p. 763.
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Chapter 8.3 by WM Crowell titled Documentation of
Inventions, p. 773.

6 Chapter 8.4 by DR McGee titled Invention Disclosures
and the Role of Inventors, p. 779.
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People and institutions typically look after their possessions in a much more serious
manner than if they have no stake in them. This is applicable to physical property
and to intellectual property. For this reason, governments should consider enacting
legislation or, as appropriate, implementing policies that clearly spell out how public
sector institutions can protect, own, and license inventions made in their institutions.
This equally applies to government research centers and to universities.
Arguably, the minds of scientists operate differently from those of lawyers, politicians,
bankers, and policymakers. Similarly, those engaged in managing the intellectual
property in public sector institutions face different challenges than the scientistinventors. These differences can be the source of much tension, but such tension can
often be preempted if scientists are given an opportunity to learn the basics of IP
management, including best practices, in terms of data and information management
related to inventions. Public sector institutions should have the resources to offer
limited, but essential, training to every scientist when they join an institution.
Such training programs can be given as a series of short seminars or even half-day
orientation courses. These are most effective if the institutions have clear IP policies
that include matters related to ownership of inventions, the duty to disclose inventions,
and laboratory notebook keeping. The latter is common practice in any private sector
R&D center. Comprehensive research records are fundamental to best practices in
science, IP management, and in the regulatory process.
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People and institutions typically look after their possessions in a much more serious
manner than if they have no stake in them. This is applicable to physical property and
to intellectual property. For this reason, work with your governments to implement
policies (or enact legislation, as appropriate) that clearly spell out how public sector
institutions, including government research centers and universities, can protect, own,
and license inventions developed at your institution.
Arguably, the minds of scientists operate differently from those of lawyers, politicians,
and university presidents (although many a president is a former scientist). Similarly,
those engaged in managing intellectual property in public sector institutions face
different challenges than do scientist-inventors. The differences can be a source
of much tension, but such tension can be preempted if scientists are given an
opportunity to learn the basics of IP management, including best practices, in terms
of data and information management related to inventions. Public sector institutions
and companies alike should offer and require limited, but essential, training to every
scientist, student researcher, and technician when he or she joins a research program.

Key Implications and Best Practices: SETCION 8

FOR SENIOR MANAGEMENT

Such training programs can be provided as a series of short seminars or even halfday orientation courses. And they are most effective if the institutions have clear IP
policies that include matters related to ownership of inventions, the duty to disclose
inventions, and laboratory notebook keeping. The latter is common practice in any
private sector R&D center. Comprehensive research records are fundamental to best
practices in science, IP management, and in the regulatory process.
University faculty, staff, and students do not have to become IP experts. The IP
management training programs is best offered by the technology transfer personnel
that will be interacting with scientists rather than by lawyers and outside consultants
can be useful facilitators. Part of the aim of such training is team building that
encourages communication between the scientists, technology transfer personnel,
and senior management. It is part of creating a culture of IP awareness.
Many scientists at public institutions often do not (initially, at least) appreciate the
importance of laboratory notebooks and documentation protocols. For private sector
R&D centers, this is done as a matter of routine. Some argue that good laboratory
notebook practices lead to better science. Laboratory notebooks surely lead to better
invention disclosures, prevent fraud, clarify inventorship, facilitate patent applications,
and ultimately, pay off for individuals and institutions in the long term.
If an invention is protected, then much can be gained if inventors are actively involved
in all phases of the protection and marketing of their inventions. Inventors not only
have intimate knowledge of their inventions; they may also have useful leads and
contacts in companies or have ideas about how an invention could be incorporated
into existing products or services. The practice of occasional seminars by technology
transfer personnel for scientists is a practice that will strengthen the interest and
involvement of scientists in this process.
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IP management is an important element in facilitating the translation of research into
useful products or services that benefit your community and country.
Encourage your technology transfer office (TTO) to organize occasional seminars on
the basics of IP management. Ideally, your institution should provide an IP management
primer when you join the institution that will help you understand the basic elements of IP
protection and smooth the interface with your TTO. Even if you have taken such primers or
seminars before, attend those offered by your new employer and encourage those in your
group to do so as well. This will facilitate communication with your TTO staff and answer
your questions about IP management.
One potentially controversial issue faced by many TTOs involves keeping laboratory
notebooks. For private sector R&D centers, this is done as a matter of routine. Make it a habit
to use laboratory notebooks, as doing so can lead to better science and easier invention
disclosures and can facilitate patent applications.
Good practices in laboratory notebook keeping should include the signing of each page by
a supervising scientist, occasional spot checks, and the setting aside of time for recording
experiments and results. This applies to research assistants, students, post docs, and
everyone else working in a laboratory.
Good record keeping is important. It includes linking research proposals with material
transfer agreements, publications, invention disclosures, and so forth. It promotes both
scientific goals (it facilitates the writing of publications and grant proposals) and legal goals
(good records make it easier to obtain and defend patents).
Good record keeping goes beyond publications and IP management. Especially in institutions
dealing with the development of products and clinical trials in health, or biosafety research in
agriculture, record keeping may be essential for providing regulators the necessary evidence
that good laboratory practices have been followed and may underpin regulatory filings. In
many cases, experiments conducted years before regulatory filings can become valuable for
those filings and, unless laboratory detailed notebooks were kept, experiments may have to
be repeated at great cost and may also delay filings.
Invention disclosures are the first step in protecting intellectual property. Disclose early and
often. Rather than wait until your scientific paper is accepted, make it a habit every few
months to think what might be disclosed and what should be disclosed, and then disclose it.
But expect only a small portion of your invention disclosures to lead to patent applications.
Recognize when you actually have an invention. Often, it is much earlier than you think. By
filing an invention disclosure with your TTO, you are initiating a dialogue. Even if the TTO
does not immediately file a patent based on your first invention disclosure, it is a process
that has started, and follow-up invention disclosures will be much easier.
Ideally, you should invite your TTO liaison to visit your laboratory occasionally and discuss
with you and your research team what you have been doing. Discussions with technology
transfer experts, especially patent attorneys, can help you to identify inventions.
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Arguably, the minds of scientists operate differently from those of bankers, politicians,
and licensing executives. Similarly, those engaged in managing intellectual property
in public sector institutions face different challenges than do scientist-inventors. The
differences can be a source of much tension, but such tension can be preempted if
scientists are given an opportunity to learn the basics of IP management, including
best practices, in terms of data and information management related to inventions.
Public sector institutions and companies alike should offer and require limited, but
essential, training to every scientist, student researcher, and technician when he or she
joins a research program.

Key Implications and Best Practices: SETCION 8

FOR TECHNOLOGY TRANSFER OFFICERS

Such training programs can be provided as a series of short seminars or even halfday orientation courses. And they are most effective if the institutions have clear IP
policies that include matters related to ownership of inventions, the duty to disclose
inventions, and laboratory notebook keeping. The latter is common practice in any
private sector R&D center. Comprehensive research records are fundamental to good
research practices in science, IP management, and regulatory areas.
University faculty, staff, and students do not have to become patenting experts. Keep
any such training programs simple and practice oriented. Generally, the intricacies of
patenting legislation is not what motivates a scientist; rather, it is a vision of how his
or her invention can eventually make a difference in people’s lives. The IP management
training programs should thus be practical and offered by technology transfer
personnel that will be interacting with scientists rather than by lawyers. Contractors
can be useful as facilitators. Part of the aim of such training is team building that
encourages communication between your office and the scientists in your institution.
It is part of creating a culture of IP awareness.
It is good practice to include senior management as participants in the training
sessions. This is especially useful when the training program includes case studies.
Prepare simple brochures and Web sites that encourage scientists to contact you with
their questions and inventions. Similarly, make an effort to attend seminars given by
the researchers in your organization. It is a great way to show your interest in their
activities and to build a good understanding of what the researchers actually do.
Overall it helps to get scientists involved in all phases of protecting and marketing
their inventions.
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CASE STUDY 1

Somatic Embryogenesis of Grapes:
Fundación Chile
Fundación Chile is a private nonprofit organization. Its
mission is to add economic value to Chile’s products and
services by promoting innovation and technology transfer for Chile’s natural resource, agricultural, and manufacturing sectors. Fundación Chile’s primary strategy is
to develop new technology-based companies in Chile
that can have a significant economic and social impact. These new companies are generally joint ventures
with strategic partners, although other models, such as
licensing, are used. The main activities are focused in
the area of agribusiness, marine resources, forestry and
forest products, environment, information technology,
education and human resources, and tourism.
Fundación Chile is unusual as a nonprofit institution that participates in the creation of innovative
private companies. In fact the foundation is involved
in a wide range of activities relevant to different stages
of development of new businesses, including technology services, R&D, incubation, scale-up, seed capital,
and financial innovation. Fundación Chile’s activities
are focused on Chilean production of goods that can
be exported or that can replace imports, but possibilities for production in additional territories that can
increase the volume and value derived from Chilean
production are also considered.
Since 1997, Fundación Chile has been active in
developing applications of biotechnology that can
improve productivity, add value to existing products, and promote introduction of new products.1
Biotechnology activities are mainly focused in forestry,
horticulture, and aquaculture, with increasing emphasis on quality enhancement. Biotechnologies used include recombinant proteins, tissue culture, molecular
genetics, functional genomics, and genetic engineering. Strategic alliances in biotechnology in the private
sector include a licensing agreement for a salmon

vaccine with Syngenta, a strategic alliance in forestry biotechnology with CellFor Inc. (Vancouver, BC,
Canada), a collaboration in stone fruit biotechnology
with Okanagan Biotechnology Inc. (Summerland, BC,
Canada), and a joint venture in grape biotechnology
with Interlink Associates LLC (Princeton, NJ, U.S.A.).
Fundación Chile seeks to establish strong IP positions
through the licensing of key existing IP and the development of new intellectual property in areas of specific
strategic importance in Chile.
Fundación Chile’s biotechnology activities involve an extensive network of Chilean and foreign
research centers and universities, as well as participation in key international consortia. Collaborators
within Chile include Fundación Ciencias para la
Vida, the Chilean National Institute for Agricultural
Research, the University of Chile, the University of
Concepción, the University of Santiago, the University
of Talca, University Federico Santa Maria, Andres
Bello University, and Austral University. Alliances
with foreign research centers and universities include the University of California, Cornell University,
the University of Florida, the U.S. Department of
Agriculture (USDA), New Zealand HortResearch,
and New Zealand Forest Research. Fundación Chile is
a member of PIPRA (the Public Intellectual Property
Resource for Agriculture) and the California Institute
of Food and Agricultural Research and is a participant
in the ALCUE-Food Specific Support Action funded
by the 6th European Framework.
As a result of this networking, Fundación Chile
has been able to participate in the development of
products within a relatively short time frame. A recombinant protein vaccine for salmon, developed in a collaboration of Fundación Chile and Fundación Ciencias
para la Vida, has been licensed to Syngenta and is being

Fernandez C. 2007. Somatic Embryogenesis of Grapes: Fundación Chile. In Executive Guide to Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR
(Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
© 2007. C Fernandez. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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introduced into the market. Elite clones of radiata pine
developed through somatic embryogenesis in collaboration with CellFor are in advanced stages of testing
and are being scaled up for market introduction by the
Fundación Chile company GenFor. Other biotechnology programs of Fundación Chile, including genetic
engineering of varieties of pine trees, peaches, and
grapes, are in earlier stages of development.

THE Technology
Importance of institutional support
for a long-term R&D program
Agricultural biotechnology R&D programs are long
term, expensive and controversial; an institution undertaking such a program must be committed to the
process for the long term. In the late 1990s Fundación
Chile made a strategic decision to invest in development
of biotechnology applications for strategic sectors of the
Chilean economy, particularly forestry, agriculture, and
aquaculture. Genetic engineering was clearly a key technology with large potential impact, as demonstrated by
the rapid adoption of genetically engineered varieties of
maize, soybeans, and cotton in some parts of the world.
However, these major crops play a relatively minor role
in Chile. Little effort was being expended to make improvements in perennial crop species, such table grapes,
in which Chile is a major player.
Building a foundation for the program
Typically, three different types of technological components are needed for development of a genetically
engineered plant product:
• germplasm that provides a competitive genetic
background
• specific genes that confer new traits of interest
• enabling tools, such as genetic markers, promoters, tissue culture and regeneration systems, and transformation methods
In addition, human resources, laboratory infrastructure, and financing are needed to carry out the
R&D required to adapt and combine these components to produce a product. Laboratory infrastructure existed in Chile, but improvements were needed.
There were capable researchers in Chile, but they were
limited in number. Research efforts were spread across
many different objectives, and sustained support for
any one specific program was rare.
In the case of grapes, the foundation technologies were not available in the local R&D institutions
at the start of the program, except, to a limited degree,
germplasm. A global search led to the identification of
sources of technologies and expertise. The availability
and priority of different components were assessed,
and efforts were initiated to access, license, and transfer the key components.
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IP and freedom to operate
The IP and freedom-to-operate issues confronted were
complex, largely due to the need to address the situation in Chile and the situations in Chile’s major export
markets, the long and uncertain time frames for development and commercialization of genetically engineered perennial fruit crops, and the concentration of
rights to core technologies in the hands of companies
with little or no interest in the development of minor crops. A complete solution was not possible in the
short term with the resources available. However, it
was possible to establish a position in key technologies
that maximized the likelihood of being competitive
within a specific niche.
A critical aspect was the active involvement of
personnel with professional experience in commercial R&D programs and major agri-biotech research
centers in other countries, as well as experience in the
licensing of agricultural biotechnologies. Practices
vary from country to country and from institution to
institution within a country. At the initiation of the
program there was little experience in Chile with patenting and licensing technologies developed in public
research institutions. The involvement of personnel
with international experience, providing appropriate
examples drawn from a number of sources, played
an important part in bridging gaps in experience and
expectations.
Establishment of a grape
biotechnology platform
At the time the program was initiated there were only
a few published reports of transformation of Vitis vinifera. In order to be able to obtain R&D funding
from public and private sources, and to be considered
seriously as a potential licensee by technology providers, it was considered critical to demonstrate the ability to reproducibly transform the target species. For
many transformation systems, an important factor is
the availability of a robust tissue culture system that
makes it possible to regenerate plants efficiently. In our
experience, tissue culture systems involve considerable
art and are often difficult to reproduce in other laboratories. Thus, establishment of a strong position in
grape tissue culture was given the highest initial priority. The process and progress in this area are discussed
below. The second priority was access to specific gene
candidates for engineering a trait of commercial interest in the Chilean market. This was carried out in
parallel in order to ensure that the tissue culture and
transformation platform developed could be applied
to the production of prototypes with traits of interest
with a minimum lag.
Identification of suitable laboratories
The search used different and complementary channels,
including reviews of research publications, project databases, conference proceedings, patent documents,

CASE study 1

news items, and personal contacts. All of them are
relevant, and each provides unique and useful kinds
of information.
Access to many of these sources has been facilitated by the rapid improvement of the Internet, both
in terms of content and ease of access. Even for people
without good Internet access, the availability of highquality documents in electronic form has greatly reduced the cost of access.
Open sites such as PubMed (www.ncbi.nlm.nih.
gov) and HighWire (highwire.stanford.edu) provide
convenient access, not only to bibliographic information, but to many full papers. More and more, full papers are available at no charge, some can be downloaded
for a fee from sites of journal publishers or specialized
clearinghouses. Even for people without good Internet
access, the availability of high-quality documents in
electronic form has greatly reduced the cost of access.
Online databases such as those at the World
Intellectual Property Office (www.wipo.int/ipdl),
the European Patent Office (www.espacenet.com),
the U.S. Patent and Trademark Office (www.uspto.
gov), and many other national patent offices provide
increasingly convenient access to issued patents and
published applications.
Less widely appreciated, but valuable due to their
more specialized content, are online databases of research projects. These often include information that
is otherwise difficult or impossible to find. Examples
include the European Union Community Research
& Development Information Service (cordis.europa.
eu), the Current Research Information System of the
USDA (cris.csrees.usda.gov), the FAO-BioDeC database of biotechnology projects in developing countries (www.fao.org/biotech/inventory_admin/dep/default.asp), and a database of biotechnology activities,
by country, of the Red de Cooperación Técnica en
Biotecnología Vegetal para America Latina y el Caribe
(www.redbio.org). In Chile, the Web sites of the major funding agencies for R&D, CONICYT (www.
conicyt.cl), CORFO (www.corfo.cl), and FIA (www.
fia.cl), include databases of projects. Many research
institutions provide databases of internal research activities and funded projects, which may be useful once
specific institutions of interest have been identified.

•
•
•
•
•
•
•
•
•
•
•
•
•

reports and conferences for proper follow up of
activities
costs, payments, and other support
publications
intellectual property
grant of rights
confidentiality and publicity
term and termination
insurance and indemnification
governing law
assignment
agreement modification
notices
counterparts and headings

It is important to emphasize that this standard
form was designed for use in the United States.
Intellectual property laws vary among countries, so,
it is important that the content of any agreement
is reviewed by a local lawyer knowledgeable in IP
matters.
Most universities in the United States, and many
other public research institutions, will require that
the public institution be able to continue to use the
technology for research and education purposes even
if exclusive rights for commercial use are granted.
Our general approach has been to negotiate
agreements that provide rights to use technologies for
R&D, along with an option for a future commercial
license. We want to avoid situations where resources
are invested in research if the results cannot be commercialized. Due to the high degree of uncertainty in
the development and commercialization of agri-biotechnology products, we also want to avoid paying at
the outset for full commercial rights, if in the end they
will not be used. In technology access agreements we
have generally tried to structure compensation in ways
that reduce the up-front costs in favor of sharing any
benefits eventually realized after commercialization.
This is important for making effective use of the resources currently available, but, more importantly, it
helps to align the interests of the technology provider
with our interests. The agreements typically contain
modest up-front payments, milestone payments based
on successful transfer of the technology, additional
milestone payments if a commercial license is entered
into and a product is introduced to market, and royalNegotiation of a research
ties based on revenue derived from commercialization
and option agreement
of products produced using the technology.
Once the identification of the laboratory or institution
In the case of grape tissue culture technology
has been made, documents are typically exchanged via
sought by Fundación Chile, the university at which
e-mail. Most large private companies and universities
the technology had been developed already had
have standard forms that are adapted to the specific
agreements in place with a private company. Thus,
needs of a project. Typically, research agreements will
initially we had to negotiate a sublicense agreement
include the following information:
with that company. Later, changes in the scope of that
• date
company’s activities led to a return of the IP rights
• parties
• definitions of terms such as project, project pro- to the university. We then entered into additional neposal, sponsor, and joint and recipient intellec- gotiations with the university. Similar events affected
tual property
other agreements related to the project. It is important
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to recognize that management of such agreements is a
dynamic process.

Material transfer agreements (MTAs)
In addition to intellectual property, the transfer of agricultural biotechnologies often requires, or is at least
facilitated by, the transfer of actual biological materials such as plant tissue cultures, plasmids, vectors, or
reagents. The physical transfer and use of the materials
are generally covered by an MTA.
In countries with limited international innovation
programs, lawyers have not been exposed to or do not
have enough experience on matters related to MTAs.
In Fundación Chile’s case, the most practical approach
was to use, as a reference, MTA forms prepared by
the technology transfer offices of universities in the
United States and other countries with experience in
these matters. Some of these offices have sample forms
posted on their Web sites.2
An MTA should be carefully reviewed. In the
past, investigators have sometimes carelessly accepted
terms that could have critical affects on the value of
the R&D being conducted, terms such as reporting
requirements and rights given to the provider of the
material to use information generated by the recipient.
It is also critical to consider whether the material provided incorporates materials or technologies already
owned by third parties. If so, it is advisable to request
clarification of any restrictions that my be “inherited”
with those materials.
Importation of materials
Each country has its own regulations regarding the
importation of biological materials. In Chile, there are
forms and procedures that must be followed. Samples
of grape tissue culture were imported following these
procedures without major obstacles, although significant time and resources were required.
Exchange of professionals
between laboratories
Good communication between parties is essential for
a successful outcome. For transfer of some technologies, the exchange of written information and materials supplemented by phone calls and e-mails may be
sufficient. However, in many cases, successful transfer
is greatly facilitated by the active participation of
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investigators from the provider and recipient laboratories in activities in both laboratories.
In the case of the grape tissue culture system, a
Chilean investigator first spent time in the laboratory
of the inventor, to get hands-on experience with the
procedures, and then returned to set up the system
locally. Several months later, the inventor spent a full
week working side by side with local investigators, reinforcing the training and providing an opportunity
to resolve issues that had arisen during initial implementation. Some time later, the project leader visited
the inventor’s laboratory to observe the procedures
there, with experience accumulated in Chile providing
a foundation for increased “receptivity.” At the end of
each exchange, written reports were prepared, disseminated, and discussed.

CONCLUSIONS

Currently the lab in Chile has been able to master
grape embryogenic tissue culture and regeneration
techniques and apply them to genetic engineering.
The genetic transformation of grape tissue cultures has
allowed the production of thousands of transformed
grape lines, from which several promising lines have
been advanced to the field for additional testing. n
For further information, please contact:
Carlos Fernandez, Director, Strategic Studies, Foundation
for Agriculture Innovation (FIA), Loreley 1582, La Reina,
Santiago, Chile. carlos.fernandez@fia.cl
1

Fernandez C and MR Moynihan. 2007. A Model for the
Collaborative Development of Agricultural Biotechnology Products in Chile. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney,
L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis,
U.S.A. Available online at www.ipHandbook.org.

2

The online version of Intellectual Property Management
in Health and Agricultural Innovation: A Handbook of
Best Practices provides many sample forms from a host
of different organizations around the world (see www.
ipHandbook.org).
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The Groundnut Story:
A Public-Private Initiative Focused on India
Groundnut, or peanut (Arachis hypogaea) is a staple
oilseed crop grown for food and for forage in India. It
is cultivated on 7.5 million hectares with annual production of about eight million tons. More than five
million small and marginal farms depend on this crop
for their viability.
During the monsoon season of 2000, a new
groundnut disease emerged in India. The spread of
the disease grew to epidemic proportions causing crop
loss corresponding to more than US$65 million. The
causal agent of this devastating disease was found to
be tobacco streak virus (TSV), which causes stem necrosis in the groundnut plant resulting in complete
destruction of the crop. In addition, TSV infects several other economically important crop plants, such
as sunflower and marigold, and lives in many weed
hosts. Parthenium, a prevalent weed, is a symptomless
carrier of TSV and plays a major role in the perpetuation and spread of the disease. The constant threat of
TSV outbreak has caused food shortages and financial
insecurity for groundnut farmers.
By nature, groundnut plants show little resistance
to TSV. Moreover, all currently grown cultivars are
susceptible to TSV infection. Therefore, a nonconventional method of incorporating disease resistance in the
cultivars was needed to control the disease. Transgenic
crop plants that express the coat protein (CP) gene
of the target virus pathogen have been shown to provide a high degree of resistance to many plant viruses.
The Agricultural Biotechnology Support Project II
(ABSPII), which focuses on safe and effective development and commercialization of bioengineered crops
in order to benefit resource-poor farmers in developing countries, decided to fund the bioengineering of
groundnut genotypes to incorporate the CP gene for
conferring TSV resistance.1

LICENSING ARRANGEMENTS

Sathguru Management Consultants, the regional coordinator of the ABSPII project in South Asia, approached the Donald Danforth Plant Science Center
(the Danforth Center) for the development of a vector
construct containing the TSV-resistance gene for conferring viral resistance to groundnut plants.
The CP technology for conferring resistance to viral infection is owned by Monsanto Company. A patent nonassertion agreement2 from Monsanto for the
CP technology to be used for nonprofit public good
was obtained by the Danforth Center. This non-assert
was facilitated by the ABSPII project. The Danforth
Center further developed the technology for TSV-CPmediated-resistance in groundnut to be deployed in
South Asia and Southeast Asia.
A consortium of public institutions was formed
by ABSPII with International Crops Research Institute
for the Semi-Arid Tropics (ICRISAT) and Acharya
N. G. Ranga Agricultural University (ANGRAU) in
the state of Andhra Pradesh. These institutions were
the primary licensees of the technology developed by
the Danforth Center for TSV-resistant groundnut
cultivars.
With Sathguru Management Consultants as facilitator of the technology transfer, a nonexclusive licensing agreement was penned for nonexclusive licensing of the CP technology, free of royalties and upfront
payments, to public institutions planning to develop
the varietal groundnut. A tripartite agreement was arranged, with the Danforth Center as the technology
licensor and Sathguru Management Consultants and
ICRISAT as licensees. Development efforts of TSV-resistant groundnut by the public research institutions
are underway and slated for commercialization in
2009.

Medakker A and V Vijayaraghavan. 2007. The Groundnut Story: A Public-Private Initiative Focused on India. In Executive
Guide to Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger
A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro,
Brazil), and bioDevelopments-International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
© 2007. A Medakker and V Vijayaraghavan. Sharing the Art of IP Management: Photocopying and distribution through the
Internet for noncommercial purposes is permitted and encouraged.
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Similar nonexclusive licensing arrangements have
been made with private organizations for the development of hybrid groundnut cultivars. These licenses
include upfront and royalty payments and an understanding with regard to benefit sharing.

POLICY COMPONENTS

Because groundnut is a so-called orphan crop, there
was little interest in producing and selling open-pollinated varieties owing to their susceptibility to viral
infection. Moreover, private industry lacked the motivation to commercialize hybrid varieties. Key policy
makers for the ABSPII project secured financial support for developing and distributing the TSV-resistant
groundnut and for facilitating the project through
planning and implementation.

KEY LESSONS LEARNED

Technology can be a major force in alleviating poverty
and increasing food security in developing countries.
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Moreover, investment gains can be multiplied by
adopting technologies in different regions through the
creation of synergic partnerships for product development, implementation, and commercialization. n
For further information, please contact:
Akshat Medakker, Associate Consultant-Technology
Management, Sathguru Management Consultants Pvt. Ltd.,
15 Hindi Nagar, Punjagutta, Hyderabad 500034, India.
akshatm@sathguru.com
VijayVijayaraghavan, Founder and Director, Sathguru
Management Consultants Pvt. Ltd., 15 Hindi Nagar,
Punjagutta, Hyderabad 500034, India. vijay@sathguru.com

1

www.absp2.cornell.edu.

2

See also, in the Handbook, Chapter 7.6 by Anatole
Krattiger titled, The Use of Nonassertion Covenants: A
Tool to Facilitate Humanitarian Licensing.

CASE STUDY 3

Golden Rice: A Product-Development Partnership in
Agricultural Biotechnology and Humanitarian Licensing
IP (intellectual property) constraints are often perceived as barriers to market entry, especially when it
comes to developing countries. This case study examines the IP management component in the development of Golden Rice1 (or beta-carotene-containing
rice) and the transfer and introduction of Golden Rice
to developing countries.
Rice, one of the most widely grown food crops,
contains neither vitamin A nor beta-carotene, yet it
is a staple food crop for billions of people, especially
in Asia. Here, and in other developing countries, vitamin A deficiency (VAD) is a major problem affecting
primarily children under age five and pregnant and
lactating women. Thousands of impoverished people
lose their eyesight because of VAD. Severe VAD (xerophthalmia, or night blindness) leads to permanent
blindness: 500,000 people, 250,000 of them children,
lose their sight every year due to VAD.2 The deficiency
also leads to a depressed immune system that increases
the incidence and severity of infectious diseases and
infant mortality rates.
There are several avenues for mitigating VAD, including programs to fortify food with vitamin A and
beta-carotene and to distribute vitamin A supplements
to affected populations. For the supplement distribution, more than US$100 million are spent every year.
An alternative, and complementary, approach is to insert relevant genes in rice. This allows farmers to grow
beta-carotene-rich rice. By enhancing those varieties
primarily grown or consumed by poor people, betacarotene can be delivered at essentially no cost once
the Golden Rice has been developed and bred into local varieties.
Interestingly, rice plants synthesize beta-carotene in foliage and other parts of the plant, but not
in the grain, and all but two steps of the biosynthetic
pathway are present in the grain. By the addition of

only two genes, phytoene synthase (psy) and phytoene
desaturase (crt I), the pathway is reconstituted and
beta-carotene accumulates in the endosperm (the endosperm being the edible part of the grain).3

Intellectual property
Features of the case

The development of Golden Rice led to a significant
change in the relationship between the public sector and intellectual property. A freedom to operate
(FTO) review of pro-Vitamin A-containing Golden
Rice was commissioned by the International Rice
Research Institute, a center of the Consultative Group
on International Agricultural Research (CGIAR),
with funding from the Rockefeller Foundation (led
by one of us [AK]). The review showed that about 70
patents and patent applications were applicable to the
improved rice when all patents issued in or applied
for in all countries, including patents on commercially accessed research tools, were considered.4 The
published analysis also showed, in accordance with
analysis by Zeneca (which later merged with Novartis
to form Syngenta) that, in practice, only a few, if any,
patents pertaining to Golden Rice were applicable in
developing countries, together with a few material
transfer agreements.

Obtaining Freedom to Operate
Fortunately, these potential—and arguably perceived—
constraints were resolved in a few months in the year
2000 by a straightforward IP management strategy
comprising four goals:
• identification of major IP components (the
above-mentioned FTO review)
• interpretation, with Zeneca, of the relevance of
the FTO review to the proposed humanitarian
use in developing countries

Krattiger A and I Potrykus. 2007. Golden Rice: A Product-Development Partnership in Agricultural Biotechnology and Humanitarian Licensing. In Executive Guide to Intellectual Property Management in Health and Agricultural Innovation: A
Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz
Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). Available online at
www.ipHandbook.org.
© 2007. A Krattiger and I Potrykus. Sharing the Art of IP Management: Photocopying and distribution through the Internet
for noncommercial purposes is permitted and encouraged.
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• in licensing for humanitarian use, led by Zeneca,
of IP components it did not already own
• licensing by Zeneca, as Syngenta, via the inventors of the assembled (or bundled) intellectual
property to public sector institutions in developing countries that could use the rights for the
benefit of resource-poor farmers, and others,
deficient in vitamin A
The patented key technologies for Golden Rice
production include core patents related to the specific
biosynthetic pathway. These patents were filed by the
inventors, Potrykus and Beyer. Their work built on
myriad other technologies that were published in issued patent documents and scientific literature. These
core patents were licensed to Zeneca, which already
owned its own plant-biotechnology-related patents.
Zeneca then negotiated access to all possibly necessary
patents, including intellectual property from Bayer
AG, MonsantoCompany, Novartis AG, Orynova BV,
and Zeneca Mogen BV.
All of these companies, including Zeneca (which,
coincidentally, almost immediately merged with
Novartis Agribusiness to form Syngenta), provided
access to their technologies, free of charge, for defined humanitarian research and use of Golden Rice
in developing countries. It is important to note that,
contrary to what many commentators state, the licensing process was relatively uncomplicated, with the involvement of commercially experienced people.

Licensing
Within a short time, 16 further licenses, including licenses with the right to further sublicense (for example,
the license issued to IRRI), were issued to public sector licensees. Thus national programs in Bangladesh,
China, India, Indonesia, the Philippines, South Africa,
and Vietnam obtained licenses for use of the technology in local rice varieties important in VAD areas.
Terms of the humanitarian license agreement
The Golden Rice Humanitarian Board, although not
a legal entity, provides a forum for discussion of strategic and tactical issues relating to the humanitarian
project. Both Potrykus and Beyer have the right to issue licenses. Two licensees also have that right, as does
Syngenta, which has not exercised its right. All the licenses are in the same form, as proposed by Syngenta
and agreed to by the inventors.
The essential elements of the licenses include the
following points:
• Syngenta retains commercial rights, although it
has no current plans to commercialize Golden
Rice. Humanitarian use, and research leading
to it, is allowed.
• Humanitarian use is defined as use in developing countries by resource-poor farmers (earning
less than US$10,000 per year from farming).
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• The technology must be introduced into public
seed varieties, as a way to optimize public sector
benefit and use.
• No technology fee (or surcharge) may be
charged for Golden Rice, as a way to optimize
public sector benefits.
• Sale of Golden Rice is authorized by farmers, as
a way to reach urban poor.
• Farmers are allowed to reuse harvested seeds.
• Golden Rice may not be released in a country
that lacks biosafety regulations and where official government review has not been made to
ensure health and environmental safety.
• Export of Golden Rice is not permitted, except
to other licensees for humanitarian research and
subsequent use. (Export of crops is a commercial activity. The purpose of the humanitarian
project is to assist resource-poor people in overcoming VAD).
• With regard to improvements to the Golden
Rice technology:
o Humanitarian use of any improvements to
Golden Rice is guaranteed under the same
terms of the original agreement (and thus
any improvements to the technology will
serve the humanitarian purpose). Syngenta
has acted on this—donating to the humanitarian project new transformations, including the intellectual property and results reported in Paine and colleagues.5
o Commercial rights to improvements of the
technology are granted back to Syngenta.
• No warranties are given by the licensor or licensors (as is common for licenses), and each party
is responsible for what it controls.

KEY LESSONS LEARNED

The rapid resolution of the IP constraints surrounding
Golden Rice demonstrated, first of all, how effective IP
management, coupled with strong collaborations between the public and private sectors, can help achieve
global access to new technologies and products for
humanitarian goals. The IP constraints identified by
Kryder and colleagues6 did not delay the development
of the product, and their clarification and resolution
required only managerial and influencing skills and
the resulting goodwill of IP owners.
More specifically, three specific lessons have been
learned:
1. Intellectual property and patents did not delay
the development and introduction of Golden
Rice by a single day. Notwithstanding this, the
resolution of the potential IP constraints could
not be ignored.
2. Other constraints are much more critical to the
introduction of Golden Rice, in particular, and
to potentially life-saving food biotechnology

CASE study 3

applications, in general. These constraints are,
in decreasing order of importance:
• the necessity of governments to establish
a sustained and positive policy priority for
the adoption of all relevant, including novel,
technologies in agriculture
• the importance of the establishment of affordable, workable, and science-based regulatory systems designed to comply with
international obligations and to address local needs and concerns (The unnecessarily
burdensome, overly politicized regulatory
requirements for genetically modified organisms [GMOs] and the absence of consideration of benefit has led to years of delay in
the introduction of Golden Rice technology.
Yet there is no evidence to justify such a burdensome regulatory system.)
• the need for the capacity and funding of national agricultural rice research institutions
to keep segregated different versions of genetically modified crops, including conducting field trials with them
• the anticipated need to develop effective seed
distribution systems for reaching farmers in
remote areas, including the presence of private sector entities willing to invest in seed
distribution systems (However, a major aim
is also to have farmers pass the seed on to
neighboring farmers to reach “infrastructure
remote” areas often associated with VAD.)
3. Recognizing that universities are not set up to
develop products, Syngenta was instrumental in converting the proof-of-concept results
generated at ETH Zurich and University of
Freiburg into deliverable products. Although
Syngenta retained commercial exclusivity for
the technology, the company decided not to
develop a commercial product of Golden Rice
for markets in developed countries. Syngenta’s
continued support of the project with advice
and scientific know-how has proven absolutely
essential for the success of the product-development partnership.
From a broader perspective, the FTO review of
Golden Rice, in particular before “commercial analysis,” served as a wake-up call to the public sector to
pay more attention to IP management as a powerful
tool for meeting public sector goals. Concern about
potential constraints on public sector research and innovation in agriculture spurred the public sector’s interest in intellectual property. One important response
was work that led to the formation of the Public
Intellectual Property Resource for Agriculture (PIPRA).
Supported by, among others, the Rockefeller and
McKnight foundations, PIPRA is a public sector initiative that recognizes that continuing and enhancing

relationships with the private sector, and between the
public sector institutions, are critical components of
the utilization of intellectual property to meet public
sector goals. As part of its initial work, PIPRA began a
study of the structure of IP ownership in agricultural
biotechnology. In the words of the study’s authors,
Richard C. Atkinson and colleagues: This study found
that roughly one-fourth of the patented inventions were
made by public-sector researchers, which is substantially
larger than the IP portfolio held by any single agricultural
biotechnology company. It is, however, highly fragmented
across institutions and across technology categories. And
much of this IP has been licensed, often under terms that
are confidential but which have likely resulted in greatly
restricted access to the underlying technologies.7 This study
suggested that, apart from a few important exceptions,
public-sector scientists have invented many of the types
of technologies that are necessary to conduct basic biological research and develop new transgenic plant varieties.
For instance, they have developed technologies to transfer
genes into plant cells; have characterized specific DNA elements that drive unique patterns of gene expression; and
have identified many genes that confer important plant
traits. Such discoveries underscore the fact that public-sector research institutions have been significant sources of
technological innovation.8
We believe that this study involving Golden Rice
shows how public and private sector innovations can
be put to work directly to help the poor with more focused public sector IP management. Indeed, IP management is merely one of the components needed to
bring innovation to the poor.9 Other factors, such as
regulatory requirements, can be much more costly and
do constitute tremendous barriers to the poor benefiting from innovations that are becoming commonplace
in much of the world. n
For further information, please contact:
Anatole Krattiger, PO Box 26, Interlaken, NY 14847,
U.S.A. afk3@cornell.edu
Ingo Potrykus, Im Stigler 54, 4312 Magden, Switzerland.
ingo@potrykus.ch
Jorge E. Mayer, Golden Rice Project Manager, Campus
Technologies Freiburg, Stefan-Meier-Str 8, 79104 Freiburg,
Germany. jorge.mayer@goldenrice.org
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Saving Forests and Creating a New Cash Crop in the
Middle East and Asia: University of Minnesota
The high demand for agarwood—wood soaked with a
resin produced by a small portion of Aquilaria trees in
southeast Asia and Indonesia—nearly decimated the
species. The trees produce the resin only when injured
and, before researchers stepped in, usually when the
trees were 50 or more years old.
Agarwood and its resin are highly prized in the
Middle East and Asia, particularly in Islamic and
Buddhist cultures, where the wood and resin are used
in perfumes, ceremonial incense, traditional medicine, and other applications. Unfortunately, determining whether a particular standing Aquilaria tree
contains agarwood is nearly impossible, so harvesters were felling and sawing up Aquilaria trees until
they were close to extinction in much of their natural
range.

Robert Blanchette, Ph.D., of the University of
Minnesota, and the nonprofit organization Rainforest
Project, based in the Netherlands, have jointly developed an easy and inexpensive method to induce
agarwood formation in trees that are only three to six
years old. Now, instead of cutting down trees found
in the forest, farmers can grow stands of Aquilaria
trees on plantations, induce production of agarwood
in those trees, and sell them as a new cash crop.
This practice will benefit regional farmers and
their local economies, reduce the threat of extinction to
native populations of Aquilaria trees, and ensure a longterm supply of agarwood for centuries-old cultural and
religious uses. The University of Minnesota has licensed
the technology to the Rainforest Project, which is leading distribution efforts beginning in Southeast Asia. n

AUTM. 2007. Saving Forests and Creating a New Cash Crop in the Middle East and Asia: University of Minnesota. In Executive
Guide to Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger
A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro,
Brazil), and bioDevelopments-International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us to
adapt this case study for inclusion in this Executive Guide. The original was published by AUTM. 2006. Technology Transfer
Works: 100 Cases from Research to Realization (Reports from the Field). Association of University Technology Managers,
Northbrook, IL. www.betterworldproject.net.
© 2007. AUTM. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial
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Building Healthy Forests with Early-Stage
Propagation: University of Saskatchewan
Forestry is among the world’s largest industries; it has
a significant impact on people’s lives around the world.
One of the industry’s greatest challenges is increasing
the efficiency of land areas designated for commercial forestry by improving their productivity. Another
challenge is complying with environmental standards,
which provide guidelines for reforestation, production
in environmentally sensitive areas, and long-term sustainable forest management.
A crucial step toward increased efficiency is growing stronger trees. With many plant species, horticulturalists can create new varieties by taking cuttings
from plants with desirable characteristics and encouraging the cuttings to root. This propagation method
has yielded scores of different kinds of plants including orchids, roses, grapevines, and fruit trees. But the
method doesn’t work well with most forest trees because the cuttings are less likely to take root.
Researchers at the University of Saskatchewan
developed a technology called somatic embryogenesis
(SE), a complex propagation process that relies on the
splitting of one embryo into two or more identical

embryos. The method allows scientists to grow two or
more plants that have the same genetic makeup. With
SE, propagation occurs earlier in the plant’s lifecycle
and rooting is more likely to be successful.
SE offers several economic benefits to the forestry industry including greater success in propagating desirable trees and the ability to grow seedlings
year-round. The University of Saskatchewan licensed
the patent-protected technology to CellFor based in
Vancouver, British Columbia, Canada. In 2003, the
company began working with timberland managers
to plant loblolly pine seedlings propagated from fast
growing, disease-resistant varieties in the southeastern U.S. states including Georgia and Mississippi.
Today the company maintains more than 3,000
unique genetic lines and has an extensive network of
field trials aimed at testing and further refinements.
The technology allows CellFor to produce seedlings
that grow faster, generate a higher yield, and produce
superior wood, while reducing production costs and
enhancing resistance to disease and pests.
Read more about SE at www.cellfor.com. n

AUTM. 2007. Building Healthy Forests with Early-Stage Propagation: University of Saskatchewan. In Executive Guide to
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Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us to
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DNA Hepatitis B Vaccine:
International Vaccine Institute, Korea
Intellectual property as a barrier to market entry is
examined through a study of the development and
introduction of recombinant DNA (rDNA) hepatitis
B vaccine (HBV) in developing countries. The most
widely used vaccines in the mid-1980s were produced
by Merck and GlaxoSmithKline, which were the first
two companies to introduce the rDNA HBV. Almost
a decade later, Korean and Indian manufacturers entered the rDNA HBV vaccine market. However, the
price remained relatively high (>US$7 per dose) until
the Global Fund for Children’s Vaccine (today amalgamated with the GAVI Alliance) was established
with seed funding from the Bill and Melinda Gates
Foundation.  With this funding the price dropped to
less than US$0.30 per dose. This study sought to identify factors that affected supplying low-cost vaccine to
the public sector.
Merck and GlaxoSmithKline licensed three key
patents assigned to Institut Pasteur, Biogen, and the
University of California. These patents were filed in the
United States, Europe, and a few other developed countries. The companies stated that licenses to more than
90 other patents relating to manufacturing processes
such as isolation and purification were also needed.
The Korean companies pursued collaborations or
joint ventures but chose not to focus on the United
States and European markets mainly due to regulatory and market entry costs. These companies sought
World Health Organization prequalification for their
production facilities and approval for the vaccine from
several governments in Asia and other countries in the
developing world.
A Korean company, LG Chem, formed a joint
venture with Chiron. Chiron had a license from the

University of California (key scientists at Chiron
were inventors on the University patent).   Through
the joint venture, LG scientists could learn how to
make the vaccine. Korea Green Cross entered into a
joint venture with Rhein Biotech, which had developed and patented its own method for making the
vaccine. Having surveyed globally for a partner to
exploit its technology, the German company chose
Korea because of the low cost of production achieved
by Korea Green Cross. The Korean company Cheil
Sugar also sought to enter the market for the vaccine
and attempted to develop its own technology. After
nearly 20 years of effort, Cheil Sugar (now CJ Corp.)
abandoned the effort.
These LG Chem and Korea Green Cross alliances
were formed in an environment that was supportive
of biotechnology innovation. The Korean government
accorded high priority to R&D in biotechnology and
provided strong support for overseas training and
domestic research. The biotech industry received the
backing of private sector investment, and domestic and
export markets were encouraged by the government.  
High priority was given by the Korean government to
hepatitis B immunization thereby ensuring an initial
market for the companies.
This case study concludes that intellectual property
was not a major barrier to market entry.  Korean companies took several years to enter the market because of
lack of resources, including a small cadre of scientific
staff, the need to improve national regulatory systems,
and, importantly, the small size of the global market.
The international public sector market remained underdeveloped in part because of its low priority for
large pharmaceutical companies, lack of demand by

Mahoney R. 2007. DNA Hepatitis B Vaccine: International Vaccine Institute, Korea. In Executive Guide to Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et
al.). MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopmentsInternational Institute (Ithaca, USA). Available online at www.ipHandbook.org.
Editors’ Note: This case study was originally presented at the MIHR conference Using Intellectual Property for Improved
Health in Developing Countries: An Evidence-Based Approach to Good Practice, Bellagio, Italy, June 14–18, 2004.
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developing countries, and little procurement by international donor agencies.
Each company sought to secure intellectual
property in order to bring its vaccines to market,
but patents did not hinder developing the vaccine because the companies focused on markets in
countries where the three key patents were not filed.
Intellectual property had some affect on access but
was much less important than regulatory and manufacturing issues, and market development. However,
the situation might be different post-2005 when
most developing countries are required to be TRIPS
compliant.   In the TRIPS era, patents may be routinely filed in many countries such as Brazil, China,
India and Korea thereby making it more difficult for
second comers to produce in and sell to those large
and important markets.

Features of the case
Types of agreements
Merck and GlaxoSmithKline obtained licenses to
three key patents assigned to Pasteur Institute, the
University of California, and Biogen. These patents
were filed in the United States, Europe, and a few
other developed countries. Both companies obtained
licenses to numerous other patents having to do with
manufacturing processes, including isolation and purification. The Korean companies took three different
routes. Cheil sought to develop the technology on its
own. LG Chem (previously Lucky Gold Star) formed
a joint venture through which it obtained know-how
for the production of the vaccine. Korea Green Cross
entered into a joint venture with a foreign company,
Rhein Biotech of Germany, which had developed an
alternate production method.
Patent and IP rights decisions
Merck and, to a lesser extent, GlaxoSmithKline
were primarily interested in markets in developed
countries and obtained all necessary licenses to patents filed in those countries. The Korean companies
opted not to pursue the same markets as Merck and
GlaxoSmithKline because of the costs of obtaining
regulatory approval and establishing a market presence
associated with those markets.  LG Chem decided to
proceed simply by obtaining know how and relying on
its low cost of manufacture and aggressive marketing
skills.  Korea Green Cross and Rhein Biotech formed
a joint venture in which they exploited the Rhein
Biotech patent for a manufacturing method different
from that used by Merck and GlaxoSmithKline.  Cheil
sought to develop its own proprietary technology but
eventually abandoned this effort.  
Policy implementation
All five companies complied with the laws and regulations applicable in their legal jurisdictions. Each
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company sought a clear IP path to marketing the
vaccines. To the author’s knowledge, no infringement
lawsuits were brought against any of the companies.

External factors that
affected decision making

Key factors that affected decisions made by the Korean
manufacturers were the costs of regulatory compliance with respect to and market entry into the United
States and Europe. In addition, the Korean Food and
Drug Administration had been undertaking certain
improvements, and until those improvements were
completed, the Korean manufacturers could not supply United Nations agencies. The Korean manufacturers also had to obtain World Health Organization
prequalification for their production facilities, which
LG Chem and Korea Green Cross succeeded in accomplishing in the late 1990s. The key factor in allowing the Korean manufacturers to supply low-cost
vaccine to the public sector was the establishment
of a market through the Global Fund for Children’s
Vaccine, initially funded by the Bill and Melinda
Gates Foundation.

Lessons learned and
health-access issues

Intellectual property was an important issue for all the
companies involved in the DNA hepatitis B vaccine
project, but IP issues did not significantly impede the
pace at which the Korean manufacturers were able to
enter the market. The key factors were (in approximate
order of importance):
• requirement for a global market
• need to meet international regulatory standards
• need to undertake in-house R&D or obtain
know-how from a joint-venture partner
• time it took to construct and improve production
facilities that would meet WHO requirements
Further, the ability of Rhein Biotech and Korea
Green Cross to exploit the Rhein Biotech patent on
an alternate production method provides support for
the argument that it is easier to develop and market
vaccines in a complex IP environment than it is to develop and market new defined chemical entities that
have been patented. Vaccines are complex biological products that can be made through a diversity of
procedures while defined chemical entities are single
molecules that may be easy to produce only through
one process. n
For further information, please contact:
Richard T. Mahoney, Director, Vaccine Access, Pediatric
Dengue Vaccine Initiative, International Vaccine Institute,
San Bongcheon-7dong, Kwanak-ku, Seoul 151-818,
Republic of Korea. rmahoney@pdvi.org

CASE STUDY 10

HIV/AIDS Vaccine:
Indian Council of Medical Research
This HIV/AIDS initiative is a collaborative venture
between the Indian Council of Medical Research
(ICMR), New Delhi, the International AIDS Vaccine
Initiative (IAVI), New York, National AIDS Control
Organization (NACO/Indian Ministry of Health),
New Delhi and Therion Biologics, Cambridge, Mass.
The project aims to develop a safe and effective HIV/
AIDS vaccine—such development has been mandated
by the Indian government—for India and other developing countries. The vaccine has now been developed
by ICMR in collaboration with Therion and is undergoing  clinical trials.
Under the terms of this public-private partnership (PPP), ICMR will provide technical expertise,
obtain all necessary permissions and permits, conduct
R&D to develop the vaccine in collaboration with
Therion, prepare the community (in India) for clinical trials, and conduct the trials. ICMR will select an
Indian partner for the manufacture of vaccine and has
overall responsibility for ensuring that the project is
executed according to its objectives. NACO will facilitate the execution of the project. IAVI will support
the project, facilitate development of an appropriate
vaccine through transfer of technology from Therion,
engage in capacity building and advocacy, and facilitate technology transfer for the local manufacture of
the vaccine. Therion will assist ICMR with the vaccine development and help transfer technology to the
selected Indian manufacturer.
The project involved an overall agreement between ICMR and IAVI, a patent and technology
transfer agreement between ICMR and IAVI, and an
IP (intellectual property) rights and confidentiality

agreement between ICMR and Therion Biologics. A
project management committee was set up, comprising representatives from ICMR and IAVI, to coordinate and monitor all activities and assessments of the
R&D programs. The committee is also responsible for
strategic IP management.
All new intellectual property generated will be
jointly held by IAVI and ICMR, and the Indian government shall have the exclusive right to use all patent and other new IP rights to inventions arising out
of the program to benefit India and its neighboring
countries. The ICMR will grant nonexclusive royaltyfree and sublicensable licenses to all new intellectual
property arising out of the project to selected third
parties in order to make, use, sell, and import the
HIV/AIDS vaccine in countries other than those indicated in the agreement (to the extent ICMR has the
right to permit this use). The IAVI shall have IP rights
for rest of the world.
Initially, the program was to be implemented only
in India, but the Government of India, realizing that
the program could benefit other developing countries
as well, asked for licensing rights. In arriving at this realization, policymakers (bureaucrats) of the government
needed to be educated about intellectual property and
its role in technology transfer. This case has highlighted
the importance of keeping government officials involved
in order for an international PPP to be successful.
Although no patents were filed in India, a significant amount of clinical trial data was generated. From
an IP perspective, it was crucial to recognize private
sector interests. Therion has global rights for the technology needed for the vaccine construct, but India

Satyanarayana, K. 2007. HIV/AIDS Vaccine: Indian Council of Medical Research. In Executive Guide to Intellectual Property
Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.).
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will have rights to improvements made to the vaccine.
Therion’s stringent IP regulations meant confidentiality agreements were imposed on collaborating scientists, which the Government of India appreciated.
The recruitment process for the vaccine trials envisages serious ethical concerns as well as potential liability issues, as the vaccine is for HIV/AIDS. It was
recognized that clinical trials must be conducted in a
fair and transparent manner and the interests of participants protected through informed consent as per
the ICMR’s Ethical Guidelines and that all necessary
safeguards to protect subjects of the study had to be
built into the system.
The case study recognizes (1) the role of “honest
broker” that international nongovernmental organizations like IAVI can play in a PPP, providing funding
and access to high technology from a private company; (2) the need to educate policymakers (bureaucrats)
from the beginning of a project to ensure smooth
progress; and (3) the equally crucial need to involve
policymakers, lawmakers, politicians, women’s associations, and other civil society organizations in the
execution of such projects that envisage clinical trials. This project is offered as an example of productive
North–South collaboration and broad capacity building and a partnership in which the strengths of the
partners complement each other.

Types of agreements

As part of the HIV/AIDS project, ICMR entered into
the following types of agreements:
• an overall agreement between the ICMR and
the IAVI for the entire project including provisions for development, upscaling, manufacture,
and distribution of the vaccine in India, neighboring countries, and the rest of the world
• a separate technology transfer and manufacturing agreement between Therion and the
manufacturer identified jointly by IAVI, the
Government of India, and Therion

IP rights decisions
and IP management

The project has resulted in the following arrangements
with respect to IP rights and strategic IP management
issues:
• IAVI and the Government of India-ICMR will
jointly hold the new intellectual property generated during the project.
• The Government of India-ICMR shall have exclusive rights to use all patent and other new IP
rights to inventions arising out of the program
in India and neighboring (SAARC) countries.
• ICMR grants IAVI a nonexclusive, worldwide,
royalty-free sublicensable license to all new
patents and other intellectual property arising
out of the program that would permit IAVI or
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third parties selected by IAVI to make, use, sell,
offer for sale, and import HIV/AIDS vaccines
in countries other than those indicated in the
agreement (to the extent ICMR has the right to
permit the use of the same).
• Intellectual property is jointly managed by the
ICMR and IAVI through the project management committee.

Policy implementation

Policy is implemented through a project management
committee comprising representatives from the IAVI,
ICMR and NACO, and jointly chaired by members
appointed by ICMR and IAVI. The committee is responsible for the coordination and monitoring of all
activities, periodic assessments and updates, and refinements and revisions of the R&D program.

External factors that
affected decision making

A number of external considerations influenced ICMR’s
strategies and decision making. These include:
• the potential use of the vaccine(s) in India’s
neighboring countries
• the need to provide an effective and affordable
vaccine to the people

Key lessons learned
and health-access issues

The following items represent key lessons from
ICMR’s HIV/AIDS vaccine project, which may be applicable to other entities that aim to utilize intellectual
property:
• Only through strategic public-private partnerships can such ventures succeed.
• Private sector’s interests need to be considered.
• The role of an international nongovernmental
agency such as IAVI is important and vital for
the success of such a project.
• There is a need to educate government officials
on issues relating to IP rights and technology
transfer, as the government’s role is crucial in
the clearance and approval of projects of national interest.
• The importance of (1) ethics in carrying out
clinical trials and (2) the need to involve policymakers, women’s associations, and other civil
society groups in the execution of the project
cannot be overstated. n
For further information, please contact:
Kanikaram Satyanarayana, Director, Intellectual
Property Rights Unit, Indian Council of Medical
Research, Ansari NagarNew Delhi-110, 029, India.
kanikaram_s@yahoo.com

CASE STUDY 11

Malaria Vaccine: Malaria Vaccine Institute
and GlaxoSmithKline Biologicals
Malaria remains one of the world’s deadliest killers.
Every year, the disease takes the lives of more than one
million people, mostly sub-Saharan African children
under age five. Hundreds of millions more people fall
ill from the mosquito-borne disease. Major hurdles
to traditional prevention and treatment strategies
include drug resistance by the malaria parasite and
heightened resistance to insecticides by the mosquito
that transmits it. Scientists have been working for decades to develop a preventive malaria vaccine. While
they have successfully demonstrated that such a vaccine is possible, many challenges continue to impede
progress on the road to an effective product. The complex life cycle of the malaria parasite (the most deadly
being the Plasmodium falciparum species) represents
a major hurdle. While each stage of the parasite’s
development offers an opportunity to attack it, the
parasite’s ability to evade people’s immune responses
has made the development of a malaria vaccine technically difficult.
PATH1 is an international, nonprofit organization that creates sustainable, culturally relevant solutions, enabling communities worldwide to break
longstanding cycles of poor health. The PATH
Malaria Vaccine Initiative (MVI)2 is a global program established in 1999 through an initial grant
of US$50 million from the Bill and Melinda Gates
Foundation, which has since awarded MVI an additional US$207.6 million, including US$107.6 million to complete development of the most promising
malaria vaccine candidate. MVI’s mission is to accelerate the development of promising malaria vaccines

and to ensure that they are available and accessible in
the developing world.
Among the candidates in MVI’s portfolio,
the RTS,S vaccine of GlaxoSmithKline (GSK)
Biologicals3 is the most advanced. Created in 1987,
the pre-erythrocytic vaccine candidate’s early development was undertaken by GSK Biologicals, in close
collaboration with the Walter Reed Army Institute of
Research. In January 2001, GSK Biologicals, MVI,
and other partners—with support from the Bill and
Melinda Gates Foundation—entered into an agreement to develop the vaccine for children in subSaharan Africa. Clinical evaluation of RTS,S began
in 1992 and the results since then represent a breakthrough for malaria vaccine development. RTS,S
has proved to be effective for at least 18 months in
reducing clinical malaria by 35 percent and severe
malaria by 49 percent. Time magazine highlighted
this project as one of the most important health accomplishments of 2005.

Partners

Partners in the malaria vaccine project are
• from academia, New York University
• from government, Walter Reed Army Institute
of Research
• a nonprofit organization, PATH Malaria
Vaccine Initiative
• a pharmaceutical company, GSK Biologicals
• two health-research centers, the Center for
International Health (CIH), Hospital Clínic

MIHR/PIPRA. 2007. Malaria Vaccine: Malaria Vaccine Institute and GlaxoSmithKline Biologicals. In Executive Guide to Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney,
L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
Editors’ Note: This case study was prepared by MIHR members of the Technology Managers for Global Health (TMGH), a
special interest group of the Association of University Technology Managers (AUTM) (see www.tmgh.org) and adapted
for this Executive Guide. The original version was published as part of a collection of case studies: MIHR/TMGH. 2007. Academic Licensing to Global Health Product Development Partnerships (ed. U Balakrishnan). MIHR: Oxford, U.K.
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of the University of Barcelona and Centro de
Investigação em Saude da Manhiça (CISM)
The Bill and Melinda Gates Foundation provided
funding for the project.

Technology

This vaccine candidate is a recombinant protein that
fuses a part of the P. falciparum circumsporozoite
protein with the hepatitis B surface antigen molecule.
Combined with a proprietary GSK adjuvant system,
RTS,S induces the production of antibodies and white
blood cells that are believed to diminish the capacity of the malaria parasite to infect, survive in, and
develop in the human liver. In addition to inducing
partial protection against malaria, the RTS,S vaccine
candidate stimulates a protective immune response to
hepatitis B, which commonly infects people in developing countries.

Progress, Current Status, and Goals

GSK Biologicals and MVI are currently conducting
several small-scale trials in infants and young children, the groups most vulnerable to malaria and that
would benefit most from an effective malaria vaccine.
Working with in-country research institutions, clinical trials are ongoing in partner African countries, including Mozambique, Tanzania, Gabon, and Ghana.
A variety of immunization schedules will be assessed,
and the efficacy of the vaccine will be evaluated when
administered with the Expanded Programme on
Immunization. If these trials are successful, the partners will proceed to a large-scale Phase III clinical trial
to determine the efficacy of the vaccine in the same
age group. If all goes well, the RTS,S vaccine could be
licensed as early as 2010.

About the clinical partners
The Center for International Health (CIH),
Hospital Clínic of the University of Barcelona
The Center for International Health (CIH) is a pioneering structure within the University of Barcelona’s
Hospital Clínic, the leading Spanish biomedical research center.4 The CIH is involved in health
care, training, and research in global health issues.
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The collaborative programs in Africa, particularly the
development of the Manhiça Health Research Center,
which is in close partnership with Mozambican institutions, are a central component of the activities of
the CIH.

The Centro de Investigação
em Saude da Manhiça

Centro de Investigação em Saude da Manhiça
(CISM) is the first peripheral health research center in
Mozambique to undertake medical research into key
health problems in that country. Founded in 1996,
CISM was developed under a collaborative program
between the Mozambique Ministry of Health, the
Maputo School of Medicine (Universidade Eduardo
Mondlane), and the Hospital Clínic of the University
of Barcelona with core funding from the Spanish
Agency for International Cooperation.5

Mozambique’s Ministry of Health

The mission of Mozambique’s Ministry of Health is to
promote and preserve the health of the Mozambican
population, to promote and provide quality and sustainable healthcare services, and to, with equity and efficiency, gradually increase access to sustainable healthcare for all Mozambicans. n
For further information, please contact:
GlaxoSmithKline Biologicals, Alice Grasset, Phone:
+32-2-656 8774 or +32-475-309 020.
PATH Malaria Vaccine Initiative (MVI), Ellen Wilson,
Phone: +1-301-652 1558 or +1-301-922 4969.
Centro de Investigação em Saude da Manhiça,

Hospital Clínic of the University of Barcelona, Marc de
Semir, Phone: +34-93-227 5700 or +34-62-794 7528.
1

PATH: www.path.org.

2

Malaria Vaccine Initiative: www.malariavaccine.org.

3

GlaxoSmithKline Biologicals: www.gsk-bio.com.

4

University of Barcelona Hospital Clínic:
www.hospitalclinic.org.

5

CISM: www.manhica.org.

CASE STUDY 13

Rotavirus Vaccine:
NIH Office of Technology Transfer
The National Institutes of Health (NIH), as part of
the U.S. Public Health Service (PHS), is dedicated to
improving the public health of individuals worldwide
through innovative research and the funding of critical medical research programs. Immunization against
rotavirus disease is an important public health initiative supported by several organizations worldwide.
This case study describes the partnerships between
PHS and institutions in Brazil, China, India, and the
United States that have been established to facilitate
development of a safe, effective, and affordable vaccine
for arresting the overwhelming mortality associated
with rotavirus infection in the developing world.

Partners

Partners in the rotavirus vaccine project are:
• from government: the National Institutes of
Health/U.S. Public Health Service
• nonprofit organizations: Fundação Butantan (Sao
Paulo, Brazil), Chengdu Institute of Biological
Products (Chengdu, China), and Wuhan Institute
of Biological Products (Wuhan, China)
• for-profit companies: Aridis Pharmaceuticals
(United States), Bharat Biotech International,
Ltd. (Hyderabad, India), Biological E., Ltd.
(Hyderabad, India), Shanta Biotechnics, Ltd.
(Hyderabad, India), and Serum Institute of
India, Ltd. (Pune, India)

Epidemiological Features
of Rotavirus

Rotavirus is the leading cause of severe dehydrating diarrhea in infants and children worldwide. According
to a report issued by the World Health Organization

(WHO), each year, the disease is responsible for about
25 million clinic visits, two million hospitalizations,
and between 352,000 and 592,000 deaths in children
age five and under. As one can imagine, the worldwide
economic burden associated with rotavirus disease is
staggering, exceeding $1 billion each year in medical
costs. Children in developing countries are disproportionately at risk of dying from rotavirus-related infection. In India alone, rotavirus is blamed for the deaths
of approximately one out of every 250 children each
year, and in China, the disease accounts for more than
34,000 deaths per year. This rotavirus-associated mortality is due in part to inadequate sanitation and to
inadequate access to intravenous rehydration therapy
in poor countries.

THE Technology

The human-bovine reassortant rotavirus vaccine is an
invention of Dr. Albert Kapikian and his colleagues
at the National Institutes of Allergy and Infectious
Disease (NIAID) of the NIH. The invention was
further developed through collaboration with Wyeth
Pharmaceuticals. The vaccine technology is based on
multivalent immunogenic compositions comprising
four human-bovine reassortant rotaviruses and involves the insertion of the gene-encoding VP7 protein of G1, G2, G3, and G4 human rotavirus strain
into a bovine rotavirus backbone. These VP7 serotypes represent the clinically most prevalent human
rotavirus serotypes. Additionally, the basic quadrivalent vaccine formulation can be augmented with G9
and G8 strains (or one of these additional strains for
a pentavalent formulation) to make a hexavalent formulation. Serotype 9 (G9) has emerged as an important strain in Latin America and the most important

MIHR/PIRPA. 2007. Rotavirus Vaccine: NIH Office of Technology Transfer. In Executive Guide to Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR
(Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
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strain in Brazil, whereas G8 is prevalent in many
African countries.
Originally, the human-bovine reassortant rotavirus
vaccine was intended as a second-generation rotavirus
vaccine. It was developed alongside the human-rhesus
reassortant vaccine, RotaShield, an earlier invention of
Dr. Kapikian that was commercialized by Wyeth following U.S. Food and Drug Administration approval
in 1998. RotaShield was voluntarily removed from the
market in 1999 after the vaccine was suspected of being linked to an increased risk for intussusception in
children. After the withdrawal of RotaShield from the
market, interest in the human-bovine reassortant technology increased, which led to multiple applications
for commercial licensing as detailed below.

License Agreements

Published reports and presentations by NIH NIAID
investigators generated significant interest in the
human-bovine rotavirus vaccine technology from
companies and institutions worldwide. In 2005,
eight organizations, one in the United States and
seven based in the developing world, were granted
licenses from PHS to manufacture and distribute
the rotavirus vaccine. The licensees are U.S.-based
Aridis Pharmaceuticals; Fundação Butantan, a
Brazilian government institution; Bharat Biotech
International, Biological E., Ltd., Shantha
Biotechnics, Ltd., and Serum Institute of India, Ltd.,
all India-based companies; and Chengdu Institute
of Biological Products and Wuhan Institute of
Biological Products, both funded by the government of China. The vaccine technology is covered
by issued patents (and pending patent applications)
in the United States, Europe, Canada, Japan, China,
India, Korea, Brazil, and Australia, thus NIH decisions regarding the license agreements were based
on thorough evaluation of the applicants and their
capabilities with regard to vaccine research and
manufacturing. The license agreements with all parties are based on territorial rights and include both
rights for the intellectual property and to biological
materials. The biological materials include all the
vaccine strains, as well as the analytical reagents
necessary to develop the vaccine.
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Butantan was awarded an exclusive license to
practice the invention for development of a rotavirus
vaccine in Brazil and Latin America. In cooperation with the Brazilian Ministry of Health, Butantan
plans to introduce the vaccine into Brazil’s child immunization program, which provides free vaccines for
all children of Brazil. Similarly, Chengdu and Wuhan
will manufacture and supply the rotavirus vaccine to
China’s expanded program of immunization (EPI). The
Office of Technology Transfer (OTT) at NIH granted
to the four Indian companies licenses to the IP rights
in India and rights to manufacture and distribute the
rotavirus vaccine in India and other developing countries, excluding Brazil and other Latin American countries and China. Finally, Aridis was granted an exclusive
license to IP rights covering the rotavirus vaccine in
the United States, Europe, and Canada. By using this
multipronged approach and carving out territory-specific agreements, PHS ultimately set the stage for global
distribution of the rotavirus vaccine. The terms of the
agreements were structured according to each licensee’s
mission to provide free or affordable vaccines to children in their specific territories.

Progress, Current Status, and Goals

The human-bovine reassortant rotavirus vaccine is expected to reach the market in developing countries in
five to six years. All the licensees are currently in a stage
of organization, preparing all the necessary facilities
and infrastructure for manufacturing the vaccine and
for clinical trials. The licensees plan to receive training
in the technology involving the vaccine at the laboratory of Dr. Kapikian at NIH. It is anticipated that the
Codevelopment will include collaboration with the
NIH. OTT staff was recently notified by its partners
and the staff of the Bill & Melinda Gates Foundation
that the latter will support partial development of
clinical trial procedures for screening the technology
at specific institutions in developing countries. n
For further information, please contact:
Uri Reichman, Branch Chief, Infectious Diseases, Office
of Technology Transfer, National Institutes of Health, 6011
Executive Boulevard, Suite 325, Rockville, MD 20852,
U.S.A. reichmau@mail.nih.gov

CASE STUDY 15

Gastrointestinal Medicines from African Aloe:
Baylabs (Pty) Ltd.
The plant species Aloe ferox, indigenous to the eastern
and southeastern Cape regions of South Africa, has
sustained an aloe tapping industry for more than 250
years. However, the industry has failed to substantially
improve the economic conditions of communities in
the region. Between 1,600 and 3,000 aloe tappers earn,
on average, $150 per month.
In 1998, a method for producing a novel fiber in
powder form from the discarded leaves of the plant
was patented by South Cape Aloe (SCA). A virtual
startup company with a strong emphasis on technology and intellectual property (IP) was subsequently
formed in South Africa to develop a product to treat
irritable bowel syndrome (IBS) and AIDS-related diarrhea (ARD).
The company, Baylabs, aims to form local partnerships to develop, manufacture, and distribute the
product to both developed and developing countries.
Baylabs’ strategy is to focus on R&D to generate and
protect intellectual property and products, while outsourcing noncore functions such as manufacturing,
sales, and distribution.
SCA granted the manufacturer African Aloe exclusive rights to make the powder and gained a share
hold in Baylabs in exchange for exclusive, royaltyfree, worldwide rights to exploit the powder. Baylabs
filed a Patent Cooperation Treaty application for the
novel powder formulation, with national filings in 13
European countries and prosecutions in the United
States, Japan, Australia, and China.
Baylabs has developed four over-the-counter
natural remedies from A. ferox that are distributed
to pharmacies. The revenue generated is used to file
patents and obtain scientific evidence of efficacy for

gastrointestinal (GI) problems. The products will continue to be marketed and regulated as a dietary supplement while scientific evidence is being gathered and
until the product is registered as a medicine.
The company’s value has grown through its intellectual property and clinical trials of IBS and infantile diarrhea disease (IDD). Discussions are underway
with international strategic partners regarding exclusive license agreements; efforts to secure government
or venture capital funding are in progress. Baylabs
plans to build preprocessing field plants and a facility to manufacture the powder, with the aloe tapper
community as an equity partner, which could lead to
increased salaries (almost double) for aloe tappers.
There is no traditional knowledge (TK) involved
in using the waste leaf but TK exists in using the A.
ferox. A key feature of this case study is the potential
for other treatments; the formulation can be used for
IBS in developed countries and ARD in developing
countries. Once clinical trials have been completed,
Baylabs plans to register the product as a medicine.
However, the advantages of registering the product as
a drug rather than as a food supplement have been
questioned. Such registration would require, among
other things, strict manufacturing quality standards
and could be fraught with regulatory difficulties. Many
intended herbal remedies, if subjected to full clinical
trials and toxicity (as required by regulation), would
not meet these standards.
In natural products a key issue is long-term planning and supply. If the product were to become a
blockbuster, arrangements would have to be made for
the community to benefit, such as through a trust fund.
It is important to recognize traditional harvesters and
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traditional plant users and their stake in bioprospecting. Baylabs is set to give the aloe tapping community
a stake in the project.
The Baylabs example illustrates how the development of a technology can have positive commercial
and positive moral outcomes. Through the creation
of strategic alliances and partnerships, there can arise
opportunities for securing and developing intellectual
property for the benefit of underserved communities
in both developed and developing countries.

Types of agreements

As part of the GI medicines from African aloe project, Baylabs has entered into the following types of
agreements:
• exclusive patent license agreement
• exclusive supply agreement

IP rights decisions
and IP management

Baylabs has faced key areas of IP rights decision making and strategic IP management issues including:
• securing a strong IP portfolio through international filings, scientific proof-of-concept, and
rigorous clinical trials
• securing ownership of intellectual property and
outsourcing noncore functions

Policy implementation

The SA Medicines Control Council (MCC) is presently formulating policy on traditional and herbal
medicines. Companies are therefore able to place overthe-counter products in the market without clinical
trials. These may not make any medicinal claims. This
enabled Baylabs to place four elementary products
(aloe gel, a high fiber tablet, a laxative tablet, and an
antiarthritic tablet containing aloin as the active ingredient) on the market and to secure income from
their sale. These products had to be submitted to the
traditional medicines registry at the MCC to enable
continued manufacturing and sales.
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External factors that
affected decision making

A number of considerations influenced Baylabs’ strategies and decision making. These include:
• burden of disease from ARD in developing
countries
• burden of disease from IBS in developed
countries
• commercial opportunity from IBS
• indigenous occurrence of Aloe ferox
• opportunity to exploit a by-product of the aloe
tapping industry
• regulatory issues relating to aloe mixture
• opportunity to alleviate IDD

Key lessons learned

The following items represent key lessons from the
Baylabs GI Medicines/Aloe project, which may be applicable to other companies that aim to utilize intellectual property:
• have a moral as well as a commercial reason for
existence (improve living standards of aloe tappers and alleviation of ARD, IBS, and IDD)
• have a global commercial opportunity, which
big pharma has been unable to effectively address (IBS—a US$15 billion annual industry)
• create and protect intellectual property (registers serious intent)
• create alliances and partnerships
• a startup can be successful operating as a virtual
company and securing IP ownership
• choose partners with a shared value system
• have a good IP attorney (preferably in-house)—
there are always issues! n
For further information, please contact:
Tony Bunn, Director, Technology Development and
Transfer Office, Medical Research Council, PO Box 19070,
Tygerberg, 7505, South Africa. tony.bunn@mrc.ac.za
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Lapdap™ Antimalarial Drug:
GlaxoSmithKline, WHO-TDR, and the U.K.
Department for International Development
Lapdap™ is a new combination of two off-patent malaria drugs. The U.K. Medicines and Healthcare Products
Regulatory Agency approved the drug in 2003 for the
treatment of malaria caused by Plasmodium falciparum,
which kills one to two million people every year. The
combination drug was developed in response to the
growing resistance among patients to malaria drugs,
with failure rates in Africa as high as 40 percent.
Lapdap came out of early research funded by
the Wellcome Trust and was brought to market by
a public-private partnership (PPP) involving GSK
(GlaxoSmithKline), WHO-TDR (a WHO/UNDP/
World Bank Special Program in Research and Training
in Tropical Diseases), and the U.K. Department for
International Development (DfID). This was done
in collaboration with scientists from the University
of Liverpool and the London School of Hygiene and
Tropical Medicine, African researchers and clinicians,
and the Wellcome Trust.
Under the terms of a funding partnership, GSK,
WHO-TDR, and DfID each paid one-third of the development costs. Their agreement covered the ownership of nonpublished data and the establishment of a
product-development team to continue development
and obtain regulatory approval.
Early patent applications filed on the basic biological work underlying the combination of the two
existing drugs were abandoned after filing because it
was later found that the work had already been published in scientific literature and so there was ‘prior art.’
There are currently no patents protecting the Lapdap™
product in any country.

Lapdap™ was developed to be as inexpensive
as possible, with a public sector target of less than
US$0.30 per dose. It is currently sold only through
private sector pharmacies, with the commercial sale
price varying by country. The drug is available in
South Africa, Nigeria, Kenya, and Ivory Coast.
Lapdap’s™ role in public health is still being assessed; Phase IV studies are ongoing and the WHO
has stated that after reviewing available clinical and
preclinical data, it will identify strategies for optimal
and safe use. Lapdap™ has potential for future public
health initiatives; a collaborative agreement was signed
in April 2004 between GSK, WHO-TDR, and MMV
to develop a new fixed-dose artemisinin combinationtherapy drug combining chlorproguanil, dapsone, and
artesunate for treatment of malaria.
Successful collaboration to ensure that developing countries benefit from the fruits of intellectual
property requires an integrated approach toward networking and capacity building, involving innovation,
regulatory approval, market creation, licensing, and
distribution.
The lack of formal health infrastructure in rural
Africa, where there are few physicians and where the
drug is sold over the counter, has led to great importance being attached to the packaging and distribution, as well as education to ensure proper dosage. The
establishment before registration of a public health
group, under the WHO’s auspices, provided a useful
forum for discussing how Lapdap™ would be accessed.
This case highlights the need for consensus regarding

MIHR/PIPRA. 2007. Lapdap Antimalarial Drug: GlaxoSmithKline, WHO-TDR, and the U.K. Department for International Development. In Executive Guide to Intellectual Property Management in Health and Agricultural Innovation: A Handbook
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public sector use of the product between all parties
involved in national malaria control.
This case study was considered ‘IP neutral,’ since
the academic and public health mission was neither
impeded nor driven by IP considerations. However,
the Wellcome Trust, as part of its mission, recognizes
the important role of industry and its investors (including non-commercial funders) in translating research
innovations into new health products. It therefore encourages and supports the responsible use of IP rights
to protect research findings where commercialization
or further funding which could benefit from the existence of that underlying IP is necessary to achieve the
greatest public benefit.
It could be argued that the lack of underlying
intellectual property in this case, specifically patents,
may have accelerated the research project and reduced
transaction costs. On the other hand, the absence of
patents may have slowed this process, particularly the
attainment of Phase IV studies because a patent-driven
time schedule did not drive the development process.
It was generally agreed, however, that intellectual
property other than patents was generated in the form
of regulatory dossiers (clinical trial data), know how,
terms of codevelopment agreements, and trademarks.
Recognizing the multiplicity of intellectual property
can contribute to a more comprehensive understanding of the IP management aspects of product R&D,
post-development, and manufacturing.
Lapdap’s™ pursuit of WHO endorsement raised
the broader policy issue of the global health body’s role
as a certificatory of treatment regimes. WHO approval
is a vital step in products reaching developing countries and gaining public sector acceptance. However,
responsibility within a PPP for securing such endorsement is not always clear.
Regulatory endorsement is but one aspect of product sustainability. Royalty streams should be examined
for how their use and management can contribute to
product support. Although often treated as undesirable additional costs, the generation of royalties on
public sector sales is an effective IP management tool
for keeping a product on the market.
The involvement of universities in this public
health initiative drew attention to the role of university technology transfer offices (TTOs). It appears that
TTOs are frequently given competing missions by
their institutions, with no clear priority as to whether
making money or delivering applications of research
regardless of returns is the most important goal.
Declining revenue of universities has pressured cashstrapped TTOs to increase their contribution, compelling them to turn to intellectual property. Although
exploiting university research is a legitimate goal, it
may be short-sighted to focus solely on patents; the
transfer of know-how and trade secrets is just as important, and an overemphasis on revenue generation
using IP rights may limit the potential of certain research outcomes.
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In attracting commercial interest, TTOs must
be mindful of overvalued patents and overestimated
royalties, and must know how to manage hurdles and
prevent unreal expectations. Alongside the need for
flexibility in negotiations, education about technology
management is required.
The challenge therefore is to use PPPs as an effective means of bringing drugs to the poor by drawing
on the expertise and synergies between sectors. These
partnerships afford the opportunity to segment the
market in a way in which the public body can benefit
from having an exclusive license for its stakeholders
while satisfying commercial partners.

Types of agreements

An agreement was signed relating to establishment
of the product-development team and ownership of
nonpublished data. Under the funding partnership between GSK, WHO-TDR, and the U.K. DfID, each
partner contributed one-third of the development
costs.

Patent and IP rights decisions

Early patent applications were filed between 1994 and
1996 by GSK (then SmithKline Beecham) on the basic biological work underlying the combination of the
two existing drugs, with Dr. Bill Watkins (University
of Liverpool & Wellcome Trust Research Laboratories,
Kenya) as named inventor. These applications were
later abandoned, because after filing it became clear
that the combination had already been published in
the literature and therefore was no longer novel. There
are therefore no patents protecting the Lapdap™ product in any country.

Policy implementation

Lapdap™ at present is being sold only through the
private sector (pharmacies). WHO does not currently
recommend the use of chlorproguanil-dapsone alone
as an option for national treatment policy in countries
where malaria is endemic. The role of the drug in public health is still being assessed—Phase IV studies are
ongoing, and pharmacovigilance activities in specific
patient groups are planned. WHO has stated that after
reviewing available clinical and preclinical data, it will
shortly identify strategies for the optimal and safe use
of Lapdap™ in malaria-endemic countries.
Because of Lapdap’s™ reported efficacy, relatively
short half-life, and low production cost, it has potential for future public health use in combination with
an artemisinin compound. In April 2004, a collaborative agreement was signed between GSK, WHO-TDR,
and MMV to develop a new fixed-dose artemisinin
combination-therapy drug combining chlorproguanil,
dapsone, and artesunate for treatment of malaria.

CASE study 16

External factors that
affected decision making

In the case of Lapdap™, where IP considerations did
not drive the later development of the project, some
external factors of relevance were:
• nature of the end market for Lapdap™ (poor
countries in Africa)
• multiparty cooperation and synergy

Key lessons and health-access issues

The following lessons were learned during development
of the Lapdap™ drug and subsequent distribution:
• Pharmaceutical industry expertise in clinical trials, the regulatory process, and marketing are
necessary to accelerate product development.

• Establishment of a public health group under
WHO auspices in advance of registration was a
useful forum for discussing how the product
would be accessed.
• Consensus on the use of the product in Africa
is necessary at the country level between parties
involved in malaria control. n
For further information, please contact:
Daniel Nelki, Head of Legal and Operations, Technology
Transfer, the Wellcome Trust, 215 Euston Road, London,
NW1 2BE, U.K. d.nelki@wellcome.ac.uk
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Cyclofem® Contraceptive:
Upjohn, WHO, and the Concept Foundation
The case study of the development and distribution
of Cyclofem® contraceptive as a project of Upjohn
and the World Health Organization (WHO) is an example of innovative intellectual property (IP) management in which a collaboration between a public sector
institution and a private pharmaceutical company led
to the establishment of a new nonprofit organization
that brought the product to developing country markets. The venture described in this case study was also
new type of undertaking for WHO.
Upjohn pharmaceutical company developed the
once-a-month injectable contraceptive Cyclofem®.
Despite successful Phase III trials undertaken jointly
by WHO and Upjohn, the drug company decided
there was an insufficient market for the contraceptive
and donated the clinical trial data to WHO. When
no U.S. or European commercial partner could be
found to take the product forward, WHO invited the
nonprofit organization PATH (to which it licensed
the clinical data rights) to come up with a viable
solution.
PATH proposed establishing a new nonprofit
organization, the Concept Foundation, which would
focus on developing countries. Intellectual property and know-how was transferred via PATH to the
Foundation, which licensed developing country producers on an exclusive basis in defined private sector
markets and on a nonexclusive basis for public sector
markets to ensure competition. A royalty stream of
4% was paid to the Foundation to support continued production and distribution. Manufacturers were
expected to meet national and international (current
good manufacturing practices, or cGMP) regulations.
Milestones were an important part of the package, and

were linked to territories, regulatory matters, and market penetration.
Production was established in Mexico and
Indonesia, supplying private and public sectors with
an affordable quality product that had been dropped
by its developer. This was the first pharmaceutical product to result from successful WHO product
R&D. The Concept Foundation is now self-sufficient
and provides valuable technical assistance and introduction support, alongside economic development
and technology transfer.

External factors that
affected decision making

Establishing a nonprofit organization in a developing
country was an appropriate option because WHO
could not own, manufacture, distribute, or manage
the product. PATH did not want to jeopardize its
own neutral role in improving public health. Another
consideration was liability. PATH, with assets in the
United States, could not afford to risk its well being.
Ultimately, after much discussion it was realized that
the liability risk should rest in a jurisdiction that reflected the environments in which the product would
be used.
The Foundation’s aim was to on-license to producers and distributors in developing countries. If a government wanted to buy the product, it could go to any
of the manufacturers and ask for a bid on cost prices.
As time passed, the Concept Foundation identified the
need to update the regulatory dossier for Cyclofem®. It
carried out this updating and made the new dossiers
available to current and prospective licensees.

Mahoney R. 2007. Cyclofem Contraceptive: Upjohn, WHO, and the Concept Foundation. In Executive Guide to Intellectual
Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L
Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
Editors’ Note: An earlier version of this case study was presented at the MIHR conference Using Intellectual Property
for Improved Health in Developing Countries: An Evidence-Based Approach to Good Practice, Bellagio, Italy, June 14–18,
2004..
© 2007. R Mahoney. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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lessons learned and
health-access issues

This case study is an example of innovative IP management where collaboration between WHO and Upjohn
led to the establishment of a new nonprofit organization with the purpose of bringing the Cyclofem® contraceptive to developing country markets. This case
demonstrates that clinical trial data can be important
IP that can help ensure availability of products in developing countries. Putting it simply, without clinical trial data, the product can not be marketed; thus
the data are of great value. The goal of the Concept
Foundation and similar ventures is to ensure availability of products to the poorest of the poor. It is not
enough to ensure that the private market helps public

sector distribution. As this case study shows, investing
time in updating a dossier to meet the requirements
of other countries and therefore helping to encourage
producers to go into markets that have not been served
is important. Similarly, having solid and enforceable
milestones is not an indication of lack of trust; it is
rather being serious about business and wanting to
succeed. n
For further information, please contact:
Richard T. Mahoney, Director, Vaccine Access, Pediatric
Dengue Vaccine Initiative, International Vaccine Institute,
San Bongcheon-7dong, Kwanak-ku, Seoul 151-818,
Republic of Korea. rmahoney@pdvi.org
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Improved Production of a Natural Product
Treatment for Malaria: OneWorld Health, Amyris,
and the University of California at Berkeley
In December 2004 the Bill and Melinda Gates
Foundation1 awarded a five-year product development
grant to the Institute for OneWorld Health (iOWH),2
a nonprofit pharmaceutical company, to create a
unique three-way partnership between iOWH, a university (University of California at Berkeley),3 and a
for-profit company (Amyris Biotechnologies, Inc.).4
The goal of this project5 is to significantly reduce the
cost of artemisinin, a key precursor in the production of Artemisinin Combination Therapies (ACT),
through synthetic biology, industrial fermentation,
and chemical synthesis. Artemisinin is chemically converted to one of several derivatives and then combined
with other drugs to make an ACT for the treatment
of malaria.
Malaria is a parasitic blood disease that inflicts
as many as 500 million people annually. About 1.5
million people die each year from the infection, primarily children in Africa and Asia. More than half
of the deaths occur among the poorest 20 percent
of the world’s population. Studies in Vietnam have
shown that the botanically derived medicine, artemisinin derivatives, can reduce deaths from the illness by
97 percent. However, the current cost of a three-day
course of drugs containing artemisinin is US$2.40,
which places it out of reach for people in many nations where the disease is most prevalent. Reducing
the price would make the treatment more widely
accessible.
Artemisinin is currently extracted from the wormwood plant, which is supplied by farmers in Vietnam

and China (and more recently, Africa). Seasonality
and availability of the plant contribute to the high
price of the drug. The Gates-funded project hopes to
eliminate the need for plant extraction by utilizing a
platform technology of synthetic biology developed
by Dr. Jay Keasling at the University of California
(UC), Berkeley.6 The goal is to lower the cost of artemisinin-containing drugs ten-fold by producing a
consistent, reliable, high-quality supply of artemisinin
in microbes.
The US$42.6 million grant was divided among
the three partners: US$8 million to UC Berkeley for
continued basic research, US$12 million to Amyris
for applied research on the fermentation and chemical processes, and US$22.6 million to iOWH to
perform the required regulatory work and lead the
implementation of the product development strategy
for the developing world. UC Berkeley’s role focuses
on the engineering of drug-precursor-producing microbe. Amyris’ efforts span engineering of the production microbe to optimizing the semisynthesis of the
drug through fermentation and novel downstream
synthetic chemistry. The role of iOWH includes
developing a commercialization strategy based on
a thorough understanding of the worldwide regulatory requirements and an analysis of the current ACT
manufacturing supply-chain and distribution models.
This one grant enables activities in all three areas of
development and creates an integrated team, each of
the partners applying its expertise to streamline translation from bench to bedside.

MIHR/PIPRA. 2007. Improved Production of a Natural Product Treatment for Malaria: OneWorld Health, Amyris, and the
University of California at Berkeley. In Executive Guide to Intellectual Property Management in Health and Agricultural
Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA),
Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
Editors’ Note: This case study was prepared by MIHR members of the Technology Managers for Global Health (TMGH), a
special interest group of the Association of University Technology Managers (AUTM) (see www.tmgh.org) and adapted
for this Executive Guide. The original version was published as part of a collection of case studies: MIHR/TMGH. 2007. Academic Licensing to Global Health Product Development Partnerships (ed. U Balakrishnan). MIHR: Oxford, U.K.
© 2007. MIHR/PIPRA. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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To ensure accessibility and affordability, the partners have committed to reduced returns in the malaria
field. UC Berkeley has issued a royalty-free license to
iOWH and shall grant royalty free licenses to Amyris
for IP that is developed during the collaboration for
the treatment of malaria in the developing world with
the goal of significantly reducing the price of ACT
products, and reducing the use of artemisinin monotherapies per the World Health Organization’s recommendations for uncomplicated malaria.
This arrangement has benefits for all the parties.
The university benefits from the research funding as
well as from any royalties that may be realized on
profit earned from sales by Amyris in areas outside of
malaria in the developing world. As a for-profit company, Amyris can apply the innovations developed for
the artemisinin project to other projects that rely on
the same platform technology. As a nonprofit pharmaceutical company, iOWH is able to make malaria
treatments more affordable for people in the developing world.

Partners

Partners in this project are:
• from academia, the University of California,
Berkeley
• the nonprofit pharmaceutical company Institute
for OneWorld Health (iOWH)
• the for-profit pharmaceutical company Amyris
Biotechnologies, Inc.
The Bill and Melinda Gates Foundation provided
the funding for the project.

The technology

The preferred and most effective treatments for malaria today are artemisinin-based combination therapies (ACT). Artemisinin, a complex natural product
known as an herbal remedy for thousands of years, is
typically derived from the wormwood plant. Plant
sources of the chemical are variable and crop shortages
contribute to increased cost. Chemical synthesis of the
molecule would require 30 to 40 steps and is therefore
impractical on a commercial scale.
Dr. Jay Keasling, a UC Berkeley professor of
chemical engineering, developed a process of “synthetic biology” to produce an artemisinin precursor
through a multistep process in bacteria.7 The precursor can then be chemically converted to artemisinin
through synthetic chemistry developed at Amyris.
Producing the drug precursor in microbes would lead
to a more consistent and reliable supply and therefore
reduce the cost of production.
The synthetic biology platform may also be used
to produce other drugs, nutraceuticals, and flavors and
fragrances.

Progress, Current Status, and Goals

During the five-year granting period, which began in
2005, the partners would carry out the following activities shown in Figure 1.
UC Berkeley researchers are working to identify
the genes involved in the artemisinic acid biosynthetic
pathway in the wormwood plant, Artemisia annua.
Using their expertise in synthetic biology, they are inserting this biosynthetic pathway into microbes to create hosts that manufacture this direct precursor to artemisinin. Optimizing artemisinic acid production in
these host cells is being achieved through cutting-edge
techniques in metabolic engineering, in collaboration
with scientists at Amyris Biotechnologies.
Amyris Biotechnologies is collaborating with the
Center for Synthetic Biology to build a better microbe.
Amyris will optimize the microbial strain developed
with UC Berkeley for commercial production. In addition, Amyris will develop a fermentation and purification process for the precursor. Simultaneously,
Amyris is developing a scaleable, inexpensive chemical
process to convert the precursor to artemisinin.
OneWorld Health is the product development
lead and has responsibility for directing this collaborative effort. In addition, the organization is leading the
project’s regulatory and commercialization strategies
and is conducting a risk-benefit analysis surrounding
the use of artemisinin derivatives in malaria-endemic
regions.

Deals

Agreements between the partners include the
following:
License Grants:
• The arrangement is governed by a three-party collaboration agreement and two license
agreements (from UC Berkeley to each of
Amyris and iOWH).
• UC Berkeley granted iOWH a royalty-free
license for the manufacture of artemisininbased malaria treatments used in the developing world. UC Berkeley further shall
grant royalty-free licenses to iOWH for IP
developed under the three-party collaboration agreement for use in manufacturing artemisinin-based malaria treatments used in
the developing world. OneWorld Health is
to establish partnerships for ACT manufacture and distribution.
• UC Berkeley granted Amyris licenses to
develop the manufacturing process for the
developing-world malaria market. Amyris
also has licenses for the developed-world
malaria market, nonmalaria indications
of artemisinin, and alternative uses of the
platform worldwide. UC Berkeley further
shall grant similar licenses to Amyris for IP
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Figure 1: Activities of Project Partners
(to be carried out by the end of the grant period)

developed under the three-part collaboration agreement.
• Amyris shall grant iOWH a royalty-free license for IP developed under the three-part
collaboration agreement for the manufacture of artemisinin-based malaria treatments
used in the developing world.
Royalties:
• The license from UC Berkeley to iOWH is
royalty free.
• The license from UC Berkeley to Amyris is
royalty free for the developing-world malaria
market (development for iOWH) and is
royalty bearing for the developed world and
nonmalaria indications in the developing
world.

• Patents that are the sole property of Amyris
and/or iOWH may be filed by Amyris and/
or iOWH, as the case may be, at their own
expense.
• Logistics of filing and payment of costs on
jointly owned IP will be negotiated in good
faith by the joint owners when such joint
IP arises. If the joint owners cannot agree
and if iOWH has an ownership interest in
a joint property, then iOWH may file and
prosecute on behalf of the owners at its own
expense.
Other:
• Amyris, as UC spinout company, is seeking
venture funding to leverage applications in
other markets.
• Using the process developed by Amyris and
UC Berkeley, iOWH is to establish partnerships for ACT manufacture and distribution
• Similar licenses to all relevant third-party
intellectual property will be obtained by
iOWH as the need arises. n

Patents:
• Patent costs for UC Berkeley’s pre-existing patents are shared between iOWH and
Amyris.
• UC Berkeley patents on IP arising from
the collaborative research may be filed by
UC Berkeley and licensed to iOWH and/or
Amyris under the pre-arranged terms mentioned above. Costs are shared by the licens- For further information, please contact:
ee on a pro rata basis. UC Berkeley has no
University of California, Berkeley, Carol Mimura,
obligation to file an application if it does not Assistant Vice Chancellor, IPIRA, 2150 Shattuck Avenue,
have a commitment by a licensee to pay pat- Berkeley, CA 94720, U.S.A. carolm@berkeley.edu
ent costs.
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Institute for OneWorld Health, Katharine Woo, Director,
Scientific Affairs, 50 California Street, Ste. 500, San Francisco,
CA 94111, U.S.A. kwoo@oneworldhealth.org
Amyris Biotechnologies, Inc., Neil Renninger, Vice

President–Development, 5980 Horton Street, Ste. 450,
Emeryville, CA 94608, U.S.A. renninger@amyrisbiotech.com
.
1

Bill and Melinda Gates Foundation. www. gates
foundation.org.

2

Institute for OneWorld Health. www.oneworldhealth.org/.

3

Office of Intellectual Property and Industrial Research,
UC Berkeley. ipira.berkeley.edu/index.php.

4

Amyris Biotechnologies, Inc. www.amyrisbiotech.com.

5

The Artemisinin Project. www.artemisininproject.org.

6 Keasling Laboratory, UC Berkeley. www.cchem.berkeley.
edu/%7Ejdkgrp/.
7

Martin VJ, DJ Pitera, ST Withers, JD Newman and
JD Keasling. Engineering a Mevalonate Pathway in
Escherichia Coli for Production of Terpenoids. Nature
Biotechnology. 21 July 2003. (7): 796–802.
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Nontoxic Drug Therapy for
Chagas’ Disease and Malaria:
University of Washington and Yale University
Some of the world’s most intractable diseases are pre- the infection, which spreads inside the heart and gasdominantly in the developing world. These illnesses
trointestinal tract of the victim. Drugs are difficult
are known as neglected diseases because they receive
to administer and highly toxic, leading to severe side
little attention from the medical community and the
effects in many patients. And no existing medicines
pharmaceutical industry, even though they have a
have consistently cured patients, according to a resignificant impact on vulnerable populations. One of
port from the Institute for OneWorld Health, a nonthese neglected killers is Chagas’ disease.  
profit pharmaceutical company the goal of which is
According to the World Health Organization, to develop affordable treatments for neglected infecChagas’ disease is an insect-borne, parasitic illness
tious diseases around the world.  
that infects and kills millions of people every year.
A collaborative research effort among scientists
Chagas’ disease is endemic in 21 Latin American
at the University of Washington and Yale University
countries and is a major cause of heart failure in the
recently brought forth a nontoxic drug therapy for
region. Caused by the parasite Trypanasoma cruzi, Chagas’ disease. The team included Andy Hamilton
Chagas’ disease is most often transmitted by an in- and Junko Ohkanda, both chemists at Yale, and Fred
sect known as the kissing bug, which tends to feed on Buckner and Wesley Van Voorhis, infectious disease
experts, and Michael Gelb and Kohei Yokoyama,
people’s faces. Humans, as well as wild and domestic
animals, carry the parasite, and insects infected with T. chemists, at University of Washington.
“It was a wonderful collaboration between orcruzi frequently live in the thatched walls and roofs of
homes, making it especially challenging to eradicate.   ganic chemists and parasite biologists that came
Controlling the disease is difficult, costly, and
about through reading the literature and recognizing
risky: it depends largely on treating homes in affected
potential connections,” said principal investigator
areas with residual insecticides and, in general, im- Hamilton, who has since become a provost at Yale.
proving housing by replacing traditional thatched-roof “Big problems nearly always involve collaborative sodwellings with more modern, plastered walls and metal
lutions because no one person or institution can have
roofs. Management of the illness now involves blood
all the answers.”  
screening to prevent transmission through transfusion.
Buckner, of the University of Washington
Some drug treatments are available as well.  
Medical School, agreed. He has worked for years
with a group of chemists led by Gelb to develop compounds to treat infectious diseases caused by protozoan pathogens.  
Collaborating to FIND A TREATMENT
“They would make the compounds and we would
But the standard drug treatments for Chagas’ disease
test them against the parasites to see if they would do
leave much to be desired. Most are aimed at fighting
AUTM. 2007. Nontoxic Drug Therapy for Chagas’ Disease and Malaria: University of Washington and Yale University.
In Executive Guide to Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices
(Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de
Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us to
adapt this case study for inclusion in this Executive Guide. The original was published by AUTM. 2006. Technology Transfer
Works: 100 Cases from Research to Realization (Reports from the Field). Association of University Technology Managers,
Northbrook, IL. www.betterworldproject.net.
© 2007. AUTM. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial
purposes is permitted and encouraged.
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In the meantime, Hamilton and Ohkanda were
anything,” Buckner said. “Some turned out to be acworking on a similar problem from another angle.
tive against targets that were different than what we
designed them to do, but we determined the mecha- “This was the result of many years of fundamental renism of action and showed them to be active in an
search in trying to get a novel molecular structure to
animal model.”   
target a specific enzyme,” Hamilton said. “It’s a question of how one synthetic molecule could recognize
a biological molecule in a process called molecular
recognition.”  
APPROACHING THE PROBLEM
According to Hamilton, the two universities and
FROM DIFFERENT ANGLES
The original patent application described “com- the nonprofit pharmaceutical company developed an
integrated model for drug development, perhaps just
pounds and methods for treating infections caused
as important as the chemical compound the researchby bacterial protozoal and fungal agents,” said Aline
Flower, of University of Washington TechTransfer ers had discovered. “We hope, as we make progress in
Invention Licensing.  
the pre-clinical stage, OneWorld Health will help us
When asked about the potential application of
pull together the necessary funding to allow the clinithe compound, Hamilton said, “we developed, in
cal and preclinical development of these compounds,”
collaboration with parasitologists, compounds that
said Hamilton.  
target the Chagas’ disease agent in animal models,
The Yale Office of Cooperative Research senior
and we are seeing some very encouraging data.”
licensing associate Alan Carr explained that an inBuckner and his colleagues had made inroads
terinstitutional agreement between the University of
targeting these diseases, working toward cures or vac- Washington and Yale University enabled the institutions to structure a deal with OneWorld Health to
cines. “We had discovered that protozoan parasites
contain the enzyme protein farnesyltransferase,” said
license the compound affordably.  
Buckner. “This same enzyme plays an important role
Like the drug compound, the model for drug
in cancer cells, which meant a lot of research labo- development, borne of innovative university techratories were developing drugs against it. We were
nology transfer, could well have a lasting impact on
working on the hypothesis that protein farnesyltrans- people around the world. n
ferase inhibitors might work against parasites.”
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Diagnostic Tests for Cervical Cancer: PATH
The public sector institution PATH aims to improve
global health by advancing technologies, strengthening systems, and encouraging healthy behaviors
through effective collaborations with the private sector. PATH tries to reduce risks for a commercial company developing products for resource-poor countries
by identifying gaps in the market that existing technology can fill, demonstrating value, and partnering
in development and sustainable supply. In addition,
PATH adapts products to different markets, provides
training, and engages in advocacy with WHO and
other public bodies. PATH is both a recipient and a
provider of funding.
As a nonprofit organization that creates and manages intellectual property in house, PATH recognizes
that working with private companies requires sensitivity to and awareness of commercial incentives. PATH
believes that intellectual property is just one element
of the economic environment of the technology.
Successful collaborations with private sector companies impact positively the availability, accessibility and
affordability of products in public sector health programs in developing countries.
During product development and distribution,
PATH works to change behavior and to open or improve communication. It worked with India’s Ministry
of Health to launch a hepatitis B vaccine on a project
that involved community education and communication in preparation for the vaccination program. The
program’s success has ensured national expansion of
the program.
Diagnostics is a large field with a number of disparate groupings of intellectual property generated by
scientists around the world; it is common for multiple

parties to hold key pieces of intellectual property.
PATH routinely conducts market and industry feasibility studies to determine the type of industry partner
to pursue, to determine which is best positioned to
take PATH into the target segments it is interested in,
and to identify IP issues. The public sector needs to
recognize that securing the necessary IP rights for diagnostic products is imperative before moving ahead
with development and commercialization.
Procurement in diagnostics is not as centralized
as other public health products, such as vaccines and
drugs. This makes it more difficult to plan for the
global public health sector. Marketing is generally on
a country-by-country basis, unlike family planning
products, for example, that have regional or global distribution agencies for the public sector markets.

The Cervical Cancer
Diagnostic Test Project

PATH is engaged in ongoing work with industry partners to develop rapid diagnostic tests for cervical cancer
for use in developing countries. In addition, two major
institutes, in India and China, are screening 30,000
women for cervical cancer and will then conduct the
clinical trials to validate the efficacy of these these simple and inexpensive tests. In addition, this work will
generate useful information on viruses that have not
yet been examined in detail in these countries.
Under the terms of the R&D agreements between
PATH and the industry parnters, PATH’s obligations
include funding a portion of the industry partner’s
direct R&D costs, conducting market and industry
assessments, developing an evaluation framework

Brooke S. 2007. Diagnostic Tests for Cervical Cancer: PATH. In Executive Guide to Intellectual Property Management in Health
and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK),
PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute
(Ithaca, USA). Available online at www.ipHandbook.org.
Editors’ Note: An earlier version of this case study was presented at the MIHR conference Using Intellectual Property for
Improved Health in Developing Countries: An Evidence-Based Approach to Good Practice, Bellagio, Italy, June 14–18, 2004.
© 2007. S Brooke. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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for public-health use of the new test, and conducting multicountry clinical evaluation of the new tests’
performance for registration purposes. The industry
partner is responsible for development of the products,
management of the intellectual property (patenting
costs and prosecuting infringement), manufacture and
supply for clinical evaluations, and finalizing the product for registration and commercial supply.
PATH retains ownership of specimens, but data
are either jointly or individually owned. A product-development committee was formed, and PATH only
provides funding sufficient to reach the next agreedupon milestone. During the R&D phase PATH can
terminate, without cost, at key milestones, although
industry partners terminate at a cost.
The commercialization period of the agreement
runs for ten years from the first sale of a registered
product. Both industry partners are required to provide preferential public sector pricing. If these specific
products are sold in developed countries, PATH will
earn a royalty, however PATH has forgone all royalties on developing country sales. Termination clauses
covering one industry partner involve repayment of
PATH’s direct funding and the transfer of distribution and/or manufacturing to a third party; the other
industry partner is only required to grant PATH a
nonexclusive license to the product and underlying
reagent.
Both companies are working on products that are
different from those they will launch in the United
States and Europe. Developing a product with PATH
could potentially jeopardize products in other developed countries; it is therefore critical for participating
industry partners to be able to segment markets.
PATH’s success in being able to attract industry
partners to collaborate in its effort to develop a diagnostic test for cervical cancer is an example of creating
an overarching cervical cancer prevention initiative
that made collaboration attractive and worthwhile—
in this case, a program of cervical cancer screening
including clinical work, advocacy, and policy issues.
PATH does not expect to be providing the product in
the future; its industry partners have the intellectual
property, are developing it, and are responsible for its
management.
This case study illustrates that intellectual property and technology transfer are not enough to create
a broad and lasting health impact. PATH believes it is
possible to attract top-tier industry partners, especially
if there is a comprehensive public health initiative and
not just a technology development project. Issues to
consider in developing a public health initiative include determining the value of know-how, deciding
whether to grant an exclusive or a nonexclusive license,
dealing with key reagent IP holders, and influencing
the final product price.

Types of agreements

Over the years of diagnostic-test development and
commercialization, PATH has:
• in-licensed key diagnostic reagents to PATH
from academic, government, and private company sources
• out-licensed diagnostic test and reagent production know-how from PATH to diagnostic
manufacturers
• some with geographically defined exclusive
territories
• some on global nonexclusive basis
• materials transfer agreements
• supply agreements
• confidentiality agreements
• codevelopment agreements

IP rights decisions
and IP management

PATH has faced key areas of IP rights decision making
and strategic IP management issues including:
• managing freedom to practice risks associated
with other parties’ intellectual property for certain diagnostic platforms and reagents
• determining the value of know-how developed
for efficient production of certain diagnostic
reagents even when the know-how was not
patentable
• determining whether to provide downstream
licensees with a greater or lesser level of market
exclusivity, or whether to license only on a nonexclusive basis
• dealing with holders of key intellectual property
involving particular antigens or antibodies necessary to develop particular diagnostic tests
• deciding whether to patent incremental inhouse innovations in the face of uncertain demand and usefulness
• considering how to achieve or at least positively
influence final product pricing and access when
third-party diagnostics importers/distributors
(not the PATH-licensed diagnostic manufacturer) will be the party making the sales transaction to a developing country government

Policy implementation

On an overall policy basis PATH works under its
Guiding Principles for Private Sector Collaboration,
endorsed by the board of directors, which is most
often relevant to PATH’s intellectual property and licensing activities with diagnostics. To conform to key
elements of these guiding principles, a license (and
overall collaboration) between PATH and a commercial diagnostics producer must:
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•

•

•

exhibit a clear link to PATH’s mission by improving the availability, accessibility, and affordability of important products for public health
programs in developing countries
recognize that the commercial partner must
achieve commercial benefit to ensure their
sustainable commitment to supplying the
technology
provide a clear definition of the roles, responsibilities, and expectations of both PATH and the
commercial producer
balance PATH’s need for transparent collaboration with the commercial producer’s need to
protect proprietary information
reflect a rigorous process of due diligence on
PATH’s part before executing an agreement

•

distributed nature of global public sector procurement of diagnostic reagents—no single, huge,
vertical procurement mechanism as exists for vaccines and, to a degree, family planning products

Key lessons learned
and health access issues

The proprietary control of a single key diagnostic test
reagent can give some parties control and power seemingly disproportionate to their contributions to an
•
overall diagnostic test development project. It is critical
to have either IP access and/or reagent supply agreements in place early in the product-development cycle,
•
so that access uncertainty is reduced and cost of access
is fully understood. The private sector understands this
well, while we (at PATH and in the broader public secThe IP elements, working relationships, and
tor) have not always done our homework in this area.
technology economics of every project or program
Noncommercial development and/or stewardcan vary from one extreme to the other. Because of
ship of diagnostic platform intellectual property or
this, PATH has found it counterproductive, for the
key component intellectual property can create a posimost part, to make broad institutional policies about tive impact. For example, PATH enhanced the local
specific individual elements of complex intellectual
production of key rapid-test raw materials (nitrocelproperty and collaborative development agreements. lulose filters and colloidal gold signal reagents) in
For example, there is no PATH-wide policy that states India, which created an impact beyond the transfer of
“all licensed manufacturers must sell to public sector at
technology for individual tests to specific companies.
cost plus 10%.” In some cases that structure might be
Materials suppliers are now serving additional emergappropriate, in others it might prevent the technology ing diagnostic producers.
from ever coming to market. In cases where PATH
Intellectual property and technology transfer
has developed significant technology that may have
alone are rarely enough to create a lasting impact on
value in developed country markets, PATH maintains
public health. We are all working on solutions to
the flexibility to negotiate for a royalty on developed
health problems that have fundamentally less promise
country market sales. PATH forgoes royalties on sales
as a “business opportunity,” from a commercial manof licensed technologies for developing country public
ufacturer’s standpoint, than do other health problems.
sector use.
To make a new diagnostic test that will deliver profit
to the manufacturer and be beneficial and accessible
to patients, there needs to be policy change, advocacy work, and extensive evaluations. The diagnostic
External factors that
manufacturer will rarely fund these types of activities,
affected decision making
especially for price-sensitive public health markets, so
The diagnostics arena has a number of characteristics
it is critical to involve others who will undertake this
that have historically influenced PATH’s strategies and
work. Intellectual property and technology transfer are
decision making. These include:
• extremely competitive nature of global diagnos- certainly important. However, for maximum lasting
health impact they should be managed as components
tic industry
• relative ease of entry into global diagnostics of a comprehensive public health initiative rather than
as independent activities. n
industry
• proprietary control (whether through formal patents or, simply, sole possession of key clones) of
key diagnostic reagents by individual companies For further information, please contact:
or institutions
Steve Brooke, Advisor, Commercialization & Corporate
• multilevel manufacturing and distribution Partnerships, PATH, 1455 NW Leary Way, Seattle, WA,
channels typical for diagnostic products
98107, U.S.A. sbrooke@path.org
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Evaluation and Valuation of Technologies
Oftentimes, the first question that arises with an
invention is whether or not it should be patented.
When devising a patent strategy, three questions
should be considered:
• Should a patent application be filed or
should the invention simply be published?
• Should the invention be marketed to existing companies or be used to develop a spinout company?
• What is the potential value of the invention?
Should a patent application be filed or should
the invention simply be published? The answer
depends on a number of factors: the needs (and
dynamism) of the market, the uniqueness and
usefulness of the invention, the likelihood that
patent protection can be obtained, the specific
mission of an institution, and the “attitude” of
the inventor, that is, whether he or she is inclined
to assist the technology transfer office (TTO).
This latter point merits discussion. For practical purposes, an invention can be defined according to patent statute: it must be novel, contain an inventive step (be nonobvious), and be
useful or have industrial applicability. But often
an invention is many years away from “working”
in the real world. In other words, an invention is
not an innovation until the new knowledge and
invention are introduced into and utilized in an
economic or social environment. Determining
how to translate an invention into an innovation

that makes a difference in people’s lives (economically or socially or both) is one of the principal reasons for which technology transfer offices exist.
Should the invention be marketed to existing
companies or be used to develop a spinout company?
Each approach has advantages and disadvantages.
An existing company usually has an established
infrastructure, as well as access to financial instruments and distribution networks. Its financial
health can be readily assessed. However, connecting with existing companies might be challenging, partly because they already have research
agendas, networks, and priorities. The biggest risk
with an established company is that it will lose
interest in the technology before anything develops. Spinout companies, on the other hand, are
focused on their own inventions, but because the
companies are nascent, they are also fragile.
According to Nelsen,1 who has led the
M.I.T.’s Licensing Office for the past 20 years, a
number of other factors should also be considered
when deciding whether or not patenting a new
invention is in the public interest. For example:
• Is the technology self-evidently useful as-is?
Will it be widely used even if it is not patented
but instead released into the public domain?
• Can the patent-holding institution devise
a nonexclusive licensing strategy that will
bring in revenue without restricting the
availability of the technology?

Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 2007.
9: Evaluation and Valuation of Technologies. In Executive Guide to Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis,
USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA).
Available online at www.ipHandbook.org.
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for
noncommercial purposes is permitted and encouraged.
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• If the technology will not be useful without substantial high-risk investment, then
it will have to be patented and exclusively
licensed in a developed country in order to
bring in the adequate revenue. However, if
this path is taken, then an additional question must be asked: should patents be pursued in developing countries in order to encourage companies to produce competing
(lower-cost) generics in those countries?
• Can the patent holder require the licensee
to sublicense in order to promote lowcost manufacture and distribution of the
technology?
• If the drug (or vaccine) is expected to be
used only in developing countries, will the
patenting and distribution of a limited
number of licenses attract sufficient investment and create a market? Put differently,
will such a market be sufficiently profitable
that it will encourage further development
and testing of the drug or vaccine?
• Should the patent holder reserve for itself the
unrestricted use of a patented research tool?
Answers to the above questions will act as
guidance for patenting decisions. Above all, institutions should determine whether or not patenting is the most effective way to ensure global
access to their technologies. Broad licensing
strategies should also be considered at this stage,
and through licensing only comes in later. In this
context, it should be remembered that it can be
challenging to negotiate a licensing agreement
that is fair to everyone—licensor, licensees, and
the public sector. However, Nelsen asserts that it
is far better to make an imperfect deal than no
deal at all. People do not benefit until technology
is developed and brought to market.
What is the potential value of the invention?
While many inventors believe that their product
is of supreme importance, many fail to see the potential value of the product. Putting a “price tag”
on an invention is difficult. In other words, determining the value of an invention and the resulting
technology, product, or service will be complicated and at times nearly impossible. Fortunately,
the “full worth” of an invention need not be
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determined at the time the invention is made,
nor even when the invention is transferred or licensed to a third party through a patent license.
Value can be realized through the use of royalties—payments to the inventor based on the specific (negotiated) contribution of the invention
to a new product or service that are made when
the product or service is sold. Royalties involve
a trade-off and add new complications involving decisions about what to base the royalty rate
on, how they should be calculated, and so forth.
Royalties mean revenues are coming years later,
but many institutions prefer payments now.
With respect to specific valuation techniques,
Potter2 reviews five major approaches, provides
illustrations based on agricultural technologies,
and discusses a hypothetical negotiation between
a university and a company.3 Potter outlines five
approaches to valuing technology.
Costs approach. The pricing of a product is
based on the cost of developing the product. This
approach is rarely used to assign a value to a technology because the cost of research is not usually
correlated with the value of the intellectual property that was the basis for the technology.
Income approach. The value of a technology
is determined by a pure income approach, whereby future anticipated revenues (cash flows) are
discounted to present value. The big drawback to
this approach is that, for a new technology, there
are generally no sales, markets, or cost data that
can be used to predict future revenues.
Market approach. The value of a technology
is determined based on the value of a similar or
comparable technology. The inherent weakness of
this method is that it is difficult to find a comparable technology if the technology in question is
truly novel.
Hybrid approach. The value of a technology
is determined by a combination of the income and
market approaches. This method will deliver both
the benefits and the drawbacks of both methods.
Royalties approach. The value of a technology is calculated based on royalty rates that have
been applied to similar technologies. With this
method, the inventor would typically receive a return on sales of the final product, with risk being
shared between the inventor and the developer.

Evaluation and Valuation of Technologies

Regardless of which approach to technology
valuation is used, the assessor should have the
foresight to see where the new technology could
be applied and how useful it might be. The assessor should therefore be familiar with adoption
rates of the given technology in a defined market.
The value of both formal (statutory, such as patents) and informal (such as know-how) intellectual
property (IP) rights should also be known so that
negotiation mistakes are avoided. Importantly,
there is no single best method for technology
valuation, and different methods may be used for
different technologies within the same organization. Successful technology valuation depends on
accurate estimates of how successful a product
will be and how much it will sell for. If one can
make accurate estimates, one has a good chance of
building a trustworthy relationship with licensees,
successfully bringing the technology to market,
and increasing the chances of making more technology transfer deals in the future.
More specific methods of valuation and
methods to price technologies are discussed extensively by Razgaitis4 who also authored several
books on the subject. He emphasizes that the value of a technology depends on how it is used, how
much it costs to develop, how long it will take before its sales generate returns, and the probability
that the technology will be commercially successful. Pricing, on the other hand, refers to the price
a buyer and seller agree upon. This may be in
up-front payments (in cash or equity) or deferred
royalties, or a combination of both. Razgaitis describes six of these valuation methods.
Method I. The Use of Industry Standards
Method looks at the range of published royalties
(and other forms of payment) from technology
licenses within an industry category and uses that
information to guide valuation of a technology
under consideration.
Method II. The Rating/Ranking Method looks
at several license agreements for similar technologies, comparing and ranking a technology under
consideration against the license agreements with
respect to stage of development, scope of IP protection, market size, profit margins, and other factors.
Method III. Rules of Thumb Methods, such
as the 25% Rule Method, apportion anticipated

profits from the commercial use of the technology between the seller and buyer.
Method IV. The Use of Discounted CashFlow Analysis with Risk-Adjusted Hurdle Rates
Method seeks to split expected returns but adjusts
basic profit-and-loss accounting terms to account
for the timing of investments and returns and the
risks borne by the parties. The method introduces
a discussion of some possible structures of payments, as they affect both timing and risk.
Method V. The Advanced Tools Method applies statistical methods, such as Monte Carlo simulations, to discounted cash-flow models in order to
test the influence of various value assumptions and
license terms on the possible outcomes of a deal.
Method VI. The Auctions Method allows
interested parties to bid on a technology, based
on their own independent efforts at valuing the
technology, thus comparing their respective valuations, identifying the highest valuation, and striking a price based on that highest valuation.
More than one method can be used in any
given valuation and, depending on the circumstances, it may be advantageous to use a combination of two or more methods. One should consider the commensurate level of valuation analysis
appropriate to the magnitude of the potential
licensing opportunity when choosing methods.
Razgaitis provides many valuation examples, including typical royalty rates obtained by universities for software, pharmaceuticals, diagnostics,
and others (see Table 1). The data illustrate a
trend that appears in other examples discussed by
Razgaitis: those products and industries with traditionally high operating margins (profits), such
as pharmaceuticals and software, tend to exhibit
higher royalty rates compared with, say, the materials industry. More specifically, and also for the
purpose of establishing reasonable expectations of
both licensors and licensees, Table 2 shows typical
royalty rates from the medical industry. Note that
the context of both tables is well defined: earlystage technologies out of research laboratories. In
the second table, however, note that there is an
important economic difference between the ends
of the royalty ranges given: 1% versus 3% or 2%
versus 10%, and so on. Unless the technology transfer manager understands where the institution’s
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Table 1: Example Table of Royalties Developed through Experience
by a University Licensing Office
Product

Royalty (%)

Materials processes

1–4

Medical equipment/devices

3–5

Software

5–15

Semiconductors

1–2

Pharmaceuticals

8–10
12–20

Diagnostics

Biotechnology

Comments
0.1%–1% for commodities; 0.2%–2% for processes

Chip design
Composition of materials
With clinical testing

4–5

New entity

2–4

New method/old entity

0.25–1.5
1–2

Processa/nonexclusive
Processa/exclusive

a Expression systems, cell lines, growth media/conditions
Source: L. Nelsen (M.I.T) as cited by Razgaitis5

Table 2: Royalty Rates for the Medical Industry
Technology/Industry
Reagents/process

Earned
Royalty (%)

Up-front Payments
(in US$)

Minimum Payments
(in US$)

1–3

Patent costs

2,000–10,000

2–10

Patent costs

2,000–10,000

Diagnostics in vitro

2–6

5,000–20,000

2,000–60,000

Diagnostics in vivo

3–8

5,000–20,000

2,000–60,000

Therapeutics

4–12

20,000–150,000

20,000–150,000

Medical instrumentation

4–10

5,000–150,000

5,000–20,000
(yr. 1)
10,000–25,000
(beyond yr. 1)

Reagents/kits

Source: Razgaitis6
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opportunity fits in the range identified, it is difficult to know where to begin. Further, not every
opportunity falls within even these broad ranges.
Some opportunities will have only negligible value;
others could be unusually valuable opportunities.
Many things can be transferred between a licensor and licensee: IP rights, technical data, rights
over improvements to a technology, rights to sublicense the technology, costs related to the patenting
process, and so on. The price that the licensee pays
to the licensor can consist of any combination of
various types of payments, including running
royalties, fixed payments, common stock (equity),
R&D funding, lab equipment, consulting services,
grant-backs, options, or access to other proprietary
resources. The licensing contract should make allowances for the risks that a licensee will have to
take in developing and commercializing the technology. A combination of royalties and equity
stakes is a particularly effective way of splitting
the risk between two parties. If a technology does
not deliver, then the seller only receives the equity
stake and the buyer does not need to pay any future cash. On the other hand, if the technology is
highly successful, the buyer will have accessed the
technology without forfeiting important cash that
may have been crucial in bringing the technology
to market, and the seller gains in higher royalties
and higher value of the equity.
Another way to distribute the risk fairly is
to discount expected returns with an appropriate
hurdle (or milestone) rate. Alternatively, the schedule of payments may be adjusted as a function of
milestones. Picking appropriate milestone rates or
individual payments can be informed by explicitly
modeling how different stages or factors in the
development process contribute to the overall expected returns and to the risk of not realizing those
returns.
Razgaitis provides many illustrations and offers the following broad conclusions, which are
supported with examples. There is no “right” price
for a technology with each licensing transaction
being unique. To assess the future sources of
value, the innate economic benefit that can be
captured by using the technology in some market
must be identified. That value is dependent upon
many factors, all of which may change at any

moment. But there is often only a small window
of time in which a technology can turn a profit.
Being cognizant of all information regarding the
possible market value of and possible risks associated with a technology, makes it easier to arrive at
an accurate valuation. This information may be
difficult to collect, but it will be necessary. In fact,
in order for pricing to be done properly, all of the
relevant information must be gathered, preferably
ahead of negotiations.
Early stage technologies may end up having
little or no commercial value, but there are rare
cases of immense value. As the technology ages
and patents approach expiration, the bargaining
position of the licensor weakens. This results in
an inevitable shift in bargaining power from the
licensor to the licensee, resulting in prices or royalties being renegotiated downward, not upward.
Regardless of where one is in the process, there
are methods practiced by technology transfer and
business development professionals that can be
used to guide the pricing process.
Pricing is never completely objective and always carries risk, while risk itself is subjective and
each party will perceive it differently. Certain events,
such as additional testing of a technology by the licensor, or by a government R&D grant awarded to
the licensee, or a collaborative venture between the
licensee and other R&D institutions may reduce
the risk as perceived by the licensee. The important
thing is to find a price that is acceptable to both
parties and that encourages the licensee to invest
in the development of the technology.
Concluding this section, Lesser and Krattiger7
use bioprospecting examples to examine how different valuation methods have different policy
implications for developing countries. For instance, a bioprospecting deal can provide a developing country the incentive to preserve its natural
resources if the money it receives from the developed country institution for the right to bioprospect inside the country is greater than what
the country would receive by allowing destructive
activities such as logging.
The trade-offs described earlier between
up-front payments and royalties are particularly
relevant from a policy perspective in the context
of bioprospecting. The authors show that the
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principal factors used in negotiating price are the
uncertainty of attributing value and the uncertainty of finding marketable products.
Negotiations in bioprospecting deals strive
for an appropriate balance between collection (initial) fees and royalty (delayed) payments. Lesser
and Krattiger demonstrate with examples and
calculations how changes in assumptions lead to
different outcomes. For example, collection fees
will reduce total payments except when national
interest rates are very high. In-country screening,
including the use of indigenous knowledge, is a
potentially valuable strategy as it shifts the rise of
failure to the licensee. The authors outline issues
for contract negotiators and discuss the implications for biodiversity conservation.
A discount rate is what is used to adjust future income to present net value. It is often akin
to an interest rate. Receiving, say, $100 today
would be $110 in one year’s time if an interest
rate were 10%. Conversely, receiving $100 in
one year’s time would be worth $90.90 today
if a 10% discount rate were applied. Typically,
personal and corporate discount rates are greater
than social rates, although the determination of
the social rate is open to different interpretations.
As anyone who has paid off a loan over a 10 or
20-year period recognizes, small changes in the
discount rate have major implications on the outcome. Further, the concept of personal discount
rate (that is, what the person on the other side of
the table has internalized about risk), political and
economic instability, immediate need for money,
and so forth, could play a large role in the choice
between collection payments and royalties.
Importantly for developing countries, when
fees are “shifted forward” by increasing the collection fee and reducing royalty payments, more risk
is transferred to the collecting company that develops a product, since it will have to pay the same
amount of money regardless of whether successful commercial products are developed from the
collected material. Shifting fees forward have particularly interesting possibilities in countries where
interest rates are high (since the discount value
of future payments is lower with higher interest
rates). This leads to important policy considerations for national governments, nongovernmental
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organizations (NGOs), and development agencies.
The chapter reviews these policy considerations and
concludes that providing grants/loans and training/equipment for in-country screening should be
given a high priority because in-country screening
may be productive in the long term. With regard to
national policy, Lesser and Krattiger discuss several
policy considerations8 involving both in-country
screening and the allocation of payments between
collection fees and royalties.
With adequate in-country funds lacking, international donors should seriously consider loans
or grants for training and equipment purchases.
This coupled with a series of other initiatives8 will
bring many closer to realizing the promise of bioprospecting. n
All chapters refer to: Intellectual Property Management in
Health and Agricultural Innovation: A Handbook of Best
Practices. 2007. A Krattiger, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez,
and SP Kowalski (eds.). MIHR: Oxford, U.K., and PIPRA: Davis,
U.S.A. Available online at www.ipHandbook.org. The online
version contains for each chapter a detailed Editor’s Summary, Implications, and Best Practices.
1

Chapter 9.1 by L Nelsen titled Evaluating Inventions
from Research Institutions, p. 795.

2 Chapter 9.2 by RH Potter titled Technology Valuation:
An Introduction, p. 805.
3

The online version of the Handbook provides a
spreadsheet (in Microsoft® Excel®) for the user to
see how various results are obtained depending on
different inputs and assumptions.

4 Chapter 9.3 by R Razgaitis titled Pricing the Intellectual
Property of Early-Stage Technologies: A Primer of Basic
Valuation Tools and Considerations, p. 813.
5

Ibid.

6 See supra note 4, with data adapted from an article
published by Corey G and E Kahn. 1991. How to
Negotiate Reasonable Royalty Rates for Licensing
Novel Biomedical Products. Genetic Engineering News
July–August 1991. p.4.
7

Chapter 9.4 by WH Lesser and A Krattiger titled
Valuation of Bioprospecting Samples: Approaches,
Calculations, and Implications for Policymakers, p. 861.

8 Cabrera Medaglia J. 2004. Bioprospecting Partnerships
in Practice: A Decade of Experiences at INBio in
Costa Rica. IP Strategy Today No. 11 (2004): pp. 27–40.
www.bioDevelopments.org/ip lists a number of
important policy conclusions stemming from
experiences at INBio in Costa Rica.
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Determining how to translate an invention into an innovation that makes a difference
in people’s lives (economically or socially or both) is one of the principal reasons
technology transfer offices exist.
Government policies ought to be flexible and enable research institutions to customize
technology transfer strategies that align with the institutions’ missions. Different
approaches will serve different types of research and academic organizations working
within various disciplines and cultures.
It can be challenging to negotiate licensing agreements that are fair to everyone and
conducive to making inventions become innovations. It is often better to make an
imperfect deal than no deal at all. People do not benefit until technology is developed
and distributed.
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FOR GOVERNMENT POLICYMAKERS

Public sector institutions should therefore be supported in their overall deal making
efforts rather than using individual deals as particularly good or bad examples.
A government can make technology transfer less risky and more attractive for licensees
by applying such policies as government R&D grants, subsidies, encouragement of
clusters, financing of business incubators, and offering complementary R&D inputs or
regulatory requirements that are conducive to the emergence of new technologies.
Bioprospecting and related activities raise important issues with respect to pricing.
Importantly for developing countries, when fees are “shifted forward” by increasing the
collection fee and reducing royalty payments, more risk is transferred to the collecting
company, which is developing the product, since the company will have to pay the
same amount of money regardless of whether successful commercial products are
developed from the collected material. Shifting fees forward may have particularly
interesting possibilities, as doing so allows countries to invest resources early on to
capture additional value in bioprospecting activities.
It is important to adopt national policies that facilitate access to biological resources
under fair and equitable terms with prior informed consent. Access mechanisms
should be transparent, predictable, and managed by experts.
There is a strong interaction between bioprospecting activity and national scientific
capabilities. In countries with strong scientific capability, bioprospecting is robust.
Moreover, such capacity increases the negotiating strengths and benefit sharing
stipulated in contract agreements.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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FOR SENIOR MANAGEMENT
(University President, R&D Manager, etc.)
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Determining how to translate an invention into an innovation that makes a difference
in people’s lives (economically or socially or both) is one of the principal reasons
technology transfer offices exist.
It can be challenging to negotiate licensing agreements that are fair to everyone and
conducive to “moving” inventions to innovations. It is far better generally to make an
imperfect deal than no deal at all. People do not benefit until technology is developed
and distributed.
Institutions need to assess whether or not patenting is the most effective way to
ensure high economic and/or humanitarian impact of their technologies.
A public institution’s decision with regard to patenting should depend on (1) whether
such patenting would be socially responsible, (2) whether there is public interest in
the technology, and (3) whether patenting would help the local economy (where
applicable).
Putting a “price tag” on an invention early on is difficult, if not impossible. Fortunately,
the full value of an invention need not be determined when the invention is transferred
or licensed, as value can be realized later through the use of running royalties, fixed
payments, common stock (equity), R&D funding, lab equipment, consulting services,
grant backs, or access to other proprietary resources. For public sector organizations,
in-kind contributions may sometimes be particularly appealing.
Evaluating a new technology is difficult and the evaluation will necessarily be imprecise.
It is better to encourage a TTO to make deals creatively and expeditiously, without the
imposition of minimum royalties and other restrictive terms. The important thing is
to find a price that is acceptable to both parties and that encourages the licensee to
invest in the development of the technology.
Senior management should be supportive of the overall deal making of its technology
transfer officers rather than be critical of individual deals. Naturally, TTO officers need to
follow procedures, apply policies, and be well trained and experienced in deal making.
Putting pressure on TTO officers to break even or to generate revenues can constitute a
perverse incentive, almost forcing a TTO to go with up-front payments. This may drain
a startup of critical financial resources and thus reduce the level of investment that is
allocated to making the invention work.
Probabilistic modeling software can aid pricing efforts. The most effective software is
expensive and may not be a good investment if fewer than 100 deals are made per
year. Quite often the best approach is to get as many licenses as possible completed
in a short period of time, even if an individual license does not provide the maximum
possible income. The more licenses, the higher the probability that one, or a few, will
generate returns.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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The best approach by your TTO is usually to disclose inventions early and disclose often.
You should even consider disclosing what you think might not yet be a full invention.
Experience shows that scientists are, in fact, not very good at determining when they
have an invention. In many cases, they have a dozen when they themselves think they
have none!
If your TTO officers decide not to file for patents, you shouldn’t be discouraged. This
is not a critique on your research, its importance, or its relevance. The TTO has many
priorities to balance, including financial.
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FOR SCIENTISTS

It can be challenging to negotiate licensing agreements that are fair to everyone and
conducive to “moving” inventions to innovations. It is generally far better to make an
imperfect deal than no deal at all. People do not benefit until technology is developed
and distributed.
Some of the key questions TTOs address early on when an invention has been made
is whether a patent application should be filed at all, how the invention would be
marketed, and what value the invention might add to existing processes or products or
what value might come out of a new product or process. Determining how to translate
an invention into an innovation that makes a difference in people’s lives (economically
or socially or both) is one of the principal reasons technology transfer offices exist.
Scientists must insist that the TTO have transparent procedures for reviewing invention
disclosures and making decisions. You should not only be informed of the basis and
rationale for a decision, but also, in most cases, be fully involved in the process.
It is important to keep a detailed record of your research procedures. Your records may
help determine inventorship and may provide clues as to the value of your inventions.
Once your TTO patents your invention, don’t expect a big revenue flow. For a TTO, quite
often the best approach is to get as many licenses as possible completed in a short
period of time, even if an individual license does not provide the maximum possible
income. The more licenses, the higher the probability that one, or a few, will generate
returns. Both you and senior management should be supportive of the overall deal
making of the TTO rather than criticizing individual deals. Naturally, TTO officers need
to follow procedures, apply policies, and be well trained in deal making.
Additional research by yourself or your group often increases both the likelihood of
finding a licensee and the economic value of the license. But this is only true if the
research is specifically aimed at reducing the risks of commercializing the technology.
Basic research may do little to reduce these risks. Discuss this issue with your TTO
officer. Especially in an academic environment, he or she will be reluctant to provide
unsolicited advice regarding this issue.
Remember that licensing incomes reward the commercial value, and not the scientific
value, of your invention. Technology licenses may provide you with follow-on grants
and other intangible incentives to conduct further research.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.

HANDBOOK OF BEST PRACTICES: EXECUTIVE GUIDE | 109

Key Implications and Best Practices: SECTION 9

GUIDE TO SECTION 9

FOR TECHNOLOGY TRANSFER OFFICERS
4

4

4

4

4

4

4

A combination of royalties and equity stakes is a particularly effective way of splitting
risk between two parties. If a technology does not deliver, then the seller receives only
the equity stake, and the buyer does not need to pay any future cash. Another way to
distribute the risk fairly is to discount expected returns with an appropriate milestone
rate.
Many valuation approaches exist. None is perfect. Considering that each deal is highly
context specific, each technology transfer office should be able to select the best
approach and adapt it to the specific circumstances.
Licensing is always risky and no deal will be perfect. It is often better to make an
imperfect deal than none at all.
When devising a patenting strategy, you will need to make three decisions: First, should
you seek patent protection? Second, what is the best patent-marketing approach?
Third, what license fees or royalties ought to be levied?
Since there is no single best way to assess the value of a technology, all parties should
agree on the valuation method to be used.
Probabilistic modeling software can aid pricing efforts. The most effective software is
expensive and may not be a good investment if fewer than 100 deals are made per
year. Quite often the best approach is to get as many licenses as possible completed
in a short period of time, even if an individual license does not provide the maximum
possible income. The more licenses, the higher the probability that one, or a few, will
generate returns.
Putting a “price tag” on an invention early on is difficult, if not impossible. Fortunately,
the full value of an invention need not be determined when the invention is transferred
or licensed, as value can be realized later through the use of running royalties, fixed
payments, common stock (equity), R&D funding, lab equipment, consulting services,
grant backs, or access to other proprietary resources. For public sector organizations,
in-kind contributions may sometimes be particularly appealing.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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Patents and Patenting:
Balancing Protection with the Public Domain
The nature of public and private and balancing
individual rights with public welfare has been a
perennial concern for many societies. For more
than two thousand years in the West, scholars,
philosophers, and politicians have debated questions of individual rights and of a government’s
responsibility to protect those rights while promoting the public good. Plato argued against
private property (he said it would corrupt the
personality by infecting it with greed), while
Aristotle essentially argued for private property
stating it would enhance an individual’s sense of
identity and self-esteem and, in addition, allow
for the optimal economic use of the commons.
Private goods are those over which there can
be competition or rivalry, their use can be excluded from nonowners. Private goods typically are
traded in markets. If a market is able to agree on a
price (such as for bread), the ownership or use of
the good (the bread) is transferred. Further, once
the good is consumed (the bread has been eaten)
others are precluded from also eating it.
Public goods are goods the use of which
neither competes with nor rivals use by others (nonrival), and no person can exclude other
persons from use of the goods (nonexcludable).
Sunlight, traffic lights, street signs, sewer systems,
and a smallpox-free world are examples of public
goods. Crucially, who provides the public good
is not a factor in determining whether a good
is public or private. Governments provide public

goods (such as street lights) and they also provide
private goods (for example, housing and medical care). Similarly, the private sector may provide
public goods, such as technical norms or streetlights. The example of the streetlight illustrates
how private goods (patented, high-efficiency light
bulbs, electricity produced by companies, street
posts installed by local private contractors) become public goods because they are made available to all. The creation of a public good is not
free of cost. Costs may have been borne by society
at large (the street light will have been paid for,
indirectly, by the taxpayer) but the enjoyment or
use of it is free to any and all individuals who pass
along that particular street.
Further, these examples demonstrate how
public and private are in some respects two sides of
the same coin; both are needed for the coin to exist and have value. But as Boettiger and Chi-Ham1
show, the manner in which this plays out with information and inventions generated by science is
not as straightforward as the examples above suggest. Complications are due, in part, to the fact
that inventions, unlike real and tangible property,
once they are disclosed are essentially nonrival and
nonexcludable. Unless, of course, IP rights systems
regulate ownership, access, and use.
Boettiger and Chi-Ham discuss the nexus of
public and private property and provide in-depth
guidance on using defensive publishing and the
public domain as tools to achieve a range of IP

Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski.
2007. 10: Patents and Patenting: Balancing Protection with the Public Domain. In Executive Guide to Intellectual Property
Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.).
MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopmentsInternational Institute (Ithaca, USA). Available online at www.ipHandbook.org.
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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management goals. The authors examine the extent to which the public domain can in fact be
depended upon and even leveraged to facilitate and
preserve access to technologies. The authors view
defensive publishing and utilizing public domain
research inputs as options within a broader set of
IP management strategies, including the options
of patenting, trade secrecy, trademark protection,
and bailment contracts. All of the above can be
used in various combinations to find the balance
between protection and accessibility that both
promotes technology development and fosters
ongoing innovation. They argue that the choice
of the strategic option depends on a pragmatic
and realistic understanding of the nature of the
public domain. In order to clarify and illustrate
this, the public domain is compared to two different, but closely related, property rights concepts:
open source and the commons.
Open source is defined as the body of knowledge over which owners claim property rights,
but with access to that knowledge being provided
systematically by the owners under terms of a license that regulates access. According to the authors, the commons is, by its nature, a less clearly
defined concept that varies according to context,
but includes a lack of private ownership, open access, or collective management.
It should be noted that defensive publishing
strategies can be more viable than patenting in
the following two cases:
• development of the technology will not depend on private sector investment
• the leverage ownership could provide, such
as the ability to segment markets or bargain
for access to complementary technologies,
is not important
Defensive publishing can be less costly,
eliminating patent costs and transaction costs in
licensing, especially when the ultimate desired
outcome is to provide broad access to a technology. When cost or infeasibility makes enforcing a
patent unlikely, defensive publishing is the more
sensible alternative for companies. It can be very
effective when combined with patenting.
The second aspect of the chapter by Boettiger
and Chi-Ham deals with the use of public domain
112 | HANDBOOK OF BEST PRACTICES: EXECUTIVE GUIDE

technologies as research inputs. The authors outline how this approach can reduce transaction
costs and mitigate potential IP access problems in
downstream R&D. However, as for any IP management strategy, attention should be paid to the
overlapping, web-like nature of patent claims and
the ever-shifting boundary of the public domain.
Even when a technology is preliminarily believed
to be in the public domain, such as from an early
scientific publication or an expired patent, subsequent publications or patents can still claim
certain uses of the technology, such as in particular combinations, applications, or with possible
improvements.
The public domain can be a vital resource
to public sector institutions and also companies.
Judicious defensive publishing and the careful use
of public domain technologies offer IP managers
everywhere effective, flexible, and less-expensive
tools for exploiting these resources. Intellectual
property is not a panacea for the management of
innovation. Neither is open source. All have utility and limitations. Artful management involves
the creative and balanced use and handling of
both public and private goods.
If patenting is the chosen route, it must be
remembered that patenting decisions need to
be made well before it is clear whether or not
an invention has value. It makes business and
strategic sense, therefore, to minimize the initial
costs of such decisions. If the invention appears
to have significant market potential, then a costminimizing approach toward patenting is not
recommended. However, most inventions have
questionable or uncertain future value, and so a
cost-minimizing approach is an appropriate strategy for patent application filings.
One cost-minimizing approach is the filing of provisional patent applications, which is
possible in many countries. Importantly, foreign
inventors may also file provisional applications
in the United States. Provisional patents allow
inventors an extra year of protection, effectively
extending the patent period from 20 to 21 years.
As Cruz2 explains, the benefits of provisional applications include cost and simplicity. Provisional
applications are not substantively reviewed by a
patent office examiner, but are simply checked
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to ensure that they meet minimal filing requirements. A provisional application also does not
require a prior art search. Since these applications are so quick and inexpensive to prepare,
they offer an easy way for inventors to establish
a priority date for an invention and avoid statutory bars.
But there are also limitations associated with
provisional applications. While inexpensive to file,
provisional patent applications do not reduce the
costs of preparing and filing subsequent utility applications, meaning that the total cost of filing will
increase, if only by a small amount. More importantly, provisional applications require a degree of
disclosure, so inventors should be sure not to disclose something they wish to retain as a trade secret.
Also, provisional patents may not be amended; they
trigger the time line for Patent CooperationTreaty
(PCT) and Paris Convention filings, and without
filing nonprovisional patent applications, provisionals do not mature into patents.
Livne3 then discusses various avenues for reducing costs in patent filings and presents a highly useful decision tree. He cautions that the use of
patent attorney is generally an essential guide in
such matters. The stakes are often high and mistakes can be costly. When publication is imminent and patent protection in foreign countries is
desired, a provisional or nonprovisional application should be filed in the United States before
publication. Once disclosed, filing in many countries will no longer be possible.
Although licensing is discussed elsewhere,4
the manner in which patent applications are written, particularly the claims, can be instrumental
in facilitating certain licensing strategies, particularly field-of-use licensing. The foundation of an
effective field-of-use licensing strategy is a patent
application that foresees certain licensing opportunities and accommodates unforeseen opportunities. Olson5 discusses this using examples from
the agricultural, pharmaceutical, biochemical, and
chemical disciplines and illustrates how this strategy applies equally to inventions with commercial
and humanitarian applications. He urges technology managers to retain control over the patent application process and to encourage creative thinking when preparing patent applications.

Applying for patents is only one element in a
strategy to create IP portfolios of substantial value. For both public and private sectors, patents
are a central element, but an IP portfolio should
also take advantage of other forms of protection:
trademarks, copyrights, and trade secrets. Dodds6
presents various strategies for building an IP fortress and discusses the limitations and strengths
of various approaches. For example, an offensive
patent strategy is designed to build barriers to exclude competitors from proprietary technologies.
With a defensive patent strategy, a company files
patents primarily to ensure that innovations can
be practically used. To build an IP fortress of protection, several forms of intellectual property may
be used for the same invention or improvement,
with different forms of IP protection serving offensive or defensive tactics.
Notwithstanding the different missions,
objectives, and motivations of the public and
private sectors, the central forces behind their
respective IP protection strategies are identical
(though the relative strength of the forces will
vary significantly). Private sector organizations,
primarily corporations, are profit-oriented and
respond to the pressures imposed by the marketplace and by shareholders who expect returns on
their investments. Therefore, the private sector
will use defensive and offensive patenting strategies, often obtaining numerous patents with
narrowly drafted claims. In this way, a series of
patent portfolios is strategically used to build
proprietary fortifications and the private sector
organization can stake out its territory, protect
its interests, and secure its profits. In the expanding world marketplace, this strategy has only become more telling, with the increasing reliance
on foreign filing and patent families confirming
the predominant global strategic perspective of
multinational companies.
The public sector, on the other hand, has a
very different mission, which is to serve the greater public good. Patenting strategy will focus on
more broadly drafted claims that will encompass
a technology or (as is often, and more importantly, the case) a key process, method, or technique,
for example a technique of genetic transformation. These types of patents, when appropriately
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strategically licensed, enable effective development, broad dissemination, and maximum societal impact of a technological advance precisely in
line with the public sector mission of providing
for the general public, in contrast to the much
more limited constituency of the private sector.
Patent protection is limited geographically,
protecting the invention only in countries where
the patent issues. Private sector companies and
public sector institutions can reduce costs by focusing the patent protection to those geographic
areas where there are business or humanitarian
opportunities. But filing in foreign jurisdictions
is not easy or cheap. For this reason, two chapters,
one by Viksnins and McCrackin7 and the other
by Schneiderman,8 review foreign filing strategies and tactics, with particular emphasis on filing patent applications using the PCT. The two
chapters are complementary and discuss the practical aspects from different points of view.
Several key factors should be reviewed when
approaching the international production, marketing, distribution, and sales of a new and innovative product or process for which patent
protection will be sought. These factors include a
full range of various business and legal issues that,
once considered, will provide the international
patent protection options that can then be evaluated and appropriately selected, according to
an organization’s business goals and financial
resources.
Depending on an organization’s goals and
resources, specific patent-application options will
have advantages and disadvantages. One option
is to file a separate patent application for each
nation or region where protection is sought.
Another option is to file a patent application, in
accordance with the Paris Convention, which establishes a priority filing date. This gives, for one
year, the exclusive right to file for patents in other
Paris Convention countries. This approach has
advantages when filing in a very limited number
of countries. It also avoids the costs associated
with the intermediate steps of filing in the PCT
or regional patent offices prior to filing nationally. This option has the following disadvantages:
each application will be independently examined
(that is, no deference is given to a prior favorable
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review in a different country) and government filing fees and translation costs will be due early in
the patenting process.
An indispensable tool for delaying, consolidating, and minimizing international patent
costs, the PCT offers a unified and simplified
procedure for filing multiple foreign patent applications using a single initial application. The
PCT has standardized the filing and preliminary
evaluation of international patent applications.
Consisting of over 130 member countries, the
PCT is administered by the World Intellectual
Property Organization (WIPO), which reviews
PCT applications and then distributes them to
designated member countries. The process of
filing the PCT application in individual patent offices can be delayed for up to 30 months.
During this time, the applicant will receive the
results of the WIPO International Preliminary
Examination of the PCT application. For many
countries, especially those still developing capacity
in patent prosecution, national patent offices give
considerable deference to the PCT International
Preliminary Examination Report.9
Using best practices in IP management involves identifying IP assets, organizing resources,
building capacity, formulating options, and then
pursuing strategies that will maximize the value
of an organization’s IP assets. Managing patent
portfolios is always challenging, even more so
now with the rapid globalization of technology
markets. Globalization makes best practices in
patent portfolio management more critical for
effectively distributing innovations in the health
and agricultural sciences, whether for commercial
purposes or for facilitating humanitarian access.
As public and private sector institutions increasingly work in a global context, choosing where
and under what circumstances to file for patents
is becoming more important, and, according to
Yin and Cunningham,10 the following factors
should be considered:
• objectives of the organization with respect
to its issued patents
• assertion of patents offensively, either as
part of a licensing strategy or in litigation,
if companies are unwilling to license
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• assertion of patents defensively, as leverage
in licensing negotiations or to ward off litigation by others
• identifying where potential targets are located or doing the bulk of their business, if
a portfolio is to be used offensively,
• identifying where an organization may
most likely encounter licensing approaches
or litigation offensives by others, if a portfolio is to be primarily defensive
A global patent program should be proactive
as well as preemptive in its outlook, especially regarding the potentiality of patent litigation, where
knowledge of options can save time and money.
Yin and Cunningham compare and contrast the
advantages and disadvantages of pursuing patent
litigation in either a federal district court or in
the U.S. International Trade Commission (ITC).
Although the ITC’s jurisdiction is essentially limited to cases dealing with the illegal importation
of alleged infringing products, there are times
when it might be a good idea to pursue patent
litigation in the ITC. In addition, one can also
pursue litigation in both the federal district court
(patent infringement action) and the ITC (unfair
trade practices action) at the same time.
Obtaining patent protection and regulatory
approval for biotechnology and pharmaceutical
products is an extremely time-consuming and
expensive process. For nonprofit organizations
working with limited resources, it is especially
crucial to manage the process efficiently and
make the most of patent protections while they
last. Fernandez, Huie, and Hsu11 suggest that
public sector entities can use private sector techniques to maximize revenue and, in turn, provide
drugs to the public at the lowest possible price.
The authors suggest that organizations carefully
plan the timing of patent and Food and Drug
Administration (FDA) applications to maximize
the effective life of a patent and avoid unnecessary
disclosures.
Nonprofits especially should note that the
U.S. Patent and Trademark Office (PTO) gives
special priority to certain biotechnology patent
applications from small entities and nonprofits.
The FDA likewise expedites approval if there are

indications that the product will provide significant therapeutic benefit over existing therapies. At
the other end of the patent lifecycle, after having
gone through the steps of obtaining FDA approval, it is in the best interests of innovating companies to extend the patent term for as long as possible. This chapter is included in the Handbook
to show the important interface between patents
and the regulatory drug approval process and to
show how this interplay affects market entry. It
is not intended as an endorsement of extending
effective patent life to delay the market entry of
generic drugs.
As part of certain patent application filings,12
biological resources may have to be deposited in
support of a patent application. According to
Harney and McBride,13 in the United States a deposit of biological materials is not a requirement
per se, but under U.S. patent law it can satisfy
three main requirements:
• the enablement requirement, that is, that
it would allow a person skilled in the art
could make and use the invention
• the written description requirement, that is,
it would describe the invention in sufficient
detail to allow such a person skilled in the
art to reasonably conclude that the applicant was in possession of the claimed invention at the time of filing
• the best mode requirement, that is, that it
would disclose the best mode of carrying
out an invention in sufficient detail to allow a person of ordinary skill in the art to
practice it
Plant varieties constitute a biological resource. While in the United States while plant
varieties can be protected as utility patents, the
United States and many other countries also have
protection mechanisms specifically adapted to
the biological and self-replicating nature of plant
varieties. Pardee14 provides detailed and step-bystep instructions for how to obtain a U.S. Plant
Variety Protection (PVP) certificate. Although the
chapter focuses on PVP application procedures in
the United States, the chapter is generally useful
for illustrating the principles, preparations, and
procedures for applying for and obtaining a PVP
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certificate. This is because the U.S. provisions of
the PVP Act of 1970 closely follow the model developed by the Convention of the International
Union for the Protection of New Varieties of
Plants (UPOV). Moreover, UPOV procedures
have been adopted by many countries around the
world, even by many who are not members of
UPOV.
In sum, the factors that drive decisions about
what type of protection to seek and where to seek
it are complex and will heavily depend on the context in which the decisions are made. Public and
private institutions will consider the same factors
but weigh them using different criteria. For example, the prospect of litigation in a foreign jurisdiction for a public sector entity will be marginally
important per se but highly relevant to its potential
to license. The result is that both public and private
sectors will consider whether to adopt offensive or
defensive protection and litigation strategies.
Because the rights accorded to the patentee
are divisible (the right to exclude one from selling
or the right to exclude another from manufacturing) one can divide the countries of the world into
those where the invention can be manufactured
versus countries where the invention will be sold.
And even after identifying those countries where
the invention might be marketed, it is often unnecessary to file in all of the identified countries.
In order to best determine what strategy to pursue, an organization must know what it has and
decide where it’s going. The first step, therefore,
in developing an IP strategy is to document what
technologies already exist in the organization,
what technologies are in development, and what
partnerships are feasible. It will then be possible to
intelligently choose the best ways to protect intellectual property and enhance its value, be it for
economic or humanitarian objectives, or both. n
All chapters refer to: Intellectual Property Management in
Health and Agricultural Innovation: A Handbook of Best
Practices. 2007. A Krattiger, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez,
and SP Kowalski (eds.). MIHR: Oxford, U.K., and PIPRA: Davis,
U.S.A. Available online at www.ipHandbook.org. The online
version contains for each chapter a detailed Editor’s Summary, Implications, and Best Practices.
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The use of IP rights is not a panacea for the management of innovation, nor is the
public domain. Both public and private goods have utility and limitations. The art of
innovation management is in using both public and private goods and to manage the
interface between them.
Because public domain technologies play an important role in publicly funded research,
defensive publishing can be used by public sector research institutions to help
expand and reinforce the accessibility of technologies in the public domain. Academic
institutions in particular should be encouraged to publish, in addition to considering IP
protection.
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FOR GOVERNMENT POLICYMAKERS

Because of the case-specific applicability of defensive publishing, blanket policies
that require defensive publishing by national research institutions deny them the
opportunity to develop their research results strategically in combination with IP rights
protection.
In order to realize the commercial and humanitarian potential of international
markets for products and processes arising from public sector research investments,
public sector research-based institutions ought to develop strategies that judiciously
balance the public domain and IP rights. Commercial and humanitarian objectives and
strategies are not in conflict, but rather are complementary aspects of best practices in
IP management.
A country’s membership in the Patent Cooperation Treaty (PCT) can greatly help
national institutions—public and private—to strengthen international technology
transfer, licensing and research, and product development partnerships and can aid
access to global markets.
Membership in the PCT can provide significant advantages and can lead to much more
cost-effective examination of patent applications.
Harmonizing national patent systems across regions, as well as globally, can be a useful
strategy for improving the effectiveness of the IP system and improving a national
institution’s ability to reach foreign markets.
Providing for legislation, or for amendments to current statutes, that facilitates patent
filing by foreign entities can be an important component of technology transfer and
development.
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FOR SENIOR MANAGEMENT
(University President, R&D Manager, etc.)
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The use of IP rights is not a panacea for the management of innovation, nor is the
public domain. Both public and private goods have utility and limitations. The art of
innovation management is in using both public and private goods and to manage the
interface between them.
Because public domain technologies play an important role in publicly funded research,
defensive publishing can be used by public sector research institutions to help
expand and reinforce the accessibility of technologies in the public domain. Academic
institutions in particular should be encouraged to publish, in addition to considering IP
protection.
Because of the case-specific applicability of defensive publishing, blanket policies that
require defensive publishing deny the opportunity to use research results strategically
in combination with IP rights protection.
Few institutions anywhere in the world have transparent incentives for researchers or
technology transfer officers to prepare defensive publications. Encouraging publication
with maximum inventive disclosure through a balanced set of incentives for researchers
and technology transfer officers is a useful strategy.
Scientists should be encouraged to use public domain technologies as research
inputs whenever feasible to reduce possible future constraints in the downstream
commercialization of innovations. In many circumstances, however, relying on patented
technologies may be the more effective way to go, particularly when the goal is to
develop products.
Building strong institutional capacity in IP management will enable technology
managers and scientists alike to understand the complex array of options that
should be considered before publishing research results or filing patent applications.
Development of protocols and strategies will clarify options and retain and maximize
value.
One such capacity centers on the decision of whether patents for an invention should
be filed in a manner that does not delay publication of research results. Provisional
patent applications, where possible, offer one such avenue.
An important component of developing an IP strategy is to document the technologies
that already exist in the organization, plus those technologies in development (for
example, through an IP audit). Other essential components of such a strategy are the
promotion of international patent protection and the concrete steps an institution is
taking to drive innovation and technology transfer.
Management should encourage good laboratory practices and diligent record keeping
of data to ensure that research can later be used in possible regulatory filings. Doing so
could lower costs and reduce the time to market.
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Published information, or research tools provided by a colleague, may be covered by IP
rights. In the life sciences, the web of patents extends far and wide. This should neither
deter nor distract you from good science. An awareness of basic IP management best
practices will minimize possible future problems.
You can intentionally make your inventions and the associated technologies accessible
to everyone by publishing results instead of patenting them. Publishing results, however,
does not guarantee full public access. Patents can still encroach upon the technical
content of the work. Speak to your technology transfer manager about publications,
and ask him or her to help with performing the necessary steps for turning your
publication into a readily identifiable disclosure of patentable technology.
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FOR SCIENTISTS

If public disclosure is your goal as a way of preventing others from patenting a particular
invention, it may be valuable to consider posting online or in searchable databases,
with a valid date stamp, a longer working-paper version, supporting materials, or
appendices. For this purpose, consider using dedicated services, such as a university
technical disclosure bulletin or a centralized registry of unpublished papers, with
official date stamps posted on faculty Web sites for online searches.
If patenting and public disclosure are your goals, first consult with your institution’s
technology transfer manager prior to disclosure. Your institution should have an
effective mechanism in place to determine whether or not a patent should be filed
without significantly delaying publication. But be aware that premature publication
can lead to a loss of IP rights.
Your institution’s technology transfer managers will need your input in order to make
strategic decisions about where to pursue foreign patent applications. You likely know
where competitors are located and where products arising from your research are
needed.
One of the services of PIPRA is to advise researchers in the plant sciences about which
research is in the public domain and which is available for licensing on reasonable
terms. If you are engaged in the development of biotechnology crops, you may find
PIPRA’s Web site and services useful.
Good laboratory practices and comprehensive laboratory notebooks can ensure that
your research is suitable for subsequent regulatory filings. This can reduce costs and
time to market.
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The use of IP rights is not a panacea for the management of innovation, nor is the
public domain. Both public and private goods have utility and limitations. The art of
innovation management is in using both public and private goods and to manage the
interface between them.
Because public domain technologies play an important role in publicly funded
research, defensive publishing can be used by public sector research institutions to
help expand and reinforce the accessibility of technologies in the public domain.
It helps to have other tools besides patents to get technology out of the lab and into
the marketplace. Consider first whether a technology requires investment by the
private sector (and, thus, exclusivity) to be put into practice.
Defensive publishing may run contrary to your instincts if you tend to think in terms
of controlling a technology by ownership (and thus excluding others from using it).
Think instead in terms of maintaining control of the technology—or elements of it—
by casting it into the public domain and, thereby, preventing others from owning it.
Researchers will need advice on how to craft defensive publications.
It is important to understand the advantages of provisional patent applications.
They can be very useful in controlling costs and, also, in providing additional time for
weighing options as to whether it is worthwhile to pursue a full patent application.
Delaying patent applications involves risk. Subsequent prior art that blocks an
application might appear. Or, the same invention might be patented by a competitor.
For any invention, evaluate whether foreign patent rights are truly required. This will
require a combination of business, marketing, and legal analyses.
When assembling a patent application, attorney costs can be reduced by providing
a cohesive document containing all data and information relating to the invention,
such as alternative methods, compositions and/or devices. Use attorneys, at least, to
review draft patent applications and to write the all-important claims.
The foundation of an effective field-of-use licensing strategy is a patent application
that foresees certain licensing opportunities and accommodates unforeseen
opportunities. It will thus be important for your office to establish and implement
strategies for patent application preparation that seek to anticipate any and all
licensing opportunities that can arise from an invention.
It is essential to retain control of patent applications. Don’t permit a licensee to gain
control; their interests and your interests are likely very different.
Tiered or layered IP protection strategies utilize several forms of protection for a
single product or process. For example, a hybrid maize variety may be simultaneously
protected by patents, trade secret, trademark, and plant variety protection.
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Technology and Product Licensing
Buyers want to get the most for their money; sellers want to get the most for their products. Put
differently, no one wants to pay more for an item
than what is necessary. And sellers expect a fair
price for their products.1 These universal pricing
concerns apply not just to food, shelter, and any
other goods and services, but also to intellectual
property. As a licensee, how much should you pay
for a license? How much should a licensor charge
for a license? And what form should payments
take? Royalties on products sold? Fixed payments
per year? Equity in a business? Provision of services
(bartering) or some other form of remuneration?
And what exactly are you paying or charging for?
Answers to these questions are always complex.
The chapters in this section offer some points
of reference from which to explore these and
other questions that emerge during IP licensing
transactions (a license being the transfer of certain property rights between two or more parties
under a specified sharing of rights and obligations
between those parties). These considerations apply to companies and public sector institutions
alike. With a license, as distinguished from a sale,
possession of property does not transfer but remains with the original owner.
Negotiation is one way to establish the terms
under which a transaction takes place. But negotiation is just one aspect of establishing the terms
of a specific transaction. Preparation for a negotiation can—or should—require at least ten times

more time than the actual negotiation, since the
goal of a negotiation is to formulate an agreement
that meets the needs of both the licensor and the
licensee in a manner that ensures mutually beneficial future relationships between the institutions
and individuals. Anticipating the other party’s
needs and wants, and considering alternatives
for resolving possible competing interests, is just
one aspect of the preparation. Price, quite often,
will not be the most difficult aspect to negotiate.
Other terms can be more critical and of greater
relevance, and value.
The first chapter by Freeman2 discusses the
central issues that licensors and licensees need
to consider before negotiating agreements.
After providing an overview of licensing in the
field of biotechnology, he considers the main
components of a license agreement, highlighting concerns specific to the field of biotechnology. A license agreement will include several key
components:
• The background section sets out the factual
predicates for the license, including the
names of the parties, the effective date of
the agreement, and the parties’ motivations
and expectations.
• The definitions section explains key terms
used in the agreement.
• The grant section establishes whether only
the licensee may practice the invention (an
exclusive license) or whether others may

Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 2007.
11: Technology and Product Licensing.In Executive Guide to Intellectual Property Management in Health and Agricultural
Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA),
Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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practice it. This section may stipulate rights
to sublicense or rights to assign, or it may
say that there are no such rights.
The section on fixed payments and royalties
sets out payment terms of the agreement.
The confidentiality section specifies provisions for and restrictions on the disclosure
of information shared between the parties.
A section on enforcement against infringers
specifies which party shoulders the burdens and realizes the benefits of enforcing
the licensed patent against infringers. This
enforcement often involves allocating the
risks and rewards of the overall success of
the venture.
The term of the agreement and termination
procedures should be fully spelled out. As
with most licenses, the biotechnology license will often have a term that coincides
with the patent term.

Freeman discusses a series of other points
that require special attention, including the complexities of confidentiality clauses that are particularly pertinent when working with academic
and public sector research institutions. Finally, to
help make negotiations easier and more realistic,
the chapter discusses incentives for licensors and
licensees and considers some of the finer issues of
developing collaborations.
Cahoon3 addresses issues related to agricultural biotechnology (agri-biotech) licenses.
Although these license agreements are similar in
many ways to other kinds of license agreements,
agri-biotech license agreements have some unique
elements. The chapter explores the basic nature
and purpose of a license agreement, and preferred
licensing methods and terms are suggested. The
chapter then turns to the complex—but highly
important—singularities of agri-biotech licenses,
focusing on such issues as multiple property types
that cover a single technology and/or product,
freedom-to-operate issues that may drive antiroyalty-stacking provisions, philanthropic and
humanitarian-use clauses, and stewardship obligations. The chapter emphasizes the uniqueness of
agri-biotech licenses in regard to the concept of field
of use, which may be broadly or narrowly defined.
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The complex and rapidly evolving nature of
agri-biotechnology requires (at the moment) that
each license agreement be tailored to the particular context in which the invention will be used.
Still, such licenses do not have to be invented
from the beginning, and Cahoon’s chapter elucidates both the common and unique aspects of
agri-biotech licensing. For practical purposes,
any organization engaged in high-volume licensing will find it useful to develop its own internal
template agreements4 that are then modified and
adapted to suit each special circumstance.
In addition to the more generic licensing
aspects, this section of the Handbook contains
a series of chapters that review more specific IP
licensing strategies. The in-licensing and out-licensing of plant varieties are the two sides to the
licensing equation. In-licensing of plant varieties
can increase market share, building a competitive advantage by providing for customer needs.
In-licensing varieties also enhances or completes
a company’s variety portfolio, both for in-house
breeding programs (facilitating access to breeding materials) and for in-licensed varieties ready
for commercial distribution. The most common
reason for out-licensing varieties is for a company to maximize return on investment by allowing others to produce and sell varieties in
markets that cannot be reached satisfactorily
through the current marketing setup.
Importantly, the licensing of varieties is increasingly becoming more important for public sector breeding institutions. These are often
funded, at least in part, by governments, and so
they have a fundamental mission of serving the
public interest. The same applies to the Centers
of the Consultative Groups on International
Agricultural Research (CGIAR). These institutions are eager to ensure that resource-poor farmers have the greatest possible access to value-added crop varieties. The central question here is how
can these public sector breeding institutions provide broad access to improved germplasm? How
can a combination of plant variety protection
(PVP) and licensing accelerate the dissemination
and adoption of improved varieties?
Private sector licensing expert Nilsson openly addresses plant variety licensing, sharing the
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experiences and approaches of a private sector entity. Nilsson5 illustrates how plant variety licensing
is a practical tool that plant breeding companies
(in the private sector) or institutions (in the public sector) use to commercialize or provide access
to their products (crop varieties). Licensing also
facilitates technology transfer (where technology
is defined as know-how, improved germplasm, a
range of breeding tools, and genes) in a simple
delivery mechanism:
• the seed as a vehicle for technology transfer
• the seed itself as a commodity-embedding
technology
Nilsson provides practical guidance for inlicensing and out-licensing crop varieties, with
a special focus on developing countries. Because
of decreased funding of public sector breeding,
the seed sector is gradually being served by private companies, often small-scale and local enterprises. This has created increased demand for
new varieties, and seed companies are seeking to
in-licence varieties while private sector breeders
may desire to out-license their varieties. Capacity
for negotiating and executing license agreements,
therefore, is becoming all the more critical. In an
organized, detailed, and understandable fashion,
Nilsson’s chapter presents the fundamentals of
seed licensing, emphasizing how the licensee and
the licensor should focus on the practical content
of a license agreement: exclusivity to plant material and territory, plant variety protection, variety
trials, national registration, royalty payments, and
information transfer.
The best licenses are those that recognize
that relationships—like markets—are not static.
An agreement should thus include sufficient flexibility for evolution. The agreement should reflect
changes in the market, competitors, technology,
seed legislation, and PVP laws. Enabling such
flexibilities is perhaps the greatest art in drafting
and negotiating variety licensing agreements.
Overall, the successful licensing of varieties is
contingent on the strength of PVP legislation. A
PVP framework generally supports the interests
of the variety owner and the farmer, facilitates the
transfer of technology, and provides incentives for
further investments in the development of new

plant varieties. In many countries, PVP legislation
is based on the Convention of the International
Union for the Protection of New Varieties of
Plants (UPOV). The relevance of UPOV in accelerating access to improved varieties is its harmonization and documentation of a PVP aspect
that facilitates licensing by foreign seed companies and public sector institutions alike.
Due to numerous complexities in terms of
geographical, cultural, and paradigmatic distances, prospective licensors and licensees frequently
spend a lot of time becoming acquainted and
developing a certain level of trust. Over time,
they reach a point where they are speaking the
same language of contracts and licenses, and
they reach a satisfying agreement. This lengthy
process, however, can deter or derail licensing
efforts. Companies may not wish to invest such
time and energy, because even commercial licenses with entities in the developing world simply take up too much valuable management time
and resources; the necessary funds for extended
and repeated face-to-face meetings are simply
unavailable.
A complementary approach is therefore
needed—a way to bridge this communication gap
and more rapidly arrive at a common language.
Modern computer and Web technology might
provide an answer. The chapter by Krattiger,
Dodds, and Bobrowicz6 examines the potential of
a software decision tree linked to template contract language that allows individually customized contract documents to be generated and that
could ameliorate many of the aforementioned
problems. Provided that some key players agree to
the basic template, an appropriate software package could improve opportunities for assembling
a greater array of potential partners. A test version of such a computer-generated contract template (CoGenCo) system has been developed and
could be a pragmatic step toward increased licensing of proprietary and finished varieties that may
or may not incorporate proprietary technologies
for input or output traits. The CoGenCo system
is aimed at establishing a certain international
standard license, that is, a standard that all understand and agree on. In this way, a meeting of the
minds is facilitated and accelerated. A standard
HANDBOOK TO BEST PRACTICES: EXECUTIVE GUIDE | 123

GUIDE TO SECTION 11

license can be downloaded for free from the online version of the Handbook.7
The approach of CoGenCo is to facilitate the
awarding of out-licenses of germplasm to developing country institutions, including by and for
the CGIAR and national programs. Under the
legally binding terms of CoGenCo-generated license agreements, several entities in a given country could compete against one another on price
in poor countries but would not be allowed to
compete against the patent holder in developed
countries, in which revenues and the incentives
for developing new varieties and new technologies would be undiminished. Under appropriate
circumstances, the germplasm and/or traits could
be licensed royalty free. Use of out-licensing in
this way separates these fundamentally different
markets and promotes access to improved germplasm and technologies, all by reaffirming various
statutory protections as indispensable for successful agricultural research and development.
Moving on to other forms of IP licensing, the
licensing of trade secrets presents an entirely different set of challenges. A trade secret (also called
know-how in certain jurisdictions) is any proprietary technical or business information, often
embodied in inventions, know-how, show-how,
and tacit knowledge. The most common definitions agree on three requirements that should be
met for enforceable trade secrets to exist. The proprietary information should be:
1. Secret in the sense that it is not generally
known in the trade
2. Valuable to competitors that do not possess
the information
3. The subject of reasonable efforts to safeguard
and maintain the information in secrecy
Everyone knows that trade secrets are secret.
Patents, on the other hand, require inventions to
be publicly disclosed. But does this mean that
these two forms of IP protection cannot be used
together? The chapter by Jorda8 argues emphatically that trade secrets are complementary to patents. By using both trade secrets and patents, the
combined IP protection is stronger than if either
one were used alone. But how is it possible to use
both patents (which are publicly disclosed) and
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trade secrets (which are kept secret) to protect
something? In practice, there is no conflict between the two. Patent applications are usually filed
early during the research stage to get the earliest
possible filing or priority date. The patent claims
tend to be narrow to achieve distance from prior
art, and the specification normally describes rudimentary laboratory experiments or prototypes
and/or embryonic embodiments of an invention.
The best mode for commercial manufacture and
use are almost invariably developed later. The results of such later research need not be disclosed
to obtain the patent on the early invention and
can be kept as trade secrets.
As a practical matter, therefore, patent licenses are most valuable when coupled with
access to associated know-how. A patent license alone is often inadequate for commercial
development of a technology. This associated
know-how is immensely important and should
be part of licensing agreements; effective technology transfer requires not only patent licensing but also, and perhaps more importantly,
trade secret licensing.9
Anyone engaged in product development,
including developing countries in particular, will
want to keep in mind that trade secret protection
operates without delay and without undue cost.
Patents, on the other hand, are territorial and
thus expensive to obtain and maintain, and they
can be acquired only in certain countries.
When considering the forms of IP protection
available for plants, what usually comes to mind
are PVP and utility patents. But as the chapter
by Tucker and Ross10 points out, trademarks are
an effective form of IP protection for plants and
plant products, either used alone or in combination with one or more other forms of IP rights
protection. Furthermore, trademarks can be used
to effectively protect IP rights for plant varieties
internationally. Similarly, the value of trademarks
for varieties and products from developing countries can be tremendous. The relative strength of
trademarks is determined by how distinctive the
mark is. When consumers see the trademark, they
are able to easily distinguish the goods or services
of the trademark owner from the related goods or
services of competitors.
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Two international agreements, the Madrid
Arrangement and the Madrid Protocol govern
international trademark registration. For plant
trademarks, understanding and utilizing these
provisions will become increasingly important to
developing countries. Many tropical and subtropical regions are rich sources of novel fruit products, and an owner of such a product will want
to adopt a strategy that both stimulates global demand for the product and maximizes commercial
returns. Trademarks will be integral for such IP
rights protection and global marketing strategies.
In particular, three critical aspects should be considered if new branded fruit products are to be
successfully launched from developing countries:
1. Determine what is to be trademarked.
2. Promptly register the trademark in the
countries in which it will be used.
3. Enforce the trademark.
A successful global trademark program, built
around exciting products, may be more achievable than a PVP-based strategy that relies only
on licensing for returns. Instead of managers and
lawyers securing licensing deals, the market itself
can fuel value creation in the trademark. If successful, the returns can be tremendous.
Shifting topics once again, a very important
and quite difficult aspect (especially for public sector entities) is the granting of options and rights
of first refusal. As either a stand-alone agreement
or as a clause within a broader agreement, options
are a unique way of granting rights to intellectual
property. The chapter by Anderson and KeeveyKothari11 provides a detailed discussion of the
various forms of options, with tips and strategies,
sample causes, and template agreements. The
chapter delves deep into the legal and commercial promises and perils of granting options and
concludes with a helpful section on administering options.12
Of special interest to university administrators and technology transfer professionals will be
the sections on incorporating options as a part of
research agreements. Universities in the United
Kingdom and the United States have different
approaches to handling privately sponsored research. In the United Kingdom, sponsors are often

granted an option to acquire a license to develop
and commercialize results, or the sponsor might
in some cases own all the results. In contrast, a
university in the United States normally retains
ownership of any intellectual property resulting
from its own research, though the university may
grant rights to a sponsor to commercialize results.
This emphasis on university control of research in
the United States stems, in part, from provisions
in the Bayh-Dole Act that prohibit universities
from transferring ownership of intellectual property created from government-funded research.
Also instructive to university personnel will
be the chapter’s discussion of where and when
not to grant a pipeline agreement to a university
spinout company. A pipeline agreement generally refers to an option granted to a university
spinout company to acquire rights over intellectual property that may, in the future, be generated by university faculty. Although a pipeline
agreement may make sense, universities should
be careful to stipulate how pipeline intellectual
property will be identified. They will likely want
to limit the agreement to intellectual property
generated by specific faculty members and their
labs. Universities should also recognize that in
some cases spinouts may not be the licensee of
choice and should therefore craft pipeline agreements with care.
Licensing is about choices, and it can be argued that no choice is more important than the
field of use granted in a license. When licensing
complex technologies, the licensor usually can
partition patent rights based on time (duration
of license grant), location (where rights may be
practiced), and field of use. Shotwell13 explains
and clarifies the last of these three considerations.
By partitioning a bundle of patent rights and distributing them to one or more licensees, field-ofuse licensing maximizes value, optimizes delivery,
and facilitates the most effective use of new technologies, whether in agriculture, biotechnology,
pharmaceuticals, vaccines, or diagnostics.
With field-of-use licensing, the licensor gains
greater control while maximizing the use and
value of the technology. However, field-of-use
licensing requires more work. The technology licensor should identify, motivate, negotiate with,
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and manage more than one licensee—and quite
possibly many. Nonetheless, this hard work can
increase royalty streams to the licensor, since multiple licensees, each with different and specialized
access to the technology, can efficiently speed different types of products to market.
When using field-of-use licensing, a licensor
should be flexible. For example, even if a licensor envisions only one possible field of use for
an invention, it makes sense to specifically limit
a licensee to just that field. This is because technology changes so rapidly that a new use for the
invention has a very good chance of developing
later during the life of the patent. By limiting licensees to a particular field, a licensor retains the
ability to work with the best possible licensee(s)
for a new use when it arises.
Shotwell recommends that the licensor retain
control over patent prosecution, while seeking to
fairly distribute costs over field-of-use licensees.
When considering reimbursement, the field-ofuse licensor should manage patent expenses creatively. For example, the licensor can cover patent
expenses up front, later reimbursing them from
the royalty stream, or, if costs are to be reimbursed
by the licensees, language can be used to include
future licensees in that reimbursement.
One of the complexities of field-of-use licensing is that it raises the important question
of how to deal with patent infringement/interference problems with multiple licensees. As
with patent costs, the simplest approach is for
the licensor to carry interference and infringement costs alone, recovering them through royalties or settlements. This approach retains more
control for the licensor and correspondingly less
for the licensees. Another approach to address
possible infringement and interference actions
would be to work out a mechanism to share the
costs and management of these activities with
one or more licensees.
Possible problems with field-of-use licensing
include rights that overlap across licenses. This
can arise from different interpretations of the
rights granted under licenses or from unexpected
future technical developments. It is therefore
wise to lay the groundwork for resolving disputes
related to these types of potential issues.
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Licenses that include royalty stacking and
royalty packing clauses are becoming more
ubiquitous because virtually all products developed now using biotechnology, genetic engineering, and chemistry are technologically
complex and incorporate many different inputs.
As if this were not enough, there is also the
added consideration of relevant IP rights, held
by third parties that may be attached to these
many inputs. For example, a vaccine might be
identified and tested using proprietary research
tools with IP rights owned by several companies.
Later, the vaccine might be produced using patented recombinant techniques and proprietary
DNA sequences. Transformation vectors might
be owned by others. Production of the vaccine
might employ a proprietary cell line. The vaccine might be packaged with one or more proprietary adjuvants and then be delivered using
a patented device. Hence, when the vaccine is
ultimately “ready for use,” it will likely be subject to royalty obligations to several different
companies, or licensors. A dilemma results, as
the various licenses involved can combine to
impose aggregate royalty obligations, perhaps
up to 20%, and sometimes more, of the selling
price of the product. There will also be separate
reporting and accounting obligations to each of
the licensors. Similar problems arise in agriculture when a genetically engineered crop might
be made using proprietary varieties, vectors,
gene sequences, and research tools—each with
IP rights owned by different entities.
Jones, Whitham, and Handler14 discuss two
scenarios that can arise when multiple royalty
rates are attached to one product—royalty stacking and royalty packing:
• Royalty Stacking. A biotechnological product might have multiple patents attached,
and thus require multiple licenses in order
to make, use, or sell the product.
• Royalty Packing. With some biotechnologies, it usually is necessary to combine
one technology with many other technologies. (In this situation, the royalties imposed on each of the proprietary
products that are administered will be
“packed” together.)
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The chapter then presents several techniques
for managing royalty stacking and packing:
• Royalty Ceiling. A licensee may seek a ceiling for royalties in agreements it makes
with licensors.
• Royalty Floor. A licensor may seek a floor
below which its share of the royalties may
not be reduced.
• Variable Royalties. Licensees and licensors
also might agree to have variable royalties
that are conditioned on the importance of
the technology in relation to the creation of
the product.
• Royalty Alternatives. Finally, alternatives to
royalty bearing arrangements can also be
considered; these include lump-sum payments and patent pooling.
The last point shows that managing royalty
stacking and packing does not necessarily require
royalty streams. For example, a lump-sum payment for the use of a research tool may be an optimal way to disseminate and exploit a patented
technology. Some technologies may be best assembled in patent pools that provide either free
use of or fixed-price access to the technologies.
Patent pools can thereby facilitate R&D using a
variety of proprietary technologies without the
need to negotiate licenses.
As all of the above chapters make clear, in our
post-TRIPS environment, leaders in developing
countries who seek to improve economic development and public health are advised to be wellversed in the details of global IP management.
Unlike the past, today no country can comfortably remain isolated from the global IP system.
Yet among many public sector institutions in
developing countries, knowledge of IP licensing practices is often insufficient. To address this
gap in expertise, the chapter by Satyanarayana15
lays out several of the important features of inlicensing agreements, common problems faced
by developing countries in constructing and implementing these agreements, and ways to avoid
these common pitfalls.
In-licensing by public sector institutions is a
useful, if complex, method for bringing technologies into the public sector through patent license

agreements with the private sector. Although the
interests of the private and public sector entities
involved in these agreements will almost necessarily be in tension, it is possible for a well-crafted
license to allow all parties to feel as though they
have benefited from the agreement. From a public sector perspective, as Satyanarayana argues,
the goal is ultimately to provide a product (be it a
vaccine, drug, or new agricultural crop) to people
who would not have access to it without government support. For developing countries, the good
news is that legal expertise is often locally available, since many firms are already familiar with
basic licensing procedures. The trick is to put
this knowledge in the service of public officials
to develop a comprehensive and effective plan to
license and develop much-needed-technologies.
These strategies include:
• developing a business strategy that balances the needs of the public sector with the
needs of the private sector
• developing a marketing strategy that prices
products realistically and is based on good
market research to aid valuation
• forming partnerships with other suitable
agencies to help manufacture and market
new products
• making sure legal, business, and scientific
experts are working together for optimal
success
• establishing, as an important initial step, a
national technology transfer office
The final chapter by Bobrowicz16 offers a
useful checklist for negotiating licensing agreements. For the seasoned technology transfer
professional or contract attorney, the idea of
preparing a detailed checklist for every licensing
agreement may seem like unnecessary busy-work.
Yet these same professionals could probably relate stories where a missed detail or vague contract provision led to a costly and protracted legal
battle. Given the high stakes, it is certainly in the
best interest of those involved in IP deal making
to make sure that every last detail is checked and
rechecked. When multiple deals are being negotiated at once, it is only reasonable to assume
that something could get missed. To help avoid
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this unfortunate and potentially costly error, this
chapter provides a comprehensive, yet flexible,
checklist that can be deployed to help manage
the details of license agreements. Although the
author provides a template for most elements of
the license, she is quick to note that users should
feel free to alter the checklist to suit their particular business practices.
The checklist covers all the major elements
of a standard IP license, particularly as used in
agriculture, starting with a section detailing the
most basic, yet crucial, matter of getting all the
parties’ pertinent contact information. Sections
covering clauses, definitions, rights granted, sublicenses, improvements, warranties, and infringement, and other matters are discussed, with useful
sample checklists included for each component.
The chapter concludes with a consideration of
boilerplate sections, including confidentiality and
arbitration stipulations. Although each section is
annotated, an online version can be downloaded
without accompanying text.
In sum, licensing is about the development of
relationships. As important as the terms of agreements are, few are more important than the longterm opportunities offered by forging good partnerships, be they between companies or between public
and private sector entities. Negotiating an agreement
is just the beginning of what may—or should—
become a long-lasting and beneficial relationship. n
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In an ideal world, exchanges would take place based
on “fair” and “equitable” pricing, in both the eyes of
the seller and buyer. But equitable exchanges are at
least in part based on perceived moral obligations
that are difficult to capture in financial and market
terms. Such nonmonetary and moral perceptions,
often strongly personal-, cultural-, and even religionbased, are important, but there is no system, at least
for the moment, for weighing different perspectives
on morality or ethical grounds or for translating them
and making them work in the marketplace. To be sure,
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Licensing is highly context specific. For this reason, blanket policies on minimum
requirements for licensing terms applicable to public sector institutions can discourage
creative and beneficial deals and reduce the potential for national institutions to forge
international linkages.
Notwithstanding the above, public sector institutions should, as a matter of policy,
consider the routine incorporation of philanthropic use provisions in their licenses and
should always retain research and teaching rights to any of their inventions.
The dual goals of economic growth and social/humanitarian benefits through licensing
are not mutually exclusive. Indeed, they are often complementary.

Key Implications and Best Practices: SETCION 11

FOR GOVERNMENT POLICYMAKERS

Companies regularly license their own varieties to third parties as a strategy to maximize
returns on investment and reach markets that the company itself cannot easily reach.
Conceptually at least, public sector plant breeding institutions have much to gain from
variety licensing as a strategy of serving markets they do not typically reach.
Overall, the successful licensing of varieties between and among public and private sectors
is contingent on the strength of plant variety protection legislation. Such legislation
can support the interests of the variety owner and the farmer, facilitates the transfer of
technology, and provides incentives for further investments.
Recognizing that patent applications are usually filed early in the research stage and
require full disclosure, companies typically keep inventions developed later on as trade
secrets. These may include the best mode for commercial manufacture. Patent licenses
are most valuable when coupled with access to associated know-how. Comprehensive and
enforceable trade secret laws are thus conducive to the transfer of know-how through
licensing. The two, disclosed patents and protected secrets, are thus complementary.
Using trademarks as a strategy allows public and private institutions to capture more
added value. To benefit from trademarking strategies, internationally accepted legislation
is important. Also important is the maintenance of high quality standards and stewardship,
since trademarks (and geographical indications) provide the consumer with information
on the source of the products.
Although IP rights are governed by national statutory protection, contract law is arguably
even more important than statutory protection law, as contracts allow institutions to
exchange intellectual property in an orderly and predictable manner.
Along with investing in a country’s R&D infrastructure and capacity, it is important to
sustain long-term growth. Human and institutional capacity in IP management adds
value to R&D efforts. In- and out-licensing in particular enhance an institution’s economic
and social impact. Among a government’s top priorities should be providing support to
public sector institutions for establishing and operating effective technology transfer
offices, coupled with training programs for creating capacity commensurate with the
complexities of modern biotechnological products. Ideally, these capacities should reside
at the institution level because of the context-specific nature of licensing.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.

HANDBOOK OF BEST PRACTICES: EXECUTIVE GUIDE | 129

Key Implications and Best Practices: SECTION 11

GUIDE TO SECTION 11

FOR SENIOR MANAGEMENT
(University President, R&D Manager, etc.)

4

4

4

4

4

4

4

4

4

Licensing is highly context-specific. For this reason, blanket policies on minimum
requirements for licensing terms applicable to your technology transfer office can
be counterproductive to making sound deals and can reduce the potential to forge
international linkages.
Public sector institutions should, as a matter of policy, consider the routine incorporation
of philanthropic-use provisions in their licenses and should, as a matter of routine,
always retain research and teaching rights to any of their inventions.
The dual goals of economic growth and social/humanitarian benefits through licensing
are not mutually exclusive. Indeed, they are often complementary. Much will depend
on a sound institutional licensing strategy and on good relationships with licensees.
The value of trademarks for both varieties and products, from developed and developing
countries alike, cannot be understated. To benefit from trademarking strategies,
particularly of global reach, the maintenance of high quality standards is important,
since they provide the consumer with information on the source of the products. In
addition, using trademarks as a strategy allows public and private sector institutions
alike to capture more of any added value.
Licensing is about choices, and it can be argued that no choice is more important than
the field of use granted in a license. A public sector institution should have a clear policy
statement on how it deals with field-of-use licensing and may even wish to consider
making field-of-use licenses the preferred method of licensing. This is especially
applicable to platform technologies and diagnostics. However, field-of-use licensing
requires more work. A well-trained and well-staffed technology transfer office will be
essential.
A public sector institution can contribute significantly to its mission through in-licensing
intellectual property from private sector entities. For this, it is useful to develop a set
of strategies (business, marketing, partnership building, and legal) during discussions
with the licensing office that balance the needs of the public sector with the needs of
the private sector.
Business decisions, more than legal aspects, should determine licensing terms.
Nevertheless, lawyers should ensure that the contracts comply with prevailing law. This
is equally applicable to private sector and public sector deals.
Patent licenses are most valuable when coupled with access to associated know-how.
Comprehensive staff training in the handling of confidential information from third
parties is therefore critical.
But public sector organizations should exercise caution when accepting trade secrets
(as opposed to confidential information). In some jurisdictions there may be significant
liability obligations related to trade secrets, and public sector institutions may not be in
a position to cope with all such obligations.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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Ideally, you will leave detailed aspects of negotiations, such as collaboration or license
agreements, to the relevant offices of your institutions. However, do participate in
the internal discussions prior to in- or out-licensing negotiations. Your input will be
important and should be valued.
The dual goals of economic growth and social/humanitarian benefits through licensing
are not mutually exclusive. Indeed, they are often complementary. Much will depend
on a sound institutional licensing strategy and on good relationships with licensees.
Your role in the latter may be critical.
Make an effort to consistently document the origin of biological and other materials
you use in your research, and keep a comprehensive record. Although it is not your
responsibility to resolve IP conflicts, your detailed records will help if such a conflict
arises.

Key Implications and Best Practices: SETCION 11

FOR SCIENTISTS

Interface with the technology transfer office (TTO) in order to understand options
and whether you might have a role in their implementation or fulfillment. Although
options are complex and a matter most appropriately addressed by your TTO officers,
the granting of options may significantly impact your research options. Make sure you
discuss the implications with them prior to the incorporation of options in licenses
that relate to your research.
When you disclose an invention to your TTO officers, inform them of any ideas you may
have on the various fields of endeavor in which your invention could find applicability.
This will help the TTO write better patent applications and, later to draw up license
agreements for many different players under different field-of-use licenses. This
approach can maximize the value of your research and may accelerate commercial and
humanitarian development of technologies based on your research.
Your role in field-of-use licensing is essential. You can provide your TTO with valuable
information on licensable components for different applications and entities.
The products arising from your program’s research efforts, particularly from product
development activities, will invariably embody numerous technologies, including
components and processes that might have IP rights from third parties attached to the
technologies. This can create complex IP management and licensing issues as these
products approach commercialization. If you are engaged in product development,
maintain a good line of communication with your TTO and ensure that early on they
address IP ownership by third parties.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.

HANDBOOK OF BEST PRACTICES: EXECUTIVE GUIDE | 131

Key Implications and Best Practices: SECTION 11

GUIDE TO SECTION 11

FOR TECHNOLOGY TRANSFER OFFICERS
4

4

4

4

4

4

4

4

4

4

Besides reflecting the business deal that has been made, few components are more
important in a license than clear and unambiguous definitions.
For practical purposes, any organization engaged in high-volume licensing will find it
useful to develop its own internal template agreements that are then modified and
adapted to suit each special circumstance. Checklists for different types of recurring
licensing negotiations should be reviewed prior to and during negotiations.
Recognize that relationships—like markets—are not static. Any provision in an
agreement must, of course, be adhered to, but the practice of including sufficient
flexibility in licensing agreements can be a valuable strategy in forging strong
partnerships.
The granting of options (rights of first refusal, pipeline agreements, and so forth)
can be a rather controversial aspect for public sector licensing. But options can be
tremendously powerful in forging strong and lasting relationships and in optimizing
your institution’s economic returns and humanitarian effects.
Field-of-use licensing should be adopted as the preferred method of licensing
whenever possible. It allows you to gain greater control while maximizing the use and
value of your licensed technology. But be flexible and study the licensee’s motivations
and business model carefully as a way of conferring the highest possible incentives.
Always strive to retain control over patent prosecution and infringement actions when
adopting a field-of-use licensing strategy.
Familiarize yourself with the various ways to deal with royalty stacking and royalty
packing issues as a way of balancing risks and returns. The choice will depend on how
far downstream into product development your institution stays involved.
Negotiating about low-probability events can sidetrack progress toward agreement
on core issues, so care should be taken during the negotiation to attend to issues in a
manner commensurate with their strategic importance. It is often best to focus on the
overall deal before entering into discussions about specifics.
In a license agreement, the rights to sublicense and assign a license ought to be
explicitly articulated.
In research collaborations, in which employees of two or more entities share ideas and
information, confidentiality provisions are important. Make sure the scientists in your
institution understand these obligations and rights.
Licensee agreements are contracts. Hence, a practical understanding of contract law will
be fundamental to negotiating and drafting good license agreements. Many smaller
TTOs use outside counsel to ensure that agreements are compliant with national law.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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Dealmaking and Marketing Technology
to Product-Development Partners
A licensing agreement establishes, in written form,
the rules of an ongoing relationship, the success
of which will depend on many factors. Mutual
trust is one of the factors. Another is the development of a certain dependence based on the value
that is being transferred between the parties. As
Mahoney1 explains, one party may have a product that can potentially have a very large market,
while the other party has research, manufacturing, or distribution capabilities essential to reaching that market. The key to successful negotiation
is having a clear understanding of the value each
party brings to the relationship. But value is multifaceted. There is an objective value, represented
by, for example, how many units can be sold at
a certain price yielding a certain level of profit.
There are also qualitative values, for example, the
additional value assumed to exist when one company feels that a particular product, owned by a
second company, would enhance or complete a
particular product line.
Perhaps the most important element in
a negotiation is to be clear—internally and
in discussions with the negotiating partner—
about the benefits that will or could be realized
through a license agreement. Only with a clear
understanding of the transfer of value can both
parties intelligently and fairly negotiate an agreement. Mahoney discusses this along with numerous suggestions for successful licensing negotiations, including the following:

•

•

In general, the public sector organization
should consider offering the first draft of a
licensing agreement (the draft needs to cover a number of topics of particular concern
to public sector organizations that would
probably not be addressed by a company).
The use of a term sheet that lists the major
issues expected to arise in the negotiations
should be shared ahead of time indicating the outcome that the proposing party
hopes to achieve. Such a sheet could also
include the needs and wants (in other words,
the must-have terms and the desired ones)
of each party.

Furthermore, says Mahoney, negotiating
such agreements requires talent, expertise, and
sound tactics that cover the following areas:
• business strategy. The business strategist is
usually the lead negotiator with considerable
experience in structuring business relationships, assembling the inputs of other experts,
and maximizing the benefits to all parties.
• marketing. Market analysis is essential to
negotiating a good agreement. Failure to
carry out such an analysis is dangerous because it can lead either to overestimation
or underestimation of the market potential,
which, in turn, can lead to a suboptimal
agreement or rejection of an agreement
that could have been successful.

Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 2007.
12: Dealmaking and Marketing Technology to Product-Development Partners. In Executive Guide to Intellectual Property
Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.).
MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopmentsInternational Institute (Ithaca, USA). Available online at www.ipHandbook.org.
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for
noncommercial purposes is permitted and encouraged.
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legal inputs. A lawyer should be retained at
least to review agreements and, more appropriately, to be part of the negotiating team
and possess intellectual property (IP) expertise and valuation skills, understand knowledge of freedom to operate issues, and be
able to access country-specific legal advice.
scientific and regulatory. A negotiating
team must have scientific expertise and
detailed knowledge about regulatory issues,
product safety, and related matters
production. Staff members who can contribute their knowledge about required production equipment and good manufacturing
processes as well as their understanding of
time lines, cost implications of various manufacturing processes, and so forth should be
involved in the licensing negotiation.
finance. A careful financial assessment of
the project is essential, even before negotiations. The assessment often can help the
business strategist determine options for
approaching a deal, to decide which new
funds will be required to launch and sustain the project, and so forth.

In addition, Mahoney illustrates specific best
practices for public sector entities to meet public
sector goals. These are summarized in Table 1 and
serve as guidelines for public sector organizations
striving to widen and improve access to innovation through various licensing strategies. Price is
probably the most difficult area for a licensor to
get involved in.
Up to this point we have dealt with the overall strategies and best practices used to meet public sector goals. The chapter by Mongeon3 provides a broad overview of marketing tactics as a
way of understanding what buyers need and how
to meet those needs. In essence, he invites the
reader to think of marketing not as simply a way
to push technologies into the market rather than a
way of allowing the needs of buyers to pull them
in. Indeed, marketing is not merely advertising
or selling. Rather, marketing is a multistage process: first, the essential characteristics or benefits
of a technology must be quantified; next, people
who would find these characteristics or benefits
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desirable and therefore be willing to pay for them
must be identified; and finally, the benefits of the
technology must be communicated clearly and
compellingly to those potential users. Mongeon
offers five basic marketing questions that wouldbe licensors will need to address:
1. Who will buy the technology? Will the purchasers be producers or consumers?
2. What does the buyer of the technology
want? What characteristics, qualities, or capabilities of the technology are valuable to
the buyer, and how valuable are they?
3. Why would a party choose to license or
purchase a technology? What is particularly
compelling about it?
4. Where are potential users of the technology
located? In which markets? Through which
channels can they be reached?
5. When can you sell the technology to buyers? Is the technology so new that the market is not yet receptive to it?
The answers to these questions should guide
a marketing plan and be supported through market research. Such research may even reveal that a
technology can be used in a completely new and
unexpected way in a previously unanticipated
market. Perhaps the most important advice this
chapter has to offer scientists and technology
managers is that the “unique selling proposition”
of a technology—that is, the features, advantages,
or benefits that it offers the user—is rarely the
science behind the technology. Good marketing
makes a technology understandable and attractive to buyers, then allows their demand to draw
the technology into the market.
But how does one “find” potential licensees?
And how should one approach them? Marketing
workshops tend to suggest a haphazard mix of
different tools and strategies that may or may not
work. For these reasons, MacWright and Ritter4
offer a detailed and systematic approach to technology marketing (which is different from product marketing). The chapter contains many models for establishing contacts and prioritizing these
according to specific criteria, as well as numerous
worksheets that will help plan for different marketing approaches.

Dealmaking and Marketing Technology to Product-Development Partners

Table 1: Illustrations of Best Practices for Licensing to Meet Public Sector Goals
Topic

Basic concept

Public sector consideration

Areas
of use

Specifies limitations on the
application of the patent in
developing products; simplest
approach: grant an exclusive
right to all applications, including not only those specified in
the patent, but others that may
emerge as further research and
development proceeds.

The clause could grant an exclusive license only for
those products that the licensor actually wishes to
pursue. Also, the clause could grant an exclusive
license only for those products that were unlikely
to have a significant market among the poor in
developing countries.

Territory

Specifies the geographic areas
in which the licensee has the
right to exercise a patent;
simplest approach: grant a
worldwide exclusive license.
(A license is valid only in the
countries where a patent has
been issued, but rights can be
granted, at licensee’s expense,
to file for patent protection in
additional countries.)

The clause could grant an exclusive right to a set of
developed countries and another exclusive license
to other developed countries. Both licensees, and
perhaps a third one, could receive nonexclusive
licenses for an agreed list of developing countries.
Then the two (or more) licensees would have to
compete for sales to developing countries.

Price

In most licensing agreements,
there will be no conditions
with respect to price. The licensor assumes that the licensee will determine the
best price to ensure the greatest return on investment.

• The price could be specified. This is feasible when
the licensor has detailed technical knowledge of
the production, marketing, and distribution costs.
• The price could be set as cost plus (cost of production
plus a reasonable markup, say 15%). This is feasible
when the licensor has a reasonable expectation of
being able to monitor the cost of production.
• The price could be set at “no higher than the lowest price offered to any private sector buyer.” This
may be preferred when there are large bulk purchases by private sector buyers who are good at
negotiating the very best price.

Labeling

In most licensing agreements,
there will be no conditions
about labeling. The licensor
assumes the licensee will
prepare labeling in conformity
with national drug regulatory
agency requirements.

The licensor can help ensure that the product is
licensed properly, especially in developing countries
in which national regulatory agency requirements
for labeling may not be rigorous nor enforced.

White
knight
condition

This concept has been
developed by the U.S. National
Institutes of Health. It calls
for the licensee to undertake
some specific actions that
will benefit the public sector.

This could include a donation of products for clinical
evaluation in public sector research programs,
joint efforts to develop markets, free supply under
specified conditions to developing countries, and so
on.

Royalties

Usually a licensee will negotiate the highest royalty in
order to maximize revenue
from the license.

The licensor can specify that royalties apply to sales
only in developed countries and zero royalties in
developing countries. The impact for the licensor
would normally be minimal.

Source: Modified from Mahoney2
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In essence, the marketing approach comprises four basic steps:
1. Collect information about the invention
from the inventors.
2. Collect information from potential clients.
3. Review and prioritize your prospective client list.
4. Make contact with potential clients.
It is relatively easy to sell a finished product,
such as shoes, and more difficult to sell a technology to make better shoes. It is even more difficult to
sell (or license) the intellectual property for making
better shoes, especially if the intellectual property
has not yet been proven in a productive process.
For this reason, university technology managers in
particular often find it difficult to license individual patents. Burdon5 thus argues that universities
could gain a lot by pursuing a portfolio approach,
or rather, an integrated intellectual property
management (IPM) approach that blends sophisticated IP data search-and-analysis techniques with
continuous product improvement.
At the highest level, an integrated IPM approach is differentiated into strategic and tactical
decision-making. Strategic decision-making is a
broad analysis; tactical decision-making analyzes
specific products or technologies in a known
competitive landscape. Each approach to managing IP portfolios requires different types of tools,
searches, and analyses, ranging from very broad
technology scans to very specific patent infringement or validity searches. Importantly, attention
should be paid to how data analysis can be integrated with a product innovation process, how to
identify new opportunities or resolve old problems (that may also lead to the amendment of
patent applications). Perhaps the most important
reason for an IPM approach is that it enhances
understanding of the processes in which licensees are engaged and how a licensed technology
would support their endeavors, thus reinforcing
Mahoney’s earlier points on the importance of integrating business strategy, marketing, scientific
and regulatory expertise, and so forth.
Unfortunately, inventions by universities are
generally not developed in response to market
needs, which presents challenges for technology
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transfer offices (TTOs). Keiller6 addresses this
challenge and stresses the importance of having
a clear sense of the IP goals and IP strengths of
one’s own institution. An IP audit7 is a useful
way to improve an institution’s marketing prowess, because it identifies and classifies an institution’s intellectual property, whether it is owned,
licensed, or simply possessed. Unless the technologies, their IP status, and their respective levels of
development are known, at least to some extent,
it will be difficult to persuade others to pursue a
license deal. Keiller describes a range of marketing approaches and shares persuasion techniques.
In short, marketing packages should be tailored
to accommodate customers’ needs, the benefits
of the invention should be emphasized, effective
time management must be adopted, and above
all, contacts must be followed up on.
It is important with any IP management activity to be clear about the context in which it occurs. For example, dealing with a small company
will require a fundamentally different approach
than would be taken with a large one. Dealing
with an agricultural company will require a different approach than would be taken with a
pharmaceutical company. Neagley8 describes inlicensing strategies (and typical terms) as they
apply to small agri-biotechnology companies
that typically depend on strong IP portfolios.
IP portfolios are the foundation for their R&D,
encouraging outside investment and making
product commercialization possible. In-licensing is especially important as it allows a company
to obtain IP rights without having to invest in
research.
Neagley discusses the entire range of provisions in a typical license agreement, including:
• exclusive versus nonexclusive
• enabling technologies versus traits versus
plant materials
• rights granted to the licensee (covering such
topics as sole licenses, coexclusive licenses
and territoriality)
• compensation due to the licensor
• liability, diligence terms, and milestones,
• the licensee’s responsibilities vis-à-vis the patent
• license term and termination
• issues of assignability

Dealmaking and Marketing Technology to Product-Development Partners

Importantly, compensation may be a combination of fixed fees, which can be paid up-front
and/or periodically, and earned royalty fees. Both
the level and timing of compensation are important to the company with respect to its planning
and budget. In determining what compensation it
is willing to pay, the company will need to estimate the potential value of the licensed technology
and assess the potential value of any commercialized products that might be developed under the
license. But compensation may also take nonmonetary forms: stock in the licensee company, an
exchange of license grants, a cross-license arrangement, or a grant-back to the licensor (grant-back is
compensation that involves the licensee granting
the licensor rights to future inventions made by the
licensee using rights received from the licensor).
Dunn, Lund, and Barbour9 share the approaches of a multinational agri-biotech company with emphasis on market and policy factors
that influence and constrain agricultural companies regarding how to market technologies to
them, and on what these companies look for in
terms of license agreements.
Early-stage agricultural technologies, whether they are genetically modified technologies or
conventional ones, can be risky because they may
not have commercial applications or they may
fail to receive regulatory approval in the necessary markets. Gaining regulatory approval can be
a slow and costly process. In addition, a low marginal revenue is made on agricultural inputs, and
there are only a handful of crop species with sufficient acreage to generate the necessary returns
to warrant significant investments in regulatory
clearances. For these reasons, a few large corporations develop most transgenic technology; only
they have the necessary capital and can assume
the high risks involved.
For a university to market its technology successfully to a large company, it is useful to have
good contacts inside the company, someone
who is willing to accept the risk and “sell” the
deals internally. Indeed, the value of networking
cannot be overstated. For any company, though,
the value of a new technological opportunity is
determined by the risk involved, the additional
investments required to develop the technology

(and the corresponding opportunity costs), and
the type of technology in question.
These concepts are further explored by
Edwards10 who surveyed deals made by biotechnology and pharmaceutical companies during the
last ten or so years and analyzed the types of alliances and their terms. The four characteristics of
an alliance that generally defines the allocation
of value of a technology between an originator
and a commercial partner are:
• the stage of development of the technology
• the role retained by the licensor in product
supply or other ongoing activities
• the size of the market opportunity
• the scope of the market granted to the development partner
Because biotechnology companies have become highly specialized, it is no longer necessary,
or even possible, for any one company to be involved in every stage of the R&D process. Up to
half of the product candidates in pharmaceutical companies’ R&D pipelines originate from
elsewhere, and 60 to 80 percent of the leading
therapeutics on the market were developed or distributed through some form of alliance.
Edwards shows that universities and research
institutes are a significant source of early-stage technology, drug leads, and, occasionally, more mature
technologies. A biotechnology company with the
appropriate business model is most likely to find
early-stage technologies and drug leads attractive.
Once smaller biotechnology companies have developed technologies and drugs, they will probably
need to enter into alliances with larger pharmaceutical companies in order to conduct clinical trials
on, commercialize, and then market these products.
A university developing a more mature technology
might ally itself directly with larger pharmaceutical companies. Empirical evidence shows that the
more mature the technology is when an alliance
agreement is assigned, the more profitable that
technology is for the technology provider.
Edwards goes on to discuss some of the fundamental terms found in biotechnology alliance
agreements such as fixed fees, reimbursement of
expenses, development milestones, equity investments, and royalties, as well as the terms for other,
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more specialized, types of postcommercialization
payments. No matter whether a university wants
to join a commercialization alliance itself or license an innovation to a biotechnology company
that is allied to other companies, it is essential for
university TTOs to understand and influence the
terms of the alliance agreements in order to protect the value of their intellectual property.
Finally, Shotwell11 integrates the ideas of this
section in a discussion of a core theme of the
Handbook: how public sector and nonprofit efforts
can utilize intellectual property to achieve their
goals in serving society. To illustrate this important point, the chapter focuses on product development partnerships (PDPs) and their innovative IP
strategies. PDPs, in essence, facilitate and accelerate the flow of public and philanthropic investment
through the innovation pipeline, to a far greater extent than has been typical of universities alone.
With a two-pronged approach of product
specialization and taking advantage of the efficiencies of the larger marketplace for technologies,
PDPs strategically mobilize intellectual property.
Investments are made in a new product technology to advance it through the stages of development. This happens within the overall marketplace through the selective targeting of projects
based upon their risk–reward profile. Using this
approach, the measure of “reward” is not returns
to the organization, but rather the potential impact on social welfare that the new drug or vaccine
might have.
There are certain similarities between PDPs
and biotechnology companies. Both occupy a
similar niche in the innovation pipeline. Both
share many IP goals. Both seek to maintain an
appropriate mix of access and exclusivity to innovations, in order to have sufficient freedom to
operate and sufficient bargaining power to implement the overall strategy of their organizations.
There are also similarities between the IP strategies of PDPs and public research institutions.
Both PDPs and public research institutions use
intellectual property to entice or leverage private
investment, enhance access to other intellectual
property, build partnerships, and cultivate political goodwill to advance their missions.

138 | HANDBOOK OF BEST PRACTICES: EXECUTIVE GUIDE

Just as there are several business models used
by the biotechnology industry, so there are several business models used by PDPs. The business
model that a PDP chooses will depend on the
technologies it deals with, the stage of development of the technologies, and the nature of the
market. One factor that determines which kind
of business model a PDP or any other entity will
adopt will depend on whether or not the product
being developed is potentially profitable and can
therefore attract the interest of for-profit companies. Sound IP strategies and product development partnering also will uncover opportunities
to use new technologies to benefit those who are
traditionally excluded from markets. n
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Technology marketing is a process by which owners of a technology create relationships,
between themselves and potential users that will enable the technology to be
developed and made widely available, through commercialization, alliances or other
methods.
Policies that encourage alliance building between the public and private sector have
been particularly successful in bringing innovation to market.
Product development partnerships (PDPs) facilitate and accelerate the flow of public
and philanthropic investment through the innovation pipeline. The ultimate measure
of success is not maximum profit but maximum social benefit.

Key Implications and Best Practices: SETCION 12

FOR GOVERNMENT POLICYMAKERS

In addition to the IP legislative and capacity framework, other determinants of
innovation need to be addressed by governments to ensure a vibrant and innovative
technology industry. In agricultural biotechnology in particular, many current regulatory
approaches and frameworks significantly increase regulatory costs, causing years and
years of delays. The result often is that only multinational companies can afford to
introduce new technologies, thus stifling national innovation significantly.
Negotiating between public and private sectors ought not be confrontational and
should be seen as an opportunity to forge a long-lasting and mutually beneficial
relationship. Put differently, negotiating a fair licensing agreement should not be seen
just as a process of “bargaining” toward a win-win outcome.
For the private sector party, a well-tested and successful approach to negotiating an
agreement is to offer initial terms that the public sector organization would be willing
to agree to if it were on the other side of the negotiating table.
Negotiation and technology marketing skills are fundamental for successful licensing
and technology transfer. People working in the public sector need to be well qualified
and have strong negotiating skills, thereby enabling institutions to take advantage of
their own R&D efforts and to realize broad public sector and commercial goals.
Policies and legislation that are beneficial to small biotechnology companies and
startups, in general, can be instrumental in accelerating the pace of innovation in
a country, particularly when it comes to commercializing public sector–generated
inventions.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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FOR SENIOR MANAGEMENT
(University President, R&D Manager, etc.)
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For private sector companies, the ultimate purpose of IP management is to enhance
competitiveness and reduce risk. For public sector institutions, the ultimate purpose of IP
management is to serve the greater public interest. These are not mutually exclusive goals,
and they can be reconciled through sound technology marketing and licensing practices.
The four characteristics of an alliance that generally define the allocation of value
between an originator and a commercial partner are (1) its stage of development, (2) the
role retained by the licensor in product supply or other ongoing activities, (3) the size of
the market opportunity, and (4) the scope of the market granted to the development
partner under the alliance agreement.
The key to successful negotiation is having a clear understanding of the value each
party brings to a relationship. Value may be objective and quantitative, or of a more
qualitative nature.
Perhaps the most important element in a negotiation is clear communication—also
internally—with the negotiating partner about the benefits that will or could be
obtained through a license agreement.
In general, the public sector organization should consider offering the first draft
of an agreement to cover a number of topics of particular concern to public sector
organizations that would probably not be addressed by a company.
Negotiating between public and private sectors ought not be confrontational and
should be seen as an opportunity to forge a long-lasting and mutually beneficial
relationship. Put differently, negotiating a fair licensing agreement should not be seen
just as a process of “bargaining” toward a win-win outcome.
For the private sector party, a well-tested and successful approach to negotiating an
agreement is to offer initial terms that the public sector organization would be willing
to agree to if it were on the other side of the negotiating table.
Specific best practices and terms that allow public sector entities to meet public sector
goals (ensuring broad access to innovation) include area of use, territory, price, labeling,
white-knight conditions, and royalties.
Senior management can set a positive tone for negotiation that will ensure that deals
made with others are a vehicle for building strong relations and trust between parties.
Integrated IP management (IPM) considers the critical role of IP management throughout
the entire innovation life cycle. IPM allows managers to intervene, change course, amend
or enhance patent applications, and in-license useful patents or technologies.
Networking is important, if not essential, for successful technology marketing.Technology
transfer officers and scientists particularly should be encouraged to network.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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The “unique selling proposition” of your technology—in other words, the features,
advantages, or benefits it offers—is probably not the science behind the technology.
The science behind an invention is usually not its selling point.
Technology marketing is a process by which owners of a technology create relationships,
between themselves and potential users, that will enable the technology to be
developed and made widely available, through commercialization or other methods.
Negotiating between public and private sectors ought not be confrontational and
should be seen as an opportunity to forge a long-lasting and mutually beneficial
relationship. Put differently, negotiating a fair licensing agreement should not be seen
just as a process of “bargaining” toward a win-win outcome.

Key Implications and Best Practices: SETCION 12

FOR SCIENTISTS

You should think about the practical applications of your inventions. Or dream about
them! And share your ideas about what applications you think your invention might
have. Good marketing makes a technology understandable and attractive to buyers.
As much as your science may be interesting and fascinating, when you speak to potential
licensees or investors, it is often best not to place emphasis on the science. Rather, in
extremely simple language, stress the potential applications of your invention.
Remember to keep an eye on newly published patents and patent applications. They can
help inform R&D decisions and keep you abreast of the latest technical developments
in your field.
Collaborations create contacts. Contacts build networks. Networks provide
opportunities.
Your contacts and network can help your technology transfer office’s marketing
efforts. For example, private sector colleagues may facilitate licensing deals with their
organizations.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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One of your responsibilities will be to bring together individuals with different
backgrounds and experiences before negotiating agreements. Ideally, a team should
include business strategy, marketing, legal, scientific, regulatory, production, and
finance expertise.
Marketing inventions should not simply be a push of technologies; rather, it should be
an approach that allows the needs of buyers to pull inventions.
Marketing is not merely advertising or selling but a multistage process that addresses
the who, what, why, where and when of an invention.
Marketing inventions should use a systematic approach (which is fundamentally different
from product marketing). Particularly useful are portfolio approaches to marketing (also
called integrated intellectual property management which blends sophisticated IP data
search-and-analysis techniques with continuous product improvement).
Public sector institutions should pay particular attention to the following terms or
aspects of a license when negotiating with companies: exclusive versus nonexclusive;
enabling technologies versus traits versus plant materials; rights granted to the licensee
(covering topics such as sole licenses, coexclusive licenses, territoriality, duration, field
of use, and retained rights issues, as well as options or rights of first refusal, and
favored-nation clauses); grant-back clauses; compensation due to the licensor; liability,
diligence terms, and milestones; licensee’s responsibilities vis-à-vis the patent; license
term and termination; and issues of assignability.
Some people believe that licensors should stay away from conditions on final product
price because of its complexity; this is one reason why the public sector needs to
develop its skills.
You can help ensure that a licensee will fulfill the terms of the agreement if you require
milestone payments or certain reporting conditions when milestones are reached,
minimum annual royalties, or research funding-level commitments. It is particularly
important to ensure diligence for exclusive licenses.
There are three key ways that a license grant, either nonexclusive or exclusive, can be
limited or defined: territorial limitations, field-of-use limitations, and limits on duration.
Conduct comprehensive IP audits to determine where your IP assets are, when IP
protection is needed, whether there are potential IP liability issues, whether there are
licensing needs or opportunities, and whether there are inventions to be harvested.
The key implications and best practices listed for senior management are also pertinent
for TTO officers.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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The Public Sector and Entrepreneurship
Is it better to license a technology to a start up,
a spin-out, or an existing company? This is one
of the questions facing public sector technology
transfer offices (TTOs) around the world. There
is no simple answer. The choice can depend on
whether an entrepreneurial spirit characterizes
the institution that developed the technology.
The more entrepreneurial, the more likely the
institution will wish to set up a new company.
However, if an incubator infrastructure exists,
then a spinout becomes more feasible.
This section considers the benefits and risks
of dealing with spinouts by reviewing experiences, with continual reference to the situations
of developing countries. The associated factors of
venture capital, technology transfer intermediaries, and the formation of business incubators are
also discussed. Anyone engaged in dealing with
spinouts, venture capital companies, and incubators will want to read the entire section; it covers
a range of issues from licensing considerations, to
the use of milestones, to compensation, and offers plenty of elucidating analyses about realistic
expectations, based on a series of real examples
from the United States and the United Kingdom.
All of these chapters show in one way or another
that while there is certainly an “art” to entrepreneurship, reliable recipes are available.
Brown and Soderstrom1 present the rationale for, and a comprehensive practical overview
of, the creation of university spinout companies.

Based on the successful experiences of Yale
University, the authors advocate a hands-on approach, through which the university actively and
directly manages the creation of new companies
and invests in the human and physical resources
needed for their success. Such an approach may
provide a greater chance for success than licensing the university’s technology to a start-up company, which would likely be completely separate
from the university. The approach of establishing
and licensing to a spinout does, however, introduce a number of significant risks. Brown and
Soderstrom identify these risks and demonstrate
how each of them can be mitigated in order to
increase the potential for success.
The strategy of creating university spinouts,
as opposed to simply licensing technologies to existing companies, is particularly likely to appeal
to universities in developing countries for several
reasons. Licensing is often the “preferred” option
for university technology transfer. Simply because it is less complex, it requires an acceptable
licensee who is both interested in and capable of
developing the technology. In many countries
where the biotechnology industry, for example,
is in the early stages of development and where
there is a smaller chance of finding an acceptable
licensee, creating a spinout may hold more promise. To the extent that the goal of commercializing
university technologies is to generate economic
growth, the creation of new companies can have

Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 2007.
13: Public Sector and Entrepreneurship. In Executive Guide to Intellectual Property Management in Health and Agricultural
Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA),
Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for
noncommercial purposes is permitted and encouraged.
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a greater impact close to home by generating jobs,
attracting additional investment, and facilitating
the growth of a biotechnology cluster. Because
universities and public sector research institutes
are often the giants of R&D within a developing
economy, they need to be relied upon as sources
for human capital and investment in entrepreneurship, since there may be no other sources.
Despite the promise spinouts may hold,
they may not always be appropriate. Garner and
Ternouth2 address the question of what realistic
expectations universities and research institutions
should have concerning the risks of investing institutional resources in creating and spinning out
new technology-based companies and they hold
almost opposite beliefs to those of Brown and
Soderstrom. The authors conclude that publicly
funded institutions should consider how best
to achieve their primary missions of delivering
social and economic benefits, and they caution
policymakers against exerting too much pressure
on their region’s universities to create new companies, because the process is difficult, consumes
limited institutional resources, and is risky. The
authors recommend that universities and research
institutions should, as a rule, favor licensing-out
to existing companies and third-party start-up
companies and get involved only in the higherrisk strategy of investing the institution’s own
time and resources to create a spinout with measured and informed caution.
The process of creating a spinout is essentially one of providing the right social/professional
environment, legal/financial framework, and resources for something new to grow and succeed
and—given the risks—to fail “gracefully” if need
be, without causing harm beyond the loss of opportunity and the initial investment. A very important element of creating spinout companies
is to channel the enthusiasm and commitment
of those who believe in the technology, want to
see it succeed, and aspire to a positive outcome
(for example, by providing products that improve
the wellbeing of under resourced populations).
Finally, a key point is to incubate a spinout long
enough to enable it to run once it is “out there.”
Pragmatic information about how organizations can transfer their intellectual property (IP)
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rights to a spinout company (normally through
a licensing agreement) and then convert the
intellectual property into products or services
for the public’s benefit can be found in the chapter by Sandelin.3 Based on three decades of experience at Stanford University, the chapter identifies some key issues related to negotiating such
transfers. These include:
• the general attitude toward spinouts held
by a public research organization’s senior
administration and governing board
• various licensing considerations
• the use of milestones
• the amount and kind of compensation
that should be received for licensing a
technology
The chapter provides guidance on how to
best reach a successful agreement. The definitions
of particular terms in a contract, such as infringement responsibilities, sublicensing, and warranties and indemnities, are all carefully considered.
In addition, the chapter covers conflict of interest
(COI) and conflict of commitment (COC) issues
that arise when employees of public research organizations become engaged in spinout companies. The authors provide clear examples to help
policymakers and administrators better deal with
the issues involved in a licensing agreement.
Governments everywhere are encouraging
public research organizations to use their inventories of IP rights to create spinouts. Successful
spinouts create new jobs, contribute to economic
development, and potentially grow into large
multinational corporations. TTOs are key players
in this effort, but they should balance the interests and mission of public research organizations
with the objectives of the spinout and the needs
of society.
One surprising way that public research institutions can more effectively use their intellectual
property is by attracting venture capital. Wyse4
advances the premise that, rather than venture
capital driving the creation of new companies,
it is the creation of new companies that attracts
venture capital. Research institutions and government policies are able to constructively influence
the creation of new companies. The chapter seeks

The Public Sector and Entrepreneurship

to inform those in public research institutions,
and government policymakers, about the role
that venture capital can, and does, play in technology-based entrepreneurship, and the types of
environments that can encourage entrepreneurship and thereby attract venture capital.
Venture capital is a specific sector of the financial industry that channels investment from
institutional and private investors, corporations,
pension funds, and government agencies into
venture funds that in turn invest in portfolios of
equity in new companies. The model essentially
spreads out and shares the technology risks involved in each of the individual companies. It
also seeks—to the extent possible—to reduce
the risks involved by specializing in a certain
field of technology where the venture fund’s
management has expert knowledge. Venture
capital may also be actively involved in the
management of the companies, participating on
the board and even providing business services.
In return for bearing and managing such risks,
venture capitalists expect to achieve sufficiently
high internal rates of return, typically between
20 and 40 percent.
The availability of financial capital is not,
generally, the limiting factor. In 2005, US$34
billion was invested in U.S. biotech companies
from all sources (Table 1) with nearly US$4 billion in investment capital coming from venture
capital. While venture capital is concentrated
geographically to a few locations, individuals and
institutions with interests in investing in growth
opportunities can be found worldwide—including in developing countries. The fundamentals of
success are straightforward: the formation of new
companies creates an environment that increases
their probability for success. Thus, the two essential pieces that need to be provided are:
1. Planting the “seeds” of new companies—
encouraging skilled people with new ideas
to develop those ideas.
2. Creating an environment favorable for entrepreneurship and success. Universities
and research institutes can plant the seeds,
while government policies can shape the
environment.

A favorable environment for creating and
growing new companies consists of an encouraging
business culture (one that rewards success and
treats failure as a learning opportunity), access to
intellectual capital (such as that flowing from universities), sufficient financial capital, and reliable
physical capital (facilities, laboratories, communications). All of these are enhanced if a region enjoys a low cost of living and a high quality of life.
While governments cannot legislate entrepreneurship, they can encourage it by providing a
favorable environment. Once enough companies
exist, they will themselves further transform the
environment, attracting or creating the skills and
capital that can develop into a technology cluster.
Ultimately, the practice of investing venture capital is a skill that can be imported to a region or
country, where it can be mastered by local investors. Wyse clearly implies that the next stage in the
growth of the venture capital industry will involve
spreading into new regions across the globe.
He also encourages the public sector to provide more funding for translational research, that
is, research that moves a technology or product
further up the value chain and closer to market,
thus reducing both the investment needed for
commercialization and the risk (Figure 1). The
point of the figure by Wyse is that knowledgebased biotech industries in agriculture require a
greater emphasis on translational research, compared to the pharma industry, to be able to attract the venture capital and corporate investment
necessary to commercialize new products and
technologies
It is also important to know what other forces
discourage or encourage the commercialization of
inventions. Cook5 focuses on the barriers created
by cultural differences between academic institutions and business. He contends that these barriers
can be overcome by motivated technology transfer
intermediaries. Inventors are usually creative, selfmotivated, flexible individuals, but this does not
mean that they naturally pursue the commercial
potential of their discoveries. Whether or not an
inventor ever shows his or her invention to the
outside world actually depends on two variables:
1. whether he/she wants to disclose it
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Table 1: Sources of Capital in the Biotech Industry
Total investments (US$, millions)
2005
2006 (1 Q to 3 Q)

Sources of capital

st

IPOa

Public

rd

819

567

4,194

3,032

2,376
5,565
3,518

1,817
12,241
3,186

1,114

303

Total capital

17,586

21,146

Partnering

17,268 (50%)

12,463 (37%)

Total

34,854

b

Follow-ons
c

PIPES
Debt
Private (venture capital)
Other

33,609

a. IPO – initial public offering: a private company files to have a portion of its shares sold to the public on a
regulated stock exchange, such as NASDAQ .
b. Follow-ons – When public companies sell additional shares on the stock exchange to raise additional cash.
c. PIPES – Private investments in public entities: the sale of public shares to private financial institutions that
may take public shares off the public market as a way for companies to raise cash.
Source: Wyse6

Figure 1: Commercializing Knowledge-Based Biotech Industries
in Agriculture and Pharmaceuticals
Agriculture requires much translational research.

Pharmaceuticals industry

Plant and animal agriculture

Healthcare
biotech

$

Agri-biotech

$

Venture capital

Venture capital

Translational
research

Fundamental knowledge
of human, animal,
and plant genomics
Public sector
investments

Private foundations

Source: Wyse7
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2. whether the environment in which the inventor operates encourages or discourages
disclosure
Much can be done to improve the environment surrounding an inventor. If an environment
promotes creativity and is receptive to invention
disclosure, it will not matter as much if an inventor has less self-confidence or is less of a risk taker.
The manager of an institution’s technology transfer effort should make every attempt to create an
environment that fosters disclosure.
On the other hand, new companies operate in a very different environment. They generally have no established market position, are
trying to convince potential investors that the
company will succeed, and are usually understaffed and under-resourced. Such companies
are most in need of effective leadership and of
professional technology transfer intermediaries
with the ability to translate a pioneering invention into a successful product. Such intermediaries should:
• understand the value systems that drive the
inventor and the market
• be fluent in the vocabulary in both situations, so they are able to translate while
retaining all linguistic nuances
• appreciate the various types of risks and
how to mitigate them
• be credible to inventors as well as investors
These same qualities are valuable for those
who are working to establish partnerships between
the public and private sectors of developed and
developing countries. Indentifying, motivating,
and retaining individuals with the capability to be
intermediaries should be an important element of
any effort to commercialize intellectual property.
The basic message of the chapter (along with the
other chapters in this section of the Handbook) state
that the role of the university is to channel its limited public resources into activities that create new
opportunities that can be taken up by the market,
but not to intentionally supplant or engage directly
in the market. This means leaving venture creation
to the market whenever possible. Indeed, most universities do not have sufficient professional resources
or experience to manage spinout companies.

This and other chapters explore when and
how universities can work with the market to
channel investments into high-risk, high-return
opportunities. This suggests a further question:
when and how might universities work with other
nonprofit and philanthropic funding sources to
create spinout product development partnerships
(PDPs) around high-risk, high-social-return opportunities? This is a question will be explored in
the future by leading universities that have begun
to master the process of spinning-out successful
for-profit companies.
A more methodical approach has been gaining popularity over the last 15 years: the creation
of business incubators as tools for stimulating
local economic development. The concept of an
incubator is simple and appealing: it provides a facility and services (for example, business planning
and legal, accounting, and marketing support) to
catalyze small business growth. Incubators have
proven very effective. Incubated companies have
a dramatically higher rate of survival than the
average spinout. Additionally, companies that
“graduate” from incubators provided an average
of 85 full-time jobs per incubator. Used to promote the growth of entrepreneurial ventures of
every imaginable type, small business incubation
is now entrenched in both urban and rural areas
throughout the United States.
Zablocki8 discusses in detail the six steps for
setting up and operating successful incubators:
1. Conducting a feasibility study. For a proposed incubator, such a study can achieve
a number of important objectives and, if
properly done, can provide a solid basis for
judging the economic and political viability
of the proposed project.
2. Identifying and securing stakeholders.
While each incubator’s circumstances are
unique, anticipated stakeholders would
likely include local and state governments
and a variety of public and private sector
organizations (universities, major corporations) interested in fostering new-business
development in the region. Stakeholders
might also include economic-development
organizations that could fund the rehabilitation of a facility or the operation of the
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6.

incubator program. The support of these
stakeholders is critical to initiating an incubator program.
Identifying a market niche. This requires
much attention to detail. Successful businesses carefully attend to the work of defining the market position of their products
and services relative to their competitors, as
well as to modifying their market position in
response to changing customer preferences.
The formation process. The basic structure of
an incubator facility is determined by owner
attributes and regional demographics (it could
be private, local-government led, or university
led or it could be a nonprofit company).
Services. As the incubator concept has
evolved, the range of services offered by
incubators has greatly expanded. Early incubators provided access to a photocopier
and a conference room, clerical support,
and perhaps switchboard services. Today,
incubators themselves provide, or provide
access to, a broad spectrum of office support, business consulting, and professional
services. Business consulting services may
include business-plan preparation, financial planning, advertising and marketing,
strategic planning, technical and commercial communications, relocation planning,
capital development (equity and debt services), business taxes, employee relations,
R&D, and government procurement.
Strategic Planning. Strategic planning compels incubator management to confront
tough issues. How will the incubator continue to operate if revenue projections from
rental income are not achieved? How will
major facility repairs (for example, a ruptured boiler) be paid for? Addressing these
worst-case scenarios through strategic planning can provide both a clear course of action if things go as planned and, if they do
not, the necessary contingency plans to navigate what may be a difficult beginning.

Economic development programs for small
businesses proliferated in the 1980s. These programs have been referred to as incubators without
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walls. Well-managed incubators often distinguish
themselves by serving as a focal point for access
to the broad spectrum of available business services. Incubator managers thus provide the point
of contact for entry into various programs. Many
efforts to assist small business are, by contrast,
programmatic in nature and limited by the scope
of their intent. A well-positioned incubator, on
the other hand, will help its tenants to access the
range of existing programs and, in addition, provide access to informal networks for business and
financial advice and assistance. For example, a retired executive may agree to help out a struggling
firm, or a business angel may appear, discretely
looking for new investment opportunities.
Successful incubator programs are marked
by foresight, focus, and leadership. Successful
incubator programs also know how to identify,
organize, and maximize talent and resources,
making the most of community support and entrepreneurial networks. A core group committed
to starting a business incubator must recognize
that its efforts cannot be pursued in a vacuum. As
Zablocki puts it: “The dream of a few must become
the dream of many.” n
All chapters refer to: Intellectual Property Management in
Health and Agricultural Innovation: A Handbook of Best
Practices. 2007. A Krattiger, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez,
and SP Kowalski (eds.). MIHR: Oxford, U.K., and PIPRA: Davis,
U.S.A. Available online at www.ipHandbook.org. The online
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Much of the success of a spinout or start-up will depend on the entrepreneurial spirit
at the institution. The more entrepreneurial, the more likely it will be that someone
wants to set up a new company.
Governments should encourage public research organizations to use their inventories
of IP rights to create spinouts because they create new jobs, contribute to economic
development, and potentially grow into multinational companies. But governments
should recognize that setting up a new business is a high-risk activity and should allow
new companies to fail gracefully.
Rather than venture capital driving the creation of new companies, it is usually the
creation of new companies that attracts venture capital.

Key Implications and Best Practices: SETCION 13

FOR GOVERNMENT POLICYMAKERS

The formation of new companies creates an environment that increases the probability of success for other companies. Thus, the public sector should (1) plant the seed,
encouraging skilled people with new ideas to develop those ideas and (2) create an
environment that favors entrepreneurship and success. Universities and research institutes can plant the seeds, while government policies can shape the environment.
While a government cannot legislate entrepreneurship, it can encourage entrepreneurship by providing a favorable environment for creating and growing new companies.
This would be an environment with (1) an encouraging business culture that rewards
success and treats failure as a learning opportunity, (2) access to intellectual capital
(such as that flowing from universities), (3) access to sufficient financial capital, and (4)
reliable physical capital (facilities, laboratories, communications).
Public sector institutions may be the largest economic entities present in a developing
country. Hence, they can contribute much by taking the lead in developing and fostering the establishment of spinout companies that are seeded with technologies generated in the public sector and protected and managed as IP assets.
To successfully commercialize intellectual property, a country ought to have a stable
economic and institutional environment, available investment capital, commercializable intellectual property, a commercial environment that can develop intellectual
property, and competent technology transfer intermediaries.
Technology transfer of any sort is likely to succeed only if there is sustained commitment at the most senior levels of both government and research institutions.
Governments can encourage regional economic development by fostering and financing business incubators. Ideally, they ought to be located in strategically selected regions and build on potential synergies of existing institutions. Small business incubators in particular have proven to be effective economic development tools.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.

HANDBOOK OF BEST PRACTICES: EXECUTIVE GUIDE | 149

Key Implications and Best Practices: SECTION 13

GUIDE TO SECTION 13

FOR SENIOR MANAGEMENT
(University President, R&D Manager, etc.)
4

4

4

4

4

4

4

4

4

4

4

Experts are divided as to what approach should be taken by public institutions with
regard to creating companies. Some advocate a “hands-on” approach in which the institution actively and directly manages the creation of companies and invests in the
resources needed for their success. Others argue that the university should channel its
resources into activities that may result in marketable technologies, but not engage
directly in marketing activities.
The creation of business incubators as a tool for stimulating local economic development should not be underestimated. Incubated companies have a dramatically higher
rate of survival than the average spinouts.
Spinouts often create enhanced opportunities for its faculty. If spinouts remain in the
region, faculty inventors can remain active as consultants. Also, a university’s success
with spinouts can attract new talent.
Much of the success of a spinout or start-up will depend on the entrepreneurial spirit
at the institution. The more entrepreneurial, the more likely it will be that someone
wants to set up a new company.
The formation of new companies creates an environment that increases the probability of success for other companies. Thus, the public sector should (1) plant the seed,
encouraging skilled people with new ideas to develop those ideas and (2) create an
environment that favors entrepreneurship and success. Universities and research institutes can plant the seeds, while government policies can shape the environment.
When engaging in entrepreneurial activities, risks to the university include potential
impact on tax-exempt status, liabilities for the actions of the company, conflicts of interest and/or commitment, and conflicts with the university’s mission.
To be an effective entrepreneurial university, representatives of senior administration
should routinely review company-founding and business-maintenance activities.
Clear policies are needed for disposing of equity in spinout companies, both for the
sake of the university’s integrity—to prevent conflicts of interest—and for the sake of
the company—to prevent the university’s divestment from sending a damaging signal
to the market about the value of the company or its technology.
To demonstrate the importance of technology transfer, the TTO should generally report directly to upper-level administration.
In order to attract venture capital in agriculture, public sector institutions need to take
steps to reduce the risk of investing in agricultural projects.
Rather than venture capital driving the creation of new companies, it is usually the
creation of new companies that attracts venture capital.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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Not all university inventors are entrepreneurs nor are they interested in being company
founders, and not all spinout company founders from a university are the technology’s
inventors.
While inventors are treated equally under university patenting and licensing policies,
involvement as a company founder entails a greater degree of risk and commitment
to move an invention to commercialization. You may be valuable as an active partner
of a spinout company to prevent the repetition of unsuccessful experiments (blind alleys) and to add needed creativity with respect to problem solving as development and
commercialization proceeds.

Key Implications and Best Practices: SETCION 13

FOR SCIENTISTS

Participation in a spinout can be a particularly rewarding experience, financially as well
as personally, as it involves the practical application of your ideas.
Venture capital investors combine a broad view of the market with solid technical expertise. You will need to be prepared to convince investors not so much of the technical
merits of your research, but of how your ideas lead to economic returns.
Rather than venture capital driving the creation of new companies, it is usually the
creation of new companies that attracts venture capital.
Venture capital investors can be great allies, but will impose, for good reasons, distinct
conditions on the project. Be open, patient, and willing to work with investors.
Much of the success of a spinout or start-up will depend on the entrepreneurial spirit
at the institution. The more entrepreneurial, the more likely it will be that someone
wants to set up a new company.
There are many factors that determine the feasibility and success of a spinout company. The technology’s intrinsic value and your commitment to your invention are only
part of the picture. If you can find an existing partner with market penetration, the
chances of success increase. If you are still convinced, even after failing several times
to find a willing licensee for your technology, then it may be time to consider creating
a company. As these matters arise, seek the guidance of your institution’s technology
transfer office.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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Spinouts carry a number of risks, but with certain factors in place they can represent
the best opportunity for developing early-stage technology. This is particularly true because the inventor, and other university participants, will have a vested interest in, and
commitment to, the success of that technology.
Potential investors in a spinout will ask two major IP questions. Could previously existing intellectual property block the technology? Could your intellectual property
dominate the market and prevent entry by others? Other key questions involve the
characteristics of the market opportunity and the financial bottom line of revenue and
expense projections over the life of the technology.
Solid, long-term support from your institution will be required to: (1) operate the technology transfer office efficiently, so that it can evaluate invention disclosures, obtain
IP protection when appropriate, coordinate the search for people or companies that
will develop the invention into products and services, and negotiate and prepare the
necessary legal agreements (for example, license agreements for IP rights); (2) cover the
costs of obtaining IP rights; and (3) provide funding to convert good ideas into working
prototypes. (A good idea not put into use is wasted.)
Your job is complex and challenging because you have to balance the needs and expectations of many parties with divergent interests: Remain responsive to such needs
and interests; keep people informed of progress and developments; effectively utilize
available resources.
When licensing to or creating new ventures, several key attributes are essential for attracting venture capital investment: a strong management team, a viable technology,
a strong IP position, a large potential market, and location in an environment favorable
for entrepreneurship.
New ventures in developing countries have much to gain by attracting and building
on international investor networks. They have the potential to open new markets and
bring in new alliances.
Much of the success of a spinout or start-up will depend on the entrepreneurial spirit
at the institution. The more entrepreneurial, the more likely it will be that someone
wants to set up a new company.
It is necessary to strike a balance between reliance on licensing-out to existing companies and investing time and resources in creating new companies.
Rather than venture capital driving the creation of new companies, it is usually the
creation of new companies that attracts venture capital.
When creating spinout companies, always remain focused on your institution’s primary mission, such that the spinout will be consistent with, and even serve, that public
sector mission.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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Freedom to Operate and Risk Management
Freedom to operate (FTO), a simple and straightforward concept, means that for a given product
or service, at a given point in time, with respect
to a given market or geography, no intellectual
property (IP) from any third party is infringed.
But to translate this concept into a productive
strategy for companies and for public sector institutions alike is not so straightforward.
For public sector organizations, the opportunities presented by incorporating FTO considerations into product development strategies are
numerous. These may include benefits through
higher competitive intelligence, the ability to
bring about culture change, and the forging of
strong partnerships with providers of intellectual
property and technology. An FTO strategy, therefore, is a plan that begins with research into the
IP landscape of a potential product and evolves
into an attitude through a product’s R&D and
commercialization/distribution cycle. Krattiger
discusses these policy and strategy elements in
detail.1 It is useful, however, to first consider how
FTO analyses are conducted before reviewing the
principal FTO strategies.
At the beginning of a research project, a company would typically consider scientific feasibility, the effect of the research on the organization’s
business position (whether or not the research
and the product would eventually strengthen its
competitive position), the project’s impact on
financial status in terms of costs and potential

rewards, and legal aspects (such as infringement
risks). That is where an FTO analysis comes in
as an initial, cursory, or quite possibly detailed,
overview of the patent landscape and competitors’ positions. Hence an FTO analysis need not
be a costly legal FTO opinion (note that an FTO
opinion is rendered by patent counsel whereas an
FTO review can have any level of legal review,
or none). Rather, an FTO analysis is an assessment of the set of patents and other IP rights that
are or would be connected to the product and/or
method under consideration. Kowalski2 outlines
in detail how different levels of FTO analyses
are conducted in practice. Addressing scientists,
business people, and legal staff, he describes how
products and/or methods are broken down into
fundamental components, processes, and combinations thereof, and then how each component is
carefully analyzed for attached IP rights of third
parties. An FTO analysis, irrespective of the level
of detail, requires good preparation, systematic
review, and rigorous record keeping.
Although FTO is often viewed as simply a
legal issue, when approached from a more practical product-development perspective, FTO is
a strategic risk-management tool; it relies on a
synthesis of scientific and legal expertise, business
development, and strategic planning. FTO for
a given product in a given market is difficult to
achieve because it can never conclusively be established. Obtaining FTO, therefore, becomes a

Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez, and SP Kowalski. 2007.
14: Freedom to Operate and Risk Management. In Executive Guide to Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis,
USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA).
Available online at www.ipHandbook.org.
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for
noncommercial purposes is permitted and encouraged.
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strategy, or even a position, mindset, or culture.
This is because the patent landscape is dynamic:
new patents issue; old patents expire; some patents are abandoned. Therefore, freedom to operate
does not imply absolute freedom from the risk
of infringing another party’s intellectual property.
Whether or not FTO exists is an assessment based
on the analysis and knowledge of IP landscapes
for a given product, in a given jurisdiction, at a
given point in time. This statement underscores
a critically important principle: there can be no
risk-free decision.
FTO is thus a concern that remains throughout the R&D process, to commercialization and
even afterward. By setting a goal of having reasonable FTO, a set of ten FTO strategies for managing potential IP infringement are proposed and
discussed in detail by Krattiger in Chapter 14.1
(Table 1). In practice, typically two or more of
these strategies will be adopted, with the specific
mix of strategies varying. Which strategies will
be appropriate depend on, for example, how advanced the product is, the type of organization
that develops the product, and relevant market
dynamics. And not all of the listed strategies are
feasible for public sector institutions.
How much attention should a public sector organization give to FTO? Since some public sector research is not directly intended for
commercial use, the answer is sometimes quite
simple: Not much. This condition certainly
applies to a great deal of university research.
However, if the project is specifically aimed at
product development, a goal that is becoming
more prevalent in the public sector, then FTO
becomes a concern. For example, through collaborations with product-development partnerships (PDPs), the primary reason for funding
the research is to develop products to help the
poor. Such is the case also for the research centers of the Consultative Group on International
Agricultural Research (CGIAR) and for many
national agricultural research systems (NARS).
Universities, too, are shifting their research focus; some manage their innovations in novel
ways and aim to bundle technologies and intellectual property in order to license “solutions”
rather than individual patents.
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A relevant example of the importance of
the public sector managing FTO is the development of Golden Rice.4 No attention was given to
FTO until the first material was nearly ready for
transfer to developing countries. The Rockefeller
Foundation then commissioned an FTO analysis
that demonstrated, first of all, how many inventions from scientists around the world enabled—
or accelerated—the development of Golden
Rice. Although a large number of patents—and
patent applications—were identified, the FTO
analysis also demonstrated that licenses to only
a few would be required for the transfer to and
use of Golden Rice in developing countries. The
FTO analysis provided a list of primary owners of patents (and of materials that went into
Golden Rice under material transfer agreements)
for which licenses were needed. With the leadership of the Rockefeller Foundation and Syngenta,
a large agro-chemical company headquartered in
Switzerland, the relevant intellectual property was
quickly assembled (or in-licensed) into a package.
That package then was licensed, essentially royalty-free, to public sector institutions in developing countries. This approach, in essence, represents the various aspects of FTO, from analysis to
strategy, to action.
Each of the ten strategic approaches to
obtain FTO listed in Table 1 presents certain
risks and opportunities. Any action—including the decision not to take action—carries risk.
Delaying the licensing of third-party intellectual
property, for example, could lead eventually to
expensive licensing terms, the inability to obtain
a license, or the possibility of being sued for patent infringement. For some organizations, such
as those developing genetically modified crops
(GMOs), the opposite may be the case (where it
might be advantageous to delay in-licensing) due
to stewardship issues that are the main concern
with biotechnology crops. Krattiger concludes his
discussion, in Chapter 14.1, by urging the public
sector to:
• judiciously evaluate whether and when
FTO concerns should be considered
• build in-house capacity to conduct patent
searches and cursory FTO analyses (as opposed to legal opinions)

FREEDOM TO OPERATE AND RISK MANAGEMENT

Table 1: The Ten Strategic FTO Options
Option

Pros

Cons

Legal/IP Management Strategies
1. License-in

Is relatively
straightforward

May not foster in-house R&D
initiatives and may be costly

2. Cross-license

Involves give and take

In certain cases, antitrust issues
may arise

3. Oppose thirdparty patents

Can be cost effective

Can be expensive and result might
be undesirable (stronger or
broader patent)

4

Is cheap and effective

Rarely allows for the in-licensing of
valuable know-how

Allowed under TRIPS under
certain circumstances

Will not allow for the in-licensing
of know-how and brings many
constraints and complexities with it

6. Modify product

Can be fairly simple if planned early
in R&D stage

May not be possible due to lack of
readily available alternatives; incurs
opportunity costs

7. Invent around

Could lead to cross-licensing
position

Could lead to delays in product
launch and might be costly; incurs
opportunity costs

8. Wait and see

Gives time for strategic
positioning

Could lead to litigation and
jeopardize investment already made

9 Abandon project

Is simple and effective

May be costly (need to write off
R&D investments already made;
incurs opportunity costs)

10. Merger/
Acquisition

Is highly effective

May distract from main
business focus

Seek
nonassertion
covenant

5. Seek compulsory
license

R&D Strategies

Business Strategies

In Practice

A combination of several options implemented concurrently

Source: Krattiger, 2007.3 The original table in Chapter 14.1 also includes a column listing the key challenges for
the public sector for each of the ten strategies.
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One of the underlying “technologies” for
conducting an FTO analysis is the patent search.
Such searches are also relevant when an institution is deciding whether to file a patent on a
new invention (meaning when one is searching
for prior art) or when scientists want to review
patent literature. Fortunately, many IP search
tools are accessible online at no cost. The chapter by Thangaraj, Potter, and Krattiger5 provides
a “guided tour” of online patent search engines,
including a description of the major ones:
• the European Patent Office (EPO’s esp@
cenet)
• the U.S. Patent and Trademark Office (PTO)
• the Patent Cooperation Treaty (PCT) Web
interfaces of the World Intellectual Property
Organization (WIPO)
In addition, the chapter reviews subscription-based services and other paid services, such as
Delphion and Derwent World Patent Index (DWPI).
Although the discussion is by no means exhaustive,
the chapter lists links to many useful sites.
The chapter by Fenton, Chi-Ham, and
Boetiger6 provides an examination of how the
private sector thinks about FTO. Offering a
comprehensive overview of the FTO process, the
chapter sheds light on when to invest in FTO
analysis and highlights the important role played
by law firms in obtaining FTO. As mentioned
earlier, for the public sector the strategic relevance
of FTO is quite different from that of the private
sector. Even when the public sector intends to
commercialize products, its mission and goals
differ from those of the private sector, and deciding when to pursue FTO becomes a very different
question. Nonetheless, given the growing number of public-private partnerships, it is important
for the public sector to understand how private
companies approach FTO issues. This chapter
discusses both private- and public-sector considerations for deciding whether, when, and how an
FTO analysis should be conducted.
FTO analysis defines options; it provides
a map of the relevant IP landscape. Hence, an
FTO analysis presents the most viable options
for achieving institutional goals. Fenton and
colleagues conclude their discussion with a case
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study of an FTO analysis initiated by the Public
Intellectual Property Resource for Agriculture
(PIPRA). The case study explains the process used
by PIPRA, from defining the scope of the investigation, to the delivery of the findings.
In the last chapter of Section 14, Boadi7
looks at the aspect of FTO that includes legal liabilities beyond intellectual property and, appropriately, considers stewardship as the central tool
to managing liabilities. The legal framework for
dealing with liability relies on the country, or legal jurisdiction, in which the intellectual property
is being exploited. Even so, GMOs (and indeed
non-GMOs) have the potential to cross national borders. This has led to intense debate about
whether a liability regime specific to such organisms and crops should be created. Providing an
overview of current common law and statutory
theories of liability, the chapter considers liability
issues facing public sector efforts to develop and
disseminate agricultural biotechnologies.
While debate rages about liability and redress issues contained in the Cartagena Protocol
on Biosafety, developing countries need to think
carefully about how to manage liability today.
Referencing the African Agricultural Technology
Foundation (AATF), Boadi provides several liability-management practices that can be of great
value, including:
• ensuring compliance with intellectual property, license, and regulatory requirements
• including indemnification provisions in
technology transfer agreements
• using warranty disclaimers
• obtaining letters of nonassertion
• adhering to appropriate technology stewardship best practices
Already, innovative developing countries (or
IDCs), including India, Korea, China, Brazil,
South Africa, and others are embracing novel
opportunities provided by the new global IP
regime. Having established technology transfer offices (TTOs) for organizations in both the
public and private sectors, these countries have
overseen the controlled, streamlined transfer of
crucial technologies, often with clear public benefits. Such efforts, of course, require investments
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in both infrastructure and personnel to in-license, out-license, and ensure that investments
in product development are accelerated through
appropriate FTO considerations during the R&D
process and beyond. n
All chapters refer to: Intellectual Property Management in
Health and Agricultural Innovation: A Handbook of Best
Practices. 2007. A Krattiger, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez,
and SP Kowalski (eds.). MIHR: Oxford, U.K., and PIPRA: Davis,
U.S.A. Available online at www.ipHandbook.org. The online
version contains for each chapter a detailed Editor’s Summary, Implications, and Best Practices.
1

Chapter 14.1 by A Krattiger titled Freedom to Operate,
Public Sector Research and Product-Development
Partnerships: Strategies and Risk-Management Options,
p. 1317.

2

Chapter 14.2 by SP Kowalski titled Freedom to Operate:
The Preparations, p. 1329.

3

See supra note 1.

4

See Case Study 3 by A Krattiger and I Potrykus titled
Intellectual Property Management and Freedom to
Operate for Golden Rice in the insert of this Executive
Guide, p. 11-14.

5

Chapter 14.3 by H Thangaraj, RH Potter, and A Krattiger
titled How and Where to Search for IP Information on
the World Wide Web: The “Tricks of the Trade” and an
Annotated Listing of Web Resources, p. 1345.

6

Chapter 14.4 by GM Fenton, CA Chi-Ham and S Boetiger
titled Freedom to Operate: The Law Firm’s Approach
and Role, p. 1363.

7

Chapter 14.5 by RY Boadi titled Managing Liability
Associated with Genetically Modified Crops, p. 1385.
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As intellectual property becomes more prevalent in health and agricultural research,
public and not-for-profit institutions may increasingly need to consider the intellectual
property of third parties. This may allow for efficient in-licensing of intellectual
property and accelerate the development of products. For such purposes, a good
knowledge of “who owns what” is needed. That is what a freedom to operate (FTO)
analysis provides.
Translating an FTO analysis into an effective strategy requires some shifts in culture
and thinking by those public sector institutions that are engaged in the development
of products. Although a legal opinion by an attorney may be based on a solid FTO
analysis, the use of such an analysis is strategic. National governments have a great
responsibility to encourage the establishment of best practices in IP management,
through sound national policies and funding allocations.
Taking FTO into consideration as one element of any product development strategy
allows for a more judicious use of resources that can often lead to stronger and more
effective partnerships, can increase opportunities for international collaboration, and
may underpin effective public-private partnerships.
Governmental policies and programs that support capacity building in IP management
should include the training of senior management in FTO strategies, including
institutional boards. A dialogue between boards, which are responsible for policy, and
senior managers that are more concerned with implementation is essential since
an FTO analysis is a risk-management tool. This approach increases efficiency in the
handling of products for further development and/or commercialization, even if the
goal is to address the needs of the poor.
High speed Internet access and patent databases are valuable tools that can assist
research-based institutions in the undertaking of meaningful patent and information
searches that are necessary to conduct FTO analyses.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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As public sector and nonprofit institutions increasingly move in the direction of
product development, whether they do so independently or in partnership with
other organizations, freedom to operate (FTO) will contribute increasingly to sound IP
management strategy. As such, an FTO analysis is a management tool for assessing and
managing certain types of risks.
Some public sector institutions need not be concerned with FTO. For example, a typical
university that mainly licenses patents or occasionally forms a spinout company can
leave FTO concerns to others.

Key Implications and Best Practices: SECTION 14

FOR SENIOR MANAGEMENT

Public sector research institutions should not necessarily assume that they are exempt
from IP infringement liability due to their nonprofit (or governmental or parastatal)
status. Although government institutions per se may be shielded from liabilities, FTO
rarely ends with these institutions. Eventually other institutions taking on the products
may need to be able to deal with FTO (such as commodity exporters). Hence FTO analysis
is just one tool for making the technology transfer process more effective, and FTO is
particularly warranted as an institution expands its mission into product development
and distribution.
FTO opinions do not eliminate risks related to third-party intellectual property. Instead,
they allow for the development of sound risk-management strategies (which may be of a
legal/licensing nature, involve business approaches, or be research based). Implementing
the strategy requires clear pathways of communication and dialogue between science
managers, product development, licensing personnel, and senior management.
Obtaining FTO includes the review of the patent landscape (FTO analysis) and may include
a formal legal FTO opinion. But, in essence, obtaining FTO is a process to be “managed”
as an interdisciplinary endeavor and considered within the context of the institution’s
overall mission (as such it involves senior management), business development, research
and technology transfer, and tolerance for risk.
Institutional policies that support capacity building in IP management should include
the training of senior management in FTO strategies, including institutional boards.
A dialogue between boards (responsible for policy) and senior management (more
concerned with implementation) is essential, since FTO analysis is a risk-management
tool.
Commitment to the principles of FTO will demonstrate that a given institution is
committed to respecting, and of building upon, the intellectual property of others.
The more downstream a research-based institution operates, the more important FTO
considerations become. A system should be in place to help decide whether, when, and
how a public sector institution should conduct an in-house FTO analysis or commission
a legal FTO opinion.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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Collaboration among scientists and the professionals who conduct freedom to operate
(FTO) analyses is essential. The scientist is the most important person to explain the
science behind technology, to help others understand the materials and the scientific
approach, and sometimes to explain what specific patent claims mean. A scientist
is the expert in his or her area of research and can provide important leads to other
scientific groups, publications, and terms of art.
Teams conducting FTO analyses will also need to understand precisely what the
product is, how it was developed, what materials were used, and what reports were
prepared. The purpose is not to check on the work, but to ascertain that all relevant
information has been considered in the FTO analysis. It is important also to know what
tangible property from a third party contributed to a product. A scientific member of
an FTO team will need to provide this type of basic information for the FTO analysis.
One of the best ways to manage that information is through careful record keeping,
including rigorously kept laboratory notebooks.
The results of an FTO analysis may allow you to make better use of technologies in
the public domain and inform your choice of research tools or vector constructs. The
analysis also may alert you to scientific discoveries and inventions related to your
work.
An FTO analysis is a foundation of IP management, but it is also something more. It
is a way to demonstrate to your colleagues that you respect their property rights and
understand that, when properly managed, intellectual property leads to the greater
sharing of technology and related information. In a very real sense, it is a way of
building relationships based on trust.
Both patent search engines and scientific search engines are available at no cost on the
Internet (such as the U.S. Patent and Trademark Web site and Google® Scholar).
Knowledge of how to access, manipulate, and mine these tools for valuable information
will serve you and your program well. Hence, you should encourage your staff to
become well versed in Internet database search skills, and do not hesitate to ask your
technology transfer office to organize short patent search workshops.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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The management of patent infringement risks requires a good knowledge of the
strategic options available. These options include legal/licensing, business strategies,
and R&D strategies.
Unlike at a private company, where business/legal/financial conditions often determine
R&D strategies, licensing officers in public sector institutions rarely influence
research projects and institutional policy. The role of the technology transfer officer
as communicator in the public sector is therefore much more important for bringing
about an IP management “culture” throughout the organization.
A freedom to operate (FTO) analysis is an interdisciplinary endeavor best executed
through FTO teams. These teams, made up of legal, business, and scientific
professionals, are in themselves useful for strengthening intra-institutional dialogue
and communications.
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FOR TECHNOLOGY TRANSFER OFFICERS

The role of the technology transfer officer, and that of attorneys who may produce legal
FTO opinions, is generally to advise senior management. It is a manager’s purview, based
on your input, to decide how to deal with the risks identified in your FTO analysis.
Much work leading to a legal FTO opinion can be done in-house, working with scientists,
technology transfer professionals, business people, and others. The role of patent
counsel is important for formal legal FTO opinions, but this expense may not often be
required or justified in public research settings.
Evaluate the pros and cons of free versus subscription-based patent search sites. Quite
often, free services are limited in content and scope and do not allow for myriad search
capabilities of paid services. But many free sites, such as WIPO’s PatentScope, are
increasingly adding extremely valuable features.
For an academic or public institution, legal FTO opinions are unlikely to be needed
for the majority of technology transfer functions. They might be applicable if the
institution is engaged in downstream product development and commercialization.
One way to cut costs is to conduct the background research for an FTO analysis inhouse. The compiled file of relevant art can then be provided to patent counsel, who
can then further analyze, conduct additional searching to fill in suspected gaps, and
render an FTO opinion. Universities with law schools might be able to give law students
valuable internships in this manner.
Through good licensing practices (including appropriate indemnification provisions
and warranty disclaimers), much of the risk associated with IP infringement can be
transferred to licensees who take over products from the public sector.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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Monitoring, Enforcement, and Resolving Disputes
Intellectual property is not a static asset. It is
dynamic, requiring ongoing attention and management practices that will allow an institution
to protect its value and maximize its utilization.
Treating intellectual property as such is a fundamental best practice, regardless of whether an institution is public or private, whether located in
a developed or developing country or whether its
mission is directed toward commercial or public
interests. Intellectual property, if it is to be an asset, cannot be simply be shelved and left alone,
or even licensed and then left alone. Intellectual
assets, with patents, as a particularly cogent example, must constantly be managed, monitored,
maintained, and policed as part of a continual
“cultivation” of IP rights.
The larger the IP portfolio, the greater the
likelihood that disputes of one sort or another will
arise. Few disputes end up in litigation, as there
are many options and strategies for resolving disputes. Particularly in the context of partnerships
between entities in developing and developed
countries, litigation would be a complicated, time
consuming, expensive, and risk-laden process.
As Part 7 on contracts and Part 11 on licensing
demonstrated, good contracts and good licensing
practices anticipate that disputes arise with partnerships and licenses. But the best way to avoid
disputes is to manage agreements in a manner that
leads to effective resolution of disputes.

Feindt1 details how the Office of Technology
Transfer (OTT) of the National Institutes of
Health (NIH) administers its technology licenses.
Licensing is an important part of NIH’s operation
and an important part of any technology transfer
endeavor anywhere. The portfolio of licenses at
OTT includes over 1,400 active technology licenses, 750 of which generate about US$100
million in revenues.2 These licenses represent five
types of technology licenses:
1. Commercial evaluation licenses (also
known as options), which enable companies to provisionally evaluate whether a
new technology suits their needs
2. Patent commercialization licenses, which
provide access to rights in patented or patent-pending technology. These licenses can
be either:
a. Exclusive, providing a single licensee
with the right to practice the patent
b. Nonexclusive, providing patent rights
to, potentially, multiple licensees
3. Nonexclusive patent licenses for internal
use, which provide access to tools or processes, useful for research purposes
4. Biological materials licenses, which provide
access to nonpatented biological materials
5. Software licenses, which provide access to
nonpatented software

Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 2007.
15: Monitoring, Enforcement, and Resolving Disputes. In Executive Guide to Intellectual Property Management in Health
and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). bioDevelopments-International Institute (Ithaca, USA), MIHR (Oxford, UK), PIPRA (Davis, USA), and Oswaldo Cruz Foundation (Fiocruz, Rio de
Janeiro, Brazil). Available online at www.ipHandbook.org.
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for
noncommercial purposes is permitted and encouraged.
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Although the above licenses differ as to the
types of technology licensed, the specific terms
of the license, and the reporting obligations, one
aspect remains consistent: every license is written
with well-defined financial terms and clearly delineated reporting obligations.
As a licensor, the NIH OTT administers,
monitors, and enforces its technology licenses. It
accomplishes this by monitoring licensee compliance with royalty payments and reporting obligations throughout the term of the license. Typically
this is not a confrontational relationship. Instead,
the NIH OTT seeks to build cooperative relationships with its licensees that, in turn, facilitate
problem-solving discussions, resolve outstanding
issues, and identify possible opportunities for advancing commercialization of products and/or
services pursuant to the technology license.
In practical terms, OTT maintains licensee
contact lists (people within the licensee organization) as they are important when royalty payments or issues of noncompliance need to be addressed. Such a list, and a certain level of personal
rapport, greatly facilitate communication and
save much time. Another essential operational
procedure is maintenance of a well-organized filing system, possibly with archival, working, and
computer files. A computer filing system can be
structured as a searchable database for license administration, with integrated interactive modules
organizing data on contracts, inventions, patents and license applications, royalties, receipts,
and reporting. (Such a database is available for
download free of charge from the online version
of the Handbook.)3 Many of the best practices
listed and discussed by Feindt relate to licensees’
reporting obligations, to amendments to license
agreements, and to sanctions for noncompliance.
Amendments reflect mutually agreeable changes
in the expectations of licensor and licensee that
occur with the passage of time and changing circumstances; they might involve term extensions,
royalty adjustments, or changes in the field of
use. Sanctions, on the other hand, are unilateral
actions by the licensor that are triggered by licensee noncompliance (and may include a threat of
license termination and even legal action in order
to enforce lapsed financial obligations).
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A different type of dispute is that of patent
infringement. Patent infringement is, at least
conceptually, analogous to trespass in that it is
an invasion and/or misappropriation of another
party’s exclusive property right. Hence, identifying and taking action to remedy infringement is an essential part of IP asset management. There are four main categories of patent
infringement:
1. Literal infringement, in which each and every element of a patent claim is found in
the alleged infringing product or process
2. Doctrine of equivalents infringement, in
which the alleged infringing product or
process is substantially the same as the patented product or process
3. Contributory infringement, in which a party
contributes to infringement of a patent by
selling a component that has no use other
than as part of a patented product
4. Inducement to infringement, in which a
party actively and knowingly aids and abets
another who is directly infringing a patent
Maintaining the integrity and value of public sector intellectual property is, as Haeussler4
points out, a strategic process, which will vary
somewhat depending on the category of infringement. First, it is important for a patent applicant,
public or private, to consider claim structure and
scope when drafting and filing patent applications. Unless the claims of a patent are sufficiently
broad so as to confer clear economic potential,
prospective licensees will be reluctant to enter
into commercialization agreements or partnerships. Second, it is important to stay vigilant,
establishing surveillance protocols for possible
infringement of patents. For example, inventors should be contacted, on a regular basis, and
asked if they know of anyone who is, or might be,
infringing their patents; in addition, technology
transfer staff members should regularly review
key media related to the technology in order to
watch for potential infringers. Surveillance is not
only sound business practice but is essential for
maintaining and preserving patent rights. For example, lack of enforcement can lead to a loss of
patent rights.5

Monitoring, Enforcement, and Resolving Disputes

Patent infringement can also lead to a lawsuit. And litigation is expensive, risky, uncertain
and often protracted. With good negotiation, a
settlement through modified license terms often
can be amicably reached. If litigation becomes
inevitable, then a series of questions need to be
addressed including whether to use in-house or
external counsel, whether to file suit based on
patent infringement or breach of contract, and
where to file the lawsuit. Importantly, credible communication that the IP owner is serious
about protecting its IP assets will go a long way
to bringing infringers to the table to discuss the
issues and to negotiate. Haeussler concludes that
early communication with potential infringers,
and good license and licensee diligence, are the
foundations for policing and maintaining intellectual property, irrespective of whether the intellectual property is owned by a public or a private
entity. Feindt, in his chapter, illustrates the importance of early communication with infringers
using examples from NIH.
Due to the costs—and risks—associated with
litigation, alternative dispute resolution procedures, such as mediation and arbitration, should
under many scenarios be attempted first. These
forms of dispute resolution do not work through
formal legal systems, but are instead set up by the
parties involved. They are established by dispute
resolution clauses articulated when a partnership
is set up or a license granted—before any problems have arisen. The goal is to have an already
agreed-upon system when difficulties arise.
There are several elements unique to arbitration and mediation that can help parties resolve
disputes as Min discusses in detail.6 Figure 1
shows the two processes side-by-side. For arbitration, the parties have the power to decide on
the number of arbitrators, the type of arbitration
(ad hoc or institutional), the place of arbitration,
the language of arbitral proceedings, and the applicable substantive law. Unlike judges, whose
powers are defined by national laws, an arbitral
tribunal’s powers are limited to those conferred
by the parties. Mediation involves the same kinds
of choices, although unlike a judge or an arbitrator, whose mandate is to issue a binding decision
or award, a mediator does not have the power to

impose a settlement on the parties. Instead, the
mediator serves as a catalyst for party negotiations. The advantages of arbitration and mediation include the following:
• Through arbitration or mediation, the parties can, using a single procedure, resolve
disputes involving intellectual property in a
number of countries.
• In both arbitration and mediation, parties
may resolve a transnational dispute on neutral territory.
• Arbitration and mediation are based on the
consent of the parties.
• Parties can select arbitrators or mediators.
• Parties to arbitration or mediation can
keep the proceedings and any results
confidential.
• The protracted nature of litigation, which
pushes parties into multiple rounds of appeals, is a common problem when litigating
transnational disputes. The end result of arbitration, however, is a final, binding award.
• The mediator’s role is to broaden dispute
resolution options, allowing the parties,
with the help of the mediator, to craft innovative, common-sense solutions that
(preferably amicably) settle the dispute.
• Mediation involves low risk. If a party feels
that it is not making any progress, that the
procedure is becoming too costly, or that
the other party is not acting in good faith,
the party may withdraw from a mediation
process at any time and seek to resolve the
dispute through litigation or arbitration.
Min provides a list of the kinds of concerns
addressed by dispute-resolution clauses. She also
highlights the usefulness of arbitration and mediation for developing countries, but public sector entities in many parts of the world will find
the discussion, and these tools, useful. Such entities often lack the resources to pursue extended
litigation, a process that also frequently places
them on unfamiliar cultural and legal ground.
By formulating dispute resolution policies, institutions in developing countries can place
themselves in a fairer, less expensive, and less
antagonistic forum for resolving disagreements.
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Figure 1: Principal Steps in a Typical Mediations and (WIPO) Arbitrations
Mediation

Arbitration

Agreement to mediate

Request for arbitration
30 Days

Commencement/
request for mediation

Appointment of a mediator

Answer to request for arbitration

Establishment of the tribunal
30 Days
Statement of claim

Initial contacts between
the mediator and the parties
• setting up the first meeting
• agreeing on preliminary exchange
of documents, if any

30 Days
Statement of defense
30 Days
Further written statements and
witness statements

First and subsequent meetings
• agreeing on ground rules for
the process
• gathering information and
identifying issues

Hearing

• exploring the interests of the parties
• developing options for settlement
• evaluating options

Closure of proceedings
3 Months

Conclusion
Source: Min7
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Finally, the chapter discusses extensively the activities and services of the Arbitration and Mediation
Center, which functions under the World
Intellectual Property Organization (WIPO).
A different type of dispute may emerge under
parallel trade practices (involving “gray market”
imports). As Matthews and Munoz-Tellez write,8
parallel trade occurs when products produced
under the protection of a patent, trademark, or
copyright in one market are subsequently exported to a second market and sold there without the authorization of the local owner of the IP
right. Often, the local owner of the IP right will
also be a local dealer who, through a license or
other exclusive agreement, has been authorized
by the patent, copyright, or trademark holder to
market the protected product. Naturally, when
the licensed dealer has an exclusive agreement, he
or she expects to be the only party supplying the
product in the local market. Importantly, parallel trade does not refer to the trade of pirated
or counterfeit products. These are unauthorized
versions of products that infringe an IP right.
Parallel imports, on the other hand, are imports of genuine, often branded, products that
do not violate an IP right per se, but importing
the product will not have been authorized by the
right holder.
Engaging in parallel trade is a legal option
provided within the Agreement on Trade-Related
Aspects of Intellectual Property (TRIPS). The
Doha Declaration reaffirmed that developing
countries can use parallel imports to support
public health. Such countries can obtain access
to lower-priced patented and/or branded products, such as medicines and basic agricultural
inputs, by incorporating legislation to allow for
parallel imports. TRIPS permits member states
of the World Trade Organization (WTO) to design their own exhaustion of patent rights regimes.
Hence, the state’s legal framework for parallel
trade is based on its own exhaustion of patent
rights doctrine:
• national exhaustion, whereby the exclusive
rights of patent holders cease only after the
first sale of a product within the national
borders (parallel imports can be blocked at
the border)

• regional exhaustion, whereby the exclusive
rights of patent holders cease after the first
sale in the regional market (parallel trade
permitted within the regional group)
• international exhaustion, whereby the exclusive rights of patent holders cease after
the first sale in any market (parallel trade
permitted)
The chapter focuses on how parallel trade can
provide developing countries with greater access
to medicines and to basic inputs for agricultural
production (such as pesticides and fertilizers) at
lower prices.
Thus, developing countries can incorporate
into their national laws the principle of international exhaustion of rights, thus allowing for parallel imports on an international scale. In other
words, developing countries can decide whether
or not to allow parallel importation for all or particular IP rights.
Although parallel trade has obvious benefits
for developing countries, there are also potential
disadvantages. For example, the chapter notes
that parallel trade might:
• reduce incentives for investment in the
pharmaceutical and agricultural sectors
• reduce the incentives for rights holders
to donate products at low cost or free of
charge to developing countries due to fear
of re-importation elsewhere
• reduce the willingness of rights holders or
licensed local owners to supply particular
markets
When implementing measures to facilitate
parallel trade, developing countries should ensure an effective system by adequately regulating
the quality and safety of parallel imports. At the
same time, they need to prevent low-priced patented products in developing countries from entering high-priced developed country markets.
Otherwise, patent holders, particularly in the
pharmaceutical industry, could be discouraged
from pricing their products differently in different
markets in order to benefit developing countries.
The chapter offers model legislative provisions to
enable parallel imports and concludes by urging
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policymakers in developing countries to promote
access to medicines and to support poor farmers
by fully utilizing the parallel trade options available under TRIPS. n
All chapters refer to: Intellectual Property Management in
Health and Agricultural Innovation: A Handbook of Best
Practices. 2007. A Krattiger, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez,
and SP Kowalski (eds.). MIHR: Oxford, U.K., and PIPRA: Davis,
U.S.A. Available online at www.ipHandbook.org. The online
version contains for each chapter a detailed Editor’s Summary, Implications, and Best Practices.
1

through the introduction of critical advances in
health care. Furthermore, the NIH OTT fully recognizes
that potential licensees will be from both developed
and developing countries, such that the range of
beneficiaries is truly global in scope.
3

4 Chapter 15.2 by HW Haeussler titled Policing Intellectual
Property, p. 1405.
5

Chapter 15.1 by HH Feindt titled Administration of
Technology Licenses, p. 1395.

2 Although impressive, such revenue flow is not the
OTT’s principle mission. Rather, by instituting and
running an organized and professional office, the NIH
furthers its mission of a timely introduction of new
products and technologies into the marketplace. In
this way, the fruits of NIH research and development
are made commercially available, fostering economic
development and serving the greater public good
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This database has been provided by the Whitehead
Institute for Biomedical Research. See also Chapter
6.12 by A Hamzaoui titled WIIPS™: Whitehead Institute
Intellectual Property System (A Relational Database for
IP Management and Technology Transfer), p. 649.

This may happen pursuant to two defenses in
equity: (1) laches, when the patentee waits too long
(an inexcusable delay) before taking action against
a presumed infringer and (2) equitable estoppel,
when the presumed infringer, relying on actions
or communications from the patentee, reasonably
believes that he or she can practice the patented
product or process.

6 Chapter 15.3 by EJ Min titled Alternative DisputeResolution Procedures: International View, p. 1415.
7

Ibid.

8 Chapter 15.4 by D Matthews and V Munoz-Tellez titled
Parallel Trade: A User’s Guide, p. 1429.
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A fundamental best practice in IP management, regardless of whether an institution is
public or private and whether located in a developed or developing country, is to view
intellectual property as an evolving and dynamic asset requiring ongoing attention,
management, monitoring, and policing. Only such an “IP cultivation” will allow
institutions to protect the value and utility of the intellectual property.
A country’s statutory code, combined with a reliable system of fair adjudication
and judicial enforcement, is the requisite basis for enforcing institutions’ IP rights.
Supporting policies that promote this legal infrastructure is essential.
Court action is often stymied because of cost, length of procedure, legal uncertainty,
the decision maker’s lack of expertise, confidentiality/publicity, the difficulty of
seeking action in foreign jurisdictions, and the negative impact on existing business
relationships. But public and private institutions alike should always have the flexibility
to opt for court action if this seems to be in their best interests.

Key Implications and Best Practices: SETCION 15

FOR GOVERNMENT POLICYMAKERS

Policymakers should strive to promote policies and advocate for laws that encourage
alternative dispute resolution procedures as the best alternatives for settling differences
between parties to an agreement. These procedures are particularly important in
international contract dispute resolution.
Governments and public institutions can help make arbitration or mediation procedures
accessible and available by identifying and supporting neutral institutions that can
provide cost-efficient, timely dispute-resolution services. The World Intellectual Property
Organization offers such services through the WIPO Arbitration and Mediation Center.
Pursuant to the TRIPS Agreement and the Doha Declaration provisions on parallel
trade, countries can implement patent rights exhaustion regimes that either permit
or restrict parallel importation. As a result, developing countries can decide whether or
not to allow parallel importation for all or for particular IP rights. Despite the evident
benefits of parallel trade, there are also disadvantages, and both the benefits and
the risks should be carefully considered. (Drawbacks of broad parallel importation
practices include the reduction in incentives for investment in the pharmaceutical
and agricultural sectors and the reduction in incentives for rights holders to donate
products at low cost or free of charge to developing countries due to fear of reimportation to lucrative developed country markets. Re-importation hinders the ability
of governments in different countries to maintain price controls on pharmaceutical
products within their territory and reduces the willingness of rights holders or licensed
local owners to supply particular markets.)

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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FOR SENIOR MANAGEMENT
(University President, R&D Manager, etc.)
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A fundamental best practice in IP management is, regardless of whether an institution
is public or private and whether located in a developed or developing country, to view
intellectual property as an evolving and dynamic asset requiring ongoing attention,
management, monitoring, and policing. Only such an “IP cultivation” will allow
institutions to protect the value of intellectual property and maximize its utility.
Your institution’s technology transfer office should have systematic procedures to
administer, monitor, and enforce its technology licenses. This includes compliance with
royalty payments and reporting obligations in a nonconfrontational manner.
Public and private institutions alike should always have the flexibility to opt for legal
action if this seems to be in their best interests. But legal action is often stymied because
of cost, length of procedure, legal uncertainty, a decision maker’s lack of expertise,
confidentiality/publicity, the difficulty of seeking action in foreign jurisdictions, and the
negative impact on existing business relationships.
Encouraging alternative dispute resolution procedures can be a viable strategy and,
indeed, often a preferred one, for settling differences between parties to an agreement.
These are particularly important in international contract dispute resolution.
Public sector institutions should have an institutional policy on the use of arbitration
and mediation.
Public institutions can help make arbitration or mediation procedures accessible and
available, by identifying and supporting neutral institutions that can provide costefficient, timely dispute resolution services.The World Intellectual Property Organization
offers such services through the WIPO Arbitration and Mediation Center.
Where permitted by national legislation, parallel importation may provide universities
and public sector research institutes with lower-cost access to legitimate imports
produced in other markets.
For universities and research institutes in particular, parallel importation may have
substantial benefits as it allows for the lower-cost import of copyrighted products
(books, computer software, periodicals, and related products). Hospitals may also
benefit from parallel-trade imports by access to cheaper, patented pharmaceutical
products. Sometimes, however, the final cost of the parallel-imported product is higher
than locally supplied goods, while quality and warranty may be lower.
But parallel importation also has drawbacks. These include the reduction in incentives
for investment in the pharmaceutical and agricultural sectors and the reduction in
incentives for rights holders to donate products at low cost or free of charge to developing
countries due to fear of re-importation to lucrative developed country markets.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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A fundamental best practice in IP management, regardless of whether an institution
is public or private and whether located in a developed or developing country, to view
intellectual property as an evolving and dynamic asset requiring ongoing attention,
management, monitoring, and policing. Only such an “IP cultivation” will allow
institutions to protect the value of intellectual property and maximize its utility.
As a scientist, you should regularly review all of the agreements that relate to your
projects. This specifically includes ensuring that milestones are met, royalties paid, and
that any other obligations are taken care of.
Your institution should continuously monitor patent infringements through various
surveillance protocols. A lack of patent enforcement can lead to a loss of patent rights.
Your role in this is important, since you are well connected in the area of your research
and can indicate to the technology transfer office which companies might be practicing
your inventions.

Key Implications and Best Practices: SETCION 15

FOR SCIENTISTS

Keep laboratory records and notebooks organized, ideally consistent with your
institution’s laboratory notebook policy. These can be essential for drafting patent
applications, prosecuting patents and, if necessary, pursuing litigation.
If your institution conducts alternative dispute resolution procedures such as mediation
or arbitration, you might be called upon to participate, particularly if aspects of your
research program are involved in the ongoing discussions.
If your university or institution is in litigation with a partner you have been collaborating
with, do not let disputes interfere with your research or your relationships with colleagues
at the other institution. Many companies litigate with other parties while, at the same
time, negotiating on other licenses or joint ventures with that party. Litigation is nothing
personal and should never influence your research collaboration. Notwithstanding this,
you should always be cautious when speaking about matters related to the topic of
dispute. It is best never to comment on ongoing litigation matters.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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FOR TECHNOLOGY TRANSFER OFFICERS
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A fundamental best practice in IP management, regardless of whether an institution is
public or private and whether located in a developed or developing country, is to view
intellectual property as an evolving and dynamic asset requiring ongoing attention,
management, monitoring, and policing. Only such an “IP cultivation” will allow
institutions to protect the value of intellectual property and maximize its utility.
A technology transfer office must have systematic procedures to administer, monitor,
and enforce its technology licenses. This includes compliance with royalty payments
and reporting obligations in a nonconfrontational manner.
A TTO should regularly review active license agreements. This specifically includes
ensuring that milestones are met and royalties paid.
Potential patent infringements should be monitored continuously through sound
surveillance protocols, and action taken to remedy infringement is an essential part of IP
asset management. The lack of patent enforcement can lead to a loss of patent rights.
If litigation seems to become inevitable, credible communication that the IP owner is
serious about protecting its IP assets will go a long way to bringing infringers to the
table to discuss the issues and negotiate a mutually beneficial outcome. Importantly,
early communication with potential infringers and good license and licensee diligence,
are the foundations for policing and maintaining intellectual property, irrespective of
whether the intellectual property is owned by a public or a private entity.
Essential to contract management is a well-organized electronic filing system, possibly
with archival, working, and computer files with integrated interactive modules
organizing data on contacts, inventions, patents and license applications, royalties,
receipts, and reporting. A TTO should establish such a system as early as possible and
before the number of agreements and licenses becomes large.
The online version of the Handbook allows users to download an electronic contractsmanagement system free of charge.
Most IP disputes should not end up in litigation, as there are many options and
strategies for resolving disputes. Good contracts and good licensing practices anticipate
that disputes arise with partnerships and licenses.
Mediation and arbitration can be effective dispute-settlement procedures, provided
they have been agreed upon and established in contract clauses at a time when a
license or partnership is being negotiated—and before any problems arise.
The success of an arbitration or mediation depends largely on the “quality” of
the arbitrators and mediators. The challenge is often to find candidates who have
arbitration/mediation skills, have experience with the specialized knowledge of the
disputed subject matter, and are acceptable to both parties.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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Bioprospecting, Traditional Knowledge,
and Benefit Sharing
Humankind has always been—and will always
be—completely dependent on the Earth, therefore our treatment of it is paramount to our survival. We have relied particularly on its wealth of
biological resources and its biodiversity. For millennia, a balance has existed between the production and consumption of resources. The impact
of people on the environment has made relatively
few irreversible changes over this time. That is,
until recently. Suddenly, the impact of these environmental changes on human activities (such
as agriculture, increasing populations, industrialization, and rising rates of consumption and
standards of living) has became clear. The root of
biodiversity loss and environmental degradation
is the notion that biodiversity is the “common
heritage of mankind” (sic) and must be preserved
for future generations. This means that, while the
environment belongs to no one, it is entirely our
collective responsibility.
Beginning some 50 years ago, biodiversity
losses began to increase at an alarming pace.
Desertification became a recognized problem in
many regions of the world with ensuing biodiversity loss. By the late 1970s, biodiversity loss,
desertification, and even climate change, had begun to receive significant international attention
as more and more people began to recognize that
the Earth’s resources were finite and that our activities were unsustainable. Due to a accelerating
depletion of resources, these resources began to

have increasing economic value. Deep concern
over an environmental crisis was widely expressed
for the first time in an international forum at the
United Nations Conference on Environment and
Development, commonly known as the Earth
Summit, held in Rio de Janeiro, Brazil, in 1992.
Concurrent to these activities, biotechnology
emerged and with it came the promise of creating life-saving new drugs from genetic resources.
Modern biotechnologies allowed new and novel
uses of biological resources, giving additional
value to biodiversity. At the confluence of these
world events new concerns emerged over ownership, over the contributions of generations past,
and over traditional knowledge (TK) held by indigenous populations. In short, equity concerns
arose.
Equity is a moral issue that has repercussions with respect to the distribution of benefits
and environmental conservation. However, equity is in the eye of the beholder; different individuals come to different conclusions about
what is equitable and about how to achieve equity. Unfortunately, market systems created to
place a price on equity do not work because market systems are constrained in what they measure. Furthermore, with regard to indigenous
knowledge, because its products are intangible,
once the knowledge or information is disseminated, control over the knowledge is lost. From
an objective standpoint, that knowledge has no

Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 2007.
16: Bioprospecting, Traditional Knowledge, and Benefit Sharing. In Executive Guide to Intellectual Property Management in
Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford,
UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). Available online at www.ipHandbook.org.
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direct monetary value unless the knowledge can
be translated into a market-based commodity (or
service), whereby the value of different contributions (knowledge, technology, labor, capital, and
so forth) can be quantified and traded.
In addition to these problems, the western system of IP (intellectual property) rights,
particularly patenting, is based on the premise
that anything that is already known cannot be
protected. Indigenous knowledge is often communal, has been disclosed, and has been passed
on from previous generations. The very nature of
indigenous knowledge, therefore, does not meet
the criteria for intellectual property in today’s IP
system. Not surprisingly, some people view the
use of TK in modern science as a form of biopiracy, which is the unfair acquisition of biological resources and/or associated know-how. Some
even argue that the modern IP rights system has
harmful effects on indigenous peoples.
Karjala1 breaks down these arguments into
two distinct issues:
• Biopiracy: to what extent do patent systems
exploit traditional indigenous knowledge?
• Patenting of living organisms: how can we
justify patenting gene-sequence and geneproduct information taken from living organisms (especially humans) when these are
naturally occurring substances? And if patented, how do we answer the ethical questions surrounding such patents?
Karjala argues that the core of the biopiracy
problem is not patenting inventions derived from
traditional indigenous information, but rather biopiracy is unfair acquisition (misappropriation)
of knowledge and the inequitable distribution
of benefits derived from developing such information into valuable commercial products. But
he cautions against exclusive information rights
outside the patent and copyright regimes for indigenous peoples, pointing to the need for incentives for product development. Provided that traditional information is given voluntarily and that
fair compensation is paid to the group who owns
the information, it is not the use of TK in a patent that is inherently wrong. Therefore, the question becomes one of how to provide for equitable
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benefit sharing of TK that finds its way into patent
applications and is subsequently commercialized.
Policymakers ought to formulate methods
for equitable access to the TK held by indigenous societies and for compensating its owners.
However, this issue involves a delicate balance: access should be granted only via authorized permission, yet the price that is assessed for permission to
bioprospect should not be so high that it dissuades
companies and individuals from seeking access.
Although nothing in extant patent statutes
or international IP/trade agreements requires that
naturally occurring chemicals (such as DNA sequences and genes and their natural products) be
treated as patentable subject matter per se, these
can be patented once utility and novelty requirements are met. Patenting natural products, however, is not the unique concern of indigenous
peoples. It is also a concern of policymakers in
developing and developed countries.
Furthermore, patents on upstream “inventions,” (in this context, isolated genes) might inhibit subsequent downstream research and development. This is because the upstream patenting
of natural products (such as specifically isolated
gene sequences) would effectively eliminate downstream incentives for inventive activity. Also, such
patents would inhibit information flow, thus promoting over investment in the search for genes
and under investment in the utilization of genes
for advanced applications.
The important ethical issues raised by generelated patents include whether:
• private control over genes or their products monopolizes the “common heritage of
mankind”
• patents denigrate human life by reducing it
to a commodity
• patents may be inconsistent with individual
or collective privacy
• patents promote or inhibit distributive justice when they are concentrated in a few
economically developed countries. A related concern is that patents on crop varieties
might threaten biodiversity.
Importantly, Karjala notes that these issues
affect both indigenous and non-indigenous
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populations. In addition, where there are differences in how costs or benefits are distributed,
patenting is not necessarily the problem. In negotiating technology transfer and access, the author proposes that careful cost/benefit analyses
should guide decisions.
Interpreting the concept of the common heritage of mankind broadly, one can include nearly everything (in other words, the common heritage is not
limited to indigenous peoples). Therefore the concept does not represent an ideal paradigm for building a legal strategy. Hence, traditional patent law is
a better approach. The real question is not whether
a gene or a gene product should be protected as the
common heritage of humankind, but whether or not
it is even an invention within the well-established
strictures of patent rules and regulations.
As for the commoditization of genes, it is
difficult to see how this would impact most indigenous societies that, for the most part, are far
removed from the commodity markets of developed countries. Furthermore, the human genes
at issue would most likely confer some sort of
positive advantage and would therefore not implicate either privacy concerns or stigmatization.
Once again, patent law would likely most effectively address genes with potential commercial
value. Nevertheless, freely available information
should not be protected by IP rights. If IP protection is appropriate, possibly other forms of statutory protection would be more suitable, such as
breach of confidence or privacy rights.
One critical concern is whether patenting
conflicts with indigenous knowledge and value
systems. In a theoretical sense, patents can significantly add costs to new inventions and thereby act
as barriers. However, when one balances the costs
and benefits of patent law in developing counties, there may be little correlation between access
and patent status. Furthermore, as Karjala points
out, there would be essentially no financial loss
to owners of patented biotechnology products
if they were to sell at cost in such countries, assuming no redirection of such biotechnology to
more lucrative markets. However, the prevention
of product “leakage” would entail enforcement
capacity, and this sort of distribution is not feasible without strict market segmentation.

Costanza, Christofersen, Anderson, and
Short2 add to this analysis of bioprospecting by
presenting practical examples of how indigenous
peoples and companies can reach agreements
that are fair by most standards and conducive to
further collaboration. The authors explain that international agreements such as the Convention on
Biological Diversity (CBD) and the International
Treaty on Plant Genetic Resources (ITPGR) provide a broad framework for protecting and utilizing genetic resources.
For bioprospecting activities, companies
choose countries that have unique and protected
ecosystems, a solid legal framework, sufficient
political will, fair and equal treatment for all access seekers, and strong science experts or institutions to partner with. Countries will seek partnerships with foreign companies and universities
that adhere to international conventions and best
practices, and that have an established track record. Guiding principles for a successful partnership between collaborators in the host country
and a company include a commitment between
parties to maintain a fair, trusting, long-term relationship, with an efficient and reasonable authorization process, and equitable sharing of benefits
between partners.
However, international agreements do not
provide detailed guidance on structuring the
relationships between parties involved in commercial bioprospecting activities. Companies
involved in the exploration, screening, and use
of genetic resources have begun to accumulate
experience with building such relationships, including selecting countries with rich biodiversity,
selecting partners, and drafting terms in biodiversity access agreements (BAAs) that govern these
relationships.
In order to be successful, these BAAs must
have a clear definition and assignment of legal
rights to all genetic resources involved. Informed
consent from all domestic parties affected by the
bioprospecting, including landowners and managers, must be attained prior to partnership. There
must exist a clear delineation of rights to patent
and commercialization of the products derived
from these endeavors. Each BAA is a confidential
document, which supports a lack of competition
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among the partners to the agreement, and does not
allow the transfer of proprietary technologies or
technical capacity to third parties or exclusivity.
Identification of the parties to the BAA can
be complicated because there may be multiple
agencies within a country that have authority
over access to genetic resources. There may also
be multiple parties, such as landowners or company managers who could legally prevent access
to or receive compensation for the resource if and
when they are affected by the biodiversity prospecting. Each country that is a signatory to the
CBD has a responsibility to establish a national
focal point for access and benefit sharing,3 a designated individual and national office that is able
to identify all necessary authorities and potential
claimants for the partnership.
The rights that need to be spelled out in a
BAA include rights to retain or distribute samples, rights to intellectual property under different scenarios, (such as conditions of discovery
and invention) and rights to publish discoveries
and inventions. Responsibilities, such as the handling of reporting, communications, and administrative filings also need to be spelled out.
The parties should come to an understanding
about the relative importance or value of each of
their contributions (such as carrying out sampling,
cleaning, or analyzing). This will directly affect
the equitable sharing of any benefits arising from
collaborative activities. Given the nature of bioprospecting and the regions where bioprospecting
is often conducted, the full scope of returns is understood to include both financial and nonfinancial components (that is, various sources of potential value to the individual parties). The possible
returns can also be divided roughly into shortterm, medium-term, and long-term time frames.
Thus, a BAA has enormous flexibility for structuring the terms of compensation to the parties.
While advanced payments, sample fees, running
royalties, and milestone payments—terms typical of many technology agreements—are available
for financial benefit sharing, there are many more
possibilities, including the provision of equipment
and infrastructure, sharing of IP rights or rights
to product sales, funding of related research, and
assistance with conservation services.
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Despite progress on the technical side, a BAA
almost always creates controversy. The natural response of governing authorities is to move slowly,
fearing criticism from competing domestic interests and international groups that watch out
for cases of undervaluing biodiversity and nonsupport for economic development. Many such
groups consider the private sector to be inherently
corrupt; thus, no matter what benefits are offered
the arrangement is perceived to be inequitable.
Ironically, this reaction reflects negatively on those
companies taking the lead in supporting the CBD
and creates strong disincentives to engage in bioprospecting or to share information about such
endeavors. This in turn, decreases the very value
of biodiversity resources. In the end, the commitment of both parties to a sustainable and rational
use of biodiversity in a way that both encourages commercial development and protects the
unique resources of the Earth is as important as
the technical aspects of deal making.
The technical aspects of technologies, however, must still be mastered. Indeed, there is an
emerging new regime, Thornström4 calls it a
“world order,” regarding biological matter: an international regime which govern access to genetic
resources and the sharing of benefits arising from
their use. The chapters by Thornström and by
Thornström and Björk,5 explore the what, why,
and how of this new regime. The authors provide
the reader with a comprehensive road map for
understanding the details and finding the correct
path to compliance with the laws, rules, and regulations that cover access in a given country.
The new regime is driven by access and
benefit-sharing (ABS) systems, which apply to
research carried out for either scientific or commercial purposes. ABS involves accessing organisms, or parts thereof, and related TK, that are
obtained (accessed) from a country that is party
to the CBD. In addition, other international
treaties, accords, and agreements have also added
new legal ABS regimes legislation through the
acquisition and use of biological material and related information.
Everyone (tourists, nature conservationists,
scientists, photographers, journalists) is subject to these new ABS regulations, but the ABS
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system especially affects scientists and researchers
who seek to access and use proprietary genetic
resources, other biological matter, and related information, such as TK and farming know-how.
In national legislation, such knowledge may be
treated as intellectual property or confidential
trade secrets, putting it outside the public domain
and not subject to any form of unauthorized appropriation. Violation by foreign parties (such
as scientists conducting unauthorized collection
activities) of the new ABS regimes may result in
a range of negative and stringent consequences;
fines and/or imprisonment, denial of future visits
to the collection site or country, increased transaction time for obtaining formal access permits,
and/or denial of access to colleagues of the violator. Obviously, it’s important to know how to
properly proceed.
To understand the fundamental principles of
ABS, one needs to know the relevant rules, regulations, laws, customs, and conditions for benefit
sharing in the country where one intends to conduct research and/or collect samples. Basic questions to ask before collecting include:
• Under which conditions may I, as a scientist, enter another sovereign state’s territory
in my scientific capacity?
• Under which conditions may I, as a scientist, collect biological material and related
information?
• Under which conditions may I, as a scientist, carry out or export biological material
and related information from that sovereign state’s territory?
• Under which conditions may I, as a scientist, make further use of collected biological
material and related information?
Thornström and Björk present a practical
overview of the principles and procedures underlying ABS regimes that will be useful to various
types of research and access situations. The authors also provide a series of template documents
as illustrative examples of what might be necessary, depending on the specific requirements of
the collection activities. To assist in understanding the various ABS scenarios and the documents,
potentially applicable letters and agreements are

presented as examples, such as letter of intent,
research permit, prior informed consent (PIC),
mutually agreed terms (MAT), model or material
transfer agreement (MTA), and confidentiality
agreement.
Although all of this might seem daunting
initially, the documents are necessary, and in a
growing number of countries are required by
law. Careful planning and management will pay
off in the long term, since they minimize the possibility of misunderstandings and other problems
and, in turn, can reduce the chance that legal
problems will arise. Perhaps most importantly,
these ABS regimes are in place to facilitate the
building of solid, equitable, and sustainable networks for future partnerships.
Drawing on the experiences of exemplary
partnerships, Soejarto and colleagues6 explain an
organizational model for the responsible governance of bioprospecting arrangements between
institutions in developed and developing countries based upon the International Cooperative
Biodiversity Groups (ICBG) program of the
U.S. National Institutes of Health (NIH). The
model assumes that resources and expertise from
both the North and the South are required for
bioprospecting to succeed. Incentives need to
be properly aligned for both regions to be fully
engaged and committed. To align incentives, the
ICBG model offers a clear definition of the benefits that might arise from a project, a clear recognition of all parties involved, negotiation guidelines for the parties, and a formal structure for the
resulting agreement. The agreement contains the
scope and objectives of the project, the long-term
benefit-sharing scheme, and milestones, as well as
terms for IP ownership, informed consent, and
royalty distribution. Details of how the ICBG
model works in practice are illustrated with an
example of one such bioprospecting arrangement
between the University of Illinois at Chicago
(UIC), research institutes in Vietnam and Laos,
and GlaxoSmithKline.
Informed consent was another critical issued to be covered. In this case, informed consent
offered provisions for the collection and use of
plant/genetic materials and for individuals and
their communities regarding traditional medicinal
HANDBOOK TO BEST PRACTICES: EXECUTIVE GUIDE | 177

GUIDE TO SECTION 16

use or uses of a plant. In addition, prior informed
consent was to be secured before the implementation of the work. The governments of Vietnam
and Laos were acknowledged as the owners of the
genetic materials and their derivatives in their respective countries.
Fundamentally, the ICBG model recognizes and emphasizes the importance of
several parties and the outcomes they seek.
Often overlooked in typical international
research consortia and business agreements,
these additional parties include poor communities and the regional authorities in locations where biodiversity prospecting is to be
conducted. The additional objectives include
biodiversity conservation, institutional capacity building, and regional economic development. The standards established by the ICBG
program emphasize the core principles of capacity building and community reciprocity.
Bioprospecting activities such as those outlined in this chapter, in which poor communities in developing countries are cooperating
with clear understanding and goodwill, can
thus serve as a model for future similar agreements and initiatives.
This is not to say that the conceptual systems of developed countries work are transferable to developing countries, as the final two
chapters of this section demonstrate. According
to Hansen and Van Fleet,7 indigenous knowledge, or TK, particularly that which involves a
region’s native flora and fauna (biodiversity), is
not fully amenable to the legal constructs of intellectual property. Fundamentally, TK is cumulative, communal, and largely undocumented in
the formal literature. Because of these characteristics, TK often does not fulfill novelty requirements for establishing IP rights or the condition that ownership of the intellectual property
resides with an individual or individuals. Indeed,
in the case of TK, it may be exceedingly difficult
to identify the original individual inventors or
authors, or even the current holders or curators
of the knowledge. Finally, because TK is largely unrecorded but exists as “living” knowledge
passed from individual to individual orally or
through observation and apprenticeship, it is
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largely unavailable for consideration by IP offices of novelty within the complete repository
of human knowledge.
But despite these difficulties in applying the
criteria for intellectual property to TK, a number
of forms of IP rights protection (primarily trade
secrecy, geographical indications, plant variety
protections, and patents) can be and have been
used to establish ownership over elements of TK.
However, the imperfect fit of TK into the definition of intellectual property has led to two interrelated dilemmas:
• In some cases, those who were not part of
the indigenous community from which
the TK originated may be able to use, and
even to establish ownership over, elements
of the TK without acknowledgment of (or
recourse to) that indigenous community
• Those in indigenous communities who
do hold TK may not be able to establish
ownership, or even gain acknowledgment
from others.
To address the first dilemma, anyone should
make sure TK is disclosed, which will establish
it as prior art. There are a variety of strategies to
assist in establishing prior art status of TK. For
the majority of TK, a defensive disclosure in the
public domain (such as via a public registry) can
prevent illegitimate IP claims over existing TK.
For TK to which IP protections more easily apply, the TK holders may be able to themselves file
applications. In addition, governments should require prior informed consent to be obtained from
indigenous communities or national authorities
when engaging in activities that could lead to the
claiming of IP rights based on TK.
To address the second dilemma—that of
maintaining control over TK—indigenous holders of TK can seek to use forms of IP protection.
Hansen and Van Fleet discuss the advantages
and disadvantages of the various options available. At least initially, most TK approximates a
trade secret, and so it might easily be maintained
within the original community as a trade secret.
However, before the knowledge is more widely
disseminated it may be necessary to use other
forms of IP protection, including geographic
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indication, trademarks, plant variety protection,
petty patents or utility models, or patents.
In the longer term, governments may create
new forms of IP protection that accommodate the
fundamental characteristics of TK (such as under
the aegis of sui generis systems of plant variety
protection as defined under the Trade-Related
Aspects of Intellectual Property Agreement). In
addressing the dilemma of control over TK, several issues outlined in the CBD ought to be worked
out within national legal systems. Of these issues, the foremost are conditions for granting/
gaining access to genetic resources and any TK
about them and requirements for equitable sharing of revenues or other benefits that might accrue from the development and use of TK-based
technology in markets around the world.
All of these approaches to preserving and
protecting TK require a clear identification and
attribution of specific TK claims. This can be a
complex endeavor, but TK is important and often even essential to the survival of indigenous
communities. It may also be an important source
of life-giving technological innovation that could
benefit millions around the world. The ultimate
goal is to develop practical solutions within our
legal frameworks that encourage indigenous
communities both to sustain their traditions and
to equitably share their knowledge with the wider
world so that all may benefit.
Ammann8 raises a different concern about
how we think about food in developing countries
and its impact on the developing world. He argues
that the commonly held distinction between organic and technologically intensive agriculture
(focused on genetically modified organisms, or
GMOs, or more specifically transgenic crops)
has inhibited pragmatic approaches to creating
agricultural management systems that build on
local conditions, help alleviate poverty, respect
local cultures and traditions, and draw upon a
successful relationship with science. This distinction between organic and technologically intensive agriculture is based on a deeper rift between
systems of indigenous TK and western scientific
knowledge, a rift that Amman contends is not
only unproductive (hindering communication
and exchange between the two) but artificial—

reflecting differences in “worldviews, unfounded
theories, or quasi-religious beliefs” held by respective proponents.
Still, the distinction between organic and
technologically intensive agriculture is enormously significant. The designation of a technology as
organic versus transgenic can attach very different regulatory requirements and offer different
marketing opportunities for the technology, thus
strongly influencing how and whether it is used
and what its potential value is.
Ammann challenges the commonly held
distinction between organic and transgenic technologies and proposes a series of tests of the definitions and principles advanced to define and
distinguish the two. While they are different in
some aspects, Amman finds none of the major
distinguishing principles claimed by organic versus transgenic technology able to stand up to
scrutiny. These include:
• the intrinsic genetic integrity of crop species genomes (crop species genes are not
intrinsically more stable when considered
transgenic or organic)
• the unnaturalness of transgenesis (transgenics are just as “natural” as organics)
• stability and predictability of progeny (organics and transgenics have stable and predictable inheritance patterns that are reproducible over time)
• unnaturalness of monocultures (irrespective of organic or transgenic status, growing
all one type of either crop plant is not the
natural state of the environment)
• erosion of biodiversity by transgenic technologies (transgenics have not been shown
to decrease levels of biodiversity)
• systemic environmental superiority of organic versus transgenic crops (the overall
conception that organics are superior to
transgenics as a whole is not substantiated)
It is difficult, if not impossible, to consistently
maintain a clear divide with respect to organic and
biotechnology-based agricultural technology and
methods. Yet, Ammann observes, “power structures knowledge,” and interests on both sides are
using and benefiting from a substantiation of
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the distinction between organic and transgenic
agriculture.
Practical solutions to agricultural production—and practical solutions to medicine—could
indeed benefit many if only we could manage
to build bridges between TK and science-based
knowledge systems and draw upon the best existing ideas and practices of both. n
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Equity is a moral issue that has repercussions with respect to the distribution of
benefits and environmental conservation. Thus, equity is in the eye of the beholder.
The western system of IP rights, and particularly of patenting, is based on the premise
that anything that is already known cannot be protected. Indigenous or traditional
knowledge (TK) is often communal, has been disclosed, and has been passed on from
previous generations. The very nature of indigenous knowledge, therefore, does not
meet some of the criteria for intellectual property protection (such as novelty).
In the longer term, new forms of IP protection that are more amenable to the
fundamental characteristics of TK could be created by governments, such as under
the aegis of sui generis systems of plant variety protection (PVP), as defined under the
TRIPS Agreement.

Key Implications and Best Practices: SETCION 16

FOR GOVERNMENT POLICYMAKERS

Indigenous communities often play a significant role as gatekeepers to a country’s
potential biodiversity wealth. They are the regional specialists with respect to the flora
and fauna. Their knowledge can often exceed that of leading scientists.
Patent laws per se do not “create” biopiracy. Rather, biopiracy is a form of
misappropriation, unfair acquisition, and inequitable sharing of benefits with respect
to biological resources.
Policymakers ought to formulate methods for equitable access to TK held by indigenous
societies and for compensating the TK’s owners. However, this issue involves a delicate
balance: access should be granted only via authorized permission, yet the price that
is assessed for permission to bioprospect should not be so high that it dissuades
companies and individuals from seeking access.
Countries should consider implementing an access and benefit sharing (ABS) regime
that balances equitable access to biological resources, as well as related TK, with opportunities arising from R&D expertise of potential foreign partners in development. Such policies should be grounded in, and consistent with, the Convention on
Biological Diversity and the TRIPS Agreement.
ABS regimes, including the process for obtaining permits, should be transparent and
easily available to any scientist or institution that wishes to enter into biodiversity
prospecting or collection activities. A complex system discourages foreign bioprospectors
and may inhibit national researchers in their activities.
The commonly held distinction between organic and biotechnology-based agriculture
inhibits pragmatic approaches to creating agricultural management systems that
build on local conditions, help alleviate poverty, respect local cultures and traditions,
and benefit from a successful relationship with science. The world has much to gain
by reconciling organic and biotechnology-based agriculture though realizing any gain
will have to deal with the “power structures of knowledge,” and overcome limitations
imposed by those people who maintain the distinctions.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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FOR SENIOR MANAGEMENT
(University President, R&D Manager, etc.)
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The technology transfer office should work with senior management to establish
policies and systems for accessing indigenous or traditional knowledge (TK),
bioprospecting activities, and benefit sharing in an equitable manner.
Equity is a moral issue that has repercussions with respect to the distribution of
benefits and environmental conservation. Thus, equity is in the eye of the beholder.
Given the complexity of the health and agricultural industry and the enormous variety
of applications and products that could be developed through the biodiversity access
agreement (BAA), it is very difficult to know the profit margins for a company, product,
or application ahead of time. Technology transfer, as well as information and data
sharing, in the long run, may be more important than royalties.
With adequate funds often lacking in public sector research centers, international
donors should seriously consider loans or grants for training and equipment purchases.
Entering into bioprospecting activities, the public sector has much to gain by:
• having a clear institutional policy
• building national scientific capabilities, and along with it, the possibility of adding
value to biodiversity elements, which increase the negotiating strengths and benefit
sharing stipulated in contract agreements
• having internal capacity for negotiations, which includes adequate legal and
counseling skills about the main aspects of commercial and environmental law
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4

4

Managers can identify which nonmonetary benefits companies could provide (such
as capacity building,and technology transfer), that would be of greatest use to the
institution. This approach will enable flexibility in benefit sharing and sustainability in
the R&D relationships.
Public sector institutions can provide important intellectual and programmatic
leadership in how cross-cutting agricultural research programs can build bridges
between TK and science and between organic agricultural and science-based
agricultural practices. In so doing, they will help to advance the state of knowledge, the
regulatory structure, and public perceptions of agricultural systems.
The commonly held distinction between organic and biotechnology-based agriculture
inhibits pragmatic approaches to creating agricultural management systems that
build on local conditions, help alleviate poverty, respect local cultures and traditions,
and benefit from a successful relationship with science. The world has much to gain
by reconciling organic and biotechnology-based agriculture though realizing any gain
will have to deal with the “power structures of knowledge,” and overcome limitations
imposed by those people who maintain the distinctions.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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Scientists and anyone else accessing biodiversity must ask, and answer, the following
questions prior to initiating collecting activities: Under which conditions may I enter
another sovereign state’s territory in my scientific capacity? Under which conditions
may I collect biological material and related information? Under which conditions may
I carry out or export biological material and related information from that sovereign
state’s territory? Under which conditions may I make further use of collected biological
material and related information?
Scientists must be aware, not only of the biological and sociological value of indigenous
or traditional knowledge and related genetic resources, but also of their potential
commercial value. Hence, investigations and research ought to be conducted within
guidelines set by the technology transfer office, for example, appropriate and timely
disclosure of any potential inventions.

Key Implications and Best Practices: SETCION 16

FOR SCIENTISTS

Interactions with foreign colleagues and collaborators ought to be established
according to institute or university policy guidelines, guidelines that are established to
both preserve and reap the full value of these national natural resources.
When working with colleagues from foreign countries, you should be aware that
those colleagues may be authorized to make collections of biological materials only
under specified circumstances. Before proceeding with joint activities, check with your
institution’s technology transfer office to make sure that all the requirements have
been met.
It is essential to understand the fundamental principles of the Convention on Biological
Diversity (CBD) and Access Benefit Sharing (ABS) regimes. These exist to both protect
the resources of your country as well as to encourage collaborative projects in R&D
that would foster a broad and equitable distribution of benefits flowing from the
development of the country’s biological resources.
The commonly held distinction between organic and biotechnology-based agriculture
inhibits pragmatic approaches to creating agricultural management systems that
build on local conditions, help alleviate poverty, respect local cultures and traditions,
and benefit from a successful relationship with science. The world has much to gain
by reconciling organic and biotechnology-based agriculture though realizing any gain
will have to deal with the “power structures of knowledge,” and overcome limitations
imposed by those people who maintain the distinctions.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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The three guiding principles for a successful relationship in bioprospecting and related
endeavors are a commitment to maintaining a fair, trusting, long-term relationship;
efficient and reasonable authorization; and the equitable sharing of benefits between
a company and its collaborators in the host country.
The western system of IP rights, and particularly of patenting, is based on the premise
that anything that is already known cannot be protected. Indigenous knowledge is often
communal, has been disclosed, and has been passed on from previous generations. The
very nature of indigenous knowledge, therefore, does not meet some of the criteria for
intellectual property protection (such as novelty).
A successful biodiversity access agreement includes a clear definition and assignment
of legal rights to all genetic resources involved; prior informed consent from all domestic
parties affected by the bioprospecting (including landowners and managers); a clear
statement of rights to patent and commercialize products derived from discoveries
made; and terms of confidentiality. The BAA also establishes a noncompetitive
relationship between the parties; trust that no transfer of proprietary technologies
or technical capacity involved under the agreement will occur with respect to third
parties; and that no exclusivity requirements exist.
Patent laws per se do not “create” biopiracy. Rather, biopiracy is a form of
misappropriation, unfair acquisition, and inequitable sharing of benefits with respect
to biological resources.
Prior informed consent is an important principle in bioprospecting. This should include
informed consent in the case of collection and use of plant/genetic materials, as well as
informed consent of individuals and their communities regarding traditional medicinal
use or uses of a plant.
When dealing with foreign bioprospectors, your office will function as the gateway and
regulator of their activities. As such, technology transfer officers will provide oversight
to negotiating agreements for equitable sharing of rewards, defining access, discussing
possible patentability, and protecting the rights of the indigenous peoples who are the
stewards of these resources.
Negotiating access to your country’s genetic resources, biodiversity, and TK will require
a balanced, nuanced approach. Equitable benefit sharing must simultaneously ensure
fair returns to your country, yet not inhibit the R&D initiatives of foreign partners. Solid
agreements will benefit all parties: your country, your partnering organization, and
the country or community that provides the resource. Extreme situations, such as an
expectation of immediate windfall returns or wanton biopiracy by outsiders, will freeze
the resources and ultimately lead to their demise.
Both monetary and nonmonetary benefits may be attractive to the university or
institute; both, therefore, should be considered. Nonmonetary benefits could include
training opportunities for scientists and donation of equipment.

Given that IP management is heavily context specific, these Key Implications and Best Practices are intended as starting points to be adapted to specific needs and circumstances.
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Putting Intellectual Property to Work:
Experiences from around the World
“By far the best proof is experience,” wrote Francis
Bacon. Given the experience of countries—both
developing and developed—that have used intellectual property, IP (intellectual property) protection, and IP management to stimulate innovation,
there is ample proof that good IP management
has benefited multitudes of people around the
world with new technologies, products, and services. Innovations in health and agriculture have
greatly enriched lives. But does this experience
apply to all countries? If the best proof is experience, then what can be said authoritatively about
the effects of using IP systems wisely in developing countries?
The 28 case studies in this section of the
Handbook (and the 21 case studies in the insert
of this Executive Guide and more online) demonstrate that a great deal can be said. Developing
countries already have a vast amount of experience with IP protection, and this experience
proves that they can use intellectual property to
their advantage. With more chapters than any
other section, this portion of the Handbook amply
reveals how developed and developing countries
alike are deploying and adapting IP management
to meet their needs. Tapping into the dynamism
of product development partnerships (PDPs)
and utilizing the potential of their universities,
public sector institutions, and private companies, many developing countries are quickly and
creatively building on the experience of their

own institutions, of neighboring countries, and
of countries around the globe.

Experiences from around the World
Satyanarayana describes India’s experience
in the pharmaceutical sector. According to
Satyanarayana,1 during the past 50 years, India
has made great strides in science through a series of policy initiatives promoting high-quality
research. But especially since 2005, when India
became fully compliant with the agreement on
Trade-Related Aspects of Intellectual Property
Rights (TRIPS), big changes have occurred.
India’s rigorous IP rights regime and professional
IP management in both private sector companies
and public sector research institutions are driving success. But this is only part of a larger coordinated attempt that includes increased public
and private R&D expenditures, new policies governing traditional medicines, overhauled regulatory regimes for new drugs and biotechnologies,
initiatives to emphasize and build on already
competitive regions or technologies, and newly
created governmental, research, and educational
institutions.
In the pharmaceutical sector, the effects of
these policies can be seen in:
• a shift in the Indian pharmaceutical industry from an approach based solely on the
low-cost manufacture of generic drugs to

Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP Kowalski. 2007.
17: Putting Intellectual Property to Work: Experiences from around the World. In Executive Guide to Intellectual Property
Management in Health and Agricultural Innovation: A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.).
MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopmentsInternational Institute (Ithaca, USA). Available online at www.ipHandbook.org.
© 2007. A Krattiger et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for
noncommercial purposes is permitted and encouraged.
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research-driven innovation of novel drugs
for the global market
• the emergence of an entrepreneurial biotechnology sector in India
• the consideration by multinational pharmaceutical companies of investing in R&D
and manufacturing operations in India
In agriculture, these effects are apparent in a
rich pipeline of new innovations that promise to
make India’s agricultural sector more competitive
and profitable. Besides a substantial allocation of
funds for R&D by the government, two new initiatives were started in 2005: the National Agricultural
Innovation Project (NAIP) and the Indo-U.S.
Agricultural Knowledge Initiative (AKI).
India’s transition from a protected economy
to an open, global economic power has prompted the government to take a series of steps to
address the new challenges of globalization, and
the lessons it has learned apply broadly to many
developing countries. Strengthening R&D,
establishing policies to create and manage intellectual property, and fostering PDPs are all
important steps for making important health
products available for public distribution available in all countries.
According to Wolson,2 technology transfer
offices (TTOs) are a crucial part of IP management in South Africa. But a number of problems
challenge nascent TTOs there: a weak flow of invention disclosures, skepticism or a lack of awareness among faculty about the TTO’s role, low
levels of research funding, high patenting costs,
few experienced technology transfer practitioners, and unrealistic expectations about financial
returns. Indeed, many there believe that the main
motivation for undertaking technology transfer
activities at a university is to generate income.
Solutions to these problems are being addressed organizationally by the Southern African
Research & Innovation Management Association
(SARIMA), legislatively by the Framework
for Intellectual Property Rights from Publicly
Financed Research (the Framework), and financially through the Innovation Fund. Established
in 2002, SARIMA is a stakeholder organization
providing a platform for those from government,
186 | HANDBOOK OF BEST PRACTICES: EXECUTIVE GUIDE

academia, and industry with an interest in using
research and innovation management to foster
networking and promote common interests.
The Framework is intended to bridge the “innovation chasm”: the gap in South Africa between
knowledge generators (in particular, universities and research institutions) and the market.
It calls for a consistent approach to protecting
intellectual property developed with public financing and draws heavily on the U.S. BayhDole Act. Of course, as other countries have
discovered, the Bayh-Dole Act cannot simply be
imported. Its principles must be adapted to local
frameworks and needs. In South Africa, for example, research funding comes mostly from external sources and requires a different structure
for determining the use and ownership of project
intellectual property.
TTOs in South Africa have already met with
success. Some have been operating for several
years and more are being launched. A vibrant
stakeholder organization provides a platform for
networking and professional development in the
field, and links have been forged that strengthen
international research collaborations and technology transfer partnerships. All of this has government support.
Other chapters in this section describe the experiences of Brazil,3 Chile,4 China,5 the European
Union,6 and Japan.7

Public Sector Institutions
and Universities
Salicrup and Rohrbaugh8 provide more evidence
of the ability of for-profit and nonprofit institutions in developing countries to bring new products to market that meet critical regional public
health needs. The authors discuss the technology transfer and licensing approach of the U.S.
National Institutes of Health (NIH). The institution’s technology transfer experience has shown
that many combinations of licensing strategies
can be used to segment the world market to meet
each region’s needs. Even when patent protection
is unavailable, unique biological materials (for example, an essential component of a vaccine) can
be licensed for commercial use.
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Institutions in developing countries have
been found to be dependable licensees and
partners. With careful review, a capable institution with commercialization capabilities may be
found, and one should keep an open mind because, depending on the country, it may be a forprofit company, a nonprofit or government entity, or a semi-privatized company. NIH has several
examples of different strategies involving various
types of institutions that have reached the early
stages of the commercialization process.
While discussions continue about IP capacity building in developing countries, some leading institutions are simply forging ahead and
building their own capacity. The State University
of Campinas, or Unicamp, one of the leading
research universities in Brazil, is an example described by Ceron Di Giorgio.9 A large university
with a diversity of affiliated research institutes,
Unicamp has moved up the patenting league
tables in recent years to become the single largest
patentor in Brazil. The university’s current portfolio includes almost 50 granted, and 400 filed
patents. Unicamp emphasizes chemistry, which
accounts for close to half of its portfolio, and
engineering, which accounts for a third. In addition, Unicamp conducts significant research in
the life sciences (for example, a soy-based phytoestrogen for hormonal therapy licensed to a
Brazilian pharmaceutical company).
These major advances in technology transfer
at Unicamp are largely due to the efforts of its
new technology transfer office, Inova Unicamp,
founded in 2003. Inova began its operations by
assessing all of the technologies being researched
in Unicamp’s many laboratories and institutes.
It then aggressively pursued new patent applications and licensing deals for the most promising
technologies. In the short space of two and a half
years, the office signed 128 technology transfer
agreements with both private industry and government agencies. It also saw ten start-up companies in the university’s business incubator become
self-sustaining.
What lies behind these successes in Brazil?
New public policy. In particular, the work of
Inova is directly informed by two pieces of legislation. A 1996 law gave the university ownership

rights to employee inventions. A 2004 law on
innovation, however, gives the university the option to either hand over title to the employee inventors, or share 5%–33% of any royalties with
them. In addition, the government has instituted
a number of sector-specific incentives to support
innovation in Brazil, including tax deductions on
royalty payments, R&D investments, and foreign
IP filing fees, as well as subsidies to firms to help
pay scientists’ salaries.
The 2004 innovation law requires all government universities and R&D institutions to open
an IP management or a technology transfer office. One major consequence of these policies will
likely be increased patenting and licensing activities at universities throughout Brazil. Currently,
Unicamp’s rapid establishment of a functioning
technology transfer office stands as a sterling example for other institutions in Brazil to emulate.
Other case studies in this section of the experiences and approaches of a range of institutions include: Arizona State University10 in the
United States, Chinese Universities,11 the Donald
Danforth Plant Science Center12 in the United
States, the National Health Service in England,13
Stanford University’s Office of Technology
Licensing,14 the University of California System,15
and the University of California Agricultural
Experiment Station.16

Product Development
Partnerships (PDPs)
Banerji and Pecoul17 describe the Drugs for
Neglected Diseases Initiative (DNDi) that seeks
to give patients in developing countries the opportunity to directly benefit from new products
of drug R&D for diseases that lack a viable market. Only a tiny fraction (1.3%) of the drugs that
came to market from 1975 to 2004 targeted tropical diseases (such as human African trypanosomiasis, Chagas’ disease, leishmaniasis, helminthic
infections, schistosomiasis, onchocerciasis, malaria, and tuberculosis) that all together make up
12% of the global disease burden and kill more
than 35,000 people a day. The drugs that do exist
are either inaccessible to patients or unbearably
costly. DNDi believes that drug research can exist
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in the public domain, and that patented products
do not always benefit those who need them most.
As clearly articulated in its IP Policy statement, DNDi is committed to managing intellectual property to pragmatically and effectively
advance its mission of providing the most vulnerable populations in developing countries with equitable access to critically needed medicines. As
the preamble of DNDi’s IP policy states:
The DNDi IP approach will be pragmatic, and
decisions regarding the possible acquisition of patents, ownership, and licensing terms will be made
on a case-by-case basis. DNDi will put the needs of
neglected patients first and will negotiate to obtain
the best possible conditions for them. The DNDi’s
decisions regarding IP will contribute to ensuring
access and encouraging further innovations.
DNDi has led two successful campaigns to
negotiate terms that allowed them to get important drugs to the world’s neediest people at minimal cost. In the first case, DNDi approached
French pharmaceutical giant sanofi-aventis in
2003 to develop artesunate-amodiaquine, a
fixed-dose combination therapy for chloroquineresistant malaria. The negotiation process eventually led to a contract with very favorable terms
for DNDi; the drug was made available for production by generic manufacturers with no payment owed to either sanofi-aventis or DNDi,
and sanofi-aventis agreed to supply the drug at
cost to the public sector, NGOs, and international organizations. In the second case, DNDi
successfully collaborated with the University of
California, San Francisco’s (UCSF) business development office to support research leading to
treatments for the lethal human African sleeping
sickness. While conventional wisdom holds that a
university should always seek the largest possible
return on research investment, DNDi was able
to convince university officials of the seriousness
of its mission, and a compromise was reached
that advances the effort to bring new treatments
to persons suffering from this deadly and largely
neglected disease.
In pursuing its humanitarian mission,
DNDi has learned that it is crucial to thoroughly
familiarize all parties with the organization’s aims
and guiding principles. By the end of contract
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negotiations with UCSF, for example, decision
makers expressed great personal satisfaction at
helping to advance DNDi’s work. Through similar efforts DNDi hopes to have developed and
made available, by 2014, six to eight field-relevant treatments.
Boadi and Bokanga18 describe the building of
public-private partnerships in Africa by the African
Agricultural Technology Foundation (AATF).
AATF emerged from a Rockefeller Foundation initiative in the early 2000s following a wide-ranging
and unprecedented consultation among African,
European, and North American stakeholders
who were, and are, actively seeking to improve
food security and reduce poverty in sub-Saharan
Africa. AATF recognizes that new and unique
public-private partnerships (PDPs) are needed to
remove many of the barriers that have prevented
smallholder farmers in sub-Saharan Africa from
gaining access to existing agricultural technologies. Focusing on the creation of these PDPs, it
promotes efforts to create sustainable markets and
seeks to dramatically improve access to agricultural
technologies, materials, and know-how.
AATF has two unique characteristics: first,
it is prepared to in-license technologies from
the private sector, which it then sublicenses to
its partners. This is no small issue and requires
careful considerations of a range of issues, including liability. Second, AATF strongly focuses on
downstream activities or, to put it more broadly,
on technology stewardship. This includes facilitating access to local, national, and regional
markets for products based on transferred technologies. The goals are to create more sustainable
technology transfer mechanisms and to allow
national institutions to more effectively absorb
new technological concepts and adopt them for
productive use.
But the fundamental raison d’être of AATF
goes much deeper than “merely” IP management. As Gordon Conway, then president of the
Rockefeller Foundation, put it in the AATF annual report of 2005:
We should examine the current system and ask
ourselves, ‘How can those who care about the fate
of the small-scale farmer make technological options
more available?’ The rise of a sophisticated global
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IP system covering many building block technologies
has meant public researchers [in Africa] have little
access to new ideas and tools in their field. Left to its
own devices, the gap is likely to grow—with wealthy
nations’ farmers using techniques that are ever more
sophisticated and poor farmers left with the same
tools they have used for centuries.
Other case studies sharing PDP experiences
describe PATH,19 and ICIPE,20 a nonprofit that
partnered with Africert Ltd in transferring standards certification know-how, critical for the introduction of new products.

Focus on Solutions: Accelerating
Product Development and Delivery
Numerous partnership efforts are underway to
accelerate access and delivery for agricultural and
health products in developing countries. For example, in the tropics, where just about everyone
eats eggplant, it is commonly infested by eggplant
fruit and shoot borer (EFSB), which inflicts a
70% crop loss. Conventional efforts to breed for
resistance have been unsuccessful, so farmers rely
heavily on pesticides. These chemicals, however,
are expensive, and the pest is becoming more and
more resistant to them. Moreover, some pesticides
damage the environment and/or are illegal.
Recently, a new solution to the problem
of EFSB was developed in partnership with
many organizations, writes Medakker and
Vijayaraghavan,21 including by MAHYCO, a
private Indian company. It was the first company
in India to develop a transgenic hybrid eggplant
genetically engineered with a gene that provides
resistance to EFSB. The gene (cry1Ac) is obtained
from the bacterium Bacillus thuringiensis (Bt). A
spore-forming bacterium, Bt produces crystal proteins (called Cry proteins) that are toxic to many
species of insects, including EFSB. Cultivation of
the hybrid eggplant reduces the need for pesticide
applications.
This breakthrough was made possible when
MAHYCO obtained the rights under license for
the use of the Bt cry1Ac gene technology for insect
pest management from the Monsanto Company.
The license also allows for sublicensing of the
technology on a royalty-free basis to a partnership

of public institutes and agricultural universities
in India, Bangladesh, and the Philippines. This
consortium is developing a nonhybrid form of Bt
eggplant for use by farmers in developing countries. The nonhybrid form will be less expensive,
but the yield is higher for the hybrid technology.
Therefore, more farmers might choose the hybrid
technology.
Commericial release of the first transgenic
Bt hybrids developed by MAHYCO is planned
for India by the end of 2007, after the fulfillment
of all regulatory requirements. The transgenic Bt
open-pollinated varieties under development by
the public-private partnership are expected to be
commercialized about six months later. This approach to EFSB is an excellent example of how
biotechnology applications can be concurrently
commercialized for the market and subsidized for
poorer market segments.
In health, a prominent example of improvement regarding access to innovations in health is
the PATH Malaria Vaccine Initiative (MVI), a
program funded by the Rockefeller Foundation
that analyzed whether consolidating patents in
the malaria vaccine field could streamline access
by advancing and accelerating the development of
vaccines. The project was designed to ensure market access for the malaria vaccine candidates that
are most likely to receive regulatory approval and
be developed as products. The study, described by
Shotwell,22 assessed the status of the relevant patents, determined their availability for licensing,
and explored the potential of patent consolidation or technology trust to enhance access to the
vaccine. Developing a broad-based technology
trust for existing malaria antigen patents was not
recommended. Instead, several other steps were
recommended for consolidating available rights
and improving access with regard to future patent families.
Before this study, MVI had identified some
potentially obstructive IP issues for a malaria
vaccine for developing-country markets. Public
and academic institutions—institutions with
missions that in many cases include some form
of public benefit—hold many of the patents related to malaria antigenss. As the study’s findings
reveal, with few exceptions the patents held by
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public and academic institutions have been assigned or exclusively licensed to private companies and, therefore, are currently unavailable for
licensing from the original public institution patent holders.
While it may be possible to sublicense these
malarial antigen patents from the current private
holders of the technology, it is likely to be more
difficult and costly; engaging the patent holders to
contribute to a patent pool or clearinghouse also
might be challenging. Moreover, a patent pool for
a malaria vaccine might generate further obstacles: potential antitrust issues, real or perceived,
might trigger scrutiny by the U.S. Department of
Justice and the Federal Trade Commission. And
while the concept of a technology trust or patent
pool may be useful for patents filed in the future,
even some of those would be under option for
license by the private companies holding the current patents. Finally, the number of high-priority
cases for any malaria antigen is small, as is the
number of entities likely to seek access to any given patent family. This makes the expense of a patent pool even less justifiable. Taking all of these
things into consideration means fewer missteps
and faster progress towards a vaccine for malaria.
Other chapters in this section provide case
studies of licensing experience related to the
Cohen-Boyer patents at Stanford University,23
IP issues related to molecular pharming, specifically for plant-derived vaccines,24 corn/maize
breeding and the impact of biotechnology on the
breeding and commercialization process,25 the
University of California’s Strawberry Licensing
Program26 (the most successful program in terms
of the generation of licensing revenues of any
U.S. university), the successful resolution of IP
constraints that led to the introduction of virusresistant papayas,27 and a project on the somatic
embryogenesis of grapes in Chile.28

Conclusions
If indeed the best proof is experience, then the case
studies described here, in the Handbook, and in the
insert of this Executive Guide do indeed speak for
themselves. The experiences represented by these
case studies provide all the evidence needed to
190 | HANDBOOK OF BEST PRACTICES: EXECUTIVE GUIDE

spur further efforts to build upon the IP strengths
of developing countries. Many forward-thinking
people have seen the possibilities, and this section
broadly maps out work that is already underway
around the globe to make these possibilities into
realities. Such experiences offer the most powerful
proof of the benefits that can be obtained through
creative IP management in developing countries
and indeed around the world. n
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Glossary
The definitions contained in the glossary are derived, in
part, from McCarthy’s Desk Encyclopedia of Intellectual
Property.1 In addition to this glossary, the reader is encouraged to refer, for expanded definitions and additional terms, to online intellectual property glossaries,
including those found on the following Web sites:
• World Intellectual Property Organization:
www.wipo.int/tk/en/glossary/index.html.
• U.S. Patent and Trademark Office:
www.uspto.gov/main/glossary/index.html.
• U.S. Department of State:
usinfo.state.gov/products/pubs/intelprp
/glossary.htm.

assignment - A transfer of intellectual property (IP)
rights. An assignment of a patent, for example, is a
transfer of sufficient rights so that the recipient has
title to the patent. An assignment can be a transfer of
all rights of exclusivity in the patent, a transfer of an
undivided portion (for example, a 50 percent interest),
or a transfer of all rights within a specified location (for
example, a certain area of the United States). Anything
less is considered to be a license transfer, rather than a
patent transfer.
Berne Convention - A major multinational copyright
treaty, with nearly 150 members. There are five main
points to the Berne Convention: (1) national treatment,
that is, nondiscrimination with respect to foreign authors
and copyright owners; (2) no formalities, that is, copyright is automatically granted and is not conditioned on
formalities such as registration or notice; (3) minimum
duration of copyright; (4) moral rights provided to authors under the national laws of member nations; and

(5) copyright protection independent of whether such
protection exists in the country of origin.
best mode - A condition for the grant of a patent, found
in the patent specification. An inventor must describe
and disclose the best method he or she knows for carrying out the invention.
claims - The section of the patent that defines an invention (the technology that is the exclusive property of the
patentee for the duration of the patent) and is legally
enforceable; that is, the claims set the metes and bounds
of the patent rights. The patent specification must conclude with a claim, particularly pointing out and distinctly claiming the subject matter that the applicant regards as the invention or discovery. The claim or claims
are interpreted as set forth in the specification: the terms
and phrases used in the claims must be sufficiently described in the specification, that is, patent claims must
read in the light of the specification. The specification
discloses and the claims define the invention.
commercialization - The process of taking an invention
or discovery to the marketplace. It involves working the
idea into a business plan, consideration of protection
options, and determining how to market and distribute
the finished product.
compulsory license - A license granted by the state upon
request to a third party that, through the license, is permitted to exploit a patented invention after the owner
of the patent has refused to provide a voluntary license
under acceptable conditions.
confidential disclosure agreement - See confidentiality
agreement.

MIHR/PIPRA. 2007. Glossary. In Executive Guide to Intellectual Property Management in Health and Agricultural Innovation:
A Handbook of Best Practices (Krattiger A, RT Mahoney, L Nelsen et al.). MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz
Foundation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments-International Institute (Ithaca, USA). Available online at
www.ipHandbook.org.
© 2007. MIHR/PIPRA. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial purposes is permitted and encouraged.
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confidentiality agreement (nondisclosure agreement,
confidential disclosure agreement) - A legal document
through which intellectual property can be disclosed by
one party to another wherein the latter party is permitted to use the information for certain purposes, and
only those purposes, that are stated in the agreement
and agrees not to disclose the information to others.
contributory infringement - An indirect infringement
of IP rights in which people, or organizations, contribute
to a direct act of infringement by another (in order to aid
or abet the act of infringement), for example, knowingly
selling an article that is used solely to practice a patented
process or to manufacture a patented product.
copyright - An exclusive right conferred by the government on the creator of a work to bar others from reproducing, adapting, distributing to the public, performing
in public, or publicly displaying said work. Copyright
does not protect an abstract idea; it protects only the
concrete expression of an idea. In order to obtain copyright protection, a work must have originality and some
modicum of creativity.
cross licensing - A legal agreement in which two or more
parties that have potentially conflicting patent claims, or
other conflicting IP rights, reach an agreement to share
the IP rights in question through a reciprocal licensing
arrangement.
dependent claim
A claim in a patent that refers back to a previous claim and
defines an invention that is narrower in scope than that in
the previous claim. A dependent claim is written in such a
way as to be more restricting than the technology defined
in the previous claim (often an independent claim).
descriptive mark - A word, picture, or other symbol that
describes some quality or trait of a product or service,
such as the purpose, size, color, class of users, or end effect on users. A descriptive term is not considered to be
inherently distinctive; to establish validity of a descriptive mark for registration or protection in court, proof
of acquired distinctiveness of the mark is needed. This
acquired distinctiveness confers secondary meaning. For
example, “Kentucky Fried Chicken” a mark that originally was descriptive, subsequently acquired secondary
meaning as a trademark for a distinctive type of commercial food product.
design patent - A government grant of exclusive rights
in a novel, nonobvious, and ornamental industrial design. A design patent confers the right to exclude others
from making, using, or selling designs that closely resemble the patented design. A design patent covers the
ornamental aspects of a design; its functional aspects are
covered by a utility patent. A design patent and a utility
patent can cover different aspects of the same article.
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differential pricing (tiered pricing) - The practice of
setting different prices for different markets—typically
higher prices in richer markets and lower prices in poorer markets.
disclosure of origin - A requirement imposed on patent applicants to disclose in patent applications the
geographic origin of biological material on which the
invention (subject of the patent application) is based.
divisional patent application - A patent application that
is carved out of a parent application, such that the parent
application is divided into one or more divisional patent
applications. Divisional applications are entitled to the
original filing-date priority of the parent application.
due diligence - Investigations undertaken to assess the
ownership and scope of one or more IP rights that are
being sold, licensed or used as collateral in a transaction.
This is done in order to identify business and legal risks
associated with the IP rights being analyzed.
duration - The term, or length of time that an IP right
lasts. A U.S. utility patent on an invention, for example,
has a duration of 20 years from the date on which the
patent application was filed, as does a plant patent. The
duration of a U.S. copyright is usually the life of the
author plus 70 years (for works created after January 1,
1978). Protection of information as a trade secret lasts
as long as the information remains secret. Duration of
a trademark continues as long as it is used (as a source
indicator) and properly maintained/protected.
examination - See patent examination.
exclusive license agreement - A legal document licensing intellectual property to another party for its exclusive
use. Exclusively licensed patent rights cannot, within the
scope or field of the exclusive license, be subsequently or
simultaneously licensed to any other party.
field-of-use restriction - A provision in an IP license that
restricts use of the licensed intellectual property by the
licensee to only in a defined product or service market.
first to file - A rule under which patent priority is determined. The rule gives priority to the party that first
files a patent application for an invention, rather than
to the party that is first to invent. First to file is followed
by almost every nation in the world except the United
States. For trademarks, priority between conflicting applications to register a trademark is handled by publishing the application with the earliest filing date for possible opposition by the applicant with a later filing date.
In the United States, ownership of a trademark is determined by who was first to use it, not by who was first to
file an application for registration. However, under the
intent-to-use system, an application for registration can
be filed prior to actual use of a mark.
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first to invent - A rule under which patent priority is
determined by which inventor was the first to actually
invent, rather than by who was the first to file a patent application. This is the rule followed in the United
States. Compare to first to file.
freedom to operate - The ability to undertake research
and/or commercial development of a product without
infringing the unlicensed intellectual or tangible property rights of others.
functionality - That aspect of design that makes a product work better for its intended purpose, as opposed to
making the product look better or to identify its commercial source.
Indigenous Cultural and IP Rights - Indigenous
Cultural and IP Rights refers to the rights to a heritage,
that its, to the objects, sites, knowledge, and methods
of transmission of communities that have traditionally
been defined by the social ownership of knowledge.
This right privileges customary law over modern law.
Heritage includes all aspects of culture (art, music,
dance, literature, and so on), indigenous knowledge
(medicinal, nutritional), and land management practices. There are numerous attempts today to give legal
substance and scientific validity to indigenous knowledge. Article 29 of the Draft Declaration of the Rights of
World Indigenous People states that “[i]ndigenous people
are entitled to the recognition of full ownership, control and
protection of their cultural and intellectual property.”
industrial property - Industrial property is a subset of
intellectual property, referring to those types of intellectual property that have an industrial application.
Specifically, it refers to patents, trademarks, designs,
mask works, and plant breeders’ rights.
infringement - An invasion of an exclusive right of intellectual property. Infringement of a utility patent includes making, using, or selling a patented product or
process without permission. Infringement of a design
patent involves fabrication of a design that, to the ordinary observer, is substantially the same as an existing
design, where the resemblance is intended to induce the
observer to purchase one thing supposing it to be another. Infringement of a trademark consists of the unauthorized use or imitation of a mark that is the property
of another in order to deceive, confuse, or mislead others. Infringement of a copyright involves reproducing,
adapting, distributing, performing in public, or displaying in public the copyrighted work of someone else.
intellectual property (IP) - Creative ideas and expressions of the human mind that have commercial value
and are entitled to the legal protection of a property
right. The major legal mechanisms for protecting intellectual property are copyrights, patents, and trademarks.

IP rights enable owners to select who may access and use
their intellectual property and to protect it from unauthorized use.
international patent application - See Patent
Cooperation Treaty (PCT).
intellectual property management - The means by
which an institutionally owned IP portfolio is managed with regard to marketing, patenting, licensing, and
administration.
invention - The creation of a new technical idea and of
the physical embodiment of the idea or the means to
accomplish it. To be patentable, an invention must be
novel, must have utility, and would not have been obvious to those possessing ordinary skill in the particular
art of the invention.
inventive step (nonobviousness) - A condition for patentability, which means that the invention would not
be obvious to someone with knowledge and experience
in the technological field of the invention. According to
the European Patent Convention, “An invention shall be
considered as involving an inventive step if, having regard
to the state of the art, it is not obvious to a person skilled
in the art.”
joint inventors - Two or more inventors of a single invention who work together during the inventive process.
know-how - Information that enables a person to accomplish a particular task or to operate a particular device or process. Refer to trade secret.
license - A grant of permission to use an IP right within
a defined time, context, market line, or territory. There
are important distinctions between exclusive licenses and
nonexclusive licenses. An exclusive license is “exclusive”
as to a defined scope, that is, the license might not be
the only license granted for a particular IP asset, as there
might be many possible fields and scopes of use that can
also be subject to exclusive licensing. In giving an exclusive license, the licensor promises that he or she will not
grant other licenses of the same rights within the same
scope or field covered by the exclusive license. The owner
of IP rights may also grant any number of nonexclusive
licenses covering rights within a defined scope. A patent
license is a transfer of rights that does not amount to an
assignment of the patent. A trademark or service mark
can be validly licensed only if the licensor controls the
nature and quality of the goods or services sold by the
licensee under the licensed mark. Under copyright law,
an exclusive licensee is the owner of a particular right of
copyright, and he or she may sue for infringement of the
licensed right. There is never more than a single copyright in a work regardless of the owner’s exclusive license
of various rights to different persons.
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licensee - A party obtaining rights under a license
agreement.
licensor - A party granting rights under a license agreement.
license out - The process by which one person, company,
or institution extends to another person, company, or institution permission to use the former’s intellectual property.
license in - The process by which a person, company,
or institution obtains permission to use the intellectual
property owned by someone else.
material transfer agreement (MTA) - A contract between the owner of a tangible material and a party seeking the right to use the material for research or other
assessment purposes. The material may be either patented or unpatented. Material transfer agreements tend
to be shorter than license agreements. The purpose of
an MTA is to document the transfer the material and
outline the terms of use, including identification of the
research or assessment project, terms of confidentiality,
publication, and liability.
maintenance fees - Fees for maintaining in force a patent. The fees typically have to be paid at irregular intervals, depending on the jurisdiction, and significantly
increase over time.
notice - A formal sign or notification attached to items
that embody or reproduce an intellectual property assset—for example, the presence of the word patent or its
abbreviation, pat., together with the patent number, on
a patented article made by a patent holder or his/her
licensees. The formal statutory notice of U.S. trademark registration is the letter R inside a circle: ®, Reg.
U.S. Pat. & Tm. Off., or Registered in U.S. Patent and
Trademark Office. Many firms use informal trademark
notices, such as Brand, TM, Trademark, SM, or Service
Mark, adjacent to words or other symbols considered
to be protectable marks. Notice of copyright consists of
the letter C in a circle symbol: © or the word Copr. or
Copyright, the copyright owner’s name, and the year of
first publication.
nonassignable - A condition whereby a licensing agreement and/or the rights, obligations, and terms thereof
may not be assigned to any party who is not a signatory
to the agreement.
nondisclosure agreement
See confidentiality agreement.
nonexclusive license
A license under which rights are granted to the licensee
but not exclusively to that licensee; the licensor reserves
the right to give the same or similar rights to use the
licensed materials to other parties.
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nonobviousness
One of three conditions an invention must meet to be
patentable. See also inventive step.
nontransferable
The licensing agreement and/or the rights, obligations,
and terms thereof that may not be sold, given, assigned,
or otherwise conveyed to any party who is not a signatory to the agreement.
novelty
One of three conditions an invention must meet to be
patentable.
obviousness
A condition of an invention that makes it ineligible to
receive a valid patent; the condition of an invention
whereby a person with ordinary skill in a field of technology can readily deduce it from publicly available information (prior art). See also ordinary skill in the art.
ordinary skill in the art
The level of technical knowledge, experience, and expertise possessed by the ordinary engineer, scientist, or designer in a technology that is relevant to an invention.
Paris Convention
The main international treaty governing patents,
trademarks, and unfair competition. The Convention
is administered by the World Intellectual Property
Organization (WIPO) and has four principal provisions: (1) national treatment for all seeking protection
of IP rights, whether foreign or nationals; (2) minimum
level of protection; (3) Convention priority, with a
specified time (12 months for patents, six months for
trademarks) for applications to be filed in other member
nations; and (4) administrative framework within the
Paris Union.
patent (U.S.)
A grant by the federal government to an inventor of the
right to exclude others from making, using, or selling
his or her invention. There are three kinds of patents in
the United States: a standard utility patent on the functional aspects of products and processes; a design patent
on the ornamental design of useful objects; and a plant
patent on a new variety of a living plant. Patents do not
protect ideas, only structures and methods that apply
technological concepts. Each type of patent confers the
right to exclude others from a precisely defined scope of
technology, industrial design, or plant variety. In return
for the right to exclude, an inventor must fully disclose
the details of the invention to the public so that others
can understand it and use it to further develop the technology. Once the patent expires, the public is entitled to
make and use the invention and is entitled to a full and
complete disclosure of how to do so.

GLOSSARY

patent application - A technical document that describes
in detail an invention for which a patent is sought.

resources shall be subject to the prior informed consent of
the country providing the resources.

patent examination - A process of review of a patent
application, undertaken by a patent examiner, to determine whether the application complies with all statutory requirements for patentability. The examination
process reviews prior art to ensure novelty, along with
determining compliance with other statutory requirements, rules, and matters of procedure and form.

priority date - The date of the first filing of a patent application that describes an invention in detail. Priority
date, as well as patentability, with respect to novelty of
invention, is determined in light of any relevant prior art
existing at the time of filing. In other words, depending
on the specific jurisdiction, if the invention was known
or published previous to the priority date, the applicant
will be unable to obtain a patent.

Patent Cooperation Treaty (PCT) - An international
treaty that provides a mechanism through which an applicant can file a single application that, when certain
requirements have been fulfilled, may then be pursued
as a regular national filing in any of the PCT member
nations. There are currently more than 120 PCT member nations.
patent pooling - A patent pool is an agreement between
two or more patent owners to license one or more of
their patents to one another or to third parties. A patent
pool allows interested parties to gather all the necessary
tools to practice a certain technology.

provisional application - A provisional application is a
document in patent actions that serves to establish an
early priority date of an invention. A provisional application will not mature into a regular application, and
does not form the basis of a grant of a patent. It is a
document that precedes the complete application upon
which the grant is based. A provisional application establishes a priority date for disclosure of the details of an
invention and allows a period of up to 12 months for
development and refinement of the invention before the
patent claims take their final form in a complete, regular
patent application.

patent searching - A process carried out by the patent
examiner for checking the novelty of a patent application. The subsequent patent research report lists published items comprising both patent and nonpatent literature relevant to the subject of the invention.

process claim - A claim of a patent that covers the method by which an invention is performed by defining the
steps to be followed. This differs from a product claim
or an apparatus claim, which covers the structure of a
product.

plant breeders’ rights - Plant breeder’s rights are used to
protect new varieties of plants by giving exclusive commercial rights to market a new variety or its reproductive material.

product-by-process claim - A patent claim through
which a product is claimed by defining the process by
which it is made. The product-by-process form of claim
is most often used to define new chemical compounds,
since many new chemicals, drugs, and pharmaceuticals
can practicably be defined only by describing the process of making them.

plant patent - In the United States, the Plant Patent Act
of 1930 provides a grant of exclusive IP rights to applicants who have invented or discovered a new asexually propagated variety of plant. Tuberous plants are not
covered by plant patents.
plant variety protection (PVP) - A form of patentlike protection for sexually propagated plants, as well
as hybrids, tubers, and harvested plant parts. The Plant
Variety Protection Act of 1970 is administered by the
U.S. Department of Agriculture and not the U.S. Patent
and Trademark Office (which does issue plant patents).
prior art - The existing body of technological information against which an invention is judged in order to
determine whether it is novel and nonobvious and can
thus be patented.
prior informed consent - The consent given by a party
with respect to an activity after being fully informed of
all material facts relating to that activity. The Convention
for Biological Diversity requires that access to genetic

public domain - The status of an invention, creative
work, commercial symbol, or any other creation that is
not protected by some form of IP right. Items that have
been determined to be in the public domain are available for copying and use by anyone.
reduction to practice - The physical part of the inventive process that completes and ends the process of invention by demonstrating that the invention has a practical application. Reduction to practice can be carried
out either by the actual construction of an apparatus, by
performing the steps in a process, or by formally filing a
patent application (constructive reduction to practice).
research tools - The term research tool includes the full
range of tools that scientists may use in the laboratory,
including cell lines, monoclonal antibodies, reagents,
animal models, growth factors, combinatorial chemistry and DNA libraries, clones and cloning tools (such
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as PCR), methods, and laboratory equipment and machines.2 There is concern about the patenting of research
tools, because such patents may inhibit the free undertaking of research.
royalty - Income derived from the sale or use of a licensed product or process.
tiered pricing - See differential pricing.
trademark - (1) A word, slogan, design, picture, or other
symbol used to identify and distinguish goods. (2) Any
identifying symbol, including a word, design, or shape
of a product or container, that qualifies for legal status as
a trademark, service mark, collective mark, certification
mark, trade name, or trade dress. Trademarks identify
one seller’s goods and distinguish them from goods sold
by others. They signify that all goods bearing the mark
come from, or are controlled by, a single source and are
of an equal level of quality. And they advertise, promote,
and generally assist in selling goods. A trademark is infringed by another if the second use causes confusion of
source, affiliation, connection, or sponsorship.
trade secret - Business information that is the subject of
reasonable efforts to preserve confidentiality and has value because it is not generally known in the corresponding trade. Such confidential information is protected
against those who gain access to it through improper
methods or by a breach of confidence. Misappropriation
of a trade secret is a type of unfair competition.
traditional knowledge - Tradition-based creations, innovations, literary, artistic or scientific works, performances
and designs originating from or associated with a particular people or territory.
Trade-Related Aspects of Intellectual Property Rights
(TRIPS) - An international agreement that was initiated
under the forerunner of the World Trade Organization
(WTO), the General Agreement on Tariffs and Trade
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(GATT), under the Uruguay round of trade negotiations. The TRIPS Agreement is the most comprehensive
multilateral agreement on Intellectual Property covering
all IP instruments. It was the first IP rights accord to
legitimize the patenting of living organisms. TRIPS provides the guidelines for the harmonization of IP rights
laws under the WTO. All WTO member countries have
substantive TRIPS obligations.
unfair competition - Commercial conduct that the law
views as unjust, providing a civil claim against a person who has been injured by the conduct. Trademark
infringement has long been considered to be unfair
competition. Other recognized legal categories of unfair
competition are false advertising, trade libel, misappropriation of a trade secret, infringement of the right of
publicity, and misappropriation.
UPOV (the Convention of the International Union for
the Protection of New Varieties of Plants) - An international treaty that guarantees to plant breeders in member nations national treatment and a right of priority.
National plant variety protection statutes of member
nations are brought into harmonization with the various UPOV provisions, for example, the requirements of
distinctness, uniformity, stability, and novelty for new
crop varieties.
utility - The usefulness of a patented invention. To be
patentable an invention must operate and be capable
of use, and it must perform some “useful” function for
society. n
1

McCarthy JT, RE Schechter and DJ Franklyn. 1995 and
2004. McCarthy’s Desk Encyclopedia of Intellectual
Property, 2nd and 3rd editions. The Bureau of National
Affairs: Washington, DC.

2

From NIH Research Tools Guidelines. ott.od.nih.gov/
policy/rt_guide.html.

BIOS

Biographical Sketches of Authors
and Members of the Board of Patrons
ARNTZEN, Charles J.
Charles Arntzen is the Florence Ely Nelson Presidential
Endowed Chair at Arizona State University (ASU) in
Tempe and a Regents Professor. He was Director of
Research at the DuPont Company in Delaware from
1984 to 1988, followed by service as Deputy Chancellor
for Agriculture, Dean, College of Agriculture and Life
Sciences and Director, Texas Agricultural Experiment
Station at the Texas A&M University System. In 1995
became President and CEO of Boyce Thompson
Institute, a not-for-profit corporation affiliated with
Cornell University. He was elected to the US National
Academy of Sciences in 1983 and to the National
Academy of India the following year. He currently serves
as a member of the Council of Advisors on Science &
Technology of President George W. Bush and the US
Nanotechnology Advisory Board.
He is a fellow of The American Association for
the Advancement of Science and received the Award
for Superior Service from the U.S. Department of
Agriculture for international project leadership in India.
He served as chairman of the National Biotechnology
Policy Board of the National Institutes of Health,
as chairman of the National Research Council’s
Committee on Biobased Industrial Products, and on
the National Research Council’s Committee on Space
Biology and Medicine. He served for eight years on
the Editorial Board of Science. Dr. Arntzen currently
serves on the Board of Directors and the Scientific
Advisory Board of Advanced BioNutrition, Inc., and
is on the Advisory Board of the Burrill & Company
Agbio Capital Fund and The Nutraceuticals Fund. He
also serves as a Distinguished Advisor on the Council
for Biotechnology, and is a member of the Board of
Directors of the National Center for Genome Resources
in Sante Fe, New Mexico.
Beachy, Roger
Roger Beachy is president of the Donald Danforth Plant
Science Center in St. Louis, Missouri. He previously
held academic positions at Washington University,
St. Louis, and the Scripps Research Institute, La Jolla,
California. His research includes projects to reduce virus infection in plants via biotechnology, and in studies
of the control of gene expression in plants. Beachy is a
member of the U.S. National Academy of Sciences and a
Fellow of the Academy of Microbiology; he has received

several awards for his work, including the Wolf Prize
in Agriculture. The Danforth Center has committed
significant efforts to research in developing countries,
including through private-public partnerships, and
Beachy is involved in a variety of efforts with regard to
rationalizing regulations that control commercialization
of agricultural biotechnology.
Beachy is President of the International Association
of Plant Biotechnology. He belongs to numerous institutional boards, including the PNAS Editorial Board, the
NRC Governing Board, the Board on Agriculture and
Natural Resources (National Research Council of the
National Academy of Sciences), Malaysia’s International
Advisory Panel, and the Governing Board of Directors
of the International Crops Research Institute for the
Semi-Arid Tropics (ICRISAT), and the Burrill and
Company Board of Advisors.
Bennett, Alan B.
Alan Bennett currently serves as the Associate Vice
Chancellor for Research at U.C. Davis. He is responsible
for technology transfer, strengthening research-based alliances with industry, and supporting technology-based
economic development in the Sacramento/Davis region.
He is the founding Executive Director of the Public
Intellectual Property Resource for Agriculture (PIPRA),
an organization consisting of 37 universities in nine
countries that is dedicated to the collective management
of intellectual property and supports broad commercial
innovation and humanitarian uses of technology in
agriculture. From 2000 to 2004, Dr. Bennett served as
the Executive Director of the University of California
Systemwide Office of Technology Transfer and Research
Administration, where he was responsible for IP management and research policy for the University of California
system; this task involved managing a portfolio of more
than 5,000 cases, 700 active licenses, and revenue in
excess of US$350 million for the four-year period. He
earned B.S. and Ph.D. degrees in Plant Biology at U.C.
Davis and Cornell University, respectively. He joined
the U.C. Davis faculty in 1983. His research in plant
molecular genetics has focused on cell-wall disassembly
and fruit development. Dr. Bennett has published over
130 research papers in leading scientific journals, holds
several utility patents related to crop quality traits, and
is a regular speaker at universities, international symposia, and private companies. He is a Fellow of the
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American Association for the Advancement of Science
(AAAS) and of the California Council for Science and
Technology (CCST).

and Vice-Chairman of the Council of Scientific Advisers
to the International Center for Genetic Engineering and
Biotechnology (ICGEB) in Italy and India.

Borlaug, Norman E.
In 1970, Norman Borlaug won the Nobel Peace Prize
for his lifelong work to feed a hungry world. His work,
more than that of any other person, is credited with saving lives.
In 1944, Dr. Borlaug joined the Rockefeller
Foundation’s pioneering technical-assistance program in Mexico, at which he was a research scientist
in charge of wheat improvement. For the next two
decades, he worked to solve a series of wheat production problems in Mexico and to train a generation of
young scientists.
With the establishment of the International Maize
and Wheat Improvement Center (CIMMYT) in
Mexico in 1966, Borlaug assumed leadership of the
wheat program; he continues to serve as a consultant for
it. The high-yielding, disease-resistant wheat cultivars he
developed, along with improved management practices,
transformed agricultural production in Mexico during
the 1950s and in Asia and Latin America in the 1960s
and 1970s. This transformation has come to be known
as the Green Revolution.
In 1984, Dr. Borlaug joined Texas A&M University
and was named Distinguished Professor of International
Agriculture. Since 1986, he has also served as president of the Sasakawa Africa Association and leader of
the Sasakawa-Global 2000 agricultural program in
Sub-Saharan Africa, in partnership with former U.S.
President Jimmy Carter and Yohei Sasakawa.
Borlaug has been awarded 58 honorary doctorate
degrees, and is a member or fellow of the academies
of science in 12 nations. The U.S. National Academies
of Science awarded him the National Service Medal
in 2002 and in 2004 President Bush bestowed upon
Borlaug the U.S. National Medal of Science. He was
the driving force behind the establishment of the World
Food Prize in 1985 and serves as Chairman of its
Council of Advisors.

DIOUF, Jacques
Jacques Diouf is Director-General of the Food and
Agriculture Organization of the United Nations
(FAO). He has held this position since 1994 and is
currently serving his third six-year term, which began
in January 2006. Over the years, he has held numerous position including Ambassador for the Senegalese
Permanent Mission to the United Nations, member of
the Senegalese Parliament, and Secretary of State for
Science and Technology for Senegal. In addition, he
has represented Africa in the Consultative Group on
International Agricultural Research and served on the
Council of African Advisers of the World Bank. The
recipient of numerous awards from countries in every
corner of the world for his work in agricultural development, Dr. Diouf has undertaken field trips to various
agricultural institutions around the world and has participated in major international meetings representing
Senegal and the Central Bank for West African States.
He has been a leading voice on issues related to agricultural development and the environment.

CHEN, Zhang Liang
Zhang Liang Chen was born on February 3, 1961, in
Fujian, China. He received his Ph.D. in 1987 from
Washington University for his research in the Division
of Biology and Biomedical Sciences in the field of plant
molecular biology and his work in early transgenic
plant research. He then returned to China as an associate professor. Two years later, he was a full professor
at Beijing University. He has continued his research
in transgenic plants and biosafety. He served as director of National Key Laboratory of Protein Engineering
and Plant Genetic Engineering. In 1995, he became
vice-president of research at Peking University. In
2002, he became the president of China Agricultural
University. He and his research group have published
over 190 international papers and seven book, and
hold over eight patents.
Dr. Chen is also Chair of the Plant Biotech Committee
of UNESCO, Consultant for the International Society
for Plant Molecular Biology (ISPMB), and member of the Sino-Euro Administration Committee for
Biotechnology Cooperation. He also serves as a member
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Dryden, Sam
Sam Dryden is internationally recognized as a successful
investor and developer of life-sciences ventures. His
particular expertise is in the application, scale-up and
commercialization of early-stage technologies worldwide.
Sam is a Managing Director of Wolfensohn &
Company, a corporate advisory and investment firm
located in New York, where he focuses on private equity
investments in biofuels and other alternative energies.
He is also CEO of Emergent Genetics, LLC—a lifesciences investment holding company.
Until June 2006, Sam served as the Chair and
Corporate CEO of Emergent Genetics, Inc.—a
global leader in the development and marketing of
biotechnology-enhanced seed products. Emergent
Genetics’ operations were based in Europe, the United
States, Argentina, and Brazil and comprised one of the
largest seed companies in India. The largest portion
of the company’s worth was acquired in April 2005
by Monsanto Company. Remaining operations were
acquired in June 2006 by Syngenta AG.
Sam began his career as an analyst with the U.S.
Department of Commerce, Bureau of Economic
Analysis, where he was responsible for modeling and
forecasting selected sectors of the U.S. economy. He
was then employed by the Union Carbide Corporation
from 1974 to 1980, with responsibilities for various
aspects of new corporate ventures. These transactions
involved extended assignments in Japan, Europe, and
South America.
In 1980, Sam led the spinout of Union Carbide’s
biotechnologies and related business operations and
subsequently cofounded Agrigenetics Corporation and
served as its president and CEO. The company grew to
become one of the world’s largest seed enterprises and was
acquired in 1985. It is now part of Dow AgroSciences.
During this same period, he was also chairman of an
affiliated partnership that managed and invested US$60
million in proprietary plant sciences research conducted

BIOS

in leading universities, as well as private and public
research institutions worldwide.
Following the sale of Agrigenetics, Sam founded and
became President of Big Stone Inc.—a private venture
investment and development company focused on the
life sciences. The firm participated in founding over a
dozen companies in areas such as biopesticides, novel
nucleic acid-based therapeutics and diagnostic products,
transgenic animals, fermentation-based production of
vitamins, pharmaceutical clinical trialing, environmental
toxicological testing, and biotherapeutics. Sam also
served as the nonexecutive chairman of Celgro Inc.,
independent venture of Celgene Corporation and a
company focused on the development of novel, singleisomer, agricultural chemical compounds.
In addition to his for-profit activities, Sam has
extensive pro bono involvement in efforts relating to
food security and international economic development.
Currently he is an advisor to the World Bank regarding
rural development strategy. He is a member of the board
of directors of the Global Crop Diversity Trust. Sam
serves on the National Academies Panel on Science
and Technology for Global Sustainability. In the past,
he served on the steering committee for the Global
Assessment on Agricultural Science and Technology, led
by the World Bank. He was a member of the executive
council, as well as chair of the Private Sector Committee
of the Consultative Group on International Agricultural
Research. He has been an advisor to the Rockefeller
Foundation and a member of the Design Advisory
Committee and Scientific Advisory Board of its African
Agricultural Technology Foundation—an organization
created for the advancement of African food security. In
the mid-80’s, Sam chaired a Rockefeller Brothers Fund
development initiative to benefit developing country food
security. He also served on the Board of the South/North
Development Initiative—a private Rockefeller Family
foundation for alleviation of rural poverty in less-developed
countries through entrepreneurial development. He is
a past member of the U.S. Government’s Agricultural
Sciences and Technology Review Board.
Sam is a member of the Council on Foreign Relations
and serves on its Advisory Committee on Intellectual
Property and American Competitiveness. He has
also served on its study group analyzing trade issues
between the United States and Europe surrounding
genetically-modified foods.
He has written and lectured widely on the policy
issues of food security, the evolving nature of global
public goods and new mechanisms for public and private
sector relations. In this regard, his travels have taken
him on missions to most countries in Latin America,
including Cuba, as well as Europe, Asia, Africa, and the
Middle East.
Sam, a native of eastern Kentucky, received his BA in
economics from Emory University in 1973.
FATHALLA, Mahmoud F.
Dr. Fathalla is a professor of Obstetrics and Gynecology
and former Dean of the Medical School at Assiut
University in Egypt and is currently the chairman of the
World Health Organization (WHO) Global Advisory
Committee on Health Research. He has served as the
Director of the UNDP, UNFPA, World Bank, WHO
Special Programme of Research, Development and

Research Training in Human Reproduction and has
served as a consultant to various international bodies
such as the WHO, UNPF, IPPF, Population Council,
and the Ford and Rockefeller foundations. He is the author of more than 150 scientific publications. Professor
Fathalla has been an international campaigner for Safe
Motherhood and a founder of the Safer Motherhood
Initiative. His scientific interests include women’s health,
safe motherhood, reproductive health, ethics and human
rights, and contraceptive research and development.
Fernández, Carlos
Carlos Fernández studied agronomy at Universidad
de Chile. After working as an Assistant Professor at
the Agronomy Faculty of the same university, he received a Ph.D. in Plant Physiology at the University
of California, Davis. Upon graduation, he joined
Monsanto Company, where he held various management positions that gave him responsibilities in several countries. He led the development of agricultural
technologies in Latin American countries, first from the
company headquarters in St. Louis and later from Sao
Paulo, Brazil. Among other things, he contributed to
the development of new applications for Roundup, the
most successful herbicide in the world, and the development of nontillage systems for various crops. In Europe,
he developed new products and actively participated
in the design of the Roundup post-patent policy for
Europe and Africa.
While working for Monsanto in California, he evaluated and contributed to the development and introduction
of transgenic crops to the market. During his stay in
California, he returned to the University of California,
Davis, and earned an M.B.A. In 1999, he returned to
Santiago, Chile, and began working at Fundación Chile,
where he coordinated programs related to technology
transfer, intellectual property, regulatory matters, and
the development of transgenic crops. He contributed to
the Cooperative Agreement between the University of
California, Davis and Fundación Chile. In addition to his
work at Fundación Chile, he serves as a consultant to the
Food and Agricultural Organization of the UN and the
Chilean Ministry of Economy. Some of his latest contributions as a consultant include two studies sponsored by
the Ministry of Economy of Chile: “Comparative Analysis
of Biotechnology Policies in N. Zealand, Canada, United
States, Australia, Japan, China, Argentina, Brazil, Spain
and Chile” and “Formulation of a Model for a Technology
Transfer Office for Chile.” He also contributed to a recent
study, sponsored by UNDP, titled “Commercialization
Impact on Agricultural Export Products Caused by the
Introduction of GMO in Chile.”
As of July 2006, Dr. Fernández is the Head of
Strategic Studies and the technology transfer unit of the
Foundation for Agriculture Innovation.
FREIRE, Maria
Dr. Maria C. Freire is CEO and President of The Global
Alliance for TB Drug Development, a position she has
held since 2001. During her service, the Alliance has
built the largest pipeline of TB drugs in the world, advanced compounds into clinical testing, and pioneered
precedent-setting agreements with industry.
From 1995 to 2001, Dr. Freire directed the Office
of Technology Transfer at the NIH, where she was
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responsible of technology transfer policies and procedures
for the Department of Health and Human Services and
for patenting and licensing activities at the NIH and
the FDA.
Dr. Freire is an internationally recognized expert
in technology commercialization. She is a member
of the NIH Advisory Board for Clinical Research, a
Governor of the New York Academy of Sciences, and
the Chair of the Working Group for New TB Drugs for
the global Stop TB Partnership. Dr. Freire was selected as one of ten Commissioners of the World Health
Organization’s Commission on Intellectual Property
Rights, Innovation and Public Health (CIPIH) and a
member of Time magazine’s Global Health Summit
Board of Advisors.
Born in Lima, Peru, Dr. Freire trained at the
Universidad Peruana Cayetano Heredia. She holds a
Ph.D. in biophysics and completed post-graduate studies in immunology and virology at the University of
Virginia and the University of Tennessee, respectively,
and at the John F. Kennedy School of Government at
Harvard University. She has received numerous national and international awards, including the Arthur
S. Flemming Award, DHHS Secretary’s Award for
Distinguished Service, and the Bayh-Dole Award.
Graff, Gregory D.
Gregory D. Graff is an applied economist with expertise
in the economics of innovation, entrepreneurship, intellectual property, and technology transfer, especially as
they apply to the agricultural life sciences and biotechnology. He applies microeconomic and econometric
tools to scientific, patent, regulatory, and commercial
data, building uniquely thorough industry-level datasets to analyze the impacts of innovation and technology
transactions on markets, industrial organization, and
the political economy of science policy.
Dr. Graff currently manages research projects for
the Public Sector Intellectual Property Resource for
Agriculture (PIPRA), a consortium of 37 agricultural
research universities and institutes that is hosted by
the University of California. PIPRA uses an innovative model of collaborative intellectual property management to mobilize its members’ technologies for the
purpose of genetically improving “orphan” crops. Dr.
Graff has taught as a university lecturer at both U.C.
Berkeley and U.C. Davis and has recently published
articles in The Review of Economics and Statistics, World
Development, California Management Review, and Nature
Biotechnology as well as chapters in several books. Dr.
Graff has a Ph.D. in agricultural and resource economics from U.C. Berkeley (2002), an M.A. in economics
from Ohio State University (1995), and a B.S. in biology from Cornell University (1992).
HENNESSEY, William O.
William Hennessey is Professor of Law at the Franklin
Pierce Law Center. He directed Pierce Law’s graduate
programs in intellectual property and summer from 1986
until 2003. A noted IP expert, author, and lecturer, he recently directed the fourth annual Pierce Law Intellectual
Property Summer Institute at Tsinghua University
School of Law in Beijing, China. He co-authored a legal
casebook on international IP law and policy.
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Professor Hennessey has served as a legal advisor to the governments of Indonesia and the People’s
Republic of China and has served as a consultant to
the World Bank, Asian Development Bank, United
Nations Development Programme, U.S. Agency for
International Development, U.S. Department of State,
and the U.S. Patent and Trademark Office. He has also
served as consultant for the World Intellectual Property
Organization in many countries on various issues concerning IP protection and economic development.
IDRIS, Kamil
Dr. Kamil Idris has been Director General of the World
Intellectual Property Organization (WIPO) since
November 1997. He is head of the International Union
for the Protection of New Varieties of Plants (UPOV).
He was formally re-appointed to a second six-year term as
Director General of WIPO on May 27, 2003. His mandate will end on November 30, 2009. Formerly, Kamil
Idris was a member of the International Law Commission
from 1992 to 1996 and from 2000 to 2001.
Kamil Idris holds a Bachelor of Law (LL.B.) from
Khartoum University, Sudan; a Bachelor of Arts in
Philosophy, Political Science and Economic Theories
from Cairo University, Egypt; a master’s in International
Law and International Affairs from Ohio University,
United States; and a Doctorate in International Law
from the Graduate Institute of International Studies,
University of Geneva, Switzerland.
JAHN, Molly
Molly Jahn holds degrees from Swarthmore College,
M.I.T., and Cornell University, and pursued
postdoctoral work at U.C. Berkeley. At Cornell, Molly
focused her research on plant breeding, genetics, genomics and molecular biology and on the development
of improved crop germplasm. Her group at Cornell has
produced a number of globally successful crop varieties currently grown commercially on six continents.
Molly has worked extensively internationally in Latin
America, Asia and Africa to link crop breeding objectives to outcomes that improve human welfare, such
as nutritional status and income. Molly was recently
named a Fellow of the AAAS and was elected to the
Board of Directors of The World Vegetable Center, the
international research center for vegetables. On August
1, 2006, she was named the twelfth dean of the College
of Agricultural and Life Sciences at the University of
Wisconsin - Madison.
KHUSH, Gurdev Singh
Dr. Khush was born in a small village in Punjab. After
receiving his education at the Punjab Agricultural
University and the University of California, Davis, Dr.
Khush, in 1967, joined the International Rice Research
Institute in the Philippines where he served as the Head
of Plant Breeding, Genetics, and Biochemistry Division
until 2002. As a result of wide-scale adoption of his
high-yielding varieties, rice production increased 135%
between 1967 and 2000, to feed an estimated one billion additional consumers. His contributions to rice
genetics and biotechnology are equally well recognized.
He has written three books, more than 80 book chapters
and 160 research papers.
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Dr. Khush has served as consultant to rice breeding programs of 15 countries as well as The Rockefeller
Foundation, the Third World Academy of Sciences,
Italy, and the International Science Foundation,
Sweden. He is now serving as a member of Scientific
Advisory Committee (overseas) to the Department of
Biotechnology, Government of India and member of
Science Council, an advisory body to Chinese Academy
of Agricultural Sciences, Beijing.
For his monumental contributions to the World
Food Security, Dr. Khush has been honored with
numerous awards and honors such as the Japan
Prize (1987), World Food Prize (1996), Rank Prize
(1998), Wolf Prize (2000), International Scientific
and Technological Cooperation Award from the
Government of China (2001), and Padma Shriaward
from the president of India. He is one of five Indian scientists who have been elected to membership of Royal
Society (FRS) as well as the U.S. National Academy
of Sciences. Dr Khush has received Doctor of Science,
honoris causa, degrees from nine universities including
from University of Cambridge in England and Ohio
State University.
Commenting on his life work, Dr. Cantrell, Director of
the International Rice Research Institute said, “While Dr.
Khush’s name may have passed the lips of many, his life’s
work has passed the lips of almost half of humanity.”
KOwalski, Stanley P.
Stanley P. Kowalski was born and grew up in a workingclass neighborhood in Pittsburgh, Pennsylvania, where
he attended Catholic primary and public high school.
He matriculated at the Pennsylvania State University,
and later at the University of Pittsburgh, earning B.S.
degrees in horticulture and biology, with emphases in
genetics and biochemistry. Later, he earned a Ph.D. in
plant breeding from Cornell University. Dr. Kowalski’s
experience as a research scientist has included studies
of plant nutrition at the Pennsylvania State University,
wheat breeding at the University of Nebraska, purification and characterization of DNA polymerases at the
University of Rochester, biochemical characterization of
insect resistance in potatoes at Cornell University, lipidmediated signal transduction at the National University
of Singapore, plant genome mapping at Texas A&M
University, glycolipid biosynthesis at Cornell University,
and a study of the biochemical/genetic basis of plant/insect interactions at the U.S.D.A. Beltsville Agricultural
Research Center. He has been long interested in international development, due both to his exposure to the
dynamic international programs at Cornell and the influence of Professor Norman Borlaug, whose office was
located directly across the hall from Dr. Kowalski’s laboratory at Texas A&M University.
The second phase of Dr. Kowalski’s career has been
defined by a transition from research to international work. He received a foreign language area studies
scholarship and completed Cornell’s one-year intensive Chinese-language program (Chinese FALCON).
Subsequently, he worked for the International Service
for the Acquisition of Agri-Biotech Applications
(ISAAA) in the intellectual property/technology transfer initiative, during which time he conducted the
preliminary freedom-to-operate analysis of GoldenRice.
After working at ISAAA, he earned a J.D. with an

emphasis in intellectual property at the Franklin Pierce
Law center. He has published numerous research and
legal articles.
Krattiger, Anatole
Anatole Krattiger, a Swiss citizen, began his career as
a farmer, lived in many parts of the world, and is currently a research professor at the Biodesign Institute at
Arizona State University (ASU). As adjunct professor
at the Sandra Day O’Connor College of Law at ASU,
he co-teaches a course on innovation management and
controversies in health and agri-biotechnology. He is
an Adjunct Professor at Cornell University where he
co-teaches a course on IP management in the life sciences. He founded, and serves as Chairman of, bioDevelopments-International Institute, a nonprofit organization that brings people together to jointly develop
solutions to problems that extend beyond geographic
and cultural frontiers. He recently served as Executive
to the Humanitarian Board for GoldenRice, a position
that required him to work on licensing, technology
transfer, and regulatory issues; he also served as Director
of Research at MIHR in the U.K. during its formative
years. In the early 1990s, he contributed to the international establishment of ISAAA, a global agri-biotechnology broker developing public-private partnerships
in agriculture; he served as executive director of ISAAA
until 2000. He also briefly worked on biodiversity-policy
issues at the International Academy of the Environment
in Geneva, Switzerland, and as a scientist in biotechnology at CIMMYT in Mexico.
Dr. Krattiger is a member of the Advisory Council
on Intellectual Property of the Franklin Pierce Law
Center in Concord, New Hampshire, and a member of
the board of the Black Sea Biotechnology Association.
He is editor-in-chief of Innovation Strategy Today and
a member of the editorial boards of the International
Journal of Biotechnology and the International Journal
of Technology Transfer and Commercialization. He
was a Distinguished Advisor to the Council for
Biotechnology Information in Washington, D.C., until the Council merged with BIO. He holds a diploma
in farming, a bachelor’s degree in agronomy from the
Swiss Agricultural College, a master’s degree in plant
breeding, and a Ph.D. in biochemistry and genetics
from the University of Cambridge, U.K.
Mahoney, Richard T.
Richard T. Mahoney is Director, Vaccine Access, for
the Pediatric Dengue Vaccine Initiative, a program
of the International Vaccine Institute (IVI) in Korea.
Previously, he was Research Professor in the School of
Life Sciences and in the Biodesign Institute of Arizona
State University. As a consultant to the Rockefeller
Foundation, he played a lead role in the consultative
process that led to the formation of MIHR. Previously,
he was responsible for institutional development in
the establishment and launching of the IVI in Seoul,
Korea. In this role, he was responsible for cultivating relations with vaccine manufacturers and managing intellectual property, among other things. Dr.
Mahoney has had a long career in public health and is
known for his work with the International Task Force
on Hepatitis B Immunization, accomplished while
he was with the Program for Appropriate Technology

HANDBOOK OF BEST PRACTICES: EXECUTIVE GUIDE | 203

BIOS

in Health (PATH). Before co-founding and joining
PATH, he was a Program Officer in Population with
the Ford Foundation. He oversaw the development
and implementation of IP management policies for the
Ford Foundation, PATH, and IVI. Prof. Mahoney continues to write on policy and economic research.
MANGENA, Mosibudi
Mosibudi Mangena is the Minister of Science and
Technology in South Africa and President of the
Azanian People’s Organisation (AZAPO). He was born
in Tzaneen, matriculated from Hebron Training College
in 1969, and received an M.Sc. degree in Applied
Mathematics from the University of South Africa (called
the University of Azania on the AZAPO website). He
joined the South African Students’ Organisation (SASO)
and was elected to the Student’s Representative Council
at the University of Zululand in 1971. Moving back to
Pretoria, he became chairperson of the SASO Pretoria
branch in 1972. He chaired the Botswana region of the
Black Consciousness Movement of Azania (BCMA)
in 1981 and the BCMA central committee from 1982
to 1994. He returned from exile in 1994 and became
leader of Azapo. He was appointed Deputy Minister
of Education in South Africa by Nelson Mandela in
2001, and became Minister of Science and Technology
in 2004.
Mashelkar, R.A.
Dr. R.A. Mashelkar is presently the President of the
Indian National Science Academy (INSA) and President
of Global Research Alliance (GRA), a network of publicly funded R&D institutes from five continents with
over 60,000 scientists. Prior to this, for over eleven
years Dr. Mashelkar served as the Director General of
Council of Scientific and Industrial Research (CSIR),
an organization with thirty-eight laboratories and about
20,000 employees. His leadership transformed CSIR
into a user-focused, performance-driven organization,
a process of transformation that has been recently heralded as one of the ten most significant achievements of
Indian Science and Technology in the 20th century.
Dr. Mashelkar is only the third Indian engineer to
have been elected as a Fellow to the Royal Society (FRS),
London, in the 20th century. He was elected Foreign
Associate of the National Academy of Science (U.S.)
in 2005, and was only the eighth Indian since 1863
to be elected. He was elected a Foreign Fellow of the
U.S. National Academy of Engineering (2003), Fellow
of the Royal Academy of Engineering (U.K.) in 1996,
and Fellow of the World Academy of Art & Science
(U.S.) in 2000. Twenty-six universities have honored
him with honorary doctorates, including the universities of London, Salford, Pretoria, Wisconsin, and Delhi.
He is currently the President of the Materials Research
Society of India.
In post-liberalized India, Dr. Mashelkar has played a
critical role in shaping the country’s S&T policies. He was
a member of the Scientific Advisory Council to the Prime
Minister and also of the Scientific Advisory Committee
to the Cabinet set up by successive governments.
Dr. Mashelkar has won more than 50 awards and
medals, including the S.S. Bhatnagar Prize (1982), the
Pandit Jawaharlal Nehru Technology Award (1991),
the G.D. Birla Scientific Research Award (1993), the
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Material Scientist of Year Award (2000), the IMC Juran
Quality Medal (2002), the HRD Excellence Award
(2002), the Lal Bahadur Shastri National Award for
Excellence in Public Administration and Management
Sciences (2002), the World Federation of Engineering
Organizations (WFEO) Medal of Engineering
Excellence by WFEO, Paris (2003), the Lifetime
Achievement Award by the Indian Science Congress
(2004), the Science Medal by the Academy of Science
for the Developing World (2005), and the Ashutosh
Mookherjee Memorial Award by the Indian Science
Congress (2005), among others.
The President of India honored Dr. Mashelkar with the
Padmashri (1991) and with the Padmabhushan (2000),
which are two of the highest civilian honors in India, in
recognition of his contribution to nation building.
MCCALLA, Alex F.
Alex is Professor of Agricultural and Resource
Economics, Emeritus, at the University of California,
Davis. He was born in Alberta, Canada, and received his
first two degrees from the University of Alberta before
moving on to the University of Minnesota where he received his doctorate in Agricultural Economics in 1966.
Throughout his academic career he was associated with
the University of California-Davis where he served as
Dean of the College of Agricultural and Environmental
Sciences and Associate Director of the California
Agricultural Experiment Station (1970–1975) and
Founding Dean, Graduate School of Management
(1979–1981).
Dr. McCalla is best known for his research in international trade where he has published extensively.
The quality of his research and communication skills
has been recognized by the American Agricultural
Economics Association, which presented him with its
Quality of Communication Award in 1979 and its
Quality of Research Discovery Award in 1982. He was
elected Fellow of the American Agricultural Economics
Association in 1988, Fellow of the Canadian Agricultural
Economics Society in 2000, and a Distinguished Scholar
of the Western Agricultural Economics Association
in 2004. He was a founding member and co‑convener of the International Agricultural Trade Research
Consortium. He served as the Chair of the Technical
Advisory Committee (TAC) of the Consultative Group
on International Agricultural Research (CGIAR) from
1988 to 1994.
He elected early retirement from the University of
California in June 1994 and was appointed Director
of the Agriculture and Natural Resources Department
of the World Bank in Washington, D.C., effective
September 12, 1994. During his tenure he led a major effort to revitalize the World Bank’s commitment
to Rural Development. He was appointed Director of
Rural Development in July 1997, following a Bank reorganization. He retired from the World Bank December
31, 1999.
In June 1998 he was awarded the Degree of Doctor
of Science, honoris causa, by McGill University in
Montreal, Canada. On December 28, 1999, he was
awarded the Doctor’s Degree of Honor by the Georgian
State Agrarian University. In September of 2004 he
received the Distinguished Alumni Award from the
University of Alberta.
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He served as Chair of the Board of Trustees of
CIMMYT, the International Maize and Wheat
Improvement Center with Headquarters in Mexico,
(2001–2005) and is a member of the Board of Directors
of the Danforth Plant Science Center in St. Louis.
MOREL, Carlos
Dr. Carlos M. Morel is currently the Director of the
Centre for Technological Development in Health
(CDTS), a new unit being implemented at the Oswaldo
Cruz Foundation (FIOCRUZ, Rio de Janeiro, Brazil) to
stimulate health product innovation.
A molecular biologist and medical doctor by training, Dr. Morel received his M.D. from the Medical
Faculty of the Federal University of Pernambuco.
He completed his graduate studies at the Biophysics
Institute of the Federal University of Rio de Janeiro
and at the Molecular Biology Department of the Swiss
Cancer Institute in Lausanne (ISREC), Switzerland. His
research has been in the field of molecular parasitology,
and he has collaborated with various international organizations and research programs working on neglected
diseases and capacity building.
Dr. Morel was previously a Professor at Brasilia
University (UnB, Brasilia, Brazil) and President of
FIOCRU. He was also Director of the UNICEF/
UNDP/World Bank/WHO Special Programme for
Research and Training in Tropical Diseases (TDR) at
the World Health Organization in Geneva, where he
established close working relationships with productdevelopment public private partnerships and global
ventures committed to public health. He participated
actively in the establishment of the Medicines for
Malaria Venture (MMV), the Global Alliance for TB
Drug Development (GATB), the Drugs for Neglected
Diseases Initiative (DNDi), and the Foundation for
Innovative New Diagnostics (FIND).
A member of the Brazilian Academy of Sciences and
an Honorary Fellow of the Royal Society of Tropical
Medicine and Hygiene in London, Dr. Morel holds
the National Order of Scientific Merit (Brazil) and
Doctor Honoris Causa from the Federal University of
Pernambuco (Brazil). He has been a member of the
MIHR Board of Trustees since its founding.
Nelsen, Lita
Lita Nelsen is the Director of the Technology Licensing
Office at the Massachusetts Institute of Technology,
where she has been since 1986. Every year, the office manages over 400 new inventions originating
from M.I.T., the Whitehead Institute, and Lincoln
Laboratory. Typically, the office negotiates over 100
licenses and starts up over 20 new companies each
year. Ms. Nelsen earned her B.S. and M.S. degrees in
Chemical Engineering from M.I.T., as well as an M.S.
in Management from M.I.T. as a Sloan Fellow. Prior
to joining the M.I.T. Technology Licensing Office,
Ms. Nelsen spent 20 years in industry, primarily in
the fields of membrane separations, medical devices,
and biotechnology; she worked at such companies as
Amicon, Millipore, Arthur D. Little, Inc., and Applied
Biotechnology. Ms. Nelsen was the 1992 President of
the Association of University Technology Managers. She
serves on the board of the Mount Auburn Hospital and
the Scientific Advisory Board of the Children’s Hospital

Oakland Research Foundation. She also serves as the
intellectual property advisor to the International AIDS
Vaccine Initiative and is a founding and current board
member of MIHR. Ms. Nelsen is widely published in
the fields of technology transfer and university/industry collaborations. She was a CMI Fellow at Cambridge
MIT Institute (at the University of Cambridge), where
she studied the role of university/industry/government
partnerships in technology transfer and local economic
development. She is a co-founder of Praxis, the U.K.
University Technology Transfer Training Programme.
POTRYKUS, Ingo
Ingo Potrykus is the engine behind the GoldenRice
Project and the Humanitarian Board. Together
with Peter Beyer, he was one of the inventors of the
GoldenRice technology. Since his retirement as a professor in 1999, far from settling down, he has devoted
enormous efforts to bringing biofortified GoldenRice to
those who need it.
Prof. Potrykus was born in 1933 in Hirschberg, Silesia,
Germany. He has been married since 1960, and has three
children and eight grandchildren. In 1968, he earned a
Ph.D. in Plant Genetics at the Max-Planck-Institute for
Plant Breeding Research, Cologne, Germany.
He conducted research in botany at the University
of Basel, Switzerland, and was an Assistant Professor at
the Institute of Plant Physiology, Stuttgart-Hohenheim
from 1970 to 1974. From 1974 to 1976, he was
Research Group Leader at the Max-Planck-Institute for
Genetics, Ladenburg-Heidelberg, and then, until 1986,
at the Friedrich Miescher-Institute, Basel, Switzerland.
From 1986 until his academic retirement in 1999, he
was Full Professor in Plant Sciences at the Swiss Federal
Institute of Technology (ETH), Zurich.
Since 1974, his research has focused on plant-science-based contributions to food security in developing
countries, where he was involved in the development
and application of genetic engineering technology for
“food security” crops such as rice (Oryza sativa), wheat
(Triticum aestivum), sorghum (Sorghum bicolor), and
cassava (Manihot esculenta). Focusing on problems in
the areas of disease and pest resistance that were difficult
to solve with traditional techniques, he worked to improve food quality and yield, improved exploitation of
natural resources, and improved biosafety. This work was
performed by an international team of 60 coworkers, on
average, that was financed from competitive grants and
core funding. The GoldenRice project, initiated in 1991
as Ph.D. project, was possible only because of that core
funding. Details of the GoldenRice project can be found
in approximately 340 publications in refereed journals
and 30 international patents.
Professor Potrykus’s teaching activities have included lectures and courses in basic and advanced
plant biology and plant biotechnology in Biology,
Agronomy, Pharmacy, Forestry, and Environmental
Sciences departments, as well as International
Training Courses such as EMBO. His numerous
awards include: the KUMHO (ISPMB) Science
International Award in Plant Molecular Biology and
Biotechnology in 2000, the American Society of
Plant Biologists (ASPB) Leadership in Science Public
Service Award in 2001, the Crop Science of America
(CSSA) Klepper Endowment Lectureship in 2001, the
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CSSA President’s Award in 2002, and the European
Culture Award in Science in 2002. He received an
Honorary Doctorate from the Swedish University
of Agricultural Sciences in 2002. He is a member of
Academia Europaea, the World Technology Network,
the Swiss Academy of Technical Sciences, and the
Hungarian Academy of Sciences.
Reddy, K. Anji
Dr. K. Anji Reddy is the founder of Dr. Reddy’s
Laboratories. He spent his early life in Tadepalli village,
Guntur, Andhra Pradesh. His father was a peasant and
grew turmeric. After completing his schooling at the local
high school, Dr. Reddy earned a degree in science in 1958
from the A.C. College in Guntur City. He also earned a
BSc in pharmaceuticals and fine chemicals from Bombay
University. Later he obtained a PhD in chemical engineering from the National Chemical Laboratory in Pune.
Dr. Reddy started his career working for a state-owned
company, then called Indian Drugs and Pharmaceuticals
Ltd. He was the founder and managing director of
Uniloids Ltd., where he worked from 1976 to 1980,
and Standard Organics Ltd., where he worked from
1980 to 1984. In 1984, Dr. Reddy laid the foundation
for Dr. Reddy’s Laboratories. The company established
new standards in the Indian pharmaceutical industry
and transformed the Indian bulk-drug dependency of
the mid-80s into a self-sufficient industry in the mid90s. By then, the Indian pharmaceutical industry had
developed into an export-oriented industry and has remained such ever since.
In 1993, Dr. Reddy’s Laboratories emerged as India’s
first drug-discovering company, and in April 2001, it
became the first non-Japanese, Asian pharmaceutical
company listed on the New York Stock Exchange
Dr. Reddy is an active member of the Prime Minister’s
Council on Trade and Industry. Dr. Reddy founded and
has donated generously to Dr. Reddy’s Foundation for
Human and Social Development, which works to support development. During his long career, Dr. Reddy
has been the recipient of many awards and civic honors. These include the Padma Shri Award, Sir P. C.
Ray Award, FAPA-Ishidate Award for Pharmaceutical
Research (1998), Businessman of the Year (2001), and
the Achiever of the Year (2000).
Rodin, Judith
Judith Rodin has served as president of the Rockefeller
Foundation since March 2005. Trained as a research
psychologist, Dr. Rodin was previously the president of
the University of Pennsylvania, and earlier the provost
of Yale University. The Rockefeller Foundation was established in 1913 by John D. Rockefeller, Sr. to “promote the well-being” of humanity by addressing the
root causes of serious problems. The Foundation works
globally to expand opportunities for poor and vulnerable people and to help ensure that the benefits of globalization are shared more equitably.
Judith Rodin was born and raised in Philadelphia,
Pennsylvania. She graduated from the University of
Pennsylvania, and received her Ph.D. from Columbia
University. A pioneer in the behavioral medicine movement, she taught at New York University before embarking on 22 years on the faculty at Yale, where she
ultimately held appointments in both the School of Arts

206 | HANDBOOK OF BEST PRACTICES: EXECUTIVE GUIDE

and Sciences and the School of Medicine. Named president at Penn in 1994, she was the first woman to serve
as president of an Ivy League institution.
Dr. Rodin serves on a number of leading nonprofit
boards, as well as on the boards of AMR Corporation,
Citigroup, and Comcast Corporation. She is the author of more than 200 academic articles and chapters
and has written or co-written 11 books. She served on
President Clinton’s Committee of Advisors on Science
and Technology. A member of a number of leading academic societies, including the Institute of Medicine of
the National Academy of Sciences, she has received nine
honorary doctorate degrees.
SALIM, Emil
Emil Salim is on the faculty of economics at the
University of Indonesia. Previously, he was the State
Minister for Population and Environment from 1978
to 1993. He currently serves as a member of many international and national committees, including the United
Nations High Level Advisory Board on Sustainable
Development. He serves as Chairman of the National
Economic Board, an economic expert team to President
Abdurachman Wahid. He was a member of the economic expert team to President Suharto on debt and
development issues of the nonaligned countries, and a
member of the Indonesian Peoples’ Assembly. In addition, he was Co-chairman of the World Commission on
Forestry and Sustainable Development.
Dr. Salim also serves as Chairman of the Board of
Trustees for a number of leading Indonesian environmental organizations, including the Indonesian
Biodiversity Foundation, the Foundation for Sustainable
Development, and the Indonesian Ecolabelling Institute.
He received his master’s degree and his doctorate in economics from the University of California, Berkeley, in
the United States.
SASSON, Albert
Professor Albert Sasson, a Moroccan, is a world-renowned international consultant in biotechnology. He
has authored more than 200 publications concerning his
research and popularization activities in soil microbiology, algology, and agrobiology. He has published books
and contributed to publications on biology teaching,
environment and development issues, biotechnologies,
and food and nutrition. Biotechnologies in Developing
Countries is one of his outstanding publications.
Professor Sasson is a prolific speaker, with invaluable information and insight in the areas of cloning,
genetically modified foods, the use of biotechnology in
agriculture and its possible impact on man and the environment, and ethical and legal issues related to biotechnology. He has expert knowledge of how biotechnology
can reduce poverty and the successes and failures of its
application worldwide.
After a career as a university dean, he joined UNESCO
in 1974, where he served as Special Advisor to the UN
for over 27 years. Since January 2000, Prof. Sasson has
been senior consultant to UNESCO, Moroccan institutions, and the company Publicis Dialog (Paris). He provides special advice to governments worldwide on the
development of national policies on biotechnology, and
is an advocate for the adaptation of technologies by the
third world for their social and economic development.
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Professor Albert Sasson is a man with a passion for
science, especially for discoveries in the life sciences.
He is truly fascinated with the application of science to
food, agriculture, medicine, pharmaceuticals, energy,
the environment, and bio-remediation.
Satyanarayana, Kanikaram
Kanikaram Satyanarayana holds a doctorate degree in
biosciences. After a brief postdoctoral stint, he joined
the Council of Scientific and Industrial Research in
New Delhi. In 1980, he moved to the Indian Council
of Medical Research (ICMR). He is involved in science
and technology policy and evaluation, and is Chief of
the Intellectual Property Rights Unit. For over twenty
years, he has worked extensively in the areas of science
and technology evaluation and science policy issues; he
was instrumental in the formulation of Indian national
policies in these areas.
In 1996, Dr. Satyanarayana published the first guidelines for promoting industry-academia partnerships in
medical research in Contract Research, Consultancy and
Technology Transfer policy of the ICMR. These guidelines
are currently being revised to be in agreement with the
new WTO and IPR regimes. He has organized several
training workshops on WTO and IP rights issues for the
benefit of scientists at ICMR institutes, medical colleges,
and other institutes. Some of these training workshops
were conducted with international funding (WHO).
He set up the Intellectual Property Rights Unit at the
ICMR in 1999 and brought out the Intellectual Property
Rights Policy of ICMR in 2002. He is a member of several national committees on intellectual property and has
participated in several national and international conferences on such topics as globalization, the impact of
TRIPS on public health, access to health care in developing countries, and so on. An active researcher, he has
obtained competitive grants from various agencies in
India and the World Health Organization. He has also
published several papers in national and international
journals. He is closely associated with the U.K.-based
Centre for the Management of intellectual property
in Health R&D (MIHR) and has contributed to their
Manual for Technology Transfer Managers. Currently, he
is the only member of the International Editorial Board
of the second edition of this Handbook who is from a
developing country. He is a founder and Secretary of
the Society for Technology Management, India, and is
currently a Senior Deputy Director-General and Chief
of the Intellectual Property Rights Unit at the ICMR.
SEKI, Akinori
Akinori Seki is president of the Sasakawa Peace
Foundation (SPF), an organization committed to fostering international understanding, exchange, and cooperation. Seki studied at the Gakushuuin University
of Economics and received his Ph.D. from the London
School of Business.
He worked for many years for the Marubeni
Corporation, where he became General Manager
(Strategies and Coordination) and Deputy Executive
Officer (Corporate Strategies Department). He also
lived in Africa briefly as President of Gambia Fisheries’
Co. Ltd. He joined the SPF in 1999, initially as Program
Director, before becoming Chief Operating Officer,
then Executive Director, and now President.

He has served as an advisor to many organizations,
including the Myanmar Economic and Management
Institute, the United Nations Industrial Development
Organization (UNIDO), and the University of
Cambodia, and he was a committee member of
KEIDANREN and of the study group for Indo-China.
He serves on the Board of Directors of the Bellagio
Forum and is Member of the Advisory Committee,
UNIDO (Tokyo Office). He is an Honorary Professor
of Tafaccur University, in the Republic of Azerbaijan.
SERAGELDIN, Ismail
Ismail Serageldin is Director of the Library of Alexandria
and also chairs the Boards of Directors for each of the
Biblioteca Alexandria’s affiliated research institutes
and museums. He is also a Distinguished Professor at
Wageningen University in the Netherlands. He serves as
Chair and Member of a number of advisory committees
for academic, research, scientific and international institutions and civil society efforts, including the Institut
d’Egypte (Egyptian Academy of Science), TWAS (Third
World Academy of Sciences), the Indian National
Academy of Agricultural Sciences, and the European
Academy of Sciences and Arts. He is former Chairman
of the Consultative Group on International Agricultural
Research (CGIAR, 1994-2000), Founder and former
Chairman of the Global Water Partnership (GWP,
1996-2000) and the Consultative Group to Assist the
Poorest (CGAP), a microfinance program (1995-2000).
Serageldin has also served in a number of capacities
at the World Bank, including as Vice President for
Environmentally and Socially Sustainable Development
(1992-1998), and for Special Programs (1998-2000).
He has published over 50 books and monographs
and over 200 papers on a variety of topics, including
biotechnology, rural development, sustainability, and
the value of science to society. He holds a Bachelor of
Science degree in engineering from Cairo University
and a Master’s and Ph.D. from Harvard University. He
has received 19 honorary doctorates.
Shevelukha, Victor S.
Victor Shevelukha was born in 1929, currently lives in
Moscow, and is head of the Agricultural Biotechnology
Department, Russian State Agrarian University, Moscow.
He is a member of the V.I. Lenin All-Union Academy of
Agricultural Sciences (VASKhNIL), the Russian academy
of Agricultural Sciences, the International Academy of
Agrarian Education, the Slavonic Academy, the Agrarian
Academy of the Belarus Republic, the International
Academy of Informational Sciences, and the Academy of
Natural Sciences, among other public academies.
Victor has authored more than 400 scientific works,
including 10 monographs and manuals on plant production, plant breeding, seed production, agricultural
biotechnology, plant physiology, and agricultural economic policy. He has advised 45 Ph.D. students and
12 doctors of sciences and is currently Chairman of the
Scientific Council in RSAU-MAAS, which confers doctorate degrees in the fields of genetics, biotechnology,
plant breeding, and seed production.
He worked as a senior agronomist at MAAT’s training farm, Druzhba, in the Yaroslavl region (19551957); as a secretary of the Ryazantcev CPSU district
committee, Yaroslavl region (1957-1959); as the head
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of agricultural department, Yaroslavl CPSU regional
committee; as the first vice-chairman of Yaroslavl regional executive committee (1959-1964); as senior
lecturer, associate professor, professor, and head of
Crop Science Department at the Belarus Agricultural
Academy (1964-1973); the director of Belarus Research
Institute for Arable Farming (1973-1974); a secretary
of the Central Committee, Belarussia Communist
Party (1974-1979); a Deputy Minister of Agriculture
of the USSR; a member of Collegium in the USSR
Ministry of Agriculture (1979-1983); academic-secretary of Plant Production and Breeding Department,
V.I. Lenin All-Union Academy of Agricultural Sciences
and Russian Academy of Agricultural Sciences (19831994); a deputy of the State Duma, Federal Assembly
of the Russian Federation; and vice-chairman of the
Committee for Education & Science, the State Duma
(1994-2000).
Prof. Shevelukha is also a member of both the Russian
Federation Union of Writers and the Russian Federation
Union of journalists. He has written and published 10
volumes of fiction and sociopolitical journalism.
Finally, Victor has been awarded the K.A. Timiryazev
and V.I. Vernadsky gold medals, orders and medals of the
USSR, Russia, and foreign countries, and honorary deeds
and titles from the State Duma (Russian Parliament),
the Federal Assembly of the Russian Federation, the
Ministry of Agriculture, and the Ministry of Education
and Science.
SWAMINATHAN, M. S.
Professor M. S. Swaminathan has been acclaimed by
TIME magazine as one of the twenty most influential Asians of the 20th century, one of the only three
from India, the other two being Mahatma Gandhi and
Rabindranath Tagore. He has been described by the
United Nations Environment Programme as “the Father
of Economic Ecology,” and by Javier Perez de Cuellar,
Secretary General of the United Nations, as “a living
legend who will go into the annals of history as a world
scientist of rare distinction.” He was Chairman of the
UN Science Advisory Committee, set up in 1980 to
take follow-up action on the Vienna Plan of Action. He
has also served as Independent Chairman of the FAO
Council and President of the International Union for
the Conservation of Nature and Natural Resources. He
is the current President of the Pugwash Conferences on
Science and World Affairs.
A plant geneticist by training, Professor
Swaminathan’s contributions to the agricultural renaissance of India have led to his being widely referred to as
the scientific leader of the green revolution movement.
His advocacy of sustainable agriculture leading to an
“evergreen revolution” has made him an acknowledged
world leader in the field of sustainable food security. The
International Association of Women and Development
conferred on him their first international award for his
significant contributions to promoting the knowledge,
skill, and technological empowerment of women in agriculture, and for his pioneering role in mainstreaming
gender considerations in agriculture and rural development. Professor Swaminathan was awarded the Ramon
Magsaysay Award for Community Leadership in 1971,
the Albert Einstein World Science Award in 1986, and
the first World Food Prize in 1987.
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Professor Swaminathan is a Fellow of many of the leading scientific academies of India and the world, including the Royal Society of London and the U.S. National
Academy of Sciences. He has received 55 honorary
doctorate degrees from universities around the world. He
currently holds the UNESCO Chair in Ecotechnology at
the M. S. Swaminathan Research Foundation in Chennai
(Madras), India, and was Chairman of the National
Commission on Agriculture, Food, and Nutrition
Security of India until October 2006.
Thomson, Jennifer A.
Jennifer Ann Thomson is Professor of Microbiology
in the Department of Molecular and Cell Biology at
the University of Cape Town, South Africa (UCT).
Previously, she had held the positions of Head of the
Department of Microbiology at UCT, the Director
of the Laboratory for Molecular and Cell Biology at
the Council for Scientific and Industrial Research, and
Associate Professor in the Department of Genetics at the
University of the Witwatersrand in Johannesburg. Her
research involves the development of genetically modified maize that is resistant to the Maize streak virus (endemic to Africa) and tolerant to drought. She received
an honorary doctorate from the Sorbonne University,
Paris in 2005, and the UNESCO/L’Oreal award for
Women in Science in 2004. She is Chair of the Board
of the African Agricultural Technology Foundation,
based in Nairobi, Kenya. She is a Director of the South
African Pebble Bed Modular Reactor (Pty) Ltd. She has
published a book, Genes for Africa: Genetically Modified
Crops in the Developing World.
VAN MONTAGU, Baron Marc
Baron Marc Van Montagu is an Emeritus Professor at
Ghent University, and founder and Chairman of the
Board of IPBO, the Institute for Plant Biotechnology
for Developing Countries. He received a Ph.D. in organic chemistry/biochemistry from Ghent University
in 1965, and served as the Director of the Department
of Genetics at the Flanders Interuniversity Institute
for Biotechnology, before joining the faculty at Ghent
University in 1999.
Dr. Van Montagu has made pioneering contributions to plant gene discovery, including the discovery
of the gene transfer mechanism between Agrobacterium
and plants, which was central to the development of
transgenic plants. His work at the Lab of Genetics,
Ghent University, produced two spin-off biotech companies, Plant Genetic Systems (PGS) and Crop Design.
His research at PGS led to the construction of the first
herbicide tolerant plants, as well as the construction of
the first plants producing the Bt (Bacillus thuringensis)
insecticide. His was listed among the top 100 living
contributors to biotechnology by The Scientist magazine
and, until 2004, was the most cited scientist in the field
of Plant and Animal Science.
XUAN, Vo-Tong
Dr. Vo-Tong Xuan is a distinguished agricultural scientist, an outstanding educator, a low-profile institution
builder, and a national and international leader in agricultural development.
As a scientist, he is widely recognized for his expertise
in the management of saline and acid-sulphate soils and
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other problem soils in Vietnam. He is an expert in rice
production and in rice-based farming systems, as well as
in agricultural diversification in the Mekong Delta. His
technical expertise and strong farmer-focused leadership
in the Mekong Delta greatly increased rice productivity and contributed to the emergence of Vietnam as the
third-largest rice exporting country in the world. Xuan
has authored and co-authored six books and more than
100 technical papers about agricultural, rural development, and sustainable food security.
As an educator, he emphasized scientific as well as
down-to-earth hands-on-training in the University
of Cantho, at which he served as Chairman of the
Departments of Bio-Agronomy and Agronomy, and
Assistant Dean of Agriculture. He rose to the rank of
Vice Rector of the University of Cantho and, in 2000,
was elected President of Angiang University, a position
he still holds.
As an institution builder, Xuan developed and strengthened the Mekong Delta Farming Systems Research
and Development Institute and served as its Director
from 1983 to 2001. He also served as FAO Project
Coordinator for the establishment of Agricultural
Service Centers for Small Farmers. He organized the
Vietnam Farming Systems R & D Network and has
been serving as its Coordinator since 1991.
As a national leader in agriculture, Dr. Xuan was appointed member of the National Council on Science
and Technology, the National Council on Education,
the National Council on Professorial Titles Advisory
Council of the Vietnam Chamber of Commerce and
Industry, the Steering Committee of the VietnamHolland Research Program on Rural Development, and
the Consultants’ Group to the Prime Minister.
As an international leader in agriculture, he is widely
recognized for his integrated approaches to agricultural
development and deep concern for efficient and effective use of natural resources, sustainability, and environmental issues, as well as, for food security problems
of developing countries. He is a strong advocate of the
farming system approach in agricultural development.
He has served in key positions in the following international organizations: Member, Board of Governors,
Asian Institute of Management in Manila; Member,
Board of Trustees of IRRI; Member, Board of Trustees
of The Rockefeller Foundation; Member, Board of
Trustees of the International Potato Center at Lima,
Peru; Member, FAO’s Advisory Committee on FarmerCentered Agricultural Resource Management Program;
Member, Technical Advisory Committee of the CGIAR;
Member, Policy Advisory Council, Australian Centre for
International Agricultural Research; Member, Advisory
Council of the Asian Development Research Forum.
Dr. Xuan served as international consultant, lecturer of
IFAD, FAO, DANIDA, SIDA, and IDRC-Singapore
since the 1980’s.
He received from the Prime Minister of Canada a
certificate of recognition for his “dedication and contribution to the world of sciences.” The Ministry of
Agriculture, Fisheries and Forestry of the Republic
of France, awarded him the “Chevalier de l’Ordre du

Merite Agricole Medal.” He was elected the 2002 Nikkei
Asia Prize for Regional Growth; Most Distinguished
Alumnus of the University of the Philippines College
of Agriculture Alumni Association; Ramon Magsaysay
Award for Government Service; and the 2005 ASTD
Derek Tribe Award. Other awards include: the People’s
Teacher Award, Vietnam Farmers’ Federation Medal
“For the Cause of the Farmers’ State Award as “Hero of
the Working Class,” Outstanding Scientific Achievement
Award from the Prime Minister, Most Distinguished
Alumnus Award from the University of the Philippines
at Los Banos.
YUTHAVONG, Yongyuth
Yongyuth Yuthavong is a scientist. His interests lie in
antimalarial drug development and broad issues of science, technology, and public policy. In 1962, Professor
Yuthavong was awarded a Thai government scholarship to study in the United Kingdom. He obtained a
bachelor’s degree in chemistry with first-class honors
from the University of London in 1966 and a doctoral degree in organic chemistry from the University
of Oxford in 1969. He spent many years at Mahidol
University in Thailand, where, beginning in 1983, he
served on the faculty as a professor of biochemistry.
He was actively engaged in the establishment in 1992
of the National Science and Technology Development
Agency (NSTDA) of Thailand (1992) and became the
agency’s first president, serving two terms. In 1998, he
returned to the research career at the NSTDA’s National
Centre for Genetic Engineering and Biotechnology
(BIOTEC), where he had once served as its director.
Currently he heads a research group in BIOTEC, where
he is working on the development of new antimalarials
with grants from the Medicines for Malaria Venture and
the Wellcome Trust.
In 2004, Yuthavong received the Nikkei Asia Prize
for Science, Technology, and Innovation from Nihon
Keizai Shimbun, Japan, for his work on antimalarial
drug targets. The same year, Thailand’s National Identity
Board named him Person of the Year. In 1984, he received the Outstanding Scientist of Thailand Award
from the Foundation for Promotion of Science and
Technology. He has received honorary doctorates from
Prince of Songkla University and Mahidol University.
In 2006, Bangkok’s The Nation newspaper named him
one of Thailand’s 35 most influential people over the
last 35 years.
Yuthavong is past chairman of the Foundation
of Thai Academy of Science and Technology and the
Foundation for Promotion of Talents in Science and
Technology. Today, he serves as a member of five state
university councils. He is a member of the National
Education Board and the National Research Council
Committee on Chemistry and Pharmaceutical Sciences.
He has coauthored 115 research articles published in international journals and 16 book chapters and books on
biomedical science, policy, and general issues of science
and technology.
Yuthavong was appointed Thailand’s minister of
Science and Technology in 2006. n
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Readers are encouraged to consult the online version (www.iphandbook.org) for fuller indexing, a robust
search engine, and a “Web log” presentation of key content areas with comments.
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biodiversity access agreements (BAAs), 175, 176
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biopiracy, 174
bioprospecting, 175
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Brazil, 187
business incubators, 143, 147, 148
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Cartagena Protocol on Biosafety, 59, 156
cervical cancer, CS38
Chile, CS5
client confidentiality and legal privilege, 77
commons, the, 112
compulsory licensing, 50
computer-generated contract template system
(CoGenCo), 123, 124
Concept Foundation, CS30
confidentiality, 86
conflict of commitment, 68, 144
conflict of interest, 68, 75, 144
Consultative Groups on International
Agricultural Research (CGIAR), 122
contraceptive, CS30
contract management system, 78
contracts, 85
Convention on Biological Diversity (CBD), 59,
175, 179
copyright, 58
Court of Appeals for the Federal Circuit
(CAFC), 45
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data, regulatory protection of, 60
data exclusivity, 60
defensive publishing, 112
desertification, 173
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dispute resolution, 163, 165
Doha Declaration (TRIPS), 167
Drugs for Neglected Diseases Initiative
(DNDi), 187

HANDBOOK OF BEST PRACTICES: EXECUTIVE GUIDE | 211

Index

E

Earth Summit, 173
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equity, as a moral issue, 173
exhaustion of patent rights, 167
F
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freedom to operate (FTO), 153–156
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geographic indications, 58
geographic information systems (GIS), 60
global access, 25, 29, 35, 38, 65
global access, innovation management and, 48
global access, strategies, 66
global intellectual property landscape, 25
Golden Rice, 154, CS11
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HIV/AIDS vaccine, CS19
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India, 185, CS9, CS19
India, pharmaceutical industry and, 185
indigenous knowledge. See traditional
knowledge (TK).
infrastructure development, 52
innovation, 25, 26
innovative developing countries, 45, 73
institutional intellectual property policies, 66, 84
integrated intellectual property management
(IPM), 136
intellectual property
assembly options, 39
audits, 67, 136
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capacity to, 27
lawyer, 77
management, 26, 47
portfolio management, 136
search tools, 156
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system, 26, 27
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J

judicial structure, 45
K

Korea, CS17
L
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licensing, public sector goals and, 135
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Madrid Arrangement, 125
Madrid Protocol, 125
malaria treatment, CS32, CS36
malaria vaccine, CS21
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marketing tactics, 143
mediation, 165
Monsanto Company, 189
mutually agreed terms (MATs), 177
N

negotiation, 121, 133
negotiation, license agreements and, 123
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OneWorld Health, CS32
options and rights of first refusal, 125
ordre public clauses, 29
organic agriculture, 179, 180
P

parallel importation, 167
parallel trade, 167
Paris Convention, 114
Patent Cooperation Treaty (PCT), 114
patent counsel, 76
patent infringement, 164
patent pools, 39, 190
patent research, 154
patent thickets, 39
patents
biotechnology applications of, 115
claim structure of, 164
ethical dimensions of, 30
filing strategies for, 29, 101
general discussion of, 37
of genetic and biological subject matter, 29,
174
portfolio management and, 114
PATH, CS38
PATH Malaria Vaccine Initiative (MVI), 189
pipeline agreements, 125
plant variety protection (PVP), 58, 115, 123
Plato, 111
prior informed consent, 30, 177
private goods, 111, 112
private sector organizations, mission and patent
strategy of, 113
product commercialization alliances, 137
product-development partnerships (PDPs), 26,
36, 39, 138, 147, 154, 187
provisional patent applications, 112
public domain, 111, 112
public goods, 48, 111, 112
Public Intellectual Property Resources for
Agriculture (PIPRA), 156
public sector organizations, mission and patent
strategy of, 113

R

remote sensing (RS), 60
regulatory approval, 115
research tools, patents and, 37
risk/benefit analysis, 51
rotavirus vaccine, CS23
royalties and calculation thereof, 126, 127
S

social capital, 50
South Africa, 186
South Africa, technology transfer offices and,
186
South African Research & Innovation
Management Association (SARIMA),
186
spinouts (university), 144, 144
startup companies, 143
Stevenson-Wydler Act, 79
stewardship, managing liability and, 156
T

technology cluster, 145
technology income, distribution of, 75
technology transfer, 27, 26, 48, 123
technology transfer intermediaries, 143, 145,
147
technology transfer offices (TTOs)
broader role of, 27
data management and, 77
establishment of, 73, 74, 75
general discussion of, 94, 142
innovative developing countries and, 157
knowledge transfer and, 78
national configuration of, 75
structure and policies of, 74
trademarks, 57, 125
trademarks, as form of protection for plants, 124
Trade-Related Aspects of Intellectual Property
Rights (TRIPS)
benefits of compliance with, 27
biotechnology and, 29
Doha Declaration and, 26
general discussion of, 37, 185
pharmaceutical products and, 48
plants and, 59
requirements of, 27
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trade secrets (know-how), 58, 124
traditional knowledge (TK), 59, 173, 174, 178,
179
training programs, 76

U.S. National Institutes of Health (NIH), 163,
177, 186, CS23
U.S. Patent and Trademark Office (USPTO),
115

U

valuation of technology/intellectual property,
102–106
venture capital, 143, 144, 145

Unicamp, 187
UPOV (International Convention for the
Protection of New Varieties of Plants),
59, 116, 123
U.S. Department of Justice, 190
U.S. Federal District Court System, 115
U.S. Federal Trade Commission, 190
U.S. Food and Drug Administration (FDA),
115
U.S. International Trade Commission (ITC),
115
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white knight condition, 135
World Trade Organization (WTO), 49, 114

—From the Foreword by Dr. Reddy

Intellectual property can be a powerful tool. When effectively and ethically
managed, it can accelerate the development of lifesaving, poverty-alleviating
innovations and provide access to them.
This Executive Guide, companion to the Handbook, discusses and summarizes
each of the 17 sections of the Handbook and distills best practices related to
each of the major topics. They are presented in brief, simply worded lists that
address the concerns of policymakers, heads of universities and R&D centers,
scientists, and technology transfer officers.
This book will be invaluable for anyone seeking to use intellectual property
strategically and put intellectual property to work.
“A resource for translating IP rights into realistic deals and practical solutions,
the Executive Guide demystifies intellectual property, making the subject accessible to all. ”
—From the Foreword by Sam Dryden

“Pragmatic IP management is building bridges between the world’s islands, be they economic,
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